1	
2	Association between Bisphosphonate use and COVID-19 related outcomes: a
3	retrospective cohort study
4	
5	
6	Jeffrey Thompson <sup>1</sup> *, Yidi Wang <sup>2</sup> *, Tobias Dreischulte <sup>3</sup> , Olga Barreiro <sup>2</sup> , Rodrigo J. Gonzalez <sup>2</sup> , Pavel Hanč <sup>2</sup> , Colette Matysiak <sup>2</sup> , Harold R. Neely <sup>2</sup> , Marietta Rottenkolber <sup>3</sup> , Tom Haskell <sup>1</sup> ,
7	Pavel Hanč <sup>2</sup> , Colette Matysiak <sup>2</sup> , Harold R. Neely <sup>2</sup> , Marietta Rottenkolber <sup>3</sup> , Tom Haskell <sup>1</sup> ,
8	Stefan Endres <sup>4,5</sup> , and Ulrich H. von Andrian <sup>2,6,\$</sup>
9	
10	
11	
12	Author Information
13	
14	<sup>1</sup> Cerner Enviza, 51 Valley Stream Pkwy, Malvern, PA 19355
15	<sup>2</sup> Dept. of Immunology, Harvard Medical School, Boston, MA 02115
16	<sup>3</sup> Institute of General Practice and Family Medicine, University Hospital of Ludwig-
17	Maximilians-University Munich, Pettenkoferstr. 10, 80336 Munich, Germany
18	<sup>4</sup> Center of Integrated Protein Science Munich and Division of Clinical Pharmacology,
19	University Hospital, LMU Munich, Germany
20	<sup>5</sup> Einheit für Klinische Pharmakologie (EKLiP), Helmholtz Zentrum München, German
21	Research Center for Environmental Health, Neuherberg, Germany
22	<sup>6</sup> The Ragon Institute of MGH, MIT and Harvard, Cambridge, MA
23	<b>3</b>
24	
25	* Equal contribution
26	
27	
28	
29	<sup>\$</sup> Send correspondence to:
30	
31	Ulrich H. von Andrian, M.D.
32	Dept. of Immunology
33	Harvard Medical School
34	Boston, MA 02115, USA
35	,, -
36	Ph: +617-432-6827
37	Fax: +617-432-6828
38	
39	Email: uva@hms.harvard.edu
40	$\sim$

#### 41 **ABSTRACT**

- 42
- 43 Background:

Although there are several efficacious vaccines against COVID-19, vaccination rates in many regions around the world remain insufficient to prevent continued high disease burden and

46 emergence of viral variants. Repurposing of existing therapeutics that prevent or mitigate

47 severe COVID-19 could help to address these challenges. The objective of this study was to

48 determine whether prior use of bisphosphonates is associated with reduced incidence and/or

- 49 severity of COVID-19.
- 50
- 51 Methods:
- 52 A retrospective cohort study utilizing payer-complete health insurance claims data from

53 8,239,790 patients with continuous medical and prescription insurance from 1-1-2019 to 6-

54 30-2020 was performed. The primary exposure of interest was use of any bisphosphonate

55 from 1-1-2019 to 2-29-2020. Outcomes of interest included: (a) testing for SARS-CoV-2

56 infection; (b) COVID-19 diagnosis; and (c) hospitalization with COVID-19 diagnosis between

- 57 **3-1-2020** and **6-30-2020**.
- 58
- 59 Results:
- 60 7,906,603 patients for whom continuous medical and prescription insurance information was
- available were selected. 450,366 bisphosphonate users were identified and 1:1 propensity
- score-matched to bisphosphonate non-users by age, gender, insurance type, primary-care-
- 63 provider visit in 2019, and comorbidity burden. Bisphosphonate users had lower odds ratios
- 64 (OR) of testing for SARS-CoV-2 infection (OR=0.22; 95%CI:0.21-0.23; p<0.001), COVID-19
- diagnosis (OR=0.23; 95%CI:0.22-0.24; p<0.001), and COVID-19-related hospitalization</li>
   (OR=0.26; 95%CI:0.24-0.29; p<0.001). Sensitivity analyses yielded results consistent with</li>
- 66 (OR=0.26; 95%CI:0.24-0.29; p<0.001). Sensitivity analyses yielded results consistent with 67 the primary analysis. Bisphosphonate-use was also associated with decreased odds of acute
- 68 bronchitis (OR=0.23; 95%CI:0.22-0.23; p<0.001) or pneumonia (OR=0.32; 95%CI:0.31-0.34;
- p<0.001 in 2019, suggesting that bisphosphonates may protect against respiratory infections
- 70 by a variety of pathogens, including but not limited to SARS-CoV-2.
- 71
- 72 Conclusions:
- 73 Prior bisphosphonate-use was associated with dramatically reduced odds of SARS-CoV-2
- testing, COVID-19 diagnosis, and COVID-19-related hospitalizations. Prospective clinical
- trials will be required to establish a causal role for bisphosphonate-use in COVID-19-related
- 76 outcomes.
- 77 78 *Funding:*
- 79 This study was supported by NIH grants, AR068383 and AI155865, a grant from MassCPR
- 80 (to U.H.v.A.) and a CRI Irvington postdoctoral fellowship, CRI2453 (to P.H.).
- 81

#### 82 INTRODUCTION

83

84 Throughout the COVID-19 pandemic, massive global efforts to repurpose existing drugs as potential therapeutic options for COVID-19 have been undertaken. Drug repurposing, 85 86 whereby a drug already proven to be safe and effective in humans for another approved 87 clinical indication is evaluated for novel clinical use, may allow for faster identification and 88 deployment of therapeutic agents compared to traditional drug discovery pipelines. Using in 89 silico and in vitro analyses, a growing list of drugs have been suggested to be potentially efficacious in treating COVID-19 by either direct or indirect antiviral actions<sup>1</sup>. Another 90 91 potentially beneficial class of drugs may be agents that boost or modulate anti-viral immune 92 responses to SARS-CoV-2 infection to reduce clinical symptoms and/or mitigate disease 93 progression. Regardless of the mechanism of action, ultimately, randomized prospective 94 clinical studies are needed to test the safety and efficacy of each candidate in treating or 95 preventing COVID-19. Observational studies can help prioritize candidates for prospective 96 clinical testing, by examining associations between the use of a candidate drug and the 97 incidence or severity of disease in users compared to a matched group of non-users. Drugs 98 with strong observational evidence for potential effectiveness against COVID-19 may then be 99 considered for prospective trials<sup>1</sup>.

100

101 Here, we have investigated bisphosphonates (BPs), a class of small-molecule drugs that

inhibit bone resorption by osteoclasts<sup>2</sup>. BPs are widely prescribed as either oral or
 intravenous formulations to treat osteoporosis, Paget disease, and malignancy-induced
 hypercalcemia. Additionally, BPs are used as adjuvant therapy for breast cancer<sup>3</sup>. BPs are
 subdivided into two classes, nitrogen-containing (amino-BPs) and nitrogen-free BPs (non amino-BPs)<sup>4</sup>. Both accumulate in bone but have distinct molecular mechanisms by which

- 107 they kill osteoclasts to prevent bone resorption<sup>2</sup>.
- 108

109 Aside from depleting osteoclasts, clinical and experimental studies indicate that BPs exert a 110 plethora of immunomodulatory effects, providing a rationale for exploring BPs as potential repurposed drug candidates for COVID-19 (ref.<sup>5</sup>). Indeed, amino-BPs regulate the activation, 111 expansion, and/or function of a major subset of human  $\gamma\delta T$  cells<sup>6-8</sup> as well as neutrophils<sup>9</sup>, 112 monocytes<sup>10</sup>, and macrophages<sup>11,12</sup>; they can modulate the antigen-presentation capacity of 113 dendritic cells<sup>13</sup>; and in animal studies, both amino-BPs and non-amino-BPs exerted potent 114 adjuvant-like activity to boost antibody and T cells responses to viral antigens<sup>14</sup>. Furthermore, 115 observational studies have reported decreased in-hospital mortality for patients in the ICU<sup>15</sup>, 116 117 and reduced incidence of pneumoniae and pneumonia-related mortality in patients treated with amino-BPs versus controls<sup>16</sup>. These immunological and clinical effects of BPs combine 118 with several other characteristics that make BPs well-suited as repurposed drug candidates 119 120 in the context of a pandemic: they are globally accessible as generics, affordable, straightforward to administer, and have known safety profiles in adult<sup>17</sup> and paediatric 121 populations<sup>18,19</sup>. 122


123

In light of these considerations, we have analysed a database of health insurance claims in
 the U.S. to determine if prior BP-use is associated with a differential incidence and/or severity
 of COVID-19-related outcomes. Specifically, we assessed the relationship between use of
 BPs and COVID-19-related hospitalizations and COVID-19 diagnosis, as well as testing for
 SARS-CoV-2 infection (as a proxy for severe COVID-19 symptoms given the restricted
 access to testing during the initial surge). Outcomes were measured from March 1, 2020 to

- 130 June 30, 2020, a period that roughly coincided with the first wave of COVID-19 in the U.S.
- and predated the advent of potential outcome modifiers, such as vaccines or other effective
- 132 treatment options.

### 133 **METHODS**

- 134 Study Design
- 135 A retrospective cohort study was performed using health insurance claims data from January
- 136 1, 2019 to June 30, 2020 (study period) in order to assess the relationship between use of
- 137 BPs and three COVID-19-related outcomes: (a) testing for SARS-CoV-2 infection; (b)
- 138 COVID-19 diagnosis; and (c) hospitalization with a COVID-19 diagnosis, whereby COVID-19-
- related hospitalization was deemed the primary endpoint and COVID-19 diagnosis and
- 140 testing were secondary endpoints. Primary and secondary endpoints were assessed during
- the observation period of March 1, 2020 to June 30, 2020, roughly corresponding to the first
- nation-wide surge of COVID-19 in the U.S. (**Fig. 1A**). In the primary analysis, the risk of
- 143 COVID-19-related outcomes was assessed among BP users compared to a matched sample
- 144 of BP non-users with similar demographic and clinical characteristics.
- 145
- 146 Data Source
- 147 Data used for this study included closed medical (inpatient and outpatient) and outpatient-
- pharmacy-dispensed claims between January 1, 2019 and June 30, 2020, from the Komodo
- 149 Health payer-complete dataset (https://www.komodohealth.com). This dataset is derived from
- 150 over 150 private insurers in the U.S. and includes patients with commercial, individual, state
- exchange-purchased, Medicare Advantage, and Medicaid managed-care insurance coverage.
- 152 The dataset also provides information on insurance eligibility periods. Closed claims within
- this dataset represent those that had undergone insurance adjudication. In total, the Komodo
- 154 Health payer-complete dataset includes health insurance claims data from over 140 million 155 individuals in the U.S. from 2015 to 2020.
- 155
- 157 Cohort Definition
- 158 All patients were required to have continuous medical and prescription insurance eligibility
- during the entire study period. Patients with missing information for age, gender, insurance
- 160 type, or state/region were excluded.
- 161
- 162 Exposures of Interest
- 163 The primary exposure of interest was the use of any amino- or non-amino BP medication.
- 164 Exposure to BPs and all other medications of interest were assessed over a 14-month pre-
- observation period preceding the COVID-19 pandemic in the U.S. This long duration was
- 166 chosen because of the extended bioavailability of BPs, which accumulate in bone where they
- are retained and slowly released for up to several years<sup>20</sup>. Patients were classified as BP
- 168 users if they had any claim at any time during the pre-observation period for one of the
- 169 following: alendronate, alendronic acid, etidronate, ibandronate, ibandronic acid, pamidronate,
- 170 risedronate, and zoledronic acid (full details in **Appendix 1**).
- 171
- 172 Timing of BP Dose
- 173 The effect of timing and formulation of BPs on COVID-19-related outcomes was more closely
- examined by varying the window between BP exposure and outcome measurement. The
- primary analysis BP user cohort, along with their propensity-score matched (see below for
- 176 cohort matching) BP non-user cohort, were stratified as follows: two cohorts were used as the
- 177 reference comparator with known BP-exposure during all or most of the pre-observation and
- the entire observation period, specifically (i) BP users who took oral alendronic acid (dosed
- 179 daily or weekly) throughout the pre-observation period (i.e. at least one claim or drug-on-hand



#### 225 Figure 1: Study Periods, Cohort Selection, and Analyses of BP use on COVID-19-**Related Outcomes** 226

- 227 A. Schematic overview of the study timeline. B. Schematic flow diagram illustrating the
- 228 identification of the study population and matched control populations for primary analysis
- and sensitivity analyses cohorts. BP: bisphosphonate; CA: California; CCI: Charlson 229
- 230 comorbidity index: CI: confidence interval: COPD: chronic obstructive pulmonary disease: FL:
- 231 Florida; IL: Illinois; NY: New York; OR: odds ratio; PCP: primary care physician; PS:
- 232 propensity score; PSM: propensity score match

233 in each guarter in 2019 and in Jan/Feb. 2020) that also had a days-supply extending past 234 June 30, 2020, and (ii) users of infusion zoledronic acid (dosed annually) with a claim in Q3 235 or Q4 2019; two cohorts with BP-exposure only during the pre-observation period, namely (iii) 236 users of alendronic acid occurring during the first six months of 2019 with days-covered ending prior to June 30, 2019 and no other BP claims thereafter, and (iv) users of zoledronic 237 238 acid in January or February 2019 with no other BP claims during the remainder of the study 239 period; and, two cohorts with short-term BP exposure, specifically new users of (v) alendronic 240 acid or (vi) zoledronic acid in February 2020, with no prior BP claims during the pre-

- 241 observation period.
- 242
- 243 Covariates

244 As covariates, we considered factors that may influence either the use of BPs or potential 245 modulators of primary or secondary study endpoints. These included: age; gender; insurance type (commercial, dual, Medicaid, Medicare); having had any primary care physician (PCP) 246 247 visit in 2019; and comorbidity burden. The variable 'PCP visit in 2019' was used to control for 248 prior healthcare-use behaviour and was assigned based on any physician office claim from 249 January 1, 2019 to December 31, 2019 with one of the following provider types: family 250 practice, general practice, geriatric medicine, internal medicine, and preventive medicine. Comorbidity score assignment was calculated following the Charlson Comorbidity Index (CCI) 251 methodology<sup>21</sup>, and was based on diagnosis codes present on any medical claim (inpatient or 252 253 outpatient) occurring during the pre-observation period. The assigned CCI score was used as 254 the comorbidity covariate for the primary cohort propensity score matching, but to better 255 control for differences in comorbidity burden when assessing outcomes, all regression 256 analyses involving the primary analysis cohort included the following individual comorbidity 257 covariates in lieu of the aggregate CCI score: osteoporosis, cancer, chronic obstructive 258 pulmonary disease (COPD), depression, dyslipidaemia, hypertension, obesity, type 2 259 diabetes, cardiovascular disease overall, sickle cell anemia, stroke, dementia, HIV/AIDS, 260 chronic kidney disease/end-stage renal disease (CKD/ESRD), and liver disease (Appendix 261 1). 262

263 Cohort Matching

For the primary analysis, BP users were propensity-score (PS) matched to BP non-users via 264 265 a PS calculated using multiple variables, including age, gender, insurance type, CCI, and any PCP visit in 2019, to yield comparable populations by demographics and clinical 266 characteristics (Fig. 1B). To account for the differential geographic spread of COVID-19 267 across the U.S. during the observation period, matching was performed within each 268 geographic region separately (Northeast, Midwest, South, West) and then combined. In 269 270 addition to this within-region stratified match, a cohort build was also performed after 271 restricting to patients from New York (NY) state only, since this state was the site of the largest outbreak in the initial COVID-19 surge in the U.S. All matching algorithms used a 272 greedy-match propensity score technique<sup>22</sup> to match BP users to non-users with a maximum 273 274 permitted propensity-score difference of 0.015.

- 275
- 276 Definition of Endpoints
- 277 Primary and secondary endpoints were assigned using inpatient and outpatient medical
- claims that occurred during the four-month observation period. The primary endpoint, COVID-
- 279 19-related hospitalization, was assigned based on the presence of an International

Classification of Diseases, Tenth Revision (ICD-10) code on any inpatient medical service
claim indicating test-confirmed 2019 Novel Coronavirus (2019-nCoV) acute respiratory
disease, specifically U07.1. The first secondary endpoint, SARS-CoV-2 testing, was assigned
using Current Procedural Terminology (CPT) codes indicating a test for active infection,
specifically 87635, 87636, and 87637. The second secondary endpoint, COVID-19-related
diagnosis, was assigned based on any medical service claim with the ICD-10 diagnosis code
U07.1.

287

#### 288 Statistical Analysis

To analyze data, mySQL, Excel, and SAS 9.4 was used on a secure hosted environment provided by Komodo Health. All data used in this study was subject to data restrictions per working agreements with Komodo Health, which dictated that only aggregate results can be exported (no patient-level data), so no deidentified data can be shared.

- 293 Unadjusted analyses assessing the association between BP-use and COVID-19-related
- 294 outcomes were performed for the primary analysis cohort using chi-square tests for
- categorical variables and calculation of the crude unadjusted odds ratio (OR) in the matched
- cohort groups overall, when stratified by region and in NY state alone, and when further
- stratified by age group and gender. Chi-square tests for categorical variables and t-tests for
- continuous variables were also performed to assess differences in demographic and clinical
- characteristics of BP users compared to BP non-users both pre-match and post-match to assess the success of the propensity-score match.
- 300 assess the success of the propensity-score match.
- 301 Multivariate logistic regression analyses, modelled separately to determine the adjusted OR
- for each COVID-19-related primary and secondary outcome while adjusting for demographic
- and clinical characteristics, were performed on the matched primary analysis cohort with all
- regions combined, when stratified by region, and in NY state alone. The primary exposure of
- 305 interest was BP-use (yes/no) during the pre-observation period. Additional
- demographic/clinical characteristics also included as regression model covariates were: age group, gender, region (for all regions-combined analyses), insurance type, PCP visit in 2019,
- 308 and the following comorbid conditions: osteoporosis, cancer, COPD, depression,
- dyslipidaemia, hypertension, obesity, type 2 diabetes, cardiovascular disease overall, sickle
   cell anaemia, stroke, dementia, HIV/AIDS, CKD/ESRD, and liver disease.
- 311 All tests were two-tailed, and *p*-values of less than 0.05 were considered significant. All
- analyses were performed using SAS 9.4 (Cary, NC).
- 313
- 314 Sensitivity Analyses
- Multiple sensitivity analyses were performed to assess the reliability of the primary analysis results and/or to address potential unmeasured confounding (full details in **Appendix 1**).
- 317 [1] The first sensitivity analysis addressed potential confounding by indication (i.e. the 318 possibility of the indication for BP use rather than BP use itself being responsible for 319 differences in outcomes among BP users and non-users) by restricting the control 320 group to an active comparator cohort of patients who had used non-BP anti-resorptive 321 bone medications during the pre-observation period. Users of non-BP anti-resorptive 322 bone medications, the smaller patient population, were then 1:1 matched to BP users, 323 providing a sample where all patients had used bone health medications during the pre-observation period ("Bone-Rx" cohort) (Fig. 1B). Cohort matching and regression 324

- modelling were performed following the same methodology employed for the primaryanalysis.
- 327 [2] The second sensitivity analysis further addressed potential baseline differences between users of BPs and users of non-BP anti-resorptive bone medications in terms 328 329 of indication for treatment and risk of SARS-CoV-2 exposure. To homogenise 330 indication for treatment, we restricted the "Bone-Rx" cohort to females aged older than 331 50 years with an osteoporosis diagnosis (ICD-10: M80.x, M81.x, M82.x), which is the 332 main (but not the only) indication for use of anti-resorptive bone medications. In order 333 to homogenise risk of COVID-19 exposure, we additionally (a) restricted both groups 334 to residents of New York, Illinois, Florida, and California (four states with a high 335 incidence of COVID-19 cases during the observation period, with each representing a geographic region)<sup>23</sup>, and (b) matched within each state by insurance-type strata (i.e. 336 337 BP non-users matched to BP users with Medicaid coverage residing in New York) to control for differences in socioeconomic characteristics. Non-BP anti-resorptive bone 338 339 medication users were then matched to BP users by age, PCP visit in 2019, and the 340 following select comorbid conditions that include those thought to impact COVID-19 341 severity: cancer, COPD, depression, dyslipidaemia, heart failure, hypertension, obesity, and type 2 diabetes<sup>24</sup>. In addition to assessing COVID-19-related outcomes, the 342 343 matched cohorts that resulted from this analysis, older female patients from New York, 344 Illinois, Florida, or California with a diagnosis of osteoporosis who were users of BP or 345 non-BP anti-resorptive medications ("Osteo-Dx-Rx" cohort), were used for the third 346 and fourth sensitivity analyses (see below).
- 347 [3] The third sensitivity analysis evaluated the relationship between BP-use and 348 exploratory negative control outcomes that were not anticipated to be impacted by the 349 pharmacological mechanism of BPs. Separate comparisons were made in the primary 350 cohort, the "Bone-Rx" cohort, and the "Osteo-Dx-Rx" cohort to evaluate the odds of 351 any acute cholecystitis or acute pancreatitis-related inpatient/emergency-room (ER) service, which were chosen since both would present in an acute manner that require 352 353 emergency intervention. These exploratory outcomes were assessed: (1) during the 354 observation period among the already matched BP user/non-user populations; and (2) 355 during a pre-pandemic period (the second half of 2019) when restricted to BP users in 356 the first half of 2019 and their previously-assigned BP non-user matched pair to 357 mitigate any COVID-19-related impacts on healthcare resource utilization.
- [4] The fourth sensitivity analysis assessed the relationship between BP-use and
  exploratory positive control outcomes (anticipated to be impacted by the
  immunomodulatory pharmacological mechanism of BPs) occurring in 2019. For this
  analysis, the primary, "*Bone-Rx*", and "*Osteo-Dx-Rx*" cohorts were restricted to BP
  users who had any BP claim during the first half of 2019 and their previously-assigned
  BP non-user matched pair to assess the relationship between BP-use and medical
  services for other respiratory infectious diseases (acute bronchitis, pneumonia).
- [5] The fifth sensitivity analysis addressed potential bias due to the 'healthy adherer' effect,
  whereby users of a preventive drug may have better disease outcomes due to their
  healthier behaviours rather than due to drug treatment itself<sup>25</sup>. Two strategies were
  employed to validate the findings from our primary analysis while controlling for the
  potential impact of healthy adherer effect-associated bias. First, we tested whether
  effects observed with exposure to BPs were similarly observed with exposure to other
  preventive drugs, namely statins, antihypertensives, antidiabetics, and antidepressants.

Second, we assessed whether the association between BP-use and COVID-19-related outcomes was maintained among the matched user/non-user populations of these other preventive drugs, i.e. BP users were compared to BP non-users within, for example, the statin user population and separately within the matched statin non-user population.

377378 **RESULTS** 

#### 379 Study Population

A total of 8,239,790 patients met the inclusion criterion of continuous medical and prescription insurance eligibility over the full study period, of which 333,107 were excluded due to missing demographic information, resulting in a total eligible sample of 7,906,603 patients (**Fig. 1B**). Of this full population, 452,051 (5.7%) and 7,454,552 (94.3%) patients were classified as BP users and BP non-users, respectively. Within BP users, more than 99% were prescribed an amino-BP, with oral alendronic acid (75.4%), zoledronic acid infusion (11.5%), and oral ibandronic acid (8.4%) as the most prevalent formulations (**Table S1**).

Prior to propensity-score matching, there were significant differences between BP users and 387 388 non-users across all demographic and clinical characteristics. BP users were older (age >60: 389 82.7% versus 27.7%; p<0.001), predominantly female (91.0% versus 57.2%; p<0.001), with a higher comorbidity burden (mean CCI 0.95 versus 0.60; p<0.001), with a larger proportion of 390 391 patients residing in the Western U.S. (21.1% versus 15.4%; p<0.001), covered by Medicare 392 (43.3% versus 13.7%; p<0.001), and having visited a PCP in 2019 (63.8% versus 44.7%; 393 p<0.001). Propensity-score matching yielded 450,366 BP users and 450,366 BP non-users 394 with no significant differences across all characteristics used in matching (**Table 1**). 395 Differences did exist, however, in the distribution of individual comorbid condition indicators

- that were used as covariates in the regression analysis, with the BP non-user cohort having a higher proportion of patients with COPD (10.2% versus 8.5%; p<0.001), cardiovascular
- higher proportion of patients with COPD (10.2% versus 8.5%; p<0.001), cardiovascular disease (25.1% versus 18.7%; p<0.001), dyslipidemia (36.9% versus 34.6%; p<0.001),
- hypertension (46.4% versus 38.8%; p<0.001), obesity (10.3% versus 6.7%; p<0.001), and
- 400 type 2 diabetes (22.9% versus 18.2%; p<0.001). Over 98% of all BP user/non-user matches
- for the primary analysis cohort were completed with differences in matched propensity scores 402 <0.000001 (overall mean difference of 0.000004, max difference of 0.0147).
- 403 Similar profiles in pre-match *versus* post-match characteristics were seen when patients were 404 stratified by region or restricted to NY-state (**Tables S2A-E**). Demographic distributions,
- including differences between BP user *versus* BP non-user characteristics pre- and post-
- 406 matching for all sensitivity analysis cohorts are detailed in **Appendix 2**.
- 407
- 408 BP use and COVID-19-Related Outcomes
- Among the full matched cohort, BP users had significantly lower rates and unadjusted (crude)
- 410 odds of testing (1.2% vs. 5.1%; OR=0.22; 95%CI:0.21-0.22; p<0.001), diagnosis (0.7% vs.
- 411 2.9%; OR=0.22; 95%Cl:0.21-0.23; p<0.001), and hospitalization (0.2% vs. 0.7%; OR=0.24;
- 95%CI:0.22-0.26; p<0.001) as compared to BP non-users (Fig. 2). Consistent findings were</li>
   seen when sub-stratifying the full matched cohort by age, gender, age\*gender, within
- 414 grouped regions, by individual region, and in NY-state alone (**Tables S3A-F**).
- 415 Multivariate regression analyses yielded similar results for all outcomes while additionally
- 416 controlling for patient demographic and comorbidity characteristics. In the full matched cohort,
- 417 BP users had lower adjusted odds of testing (OR=0.22; 95%CI:0.21-0.23; p<0.001),

- 418 diagnosis (OR=0.23; 95%CI:0.22-0.24; p<0.001), and hospitalizations (OR=0.26;
- 419 95%CI:0.24-0.29; p<0.001). These findings were robust when comparing BP users with BP
- 420 non-users when stratified by geographic region or NY-state alone.

421

## Table 1: Primary Analysis Cohort (All Regions), Patient Characteristics Pre/Post Match 423

Demographics           Age            ≤20            21-40            41-50            51-60            61-70            >81            Gender            Female            Male	All 7,906,603 7,906,603 1,840,050 1,446,999 925,309 1,250,190 1,181,261 783,775 479,019 4,670,960	%           100.0%           23.3%           18.3%           11.7%           15.8%           14.9%           9.9%           6.1%	BP Non- N 7,454,552 1,838,922 1,443,908 916,758 1,184,469 1,024,383 642,050 404,062	%           94.3%           24.7%           19.4%           12.3%           15.9%           13.7%           8.6%	BP U: N 452,051 1,128 3,091 8,551 65,721 156,878	% 5.7% 0.2% 0.7% 1.9% 14.5%	p-value	A N 900,732 2,253 6,195	II % 100.0% 0.3%	BP Non N 450,366 1,125	-users % 50.0%	BP U: N 450,366	sers % 50.0%	p-value
Demographics           Age         I           ≤20         I           21-40         I           41-50         I           51-60         I           61-70         I           71-80         I           S81         I           Gender         I           Female         I           Male         I	7,906,603       1,840,050       1,446,999       925,309       1,250,190       1,181,261       783,775       479,019       4,670,960	100.0% 23.3% 18.3% 11.7% 15.8% 14.9% 9.9% 6.1%	7,454,552 1,838,922 1,443,908 916,758 1,184,469 1,024,383 642,050	<b>94.3%</b> 24.7% 19.4% 12.3% 15.9% 13.7%	452,051 1,128 3,091 8,551 65,721 156,878	5.7% 0.2% 0.7% 1.9% 14.5%		<b>900,732</b> 2,253	100.0%	450,366	50.0%	450,366		p-value
Demographics           Age         I           ≤20         I           21-40         I           41-50         I           51-60         I           61-70         I           71-80         I           S81         I           Gender         I           Female         I           Male         I	1,840,050 1,446,999 925,309 1,250,190 1,181,261 783,775 479,019 4,670,960	23.3% 18.3% 11.7% 15.8% 14.9% 9.9% 6.1%	1,838,922 1,443,908 916,758 1,184,469 1,024,383 642,050	24.7% 19.4% 12.3% 15.9% 13.7%	1,128 3,091 8,551 65,721 156,878	0.2% 0.7% 1.9% 14.5%	<0.001	2,253					50.0%	
Age       ≤20       21-40       41-50       51-60       61-70       71-80       ≥81       Gender       Female       Male       Region	1,446,999 925,309 1,250,190 1,181,261 783,775 479,019 4,670,960	18.3%         11.7%         15.8%         14.9%         9.9%         6.1%	1,443,908 916,758 1,184,469 1,024,383 642,050	19.4% 12.3% 15.9% 13.7%	3,091 8,551 65,721 156,878	0.7% 1.9% 14.5%	<0.001		0.3%	1,125	0.2%	1 128		
≤20     2       21-40     4       51-60     6       61-70     7       ≥81     2       Gender     7       Female     1       Male     1	1,446,999 925,309 1,250,190 1,181,261 783,775 479,019 4,670,960	18.3%         11.7%         15.8%         14.9%         9.9%         6.1%	1,443,908 916,758 1,184,469 1,024,383 642,050	19.4% 12.3% 15.9% 13.7%	3,091 8,551 65,721 156,878	0.7% 1.9% 14.5%	<0.001		0.3%	1,125	0.2%	1 128		
21-40       41-50       51-60       61-70       71-80       ≥81       Gender       Female       Male       Region	1,446,999 925,309 1,250,190 1,181,261 783,775 479,019 4,670,960	18.3%         11.7%         15.8%         14.9%         9.9%         6.1%	1,443,908 916,758 1,184,469 1,024,383 642,050	19.4% 12.3% 15.9% 13.7%	3,091 8,551 65,721 156,878	0.7% 1.9% 14.5%	<0.001		0.3%	1,125	0.2%	1 128		
41-50       51-60       61-70       71-80       ≥81       Gender       Female       Male       Region	925,309 1,250,190 1,181,261 783,775 479,019 4,670,960	11.7%         15.8%         14.9%         9.9%         6.1%	916,758 1,184,469 1,024,383 642,050	12.3% 15.9% 13.7%	8,551 65,721 156,878	1.9% 14.5%		6,195				1,120	0.3%	1.00
51-60       □         61-70       □         71-80       □         ≥81       □         Gender       □         Female       □         Male       □         Region       □	1,250,190 1,181,261 783,775 479,019 4,670,960	15.8% 14.9% 9.9% 6.1%	1,184,469 1,024,383 642,050	15.9% 13.7%	65,721 156,878	14.5%			0.7%	3,104	0.7%	3,091	0.7%	
61-70       71-80       ≥81       Gender       Female       Male       Region	1,181,261 783,775 479,019 4,670,960	14.9% 9.9% 6.1%	1,024,383 642,050	13.7%	156,878			17,096	1.9%	8,545	1.9%	8,551	1.9%	
71-80       ≥81       Gender       Female       Male       Region	783,775 479,019 4,670,960	9.9% 6.1%	642,050			a · -		131,445	14.6%	65,724	14.6%	65,721	14.6%	
≥81 Gender Female Male Region	479,019 4,670,960	6.1%		8.6%		34.7%		313,822	34.8%	156,944	34.8%	156,878	34.8%	
Gender Female Male Region	4,670,960		404,062		141,725	31.4%		280,803	31.2%	140,366	31.2%	140,437	31.2%	
Female Male Region				5.4%	74,957	16.6%		149,118	16.6%	74,558	16.6%	74,560	16.6%	
Male Region														
Region	0.005.040	59.1%	4,263,524	57.2%	407,436	90.1%	<0.001	811,497	90.1%	405,746	90.1%	405,751	90.1%	0.99
-	3,235,643	40.9%	3,191,028	42.8%	44,615	9.9%		89,235	9.9%	44,620	9.9%	44,615	9.9%	
-														
Midwest	1,467,802	18.6%	1,391,835	18.7%	75,967	16.8%	<0.001	151,802	16.9%	75,901	16.9%	75,901	16.9%	1.00
	2,152,560	27.2%	2,032,832	27.3%	119,728	26.5%		238,988	26.5%	119,494	26.5%	119,494	26.5%	
	3,042,604	38.5%	2,881,718	38.7%	160,886	35.6%		319,408	35.5%	159,704	35.5%	159,704	35.5%	
West	1,243,637	15.7%	1,148,167	15.4%	95,470	21.1%		190,534	21.2%	95,267	21.2%	95,267	21.2%	
Insurance	1,243,037	13.770	1,140,107	13.470	33,470	21.170		130,334	21.270	33,207	21.270	33,207	21.270	
Commercial	3.938.603	49.8%	3,791,545	50.9%	147,058	32.5%	<0.001	294,070	32.6%	147,012	32.6%	147,058	32.7%	1.00
Dual	- , ,	2.0%		1.7%		6.9%	<0.001	-	6.7%		6.7%		6.7%	1.00
	156,497		125,090		31,407			59,936		29,980		29,956		
Medicaid	2,594,500	32.8%	2,517,020	33.8%	77,480	17.1%		154,519	17.2%	77,272	17.2%	77,247	17.2%	
Medicare	1,217,003	15.4%	1,020,897	13.7%	196,106	43.4%		392,207	43.5%	196,102	43.5%	196,105	43.5%	
PCP Visit 2019														
No	4,283,697	54.2%	4,119,831	55.3%	163,866	36.2%	<0.001	327,383	36.3%	163,659	36.3%	163,724	36.4%	0.89
	3,622,906	45.8%	3,334,721	44.7%	288,185	63.8%		573,349	63.7%	286,707	63.7%	286,642	63.6%	
Clinical Characteristics	5		[					r						
	mean	SD	mean	SD	mean	SD	p-value	mean	SD	mean	SD	mean	SD	p-value
CCI	0.62	1.38	0.60	1.35	0.95	1.76	<0.001	0.95	1.76	0.95	1.76	0.95	1.76	0.70
Regression Comorbidit	ty Covariates													
	N	%	N	%	N	%	p-value	N	%	N	%	N	%	p-value
Osteoporosis	267,020	3.4%	135,231	1.8%	131,789	29.2%	<0.001	163,814	18.2%	32,390	7.2%	131,424	29.2%	<0.001
Cancer	419,083	5.3%	366,786	4.9%	52,297	11.6%	<0.001	94,148	10.5%	41,861	9.3%	52,287	11.6%	<0.001
CKD/ESRD	361,451	4.6%	328,633	4.4%	32,818	7.3%	<0.001	68,999	7.7%	36,182	8.0%	32,817	7.3%	<0.001
COPD	466,094	5.9%	427,850	5.7%	38,244	8.5%	<0.001	84,234	9.4%	45,990	10.2%	38,244	8.5%	<0.001
CVD	1,084,031	13.7%	999,526	13.4%	84,505	18.7%	<0.001	197,243	21.9%	112,933	25.1%	84,310	18.7%	<0.001
Dementia	125,811	1.6%	113,778	1.5%	12,033	2.7%	<0.001	24,921	2.8%	12,889	2.9%	12,032	2.7%	<0.001
Depression	571,303	7.2%	531,355	7.1%	39,948	8.8%	<0.001	86,280	9.6%	46,431	10.3%	39,849	8.8%	<0.001
Dyslipidemia	1,532,254	19.4%	1,375,920	18.5%	156,334	34.6%	<0.001	322,125	35.8%	166,360	36.9%	155,765	34.6%	<0.001
HIV/AIDS	33,229	0.4%	31,711	0.4%	1,518	0.3%	<0.001	2,897	0.3%	1,379	0.3%	1,518	0.3%	0.01
Hypertension	1,899,063	24.0%	1,723,519	23.1%	175,544	38.8%	<0.001	384,059	42.6%	209,184	46.4%	174,875	38.8%	<0.001
Liver Disease	251,331	3.2%	231,664	3.1%	19,667	4.4%	<0.001	38,697	4.3%	19,031	4.2%	19,666	4.4%	0.001
Obesity	638,506	8.1%	608,083	8.2%	30,423	6.7%	<0.001	76,844	8.5%	46,498	10.3%	30,346	6.7%	<0.001
Sickle Cell Anemia	10,499	0.1%	10,292	0.1%	207	0.0%	<0.001	422	0.0%	215	0.0%	207	0.0%	0.70
Stroke	104,859	1.3%	97,001	1.3%	7,858	1.7%	<0.001	19,395	2.2%	11,569	2.6%	7,826	1.7%	<0.001
Type 2 Diabetes	978,239	12.4%	895,983	12.0%	82,256	18.2%	< 0.001	184,978	20.5%	103,031	22.9%	81,947	18.2%	<0.001

424 BP: bisphosphonate; CCI: Charlson Comorbidity Index; COPD: chronic obstructive pulmonary disease;

425 CKD/ESRD: chronic kidney disease/end-stage renal disease; CVD: cardiovascular disease (overall); PCP:

426 primary care physician; SD: standard deviation

427

Number of events / non-user patients (%)         Number of events // user patients (%)         Crude OR (95%Cl)         Adjusted OR (95%Cl)         Adjusted OR (95%Cl)           ( <i>I</i> ) All Regions Combined		Incidence of out exposure to bis		Odds o	of Event
SARS-CoV-2         22,948 / 450,366         5,189 / 450,366         0.22         0.22           Test         (5.1)         (1.2)         (0.21-0.23)         (0.21-0.23)           COVID-19         13,265 / 450,366         3,024 / 450,366         0.22         0.23           Diagnosis         (2.9)         (0.7)         (0.21-0.23)         (0.22-0.24)           COVID-19         2,995 / 450,366         715 / 450,366         0.24         0.26           Hospitalization         (0.7)         (0.21-0.24)         (0.24-0.29)           ( <i>ii</i> )         Region = Northeast         SARS-CoV-2         7,147 / 119,494         1,684 / 119,494         0.22         0.23           COVID-19         6,242 / 119,494         1,578 / 119,494         0.24         0.25         0.24           Diagnosis         (5.2)         (1.3)         (0.23-0.26)         (0.24-0.28)           COVID-19         1,191 / 119,494         1,411 / 19,494         0.24         0.22           Hospitalization         (1.0)         0.3         0.24         0.22           COVID-19         1,191 / 119,494         0.22         0.24           Diagnosis         (2.3)         (0.5)         0.23         0.24           COVID-19         1,716		non-user patients	/ user patients		OR
Test         (5.1)         (1.2)         (0.21-0.22)         (0.21-0.23)           COVID-19         13,265 / 450,366         3,024 / 450,366         0.22         0.23           Diagnosis         (2.9)         (0.7)         (0.21-0.23)         (0.22-0.24)           COVID-19         2,995 / 450,366         715 / 450,366         0.24         0.26           Hospitalization         (0.7)         (0.2)         0.23         (0.24-0.29)           ( <i>ii)</i> Region = Northeast         SARS-CoV-2         7,147 / 119,494         1,578 / 119,494         0.22         0.23           Test         (6.0)         (1.4)         (0.21-0.24)         0.25         0.24         0.25           Diagnosis         (5.2)         (1.3)         (0.23-0.26)         (0.23-0.26)         0.24           COVID-19         1,191 / 119,494         314 / 119,494         0.26         0.29         0.24           Hospitalization         (1.0)         (0.3)         (0.23-0.26)         0.22-0.26)         0.22-0.26)           COVID-19         1,716 / 75,901         383 / 75,901         0.22         0.24         0.26           Diagnosis         (2.3)         (0.5)         (0.22-0.25)         (0.22-0.27)           COVID-19         51 / 75,9	i) All Regions C	ombined			
Diagnosis         (2.9)         (0.7)         (0.21-0.23)         (0.22-0.24)           CCVID-19         2.995 / 450,366         715 / 450,366         0.24         0.26           Hospitalization         (0.7)         (0.2)         (0.22-0.26)         (0.24-0.29)           ( <i>ii) Region = Northeast</i>					
Hospitalization         (0.7)         (0.2)         (0.22-0.26)         (0.24-0.29)           (ii) Region = Northeast					
SARS-CoV-2         7,147/119,494         1,684/119,494         0.22         0.23           Test         (6.0)         (1.4)         (0.21-0.24)         (0.21-0.24)           COVID-19         6,242/119,494         1,578/119,494         0.24         0.25           Diagnosis         (5.2)         (1.3)         (0.23-0.26)         (0.23-0.26)           COVID-19         1,191/119,494         314/119,494         0.26         0.29           Hospitalization         (1.0)         (0.3)         (0.23-0.30)         (0.26-0.33)           (III) Region = Midwest         SARS-CoV-2         3,583/75,901         868/75,901         0.23         0.24           Test         (4.7)         (1.1)         (0.22-0.25)         (0.22-0.26)         0.22           COVID-19         1,716/75,901         383/75,901         0.23         0.24         0.25           Diagnosis         (2.3)         (0.5)         (0.20-0.25)         (0.22-0.27)         0.24           COVID-19         515/75,901         121/75,901         0.23         0.26         0.22         0.22           Test         (4.3)         (1.0)         (0.21-0.23)         (0.21-0.23)         0.21-0.23)           COVID-19         2,911/159,704         167					
Test         (6.0)         (1.4)         (0.21-0.24)         (0.21-0.24)           COVID-19         6,242 / 119,494         1,578 / 119,494         0.24         0.25           Diagnosis         (5.2)         (1.3)         (0.23-0.26)         (0.23-0.26)           COVID-19         1,191 / 119,494         314 / 119,494         0.26         0.29           Hospitalization         (1.0)         (0.3)         (0.23-0.30)         (0.26-0.33)           (iii) Region = Midwest         SARS-CoV-2         3,583 / 75,901         868 / 75,901         0.22         0.24           Test         (4.7)         (1.1)         (0.22-0.25)         (0.22-0.26)         COVID-19           COVID-19         1,716 / 75,901         383 / 75,901         0.22         0.24           Diagnosis         (2.3)         (0.5)         (0.20-0.25)         (0.22-0.27)           COVID-19         515 / 75,901         121 / 75,901         0.23         0.26           Hospitalization         (0.7)         (0.2)         (0.19-0.23)         (0.21-0.23)           COVID-19         2,911 / 159,704         1,553 / 159,704         0.22         0.22           Test         (4.3)         (1.0)         (0.21-0.23)         (0.20-0.24)	ii) Region = Noi	rtheast			
Diagnosis         (5.2)         (1.3)         (0.23-0.26)         (0.23-0.26)           COVID-19         1,191 / 119,494         314 / 119,494         0.26         0.29           Hospitalization         (1.0)         (0.3)         (0.23-0.30)         (0.26-0.33)           (iii) Region = Midwest         SARS-CoV-2         3,583 / 75,901         868 / 75,901         0.23         0.24           Test         (4.7)         (1.1)         (0.22-0.25)         (0.22-0.26)           COVID-19         1,716 / 75,901         383 / 75,901         0.22         0.24           Diagnosis         (2.3)         (0.5)         (0.20-0.25)         (0.22-0.27)           COVID-19         515 / 75,901         121 / 75,901         0.23         0.26           Hospitalization         (0.7)         (0.2)         (0.21-0.23)         (0.21-0.32)           (iv) Region = South         SARS-CoV-2         6,865 / 159,704         1,553 / 159,704         0.22         0.22           Test         (4.3)         (1.0)         (0.21-0.23)         (0.20-0.24)           COVID-19         2,911 / 159,704         167 / 159,704         0.24         0.26           Hospitalization         (0.4)         (0.1)         (0.18-0.21)         (0.18-0.21)			(1.4)		
Hospitalization         (1.0)         (0.3)         (0.23-0.30)         (0.26-0.33)           (iii) Region = Midwest         SARS-CoV-2         3,583 / 75,901         868 / 75,901         0.23         0.24           Test         (4.7)         (1.1)         (0.22-0.25)         (0.22-0.26)           COVID-19         1,716 / 75,901         383 / 75,901         0.22         0.24           Diagnosis         (2.3)         (0.5)         (0.20-0.25)         (0.22-0.27)           COVID-19         515 / 75,901         121 / 75,901         0.23         0.26           Hospitalization         (0.7)         (0.2)         (0.19-0.29)         (0.21-0.32)           (iv) Region = South         SARS-CoV-2         6,865 / 159,704         1,553 / 159,704         0.22         0.22           Test         (4.3)         (1.0)         (0.21-0.23)         (0.21-0.23)         (0.21-0.23)           COVID-19         2,911 / 159,704         624 / 159,704         0.24         0.26         0.22           Diagnosis         (1.8)         (0.4)         (0.19-0.23)         (0.20-0.24)         0.26           COVID-19         682 / 159,704         167 / 159,704         0.24         0.26         0.20           Hospitalization         (0		(5.2)	(1.3)	(0.23-0.26)	(0.23-0.26)
SARS-CoV-2         3,583 / 75,901         868 / 75,901         0.23         0.24           Test         (4.7)         (1.1)         (0.22-0.25)         (0.22-0.26)           COVID-19         1,716 / 75,901         383 / 75,901         0.22         0.24           Diagnosis         (2.3)         (0.5)         (0.20-0.25)         (0.22-0.27)           COVID-19         515 / 75,901         121 / 75,901         0.23         0.26           Hospitalization         (0.7)         (0.2)         (0.19-0.29)         (0.21-0.32)           (iv) Region = South         SARS-CoV-2         6,865 / 159,704         1,553 / 159,704         0.22         0.22           Test         (4.3)         (1.0)         (0.21-0.23)         (0.21-0.23)         (0.21-0.23)           COVID-19         2,911 / 159,704         624 / 159,704         0.21         0.22           Diagnosis         (1.8)         (0.4)         (0.19-0.23)         (0.20-0.24)           COVID-19         682 / 159,704         167 / 159,704         0.24         0.26           Hospitalization         (0.4)         (0.11)         (0.21-0.29)         (0.23-0.30)           (v) Region = West         SARS-CoV-2         5,353 / 95,267         1,084 / 95,267         0.19					
Test         (4.7)         (1.1)         (0.22-0.25)         (0.22-0.26)           COVID-19         1,716 / 75,901         383 / 75,901         0.22         0.24           Diagnosis         (2.3)         (0.5)         (0.20-0.25)         (0.22-0.27)           COVID-19         515 / 75,901         121 / 75,901         0.23         0.26           Hospitalization         (0.7)         (0.2)         (0.19-0.29)         (0.21-0.32)           ( <i>k</i> ) Region = South         SARS-CoV-2         6,865 / 159,704         1,553 / 159,704         0.22         0.22           Test         (4.3)         (1.0)         (0.21-0.23)         (0.21-0.23)           COVID-19         2,911 / 159,704         624 / 159,704         0.21         0.22           Diagnosis         (1.8)         (0.4)         (0.19-0.23)         (0.20-0.24)           COVID-19         682 / 159,704         167 / 159,704         0.24         0.26           Hospitalization         (0.4)         (0.11)         (0.23-0.30)         (0.23-0.30)           ( <i>v</i> ) Region = West         SARS-CoV-2         5,353 / 95,267         1,98 / 95,267         0.18         0.19           Diagnosis         (2.5)         (0.5)         (0.16-0.20)         (0.17-0.21)	iii) Region = Mie	dwest			
Diagnosis         (2.3)         (0.5)         (0.20-0.25)         (0.22-0.27)           COVID-19         515 / 75,901         121 / 75,901         0.23         0.26           Hospitalization         (0.7)         (0.2)         (0.19-0.29)         (0.21-0.32)           (iv) Region = South         SARS-CoV-2         6,865 / 159,704         1,553 / 159,704         0.22         0.22           Test         (4.3)         (1.0)         (0.21-0.23)         (0.21-0.23)           COVID-19         2,911 / 159,704         624 / 159,704         0.21         0.22           Diagnosis         (1.8)         (0.4)         (0.19-0.23)         (0.20-0.24)           COVID-19         682 / 159,704         167 / 159,704         0.24         0.26           Hospitalization         (0.4)         (0.1)         (0.21-0.29)         (0.23-0.30)           (v) Region = West         SARS-CoV-2         5,353 / 95,267         1,084 / 95,267         0.19         0.20           Test         (5.6)         (1.1)         (0.18-0.21)         (0.18-0.21)         (0.18-0.21)           COVID-19         2,396 / 95,267         133 / 95,267         0.19         0.20         (0.16-0.20)           Test         (5.6)         (1.1)         (0.16-0					
Hospitalization       (0.7)       (0.2)       (0.19-0.29)       (0.21-0.32)         (iv) Region = South					
SARS-CoV-2         6,865 / 159,704 (4.3)         1,553 / 159,704 (1.0)         0.22 (0.21-0.23)         0.22 (0.21-0.23)           COVID-19         2,911 / 159,704 (1.8)         624 / 159,704 (0.4)         0.21 (0.19-0.23)         0.22 (0.20-0.24)           COVID-19         682 / 159,704 (1.8)         167 / 159,704 (0.1)         0.24 (0.19-0.23)         0.26 (0.20-0.24)           COVID-19         682 / 159,704 (0.4)         167 / 159,704 (0.1)         0.24 (0.21-0.29)         0.26           Hospitalization         (0.4)         (0.1)         0.24 (0.21-0.29)         0.26           Korgion = West         SARS-CoV-2         5,353 / 95,267         1,084 / 95,267 (1.1)         0.19 (0.18-0.21)         0.20           COVID-19         2,396 / 95,267         439 / 95,267 (0.5)         0.18 (0.16-0.20)         0.19 (0.17-0.21)           COVID-19         607 / 95,267         113 / 95,267 (0.5)         0.19 (0.16-0.23)         0.20           Hospitalization         (0.6)         (0.1)         (0.15-0.23)         (0.16-0.25)           (vi) Region = New York State         SARS-CoV-2         2,826 / 49,862         772 / 49,862         0.26 (0.24-0.28)         0.26           COVID-19         2,796 / 49,862         811 / 49,862         0.27         0.28					
Test         (4.3)         (1.0)         (0.21-0.23)         (0.21-0.23)           COVID-19         2,911 / 159,704         624 / 159,704         0.21         0.22           Diagnosis         (1.8)         (0.4)         (0.19-0.23)         (0.20-0.24)           COVID-19         682 / 159,704         167 / 159,704         0.24         0.26           Hospitalization         (0.4)         (0.1)         (0.21-0.29)         (0.23-0.30)           (v) Region = West	ïv) Region = So	uth			
Diagnosis         (1.8)         (0.4)         (0.19-0.23)         (0.20-0.24)           COVID-19         682 / 159,704         167 / 159,704         0.24         0.26           Hospitalization         (0.4)         (0.1)         (0.21-0.29)         (0.23-0.30)           (v) Region = West					
Hospitalization         (0.4)         (0.1)         (0.21-0.29)         (0.23-0.30)           (v) Region = West			,		
SARS-CoV-2         5,353 / 95,267         1,084 / 95,267         0.19         0.20           Test         (5.6)         (1.1)         (0.18-0.21)         (0.18-0.21)           COVID-19         2,396 / 95,267         439 / 95,267         0.18         0.19           Diagnosis         (2.5)         (0.5)         (0.16-0.20)         (0.17-0.21)           COVID-19         607 / 95,267         113 / 95,267         0.19         0.20           Hospitalization         (0.6)         (0.1)         (0.15-0.23)         (0.16-0.25)           (vi) Region = New York State         SARS-CoV-2         2,826 / 49,862         772 / 49,862         0.26         0.26           COVID-19         2,796 / 49,862         811 / 49,862         0.27         0.28					
Test         (5.6)         (1.1)         (0.18-0.21)         (0.18-0.21)           COVID-19         2,396 / 95,267         439 / 95,267         0.18         0.19           Diagnosis         (2.5)         (0.5)         (0.16-0.20)         (0.17-0.21)           COVID-19         607 / 95,267         113 / 95,267         0.19         0.20           Hospitalization         (0.6)         (0.1)         (0.15-0.23)         (0.16-0.25)           (vi) Region = New York State	v) Region = We	st			
Diagnosis         (2.5)         (0.5)         (0.16-0.20)         (0.17-0.21)           COVID-19         607 / 95,267         113 / 95,267         0.19         0.20           Hospitalization         (0.6)         (0.1)         (0.15-0.23)         (0.16-0.25)           (vi) Region = New York State					
Hospitalization         (0.6)         (0.1)         (0.15-0.23)         (0.16-0.25)           (vi) Region = New York State         SARS-CoV-2         2,826 / 49,862         772 / 49,862         0.26         0.26           SARS-CoV-2         2,826 / 49,862         772 / 49,862         0.26         0.26         0.26           Test         (5.7)         (1.5)         (0.24-0.28)         (0.24-0.28)         0.27         0.28					
SARS-CoV-2 Test         2,826 / 49,862 (5.7)         772 / 49,862 (1.5)         0.26 (0.24-0.28)         0.26 (0.24-0.28)           COVID-19         2,796 / 49,862         811 / 49,862         0.27         0.28					
Test         (5.7)         (1.5)         (0.24-0.28)         (0.24-0.28)           COVID-19         2,796 / 49,862         811 / 49,862         0.27         0.28	vi) Region = Ne	w York State			
	COVID-19 Diagnosis	2,796 / 49,862 (5.6)	811 / 49,862 (1.6)	0.27 (0.26-0.30)	0.28 (0.26-0.31)
COVID-19         486 / 49,862         136 / 49,862         0.28         0.33           Hospitalization         (1.0)         (0.3)         (0.23-0.34)         (0.27-0.40)					

#### 479 Figure 2: Association of BP use and COVID-19-Related Outcomes

480 Incidence (left) and regression-adjusted results for odds (right) of SARS-CoV-2 testing (blue),

481 COVID-19 diagnosis (purple), and COVID-19-related hospitalizations (red) of BP users

482 compared with BP non-users in the all-regions combined primary analysis cohort (i) and

when stratified by region/state into: Northeast (ii), Midwest (iii), South (iv), West (v), and New
York state (vi).

#### 485 Timing of last BP exposure and COVID-19-Related Outcomes

486 The above results demonstrate that any BP exposure during the 14-months pre-observation 487 period is associated with a marked reduction in each of the three COVID-19-related 488 outcomes. To further investigate the relationship between COVID-19-related outcomes and the timing of BP exposure, we focused on the two most commonly prescribed BPs, 489 490 alendronic acid (oral formulation dosed daily or weekly) and zoledronic acid (infusion dosed 491 annually). For each BP type, COVID-19-related outcomes were assessed among users: (i-ii) 492 with exposure or days covered (based on prescription frequency) during the pre-observation 493 period and throughout the observation period; (iii-iv) with exposure or days covered ending 494 prior to the observation period; and (v-vi) newly initiating therapy prior to the observation 495 period (Fig. 3A). Strikingly, all subgroups of BP users had decreased odds of COVID-19-496 related outcomes (Fig. 3B) except for the odds of hospitalization among zoledronic acid 497 users who were last dosed in January/February of 2019 (OR=0.52; 95%CI:0.20-1.40; p=0.20) 498 or newly initiated in February of 2020 (OR=0.49; 95%CI:0.13-1.88; p=0.30).

499

#### 500 Sensitivity Analysis 1: COVID-19-Related Outcomes Among All Users of Anti-Resorptive 501 Medications ("Bone-Rx" Cohort)

502 The first sensitivity analysis was performed to address potential confounding by indication. To 503 validate our primary findings in more comparable cohorts, analysis was restricted to comparing BP users to patients using non-BP anti-resorptive bone medications during the 504 505 pre-observation period. Compared to non-BP users of anti-resorptive medications, BP users 506 had decreased odds of testing (OR=0.31; 95%CI:0.28-0.33; p<0.001), diagnosis (OR=0.35; 507 95%CI:0.31-0.38; p<0.001), and hospitalization (OR=0.45; 95%CI:0.36-0.56; p<0.001) (Fig. **4A**). Furthermore, these findings were robust when assessed separately across every 508 509 geographic region as well as NY state for all outcomes except hospitalizations when 510 restricted to the Western U.S. (p=0.08; Table S4).

511

#### 512 Sensitivity Analysis 2: COVID-19-Related Outcomes Among Users of Anti-Resorptive 513 Medications with a Diagnosis of Osteoporosis ("Osteo-Dx-Rx" Cohort)


514 The second sensitivity analysis was performed to address the fact that, even after restricting 515 the comparator cohort to users of anti-resorptive medications, differences may still exist 516 between patient cohorts that could affect COVID-19-related outcomes, including different indications for anti-resorptive medication use and other uncontrolled patient characteristics. 517 518 To address this, the association between BP use and COVID-19 related outcomes were 519 examined in a cohort restricted to female patients over 50 years old, with a diagnosis of 520 osteoporosis, using either a BP or a non-BP anti-resorptive bone medication, matched within 521 insurance-type as a proxy for socioeconomic status, and selected from four states (NY, IL, FL, CA) with high incidences of COVID-19 cases during the observation period<sup>23</sup> ("Osteo-Dx-Rx" 522 cohort). In agreement with the results reported above, the decrease in odds of COVID-19-523 524 related outcomes in BP users remained robust for testing (OR=0.28; 95%CI:0.23-0.35; p<0.001), diagnosis (OR=0.40; 95%CI:0.32-0.49; p<0.001), and hospitalizations (OR=0.45; 525

- 526 95%Cl:0.26-0.75; p=0.003) (**Figure 4B**).
- 527

528 Sensitivity Analysis 3: Association of BP-use with Exploratory Negative Control Outcomes

529 While the above sensitivity analyses were performed to control for health status differences

- between BP users and BP non-users during the pre-observation period, it remained
- theoretically possible that BP users exhibited differential health care access that might have



**Figure 3: Timing of BP use and COVID-19-Related Outcomes. A.** Schematic of BP user sub-stratification by timing of exposure to alendronic acid or zoledronic acid prior to outcome assessment. Broken lines represent periods of active BP dosing. For zoledronic acid users, days covered was considered to extend 1 year past the dosing period based on dosing guidelines. B. Incidence (left) and regression-adjusted results (right) for odds of SARS-CoV-2 testing, COVID-19 diagnosis, and COVID-19-related hospitalizations of BP users compared with BP non-users in pre-specified subgroups. *CI: confidence interval; OR: odds ratio.* 

#### 581 A ("Bone-Rx" Cohort)

	Incidence of out exposure to bis		Odds o	of Event		ted OR st Plot
-	Number of events / non-user patients (%)	Number of events / user patients (%)	Crude OR (95%CI)	Adjusted OR (95%CI)		
All Regions Con	nbined					
SARS-CoV-2 Test	2,438 / 50,498 (4.8)	760 / 50,498 (1.5)	0.30 (0.28-0.33)	0.31 (0.28-0.33)	•	
COVID-19 Diagnosis	1,307 / 50,498 (2.6)	461 / 50,498 (0.9)	0.35 (0.31-0.39)	0.35 (0.31-0.38)	•	
COVID-19 Hospitalization	276 / 50,498 (0.5)	123 / 50,498 (0.2)	0.44 (0.36-0.55)	0.45 (0.36-0.56)	•	

#### B ("Osteo-Dx-Rx" Cohort)

	Incidence of out exposure to bis	•	Odds o	of Event	Adjusted OF Forest Plot
	Number of events / non-user patients (%)	Number of events / user patients (%)	Crude OR (95%CI)	Adjusted OR (95%CI)	
All Regions Co	mbined				
SARS-CoV-2 Test	395 / 7,949 (5.0)	115 / 7,949 (1.4)	0.28 (0.23-0.35)	0.28 (0.23-0.35)	•
COVID-19 Diagnosis	300 / 7,949 (3.8)	121 / 7,949 (1.5)	0.40 (0.32-0.49)	0.40 (0.32-0.49)	+
COVID-19 Hospitalization	47 / 7,949 (0.6)	21 / 7,949 (0.3)	0.45 (0.27-0.75)	0.45 (0.26-0.75)	
	· · · · · · · · · · · · · · · · · · ·	,			0.00 0.

614

615 Figure 4: COVID-19-Related Outcomes Among the Bone-RX and Osteo-Dx-Rx Restricted Cohorts.

Incidence and forest plots summarizing regression-adjusted odds ratios of SARS-CoV-2
 testing (blue), COVID-19 diagnosis (purple), ANDD COVID-19-related hospitalizations (red)

618 in the (A) "Bone-Rx" and (B) "Osteo-Dx-Rx" sensitivity analysis cohorts.

619

620 impacted COVID-19-related outcomes. To examine such residual confounding, the third sensitivity analysis evaluated the incidence of exploratory outcomes not hypothesized to be 621 modulated by BP-use in the primary, "Bone-Rx", and "Osteo-Dx-Rx" cohorts. Outcomes were 622 623 measured during the observation period, as well as during a pre-pandemic period (the second half of 2019), to control for potential reduction in the use of healthcare services<sup>26,27</sup> 624 during the COVID-19 pandemic. The associations between BP-use and the following 625 exploratory outcomes, which were anticipated to not be impacted by BP-use, were assessed: 626 627 any acute cholecystitis or acute pancreatitis-related inpatient/ER service. Regression modelling found BP users in the primary analysis cohort to have decreased odds of any 628 629 inpatient/ER service for acute cholecystitis (OR=0.55; 95%CI:0.44-0.69; p<0.001) and acute 630 pancreatitis (OR=0.58; 95%CI:0.49-0.69; p<0.001) during the observation period (**Fig. 5A**). 631 as well as decreased odds of acute pancreatitis (OR=0.83; 95%CI:0.71-0.96; p=0.01) during 632 the second half of 2019. BP users in the "Bone-Rx" cohort displayed a decreased odds of 633 service for acute pancreatitis (OR=0.55; 95%CI:0.36-0.87; p=0.01) only during the study observation period and no significant difference in odds of service for acute cholecystitis 634 635 during either periods. Lastly, there was no difference in any outcome between BP users and BP non-users in the "Osteo-Dx-Rx" cohort, although there were very few events in this cohort. 636

637

638 Sensitivity Analysis 4: Association of BP-use with Exploratory Positive Control Outcomes

639 The fourth sensitivity analysis was performed to assess if there is an association between BP-use and incidence of other respiratory infections, which has been previously reported<sup>16</sup>. 640 641 Medical services for acute bronchitis or pneumonia were measured during the second half of 642 2019, prior to the advent of COVID-19, in the primary, "Bone-Rx", and "Osteo-Dx-Rx" cohorts. Regression modelling found that, among all cohort variations modelled, BP users had a 643 644 decreased odds of any medical service related to acute bronchitis (point estimates of ORs 645 ranged from 0.23 to 0.28) and pneumonia (point estimates of ORs ranged from 0.32 to 0.36) 646 (Figure 5B).

647

# 648 Sensitivity Analysis 5: Association of Other Preventive Drugs with COVID-19-Related 649 Outcomes

650 A potential pitfall in the interpretation of apparent effects of preventive medications on health 651 outcomes is the so-called healthy adherer effect, whereby patients may have better

outcomes due to their overall healthier behaviours and not due to active drug treatment

- 653 itself<sup>25</sup>. To address this possibility of unmeasured confounding, a final sensitivity analysis was
- 654 performed to evaluate the association between control exposures (i.e. use of other preventive
- 655 medications such as statins, antihypertensives, antidiabetics, and antidepressants) and
- 656 COVID-19-related outcomes (**Figure 6A**). In comparison to BPs, the impact of other
- 657 preventive drug classes on COVID-19-related outcomes was much weaker overall (**Figure**
- 658 6B-E) and varied between geographic regions in terms of magnitude or direction (Table S5A 659 D). Furthermore, when assessing the impact of BP-use within matched user/non-user
- 659 **D**). Furthermore, when assessing the impact of BP-use within matched user/non-user 660 preventive drug cohorts (e.g. BP users compared to BP non-users among the matched statin
- 661 user and statin non-user populations), we found BP-use to be consistently associated with
- 662 lower odds of testing (point estimates of ORs ranged from 0.21 to 0.27), diagnosis (point
- 663 estimates of ORs ranged from 0.22 to 0.30), and hospitalizations (point estimates of ORs
- ranged from 0.25 to 0.33) across all stratified preventive user/non-user cohorts (**Figure 6B-E**).

Α		Incidence of out exposure to bis		Odds o	fEvent	Adjusted OR Fores
		Number of events / non-user patients (%)	Number of events / user patients (%)	Crude OR (95%CI)	Adjusted OR (95%CI)	Plot
	Inpatient/ER s	ervice for acute chol	ec <b>y</b> stitis (observatio	on period)		
	Primary	260 / 450,366	128/450,366	0.49	0.55	
	Cohort	(0.06)	(0.03)	(0.40-0.61)	(0.44-0.69)	•
	Bone-Rx Cohort	28 / 50,498 (0,06)	22 / 50,498 (0.04)	0.79 (0.45-1.37)	0.80 (0.45-1.41)	
	Osteo-Dx-Rx Cohort	4 / 7,949 (0.05)	4 / 7,949 (0.05)	1.00 (0.25-4.00)	0.96 (0.23-3.99)	
	Inpatient/ER s	ervice for acute pand	reatitis (observation	n period)		
	Primary Cohort	428 / 450,366 (0.10)	234 / 450,366	0.55 (0.47-0.64)	0.58 (0.49-0.69)	
	Bone-Rx	56 / 50,498	(0.05) 31 / 50,498	0.55	0.55	
	Cohort	(0.11)	(0.06)	(0.36-0.86)	(0.36-0.87)	◆
	Osteo-Dx-Rx Cohort	4 / 7,949 (0.05)	5 / 7,949 (0.06)	1.25 (0.34-4.66)	1.14 (0.30-4.36)	<b>-</b>
	Inpatient/ER s	ervice for acute chol	ecystitis (Q3/Q4 201	9)		
	Primary	261/326,638	194 / 326,638	0.74	0.89	
	Cohort	(0.08)	(0.06)	(0.62-0.89)	(0.73-1.09)	1
	Bone-Rx Cohort	21/36,282	33/36,282	1.57	1.57	
		(0.06)	(0.09)	(0.91-2.72) 1.00	(0.89-2.74)	
	Osteo-Dx-Rx Cohort	4 / 5,591 (0.07)	4 / 5,591 (0.07)	(0.25-4.01)	1.03 (0.24-4.45)	
		ervice for acute pand			(0.2.1.1.0)	
	Primary	478 / 326,638	315/326,638	0.66	0.83	
	Cohort	(0.15)	(0.10)	(0.57-0.76)	(0.71-0.96)	
	Bone-Rx Cohort	60 / 36,282 (0.17)	42 / 36,282 (0.12)	0.70 (0.47-1.04)	0.70 (0.47-1.05)	•
	Osteo-Dx-Rx	7 / 5,591	5 / 5,591	0.72	0.84	
	Cohort	(0.13)	(0.09)	(0.23-2.26)	(0.26-2.71)	
						0.00 1.00 2.00 3.00 4.00 5
В			tcome events by sphosphonates	Odd	s of Event	Adjusted OR For
	1	Number of events /		Crude OF	Adjusted	Plot
		non-user patients	/ user patients	(95%CI)	OR	
	A	(%)	(%)	01	(95%CI)	_
	-	ervice for acute bro	•	-	0.00	
	Primary Cohort	19,613 / 326,638 (6.0)	4,525 / 326,638 (1.4)	0.22 (0.21-0.23	0.23 3) (0.22-0.23	) •
	Bone-Rx	2,015 / 36,282	639 / 36,282	0.30	0.31	
	Cohort	(5.6)	(1.8)	(0.28-0.33	3) (0.29-0.34	)
	Osteo-Dx-Rx	361 / 5,591	103 / 5,591	0.27	0.28	•
	Cohort	(6.5) ervice for pneumon	(1.8)	(0.22-0.34	(0.24-0.32	<u>)</u>
	Contract (	16.160 / 326.638		0.20	0.22	-
	Primary Cohort	(5.0)	4,942 / 326,638 (1.5)	0.30 (0.29-0.30	0.32 )) (0.31-0.34	) •
	Bone-Rx Cohort	2,522 / 36,282 (7.0)	996 / 36,282 (2.7)	0.38 (0.35-0.41	0.40 ) (0.37-0.43	) •
	Osteo-Dx-Rx	288 / 5,591	101 / 5,591	0.34	0.36	
	Cohort	(5.2)	(1.8)	(0.27-0.43		)
						0.00 0.50 1.00 1.50

Figure 5: Exploratory Outcomes among BP Users versus BP Non-users. Incidence and
 adjusted odds ratios of (A) expected negative exploratory outcomes and (B) other respiratory
 infections, in the primary, "Bone-Rx", and "Osteo-Dx-Rx" cohorts. Cl: confidence interval; ER:
 emergency room; OR: odds ratio.

		Patients with continuous eligibility during study period (1/1/2019-6/30/2020) [N=7,906,603]						
		Unmatched Patient Counts by Preventive Medication Class						
		Statin	Antihypertensive	Antidiabetic	Antidep	pressant		
	User	1,503,3	95 2,101,120	755.252	1.57	1.005		
	Non-user	6,403,2	5,805,483	7,151,351	6,33	5,598		
	PSM	PSM at 1:1 Matched within each Region by PS based on: Age, Gender, Insurance type, PCP visit in 2019, CCI score Matched Patient Counts by Preventive Medication Class						
		Statin	-	Antidiabetic		pressant		
	User	1.436.3		754.553		6.048		
	Non-user	1,436,3				6,048		
	<ol> <li>Sub-stratify by Preventive Medication User/Non-user</li> <li>PSM at 1:1 BP Users to BP Non-users Matched within each Region by PS based on: Age, Gender, Insurance type, PCP visit in 2019, CCI score</li> </ol>							
	Matche	d Patient (	Counts by BP-Use within Oth	er Preventive Medica	tion Class	ses		
	Statin		Antihypertensive	Antidiabetic		Antidepressant		
User	BP User/Non-user	: 213,480	BP User/Non-user: 204,396	BP User/Non-user:	79,500	BP User/Non-user: 14		
on-user	BP User/Non-user	: 124,716	BP User/Non-user: 135,724	BP User/Non-user:	72,514	BP User/Non-user: 11		

В

Α

		me events by drug osure	Odds d	fEvent	٨	
	Number of events / non-user patients (%)	Number of events / user patients (%)	Crude OR (95%Cl)	Adjusted OR (95%Cl)	Adjus	ted OR Fo Plot
Outcomes by S	Statin Use					
SARS-CoV-2 Test	80,506 / 1,436,300 (5.6)	72,629 / 1,436,300 (5.1)	0.90 (0.89-0.91)	0.87 (0.86-0.87)		•
COVID-19 Diagnosis	45,526 / 1,436,300 (3.2)	41,468 / 1,436,300 (2.9)	0.91 (0.90-0.92)	0.79 (0.78-0.81)		•
COVID-19 Hospitalization	9,228 / 1,436,300 (0.6)	10,339 / 1,436,300 (0.7)	1.12 (1.09-1.15)	0.99 (0.96-1.02)		
Outcomes by E	3P Use Among Statin	Users				
SARS-CoV-2 Test	9,943 / 213,480 (4.7)	2,334 / 213,480 (1.1)	0.23 (0.22-0.24)	0.23 (0.22-0.24)	•	
COVID-19 Diagnosis	6,204 / 213,480 (2.9)	1,662 / 213,480 (0.8)	0.26 (0.25-0.28)	0.27 (0.25-0.29)	•	
COVID-19 Hospitalization	1,610 / 213,480 (0.8)	420 / 213,480 (0.2)	0.26 (0.23-0.29)	0.28 (0.25-0.32)	•	
Outcomes by E	<b>3P Use Among Statin</b>	Non-users				
SARS-CoV-2 Test	6,195 / 124,716 (5.0)	1,466 / 124,716 (1.2)	0.23 (0.21-0.24)	0.24 (0.22-0.25)	•	
COVID-19 Diagnosis	3,604 / 124,716 (2.9)	768 / 124,716 (0.6)	0.21 (0.19-0.23)	0.23 (0.21-0.25)	•	
COVID-19 Hospitalization	770 / 124,716 (0.6)	160 / 124,716 (0.1)	0.21 (0.17-0.25)	0.25 (0.21-0.30)	•	

	Incidence of outco expo		Odds o	of Event	
	Number of events / non-user patients (%)	Number of events / user patients (%)	Crude OR (95%Cl)	Adjusted OR (95%Cl)	Adjusted OR Fores Plot
Outcomes by A	Intihypertensive Use				
SARS-CoV-2	106,990 / 1,786,001	98,075 / 1,786,001	0.91	0.87	•
Test	(6.0)	(5.5)	(0.90-0.92)	(0.86-0.88)	
COVID-19	57,001 / 1,786,001	49,458 / 1,786,001	0.86	0.75	•
Diagnosis	(3.2)	(2.8)	(0.85-0.87)	(0.74-0.76)	
COVID-19	10,147 / 1,786,001	11,505 / 1,786,001	1.13	0.98	•
Hospitalization	(0.6)	(0.6)	(1.10-1.17)	(0.95-1.00)	
Outcomes by E	<b>3P Use Among Antihy</b>	pertensive Users			
SARS-CoV-2	9,665 / 204,396	2,316 / 204,396	0.23	0.23	•
Test	(4.7)	(1.1)	(0.22-0.24)	(0.22-0.24)	
COVID-19	5,748 / 204,396	1,529 / 204,396	0.26	0.26	•
Diagnosis	(2.8)	(0.7)	(0.25-0.28)	(0.25-0.28)	
COVID-19	1,474 / 204,396	385 / 204,396	0.26	0.27	•
Hospitalization	(0.7)	(0.2)	(0.23-0.29)	(0.24-0.30)	
Outcomes by E	<b>3P Use Among Antihy</b>	pertensive Non-user:	s		
SARS-CoV-2	7,334 / 135,724	1,583 / 135,724	0.21	0.21	•
Test	(5.4)	(1.2)	(0.20-0.22)	(0.20-0.22)	
COVID-19	3,792 / 135,724	772 / 135,724	0.20	0.22	•
Diagnosis	(2.8)	(0.6)	(0.18-0.22)	(0.20-0.24)	
COVID-19	686 / 135,724	144 / 135,724	0.21	0.27	•
Hospitalization	(0.5)	(0.1)	(0.17-0.25)	(0.22-0.32)	
					0.00 0.50 1.00 1.50 2

D

С

		me events by drug	Odds o	f Event	
-	Number of events / non-user patients (%)	Number of events / user patients (%)	Crude OR (95%Cl)	Adjusted OR (95%Cl)	Adjusted OR Fores Plot
Outcomes by A	ntidiabetic Use				
SARS-CoV-2	43,103 / 754,553	42,377 / 754,553	0.98	0.92	
Test	(5.7)	(5.6)	(0.97-1.00)	(0.90-0.93)	
COVID-19	22,924 / 754,553	26,339 / 754,553	1.15	0.88	•
Diagnosis	(3.0)	(3.5)	(1.13-1.18)	(0.86-0.90)	
COVID-19	4,670 / 754,553	6,993 / 754,553	1.50	1.13	•
Hospitalization	(0.6)	(0.9)	(1.45-1.56)	(1.08-1.18)	
Outcomes by B	P Use Among Antid	iabetic Users			
SARS-CoV-2	3,536 / 79,500	943 / 79,500	0.26	0.26	•
Test	(4.4)	(1.2)	(0.24-0.28)	(0.24-0.28)	
COVID-19	2,732 / 79,500	818 / 79,500	0.29	0.29	•
Diagnosis	(3.4)	(1.0)	(0.27-0.32)	(0.27-0.32)	
COVID-19	832 / 79,500	237 / 79,500	0.28	0.29	•
Hospitalization	(1.0)	(0.3)	(0.24-0.33)	(0.25-0.34)	
Outcomes by B	P Use Among Antid	iabetic Non-users			
SARS-CoV-2	3,669 / 72,514	925 / 72,514	0.24	0.25	•
Test	(5.1)	(1.3)	(0.23-0.26)	(0.23-0.27)	
COVID-19	2,156 / 72,514	526 / 72,514	0.24	0.25	•
Diagnosis	(3.0)	(0.7)	(0.22-0.26)	(0.23-0.28)	
COVID-19	500 / 72,514	120 / 72,514	0.24	0.27	•
Hospitalization	(0.7)	(0.2)	(0.20-0.29)	(0.22-0.33)	

54 5			me events by drug	Odds o	of Event	
6 7		Number of events / non-user patients (%)	Number of events / user patients (%)	Crude OR (95%Cl)	Adjusted OR (95%Cl)	Adjusted OR Fores Plot
}	Outcomes by	Antidepressant Use				
	SARS-CoV-2 Test	91,570 / 1,536,048 (6.0)	94,958 / 1,536,048 (6.2)	1.04 (1.03-1.05)	1.00 (0.99-1.01)	
	COVID-19 Diagnosis	46,497 / 1,536,048 (3.0)	33,169 / 1,536,048 (2.2)	0.71 (0.70-0.72)	0.65 (0.64-0.66)	•
	COVID-19 Hospitalization	7,939 / 1,536,048 (0.5)	6,398 / 1,536,048 (0.4)	0.81 (0.78-0.83)	0.75 (0.73-0.78)	•
	Outcomes by	BP Use Among Antid	epressant Users			
	SARS-CoV-2 Test	7,488 / 144,282 (5.2)	2,110 / 144,282 (1.5)	0.27 (0.26-0.28)	0.27 (0.25-0.28)	•
	COVID-19 Diagnosis	3,694 / 144,282 (2.6)	1,117 / 144,282 (0.8)	0.30 (0.28-0.32)	0.30 (0.28-0.32)	•
	COVID-19 Hospitalization	838 / 144,282 (0.6)	263 / 144,282 (0.2)	0.31 (0.27-0.36)	0.33 (0.28-0.38)	•
	Outcomes by	BP Use Among Antid	epressant Non-users			
	SARS-CoV-2 Test	5,501 / 112,402 (4.9)	1,165 / 112,402 (1.0)	0.20 (0.19-0.22)	0.21 (0.19-0.22)	•
	COVID-19 Diagnosis	3,392 / 112,402 (3.0)	768 / 112,402 (0.7)	0.22 (0.20-0.24)	0.23 (0.21-0.25)	•
	COVID-19 Hospitalization	760 / 112,402 (0.7)	181 / 112,402 (0.2)	0.24 (0.20-0.28)	0.27 (0.22-0.32)	•
5 6 7						0.00 0.50 1.00 1.50 2

#### 857 858

#### Figure 6: Association of Other Preventive Drugs with COVID-19-Related Outcomes 859

**A.** Schematic illustrating the identification of study populations and matched controls for each 860 drug class. B-E. Incidence and adjusted odds ratios of SARS-CoV-2 testing (blue), COVID-19 861 diagnosis (purple), and COVID-19-related hospitalizations (red) in users and non-users of (**B**) 862 statins, (C) antihypertensive medications, (D) non-insulin antidiabetic medications, and (E) 863 864 antidepressant medications. For each class of preventive medications, further analysis was 865 performed comparing BP users and BP non-users within matched cohorts of medication users (middle) and medication non-users (bottom). BP: bisphosphonate; CCI: Charlson 866 867 comorbidity index; CI: confidence interval; COPD: chronic obstructive pulmonary disease; OR: odds ratio; PCP: primary care physician; PS: propensity score; PSM: propensity score match 868

#### 869 **DISCUSSION**

870

871 This study examined the association between recent exposure to BPs and subsequent

872 COVID-19-related outcomes during the initial outbreak of the COVID-19 pandemic in the U.S.

873 Our findings demonstrate that amino-BP users experienced a three- to five-fold reduced

incidence of SARS-CoV-2 testing, COVID-19 diagnosis, and COVID-19-related

875 hospitalization during this period. This dramatic difference in outcomes was consistently

observed when comparing BP users to BP non-users in a propensity score-matched general

877 population, when comparing to users of other anti-resorptive bone medications, when further

restricting the latter cohort to female osteoporosis patients that were matched by

comorbidities within state of residence and by insurance type, and when comparing BP users to BP non-users stratified by use of other preventive medications. Therefore, although there

are confounding-related limitations inherent within retrospective studies, the consistency and

strength of our observed associations when using various methods to control for unmeasured

confounding support the contention that further prospective research should be performed to

determine the true magnitude of the potential immunomodulatory effects of BP use.

885 Our findings are consistent with previous observational studies, prior to the advent of COVID-886 19, that had reported associations between BP use and reduced incidence of pneumonia and

887 pneumonia-related mortality<sup>16,28,29</sup>. Accordingly, we observed in our population that BP use

888 was associated with decreased odds of medical services for acute bronchitis and pneumonia 889 during the second half of 2019. Taken together, these findings suggest that BPs may play a

protective role in respiratory tract infections from a variety of causes, including SARS-CoV-2.

891 Other recent retrospective studies have explored, to some extent, associations of antiresorptive medication use and COVID-19-related outcomes, albeit in much smaller patient 892 893 populations than were analysed here. One study found no differences in the COVID-19-894 related risk of hospitalization, ICU admission, and mortality among 1,997 female patients 895 diagnosed with COVID-19 who received anti-osteoporosis medication as compared to propensity score-matched COVID-19 patients who were not receiving such drugs<sup>30</sup>. This 896 897 study did not examine the incidence of COVID-19 among BP users, but it raises the 898 possibility that the subset of BP users who do develop sufficient pathology to be diagnosed 899 with COVID-19 may have a similar clinical course as BP non-users. Another retrospective 900 cohort study in Italy examining the association of oral amino-BP use and incidence of COVID-19-related hospitalization and mortality found no difference between BP users and BP non-901 users or users of non-BP anti-resorptive medications<sup>31</sup>. However, the overall incidence of 902 903 COVID-19 hospitalization in the primary cohort (151/126,370 patients, or 0.12%) of this study 904 was markedly lower than in the present analysis (3,710/900,732 patients, or 0.41%). A third 905 study examined the influence of various anti-osteoporosis drugs, including BPs, on the 906 cumulative incidence of COVID-19 in 2,102 patients with non-inflammatory rheumatic conditions that were compared to population estimates in the same geographic region<sup>32</sup>. In 907 908 this analysis, users of non-BP anti-resorptive medications and zoledronate, but not users of 909 oral BPs, had a lower incidence and relative risk of COVID-19 diagnosis and hospitalization. 910 The observations with zoledronate are consistent with the findings reported here. However, 911 we did not detect a significant impact of non-BP anti-resorptive medications in comparison to 912 BPs, and we found a robust association between oral BP use and lower odds of COVID-19 913 diagnosis and related hospitalization. The reason for these discrepancies is unclear but could 914 potentially reflect the large disparity in sample size between our study, which differed by more 915 than three orders of magnitude. A fourth study, which used Israeli insurance data to perform

916 an analysis involving two separate case-control matched cohorts to assess the risk of

917 COVID-19 hospitalizations when stratified by recent medication use, also found that the odds

918 COVID-19-related hospitalizations were lower among users of BPs, and ranged from an OR

919 of 0.705 (95%CI: 0.522 to 0.935) to 0.567 (95%CI:0.400 to 0.789)<sup>33</sup>.

The large size of our dataset allowed for a range of fully powered, stratified analyses to be 920 921 performed to explore the robustness of our findings and to address unmeasured confounding 922 factors and other sources of potential bias that can occur in retrospective studies using 923 insurance claims data. These sensitivity analyses included: (1) comparing the effect of BP 924 use and active control exposure, namely non-BP anti-resorptive bone medication; (2) further 925 reducing unmeasured confounding by restricting sensitivity analysis (1) to females older than 926 50 years, diagnosed with osteoporosis, matched within state and insurance type and 927 matched by comorbid conditions thought to impact COVID-19 severity; (3) assessing the 928 effect of BP-use on exploratory negative control outcomes (acute cholecystitis or pancreatitis 929 related inpatient/ER service); (4) evaluating the effect of BP-use on exploratory positive 930 control outcomes (other respiratory infections); and (5) evaluating the potential bias related to 931 the 'healthy adherer effect' by assessing (a) the effect of other preventive medication use on 932 COVID-19-related outcomes (as negative control exposures) and (b) the BP effect in users 933 and non-users of other preventive medications.

934 Notwithstanding, a retrospective analysis of insurance claims data has inevitable limitations

that should be considered. For example, the interpretation of our findings depends, in part, on
 the assumption that BP users and non-users had a similar risk of SARS-CoV-2 infection
 during the observation period. However, our dataset does not allow us to restrict patient
 observations to those with known exposure to SARS-CoV-2. Therefore, to minimize potential
 differences in SARS-CoV-2 exposure between BP users and non-users in our primary study

cohort, we implemented additional analytical strategies, including the sensitivity analyses
 discussed above, as well as matching BP users to BP non-users within geographical regions
 and an arific states

942 and specific states.

943 Despite these efforts, it is important to note that we have limited information to assess and 944 match BP users to BP non-users by sociodemographic risk factors, such as socio-economic 945 status and racial/ethnic minority status, that are associated with COVID-19 incidence and 946 mortality<sup>34,35</sup>. In particular, our dataset does not include information on patients' race or ethnic 947 background. This is a relevant limitation given the documented impact of racial/ethnic disparities on COVID-19 related outcomes. Specifically, Black/African-American and Hispanic 948 patients have been shown to have significantly higher test positivity rates<sup>36-39</sup> and severity of 949 disease at the time of testing<sup>39</sup>. Furthermore, Black/African American<sup>40</sup> and Hispanic patients 950 were found to have a higher incidence of COVID-19 infection<sup>37,41</sup> and odds of COVID-19 951 related hospital admission even after adjustment for comorbidities<sup>42</sup>, residence in a low-952 income area<sup>38</sup>, and insurance plan<sup>40,43,44</sup>. The greater COVID-19 burden in these groups is 953 954 likely due to a combination of systemic health inequities as well as a disproportionate representation among essential workers<sup>45,46</sup>, which could potentially increase their exposure 955 956 risk to SARS-CoV-2. In addition, there are known variations in the prevalence of osteoporosis between different racial groups, which could potentially result in disproportionate frequencies 957 of BP prescriptions<sup>47</sup>. The potential confounding due to socio-economic status and differential 958 959 prevalence of osteoporosis among racial/ethnic groups was addressed in our analysis of the 960 "Osteo-Dx-Rx" cohort where we compared BP users to non-users after restricting to female 961 patients with a diagnosis of osteoporosis, all using anti-resorptive bone medications, and matched by insurance type (proportion of Medicaid and dual Medicare/Medicaid users) as a 962

proxy for social-economic status (Figure 4B). Nevertheless, this strategy cannot rigorously
 rule out a potential under-representation of groups with higher sociodemographic risk factors
 among BP users that could have contributed to the observed decreased odds of COVID-19
 related outcomes in our primary analyses.

967 The potential bias introduced by a putative differential racial/ethnic group composition of BP 968 users versus BP non-users is at least partially addressed by a recent study of a large Californian cohort of female BP users<sup>48</sup>. Compared to the racial composition of California at-969 large (a proxy for BP non-users)<sup>49</sup>, BP users were predominantly Non-Hispanic White (36.5% 970 971 in California versus 53.3% among BP users). The proportions of Black/African-Americans 972 and Asians among BP users in that study were similar to those in California at-large, whereas 973 Hispanic patients represented a smaller percentage (24%) of BP users as compared to 974 Hispanics in the state's general population (39.4%). Based on these findings and the reported differential case rates of COVID-19 infections among racial groups in California<sup>50</sup>, we can 975 estimate the race-adjusted incidence of COVID-19 in populations reflecting the composition 976 of BP users and non-users<sup>48</sup> to be 1.7% and 2.1%, respectively. By comparison, in our study 977 978 the actual rate of COVID-19 diagnosis in the Western US was 2.5% for BP non-users versus 979 0.46% for BP users (Fig. 2), indicating that the uneven representation of ethnic/racial groups 980 cannot fully explain the observed differences in COVID-19 related outcomes. Moreover, we 981 note that racial/ethnic minorities are also under-represented among statin users<sup>51</sup>, but statinusers in our primary cohort had similar odds of COVID-19 hospitalization as statin non-users 982 (Figure 6B). Similarly, Black/African-Americans and Hispanics have lower utilization rates of 983 antidepressants<sup>52</sup> and Hispanics were also reported to be undertreated with antihypertensive 984 medications<sup>53</sup>. Our analysis of COVID-19-related outcomes among users and non-users of 985 986 antihypertensives showed a modest decrease in COVID-19 diagnosis and minimal 987 association with COVID-19-related hospitalization (Figure 6C). By contrast, users of 988 antidepressants had uniformly lower odds for both endpoints (Figures 6E), which is consistent with other recent studies<sup>33,54,55</sup>. However, regardless of the class of non-BP 989 990 preventive drugs analysed, concomitant BP use was consistently associated with 991 dramatically decreased odds of COVID-19 diagnosis and hospitalization as well as testing for 992 SARS-CoV-2 (Figure 6B-E).

Furthermore, specifically looking at the rate of SARS-CoV-2 testing in California<sup>37,38</sup> or nation-993 wide<sup>36</sup>, the proportions of different racial and ethnic groups among tested patients were 994 995 nearly identical to estimates for the state or national population. Thus, the observed 996 association between BP use and reduced testing for SARS-CoV-2 infection in our nation-997 wide cohorts is unlikely to be explained by potential differences in racial composition between 998 BP users and non-users. It also seems unlikely that exposure to BPs reduces the actual 999 incidence of SARS-CoV-2 infections. More likely, we propose that immune-modulatory effects 1000 of BPs may enhance the anti-viral response of BP users to SARS-CoV-2 and mitigate the 1001 development of symptoms. Milder or absent symptoms may have caused infected BP users 1002 to be less likely to seek testing. Moreover, because there was a nationwide shortage of 1003 available tests for SARS-CoV-2 during the observation period, patients needed to present 1004 with sufficiently severe disease symptoms to be eligible for testing, so fewer test-seeking BP 1005 users may have gualified. Consequently, a larger proportion of uncaptured 'silent' infections 1006 among BP users could explain why fewer diagnoses and hospitalizations were observed in 1007 this group.

1008The scarceness of COVID-19 tests combined with the strain on healthcare systems during1009the observation period could potentially have resulted in a misclassification bias whereby

- 1010 some patients may have been falsely diagnosed and/or hospitalized with COVID-19 without
- 1011 having received a confirmatory test. However, this bias should equally affect BP users and
- BP non-users and bias our findings towards the null. Relatedly, limited hospital capacity
- 1013 during the observation period could have led to rationing of inpatient hospital beds based on
- 1014 severity of disease and likelihood to survive <sup>56</sup>. However, matching by age and comorbidities
- 1015 should produce patient populations with similar characteristics used for rationing.
- 1016 A further limitation of our study is the lack of information on the result of COVID-19 tests
- 1017 received by patients. Therefore, as discussed above, the incidence and odds of COVID-19
- 1018 testing should not be viewed as a proxy for the rate of infection, but rather reflects the
- 1019 incidence of patients with severe enough symptoms or exposure to warrant testing. Another
- 1020 potential source of confounding is the possibility that some patients in our study were
- 1021 classified as BP non-users due to the absence of BP exposure during the pre-observation
- 1022 period but may have received a BP during the observation period. The potential
- 1023 misclassification of BP non-users, however, would bias towards the null hypothesis, and was 1024 only seen in 1.92% of the matched BP non-user population.
- 1025 An additional limitation is potential censoring of patients who died during the observation
- 1026 period, resulting in truncated insurance eligibility and exclusion based on the continuous
- 1027 insurance eligibility requirement. However, modelling the impact of censoring by using death
- 1028 rates observed in BP users and non-users in the first six months of 2020 and attributing all
- 1029 deaths as COVID-19-related did not significantly alter the decreased odds of COVID-19
- 1030 diagnosis in BP users (see **Appendix 3**).
- Additional limitations could also arise from comorbidities and misclassification bias due to the 1031 1032 diagnostic and procedure codes used to identify study outcomes. Regarding comorbidities, 1033 one potential limitation in both the primary and "Bone-Rx" cohorts is imbalanced comorbidity burden in BP user and non-user cohorts post-match. Table 1 shows there is differential 1034 1035 prevalence of most co-morbid diseases despite matched cumulative CCI score between BP 1036 user and BP non-user cohorts. However, this limitation is in part addressed given (1) these covariates were controlled for during regression analyses on study outcomes, and (2) that the 1037 1038 key study findings were also observed in the "Osteo-Dx-Rx" cohort, which matched based on 1039 individual comorbidities. Another potential limitation, misclassification bias of study outcomes, 1040 may be present due to the specific procedure/diagnostic codes used. For SARS-CoV-2 1041 testing, procedure codes were limited to those testing for active infection, and therefore 1042 observations could be missed if they were captured via antibody testing (CPT 86318, 86328). These codes were excluded a priori due to the focus on the symptomatic COVID-19 1043 1044 population. Furthermore, for the COVID-19 diagnosis and hospitalization outcomes, all 1045 events were identified using the ICD-10 code for lab-confirmed COVID-19 (U07.1), and 1046 therefore events with an associated diagnosis code for suspected COVID-19 (U07.2) were 1047 not included. This was done to have a more stringent algorithm when identifying COVID-19-1048 related events, and any impact of events identified using U07.2 is considered minimal, as 1049 previous studies of the early COVID-19 outbreak have found that U07.1 alone has a positive predictive value of 94%<sup>57</sup>, and for this study U07.1 captured 99.2%, 99.0%, and 97.5% of all 1050 COVID-19 patient-diagnoses for the primary, "Bone-Rx", and "Osteo-Dx-Rx" cohorts, 1051
- 1052 respectively.

One large potential bias to consider when comparing BP users to BP non-users is the healthy adherer effect, whereby adherence to drug therapy is associated with overall healthier behavior<sup>58,59</sup>. During the COVID-19 pandemic, this could have potentially resulted in differences between BP users and non-users such as, for example, adherence to mask-

1057 wearing, hand washing, or social distancing. However, if this effect accounted for the

- 1058 observed association between BP use and COVID-19-related outcomes, one would expect
- that BP users would have distinct odds for outcomes not predicted to be modulated by BPs 1059
- and/or that users of other preventive medications would show similar associations. The 1060
- 1061 sensitivity analysis of exploratory outcomes in our primary cohort indicates that BP users had
- 1062 decreased odds of any ER/inpatient visit for acute pancreatitis or acute cholecystitis during 1063 the observation period and decreased odds of ER/inpatient visits for acute pancreatitis prior
- 1064 to the COVID-19 pandemic in 2019 (Figure 5A). Plausible (non-exclusive) explanations for
- 1065 BP use association with decreased odds of these exploratory outcomes could be that: (1) BP
- users may be healthier at baseline; (2) BP users may have fewer risk factors for cholecystitis 1066
- and pancreatitis such as smoking<sup>60</sup>, which can modify COVID-19-related outcomes<sup>61</sup> but was 1067
- not captured in our propensity score matching; (3) BPs directly decreased the risk of 1068
- hypercalcemia-induced cholecystitis<sup>62</sup> and pancreatitis<sup>63</sup>; and/or (4) BP users may have 1069 1070 preferentially avoided or postponed use of medical services during the pandemic.
- 1071 Thus, the healthy adherer effect could have potentially contributed to the association of BP
- 1072 use with a lower incidence of exploratory outcomes. However, as discussed above, other
- 1073 preventive drug classes had a variable directional impact on the odds of COVID-19-related
- 1074 events, and sub-analyses within each drug class identified a strong association between
- 1075 concomitant BP use and decreased COVID-19-related events (Figures 6B-E). Taken
- 1076 together, these results suggest the observed association between BP use and COVID-19-
- 1077 related outcomes cannot solely be attributed to general behaviors associated with the healthy
- 1078 adherer effect.
- 1079 Notably, several observational studies have reported that the use of one of our comparator
- 1080 preventive drug classes, statins, is associated with a lower risk of mortality in hospitalized COVID-19 patients<sup>33 64,65</sup>. Indeed, statins are currently being tested as an adjunct therapy for
- 1081
- 1082 COVID-19 (NCT04380402). In our study population, statin use was associated with
- 1083 moderately decreased odds of SARS-CoV-2 testing and COVID-19 diagnosis, though at a much smaller magnitude than BPs, and was not consistently associated with reduced odds of
- 1084 1085 COVID-19-related hospitalizations. Our analysis did not address the clinical course of
- 1086 hospitalized patients, so these results are not necessarily conflicting. However, we note that
- in our primary cohort, as many as 15.2% of statin users concomitantly used a BP. Indeed, 1087
- within statin users, stratification by BP use revealed that the decreased odds of SARS-CoV-2 1088 1089 testing, COVID-19 diagnosis, and COVID-19-related hospitalizations remained regardless of
- 1090 statin use. Future studies on disease outcomes of hospitalized COVID-19 patients with 1091 antecedent use of BPs and statins alone or in combination are needed to clarify the effects of
- 1092 each drug class.
- 1093 The differential association of amino-BPs versus statins with COVID-19 related outcomes is 1094 somewhat unexpected because both target the same biochemical pathway, albeit at different enzymatic steps<sup>13</sup>. Statins block HMG-CoA reductase, the first and key rate-limiting enzyme 1095 in the mevalonate pathway<sup>66</sup>. Amino-BPs, which account for >99% of BPs prescribed in our 1096 1097 study, inhibit a downstream enzyme in the same metabolic pathway, farnesyl pyrophosphate synthase (FPPS), which converts geranyl pyrophosphate to farnesyl pyrophosphate<sup>67</sup>. FPPS 1098 1099 blockade disrupts protein prenylation and interferes with cytoskeletal rearrangement. membrane ruffling and vesicular trafficking in osteoclasts, thus preventing bone resorption <sup>68</sup>. 1100
- 1101 However, the anti-osteolytic activity of BPs per se is unlikely to account for the observed
- 1102 association between BP use and decreased incidence of COVID-19 and, more broadly,

respiratory tract infections, because patients treated with non-BP anti-resorptive bone health medications have higher odds of respiratory infections (<sup>16</sup> and this study).

1105 Another consequence of mevalonate pathway inhibition by both statins and amino-BPs is 1106 arrested endosomal maturation in antigen-presenting cells resulting in enhanced antigen presentation, T cell activation and humoral immunity<sup>13</sup>. In addition to this adjuvant-like effect, 1107 1108 FPPS blockade by amino-BPs causes the intracellular accumulation of the enzyme's substrate, isopentyl diphosphate (IPP), in myeloid leukocytes, which then stimulate Vy9Vδ2 T 1109 cells<sup>69,70</sup>, a large population of migratory innate lymphocytes in humans that are thought to 1110 1111 play an important role in host defense against infectious pathogens<sup>71</sup>, including SARS-CoV-1 1112 (ref.<sup>6</sup>). Experiments in humanized mice that were challenged with influenza viruses have shown that amino-BP-induced expansion of Vγ9Vδ2 T cells markedly improves viral control 1113 and mitigates disease severity and mortality<sup>8,72</sup>. However, since statins act upstream of FPPS, 1114 they are expected to inhibit IPP synthesis and, hence, have been shown to counteract the 1115 stimulatory effect of amino-BPs on Vy9Vδ2 T cells<sup>69</sup>. However, statins and amino-BPs do not 1116 1117 always antagonize each other. In vitro, concomitant statin and amino-BP use has been 1118 shown to be synergistic in inhibition of cancer cell growth, but mainly through downstream 1119 inhibition of geranylgeranyl transferases and subsequent protein prenylation by statins<sup>/3</sup>. The fact that the observed reduction in COVID-19-related outcomes in BP users was not altered 1120 1121 by concomitant statin use implies that the apparent protective effects of amino-BPs may not rely solely on stimulation of Vy9V $\delta$ 2 T cells. Indeed, in mice (in which BPs are not known to 1122 stimulate γδ T cells), BPs potently boost systemic and mucosal antiviral antibody and T cell 1123 responses<sup>14</sup>. This effect was also seen with non-nitrogenous BPs, which do not antagonize 1124 1125 FPPS<sup>14</sup>. In the present study, the number of patients who used non-nitrogenous BPs was less than 20, and therefore too small to determine any impact on COVID-19-related 1126 1127 outcomes. Nevertheless, in aggregate, these clinical and pre-clinical findings raise the 1128 possibility that BPs may exert (at least some) immuno-stimulatory effects by engaging an as 1129 yet unidentified additional pathway, regardless of their nitrogen content.

1130 Irrespective of the precise molecular mechanism of action, BPs have been reported to exert a plethora of effects on additional immune cell populations in humans, including NK cells<sup>74</sup> and 1131 regulatory T cells<sup>75</sup>. Moreover, studies of patients treated with amino-BPs found impaired 1132 chemotaxis and generation of reactive oxygen species by neutrophils<sup>76,77</sup>, a population of 1133 inflammatory cells whose dysregulated recruitment and activation are strongly implicated in 1134 the pathogenesis of severe COVID-19 (refs. <sup>78,79</sup>). Thus, BPs may provide therapeutic 1135 1136 benefits during infections with SARS-CoV-2 through modulation of both innate and adaptive 1137 immune responses. However, further studies to directly test these pleiotropic immuno-1138 modulatory effects of BPs and to assess their relative contribution to the host response to SARS-CoV-2 infection are needed. 1139

1140 We conclude that, despite a number of caveats discussed above, the association between 1141 BP use and decreased odds of COVID-19-related endpoints was robust in analyses 1142 comparing BP users to BP non-users. Large differences were detected regardless of age, 1143 sex or geographic location that remained robust when using multiple approaches to address 1144 unmeasured confounding and/or potential sources of bias. These retrospective findings 1145 strongly suggest that BPs should be considered for prophylactic and/or therapeutic use in 1146 individuals at risk of SARS-CoV-2 infection. However, additional well-controlled prospective 1147 clinical studies will be needed to rigorously assess whether the observed reduction in COVID-1148 19-related outcomes is directly caused by BPs and remains true in patient populations not 1149 commonly prescribed BPs.

A number of BPs are globally available as relatively affordable generics that are generally 1150 1151 well tolerated and could be prescribed for off-label use. Rare, but severe adverse events that have been linked to BP use include osteonecrosis of the jaw<sup>80</sup> and atypical femur fractures<sup>81</sup>, 1152 1153 which are both associated with long-term BP therapy. In this context, it is important to 1154 consider the relationship between the timing of BP exposure and COVID-19-related 1155 outcomes. Remarkably, BP users of alendronic acid whose prescription ended more than 1156 eight months prior to the observation period, as well as users who initiated alendronic acid therapy immediately preceding the observation period, had similarly decreased odds of 1157 1158 COVID-19-related outcomes (Figure 3B). A likely explanation for the observed long-term 1159 protection after transient BP use may be the well-documented retention of BPs in bone resulting in half-lives of several years<sup>20</sup>. Small amounts of stored BPs are continuously 1160 released. especially in regions of high bone turnover, which may result in persistent exposure 1161 1162 of immune cells either systemically or preferentially in bone marrow, a site of active immune cell trafficking<sup>82,83</sup> where anti-viral immune responses can be initiated in response to 1163 respiratory infection<sup>84</sup>. Thus, BP use at the time of infection may not be necessary for 1164 protection against COVID-19. Rather, our results suggest that prophylactic BP therapy may 1165 1166 be sufficient to achieve a potentially rapid and sustained immune modulation resulting in profound mitigation of the incidence and/or severity of infections by SARS-CoV-2. 1167

1168

1169

#### 1170 Acknowledgements

1171

1172 The authors acknowledge Ziqi Chen, Paris Pallis, and Flora Tierney for helpful discussions 1173 on the interpretation of study results.

1174

1175 We are grateful to Komodo Health who provided all data used in this analysis at no cost, and

- 1176 we thank Vicki Guan and Ben Cohen from Komodo Health for facilitating this research.
- 1177 Special thanks to Kantar Health (now Cerner Enviza) who provided the support needed to
- 1178 complete this study with no associated financial requirements.
- 1179 This study was supported by NIH grants AR068383 and AI155865 (to U.H.v.A.) and a CRI
- 1180 Irvington postdoctoral fellowship CRI2453 (to P.H.).
- 1181

#### 1182 Competing interests

- 1183 JT and TH are full-time employees of Cerner Health. UHvA is paid consultant of Avenge Bio,
- 1184 Beam Therapeutics, Bluesphere Bio, DNAlite, Gate Biosciences, Gentibio, Intergalactic,
- 1185 intrECate Biotherapeutics, Interon, Mallinckrodt Pharmaceuticals, Moderna, Monopteros
- 1186 Biotherapeutics, Morphic Therapeutics, Rubius, Selecta and SQZ.
- 1187
- 1188

#### 1189 **REFERENCES**

- 11901.Sultana J, Crisafulli S, Gabbay F, Lynn E, Shakir S, Trifiro G. Challenges for Drug Repurposing in1191the COVID-19 Pandemic Era. Front Pharmacol. 2020;11:588654.
- Roelofs AJ, Thompson K, Ebetino FH, Rogers MJ, Coxon FP. Bisphosphonates: molecular
   mechanisms of action and effects on bone cells, monocytes and macrophages. *Curr Pharm Des.* 2010;16(27):2950-2960.
- 11953.Dhesy-Thind S, Fletcher GG, Blanchette PS, et al. Use of Adjuvant Bisphosphonates and Other1196Bone-Modifying Agents in Breast Cancer: A Cancer Care Ontario and American Society of1197Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2017;35(18):2062-2081.
- 11984.Russell RG, Watts NB, Ebetino FH, Rogers MJ. Mechanisms of action of bisphosphonates:1199similarities and differences and their potential influence on clinical efficacy. Osteoporos Int.12002008;19(6):733-759.
- Brufsky A, Marti JLG, Nasrazadani A, Lotze MT. Boning up: amino-bisphophonates as
   immunostimulants and endosomal disruptors of dendritic cell in SARS-CoV-2 infection. *J Transl Med.* 2020;18(1):261.
- 12046.Poccia F, Agrati C, Castilletti C, et al. Anti-severe acute respiratory syndrome coronavirus1205immune responses: the role played by V gamma 9V delta 2 T cells. J Infect Dis.12062006;193(9):1244-1249.
- Hewitt RE, Lissina A, Green AE, Slay ES, Price DA, Sewell AK. The bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood gd
   T cells in response to aminobisphosphonates is inhibited by statins. *Clin Exp Immunol.* 2005;139(1):101-111.
- 12118.Tu W, Zheng J, Liu Y, et al. The aminobisphosphonate pamidronate controls influenza1212pathogenesis by expanding a gammadelta T cell population in humanized mice. J Exp Med.12132011;208(7):1511-1522.
- 12149.Favot CL, Forster C, Glogauer M. The effect of bisphosphonate therapy on neutrophil function:1215a potential biomarker. Int J Oral Maxillofac Surg. 2013;42(5):619-626.
- 10. Roelofs AJ, Coxon FP, Ebetino FH, et al. Fluorescent risedronate analogues reveal
   bisphosphonate uptake by bone marrow monocytes and localization around osteocytes in
   vivo. J Bone Miner Res. 2010;25(3):606-616.
- 121911.Rogers TL, Holen I. Tumour macrophages as potential targets of bisphosphonates. J Transl1220Med. 2011;9:177.
- 122112.Wolf AM, Rumpold H, Tilg H, Gastl G, Gunsilius E, Wolf D. The effect of zoledronic acid on the1222function and differentiation of myeloid cells. *Haematologica*. 2006;91(9):1165-1171.
- 122313.Xia Y, Xie Y, Yu Z, et al. The Mevalonate Pathway Is a Druggable Target for Vaccine Adjuvant1224Discovery. Cell. 2018;175(4):1059-1073 e1021.
- 122514.Tonti E, Jimenez de Oya N, Galliverti G, et al. Bisphosphonates target B cells to enhance1226humoral immune responses. Cell Rep. 2013;5(2):323-330.
- 122715.Lee P, Ng C, Slattery A, Nair P, Eisman JA, Center JR. Preadmission Bisphosphonate and1228Mortality in Critically III Patients. J Clin Endocrinol Metab. 2016;101(5):1945-1953.
- 1229 16. Sing CW, Kiel DP, Hubbard RB, et al. Nitrogen-Containing Bisphosphonates Are Associated
  1230 With Reduced Risk of Pneumonia in Patients With Hip Fracture. *J Bone Miner Res.*1231 2020;35(9):1676-1684.
- 123217.Suresh E, Pazianas M, Abrahamsen B. Safety issues with bisphosphonate therapy for1233osteoporosis. Rheumatology (Oxford). 2014;53(1):19-31.

1234 18. Sbrocchi AM, Forget S, Laforte D, Azouz EM, Rodd C. Zoledronic acid for the treatment of 1235 osteopenia in pediatric Crohn's disease. Pediatr Int. 2010;52(5):754-761. 1236 George S, Weber DR, Kaplan P, Hummel K, Monk HM, Levine MA. Short-Term Safety of 19. 1237 Zoledronic Acid in Young Patients With Bone Disorders: An Extensive Institutional Experience. 1238 J Clin Endocrinol Metab. 2015;100(11):4163-4171. 1239 Cremers S, Drake MT, Ebetino FH, Bilezikian JP, Russell RGG. Pharmacology of 20. 1240 bisphosphonates. Br J Clin Pharmacol. 2019;85(6):1052-1062. 1241 21. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-1242 CM and ICD-10 administrative data. Med Care. 2005;43(11):1130-1139. 1243 Parsons LS. Reducing Bias in a Propensity Score Matched-Pair sample Using Greedy Matching 22. 1244 techniques. . The Twenty-Sixth Annual SAS Users Group International Conference; 2001. 1245 CDC. United States COVID-19 Cases and Death by State Over Time. https://data.cdc.gov/Case-23. 1246 Surveillance/United-States-COVID-19-Cases-and-Deaths-by-State-o/9mfq-cb36/data. 1247 Published 2021. Accessed. 1248 24. Rosenthal N, Cao Z, Gundrum J, Sianis J, Safo S. Risk Factors Associated With In-Hospital 1249 Mortality in a US National Sample of Patients With COVID-19. JAMA Netw Open. 1250 2020;3(12):e2029058. 1251 Ladova K, Vlcek J, Vytrisalova M, Maly J. Healthy adherer effect - the pitfall in the 25. 1252 interpretation of the effect of medication adherence on health outcomes. J Eval Clin Pract. 1253 2014;20(2):111-116. 1254 26. Birkmeyer JD, Barnato A, Birkmeyer N, Bessler R, Skinner J. The Impact Of The COVID-19 1255 Pandemic On Hospital Admissions In The United States. *Health Affairs*. 2020;39(11):2010-2017. 1256 27. Jeffery MM, D'Onofrio G, Paek H, et al. Trends in Emergency Department Visits and Hospital 1257 Admissions in Health Care Systems in 5 States in the First Months of the COVID-19 Pandemic 1258 in the US. JAMA Internal Medicine. 2020;180(10). 1259 28. Colon-Emeric CS, Mesenbrink P, Lyles KW, et al. Potential mediators of the mortality reduction 1260 with zoledronic acid after hip fracture. J Bone Miner Res. 2010;25(1):91-97. 1261 29. Reid IR, Horne AM, Mihov B, Stewart A, Bastin S, Gamble GD. Effect of Zoledronate on Lower 1262 Respiratory Infections in Older Women: Secondary Analysis of a Randomized Controlled Trial. 1263 Calcified Tissue International. 2021;109(1):12-16. 1264 30. Atmaca A, Demirci I, Haymana C, et al. No association of anti-osteoporosis drugs with COVID-1265 19-related outcomes in women: a nationwide cohort study. Osteoporos Int. 2021. 1266 31. Degli Esposti L, Perrone V, Sangiorgi D, et al. The Use of Oral Amino-Bisphosphonates and 1267 Coronavirus Disease 2019 (COVID-19) Outcomes. J Bone Miner Res. 2021. 1268 Blanch-Rubio J, Soldevila-Domenech N, Tio L, et al. Influence of anti-osteoporosis treatments 32. 1269 on the incidence of COVID-19 in patients with non-inflammatory rheumatic conditions. Aging 1270 (Albany NY). 2020;12(20):19923-19937. 1271 33. Israel A, Schaffer AA, Cicurel A, et al. Identification of drugs associated with reduced severity 1272 of COVID-19 - a case-control study in a large population. *Elife.* 2021;10. 1273 34. Karmakar M, Lantz PM, Tipirneni R. Association of Social and Demographic Factors With 1274 COVID-19 Incidence and Death Rates in the US. JAMA Network Open. 2021;4(1). 1275 Rogers TN, Rogers CR, VanSant-Webb E, Gu LY, Yan B, Qeadan F. Racial Disparities in COVID-19 35. 1276 Mortality Among Essential Workers in the United States. World Med Health Policy. 2020. 1277 36. Kaufman HW, Niles JK, Nash DB. Disparities in SARS-CoV-2 Positivity Rates: Associations with 1278 Race and Ethnicity. Population Health Management. 2021;24(1):20-26.

- 127937.Escobar GJ, Adams AS, Liu VX, et al. Racial Disparities in COVID-19 Testing and Outcomes.1280Annals of Internal Medicine. 2021;174(6):786-793.
- 38. Jacobson M, Chang TY, Shah M, Pramanik R, Shah SB. Racial and Ethnic Disparities in SARS CoV-2 Testing and COVID-19 Outcomes in a Medicaid Managed Care Cohort. *American Journal* of Preventive Medicine. 2021.
- 128439.Rubin-Miller L. COVID-19 Racial Disparities in Testing, Infection, Hospitalization, and Death:1285Analysis of Epic Patient Data. <a href="https://www.kff.org/coronavirus-covid-19/issue-brief/covid-19-issue-brief/co
- 40. Azar KMJ, Shen Z, Romanelli RJ, et al. Disparities In Outcomes Among COVID-19 Patients In A Large Health Care System In California. *Health Affairs.* 2020;39(7):1253-1262.
- 129041.CDC. Risk for COVID-19 Infection, Hospitalization, and Death By Race/Ethnicity.1291https://www.cdc.gov/coronavirus/2019-ncov/covid-data/investigations-1292discovery/hospitalization-death-by-race-ethnicity.html#footnote03. Published 2021. Updated
- 1293 July 16, 2021. Accessed Septebmer 7, 2019.
- 42. Nau C, Bruxvoort K, Navarro RA, et al. COVID-19 Inequities Across Multiple Racial and Ethnic
  Groups: Results From an Integrated Health Care Organization. *Annals of Internal Medicine*.
  2021;174(8):1183-1186.
- 129743.Price-Haywood EG, Burton J, Fort D, Seoane L. Hospitalization and Mortality among Black1298Patients and White Patients with Covid-19. N Engl J Med. 2020;382(26):2534-2543.
- 129944.Muñoz-Price LS, Nattinger AB, Rivera F, et al. Racial Disparities in Incidence and Outcomes1300Among Patients With COVID-19. JAMA Network Open. 2020;3(9).
- 1301 45. Statistics UBoL. Labor force characteristics by race and ethnicity, 2018.
   1302 <u>https://www.bls.gov/opub/reports/race-and-ethnicity/2018/home.htm</u>. Published 2019.
   1303 Accessed September 7, 2021.
- 130446.Selden TM, Berdahl TA. COVID-19 And Racial/Ethnic Disparities In Health Risk, Employment,1305And Household Composition. Health Affairs. 2020;39(9):1624-1632.
- 47. QuickStats: Percentage\* of Adults Aged ≥50 Years with Osteoporosis,<sup>†</sup> by Race and Hispanic
  1307 Origin§ United States, 2017–2018. *MMWR Morbidity and Mortality Weekly Report.*1308 2021;70(19).
- 130948.Black DM, Geiger EJ, Eastell R, et al. Atypical Femur Fracture Risk versus Fragility Fracture1310Prevention with Bisphosphonates. New England Journal of Medicine. 2020;383(8):743-753.
- 131149.Bureau C. Race and Hispanic Origin. <a href="https://www.census.gov/quickfacts/CA">https://www.census.gov/quickfacts/CA</a>. Published 2019.1312Accessed September 7, 2019.
- 131350.Reitsma MB, Claypool AL, Vargo J, et al. Racial/Ethnic Disparities In COVID-19 Exposure Risk,1314Testing, And Cases At The Subcounty Level In California. Health Aff (Millwood).13152021;40(6):870-878.
- 131651.Salami JA, Warraich H, Valero-Elizondo J, et al. National Trends in Statin Use and Expenditures1317in the US Adult Population From 2002 to 2013: Insights From the Medical Expenditure Panel1318Survey. JAMA Cardiol. 2017;2(1):56-65.
- 131952.Chen J, Rizzo JA. Racial and ethnic disparities in antidepressant drug use. J Ment Health Policy1320Econ. 2008;11(4):155-165.
- 1321 53. Gu A, Yue Y, Desai RP, Argulian E. Racial and Ethnic Differences in Antihypertensive
   1322 Medication Use and Blood Pressure Control Among US Adults With Hypertension. *Circulation:* 1323 *Cardiovascular Quality and Outcomes.* 2017;10(1).

- 132454.Hoertel N, Sánchez-Rico M, Vernet R, et al. Association between antidepressant use and1325reduced risk of intubation or death in hospitalized patients with COVID-19: results from an1326observational study. *Molecular Psychiatry*. 2021.
- 132755.Zimniak M, Kirschner L, Hilpert H, et al. The serotonin reuptake inhibitor Fluoxetine inhibits1328SARS-CoV-2 in human lung tissue. Sci Rep. 2021;11(1):5890.
- 132956.Emanuel EJ, Persad G, Upshur R, et al. Fair Allocation of Scarce Medical Resources in the Time1330of Covid-19. N Engl J Med. 2020;382(21):2049-2055.
- 1331 57. Kluberg SA, Hou L, Dutcher SK, et al. Validation of diagnosis codes to identify hospitalized
  1332 COVID 19 patients in health care claims data. *Pharmacoepidemiology and Drug Safety*.
  1333 2022;31(4):476-480.
- 133458.Curtis JR, Larson JC, Delzell E, et al. Placebo adherence, clinical outcomes, and mortality in the1335women's health initiative randomized hormone therapy trials. *Med Care.* 2011;49(5):427-435.
- 133659.Dormuth CR, Patrick AR, Shrank WH, et al. Statin adherence and risk of accidents: a cautionary1337tale. *Circulation*. 2009;119(15):2051-2057.
- 133860.Tolstrup JS, Kristiansen L, Becker U, Gronbaek M. Smoking and risk of acute and chronic1339pancreatitis among women and men: a population-based cohort study. Arch Intern Med.13402009;169(6):603-609.
- 134161.Shastri MD, Shukla SD, Chong WC, et al. Smoking and COVID-19: What we know so far. *Respir*1342*Med.* 2021;176:106237.
- 134362.Gleeson D, Murphy GM, Dowling RH. Changes in serum calcium levels influence biliary calcium1344levels in humans. *Gastroenterology.* 1994;107(6):1812-1818.
- 134563.Kumar A, Kumar PG, Pujahari AK, Sampath S. Hypercalcemia Related Pancreatitis. Med J1346Armed Forces India. 2010;66(4):385-386.
- 134764.Lohia P, Kapur S, Benjaram S, Mir T. Association between antecedent statin use and severe1348disease outcomes in COVID-19: A retrospective study with propensity score matching. J Clin1349Lipidol. 2021.
- 135065.Zhang XJ, Qin JJ, Cheng X, et al. In-Hospital Use of Statins Is Associated with a Reduced Risk of1351Mortality among Individuals with COVID-19. Cell Metab. 2020;32(2):176-187 e174.
- 135266.Istvan ES, Deisenhofer J. Structural mechanism for statin inhibition of HMG-CoA reductase.1353Science. 2001;292(5519):1160-1164.
- Kavanagh KL, Guo K, Dunford JE, et al. The molecular mechanism of nitrogen-containing
  bisphosphonates as antiosteoporosis drugs. *Proceedings of the National Academy of Sciences*.
  2006;103(20):7829-7834.
- 135768.Russell RG. Bisphosphonates: mode of action and pharmacology. *Pediatrics.* 2007;119 Suppl13582:S150-162.
- 135969.Wang H, Sarikonda G, Puan KJ, et al. Indirect stimulation of human Vgamma2Vdelta2 T cells1360through alterations in isoprenoid metabolism. J Immunol. 2011;187(10):5099-5113.
- 136170.Nada MH, Wang H, Workalemahu G, Tanaka Y, Morita CT. Enhancing adoptive cancer1362immunotherapy with Vgamma2Vdelta2 T cells through pulse zoledronate stimulation. J1363Immunother Cancer. 2017;5:9.
- 136471.Ribot JC, Lopes N, Silva-Santos B. gammadelta T cells in tissue physiology and surveillance. Nat1365Rev Immunol. 2021;21(4):221-232.
- 136672.Zheng J, Wu WL, Liu Y, et al. The Therapeutic Effect of Pamidronate on Lethal Avian Influenza1367A H7N9 Virus Infected Humanized Mice. *PLoS One.* 2015;10(8):e0135999.
- 136873.Abdullah MI, Abed MN, Richardson A. Inhibition of the mevalonate pathway augments the<br/>activity of pitavastatin against ovarian cancer cells. *Scientific Reports.* 2017;7(1).

- 137074.Sarhan D, Leijonhufvud C, Murray S, et al. Zoledronic acid inhibits NFAT and IL-2 signaling1371pathways in regulatory T cells and diminishes their suppressive function in patients with1372metastatic cancer. Oncoimmunology. 2017;6(8):e1338238.
- 137375.Liu H, Wang SH, Chen SC, Chen CY, Lo JL, Lin TM. Immune modulation of CD4(+)CD25(+)1374regulatory T cells by zoledronic acid. *BMC Immunol.* 2016;17(1):45.
- 137576.Kuiper JW, Forster C, Sun C, Peel S, Glogauer M. Zoledronate and pamidronate depress1376neutrophil functions and survival in mice. *Br J Pharmacol.* 2012;165(2):532-539.
- 1377 77. Chadwick JW, Tenenbaum HC, Sun CX, Wood RE, Glogauer M. The effect of pamidronate
   1378 delivery in bisphosphonate-naive patients on neutrophil chemotaxis and oxidative burst. *Sci* 1379 *Rep.* 2020;10(1):18309.
- 138078.Meizlish ML, Pine AB, Bishai JD, et al. A neutrophil activation signature predicts critical illness1381and mortality in COVID-19. *Blood Adv.* 2021;5(5):1164-1177.
- 138279.Reusch N, De Domenico E, Bonaguro L, et al. Neutrophils in COVID-19. Front Immunol.13832021;12:652470.
- 138480.Migliorati CA, Siegel MA, Elting LS. Bisphosphonate-associated osteonecrosis: a long-term1385complication of bisphosphonate treatment. The Lancet Oncology. 2006;7(6):508-514.
- 138681.Saita Y, Ishijima M, Kaneko K. Atypical femoral fractures and bisphosphonate use: current1387evidence and clinical implications. *Therapeutic Advances in Chronic Disease.* 2015;6(4):185-1388193.
- 138982.Mazo IB, Honczarenko M, Leung H, et al. Bone marrow is a major reservoir and site of1390recruitment for central memory CD8+ T cells. *Immunity.* 2005;22(2):259-270.
- 1391 83. Zhao E, Xu H, Wang L, et al. Bone marrow and the control of immunity. *Cell Mol Immunol.*1392 2012;9(1):11-19.
- 139384.Hermesh T, Moltedo B, Moran TM, Lopez CB. Antiviral instruction of bone marrow leukocytes1394during respiratory viral infections. *Cell Host Microbe.* 2010;7(5):343-353.
- 1395
- 1396

1397 1398 1399 1400	Association Between Bisphosphonate Use and COVID-19-Related Outcomes
1401 1402	APPENDIX Table of Contents
1403	APPENDIX 1: Study Methods A2
1404	Section 1: Variable Assignment A2
1405	Section 2: Sensitivity Analyses MethodologiesA6
1406	Sensitivity Analysis 1A6
1407	Sensitivity Analysis 2
1408	Sensitivity Analysis 3A8
1409	Sensitivity Analysis 4
1410	Sensitivity Analysis 5A10
1411	APPENDIX 2: Additional Results
1412	APPENDIX 3: Deceased Sensitivity Analysis A23
1413	ADDITIONAL TABLES
1414	

1415

#### 1416 **APPENDIX 1: Study Methods**

#### 1417

1424

1427

1428

1429

1431

1432

1434

1435

1436

1437 1438

1443

1445

1446

1447

1448

1454

1457

1458

1461

### 1418Section 1: Variable Assignment1419

#### 1420 Outcomes

1421 The following details the identification algorithms and associated codes that were used to identify 1422 outcomes of interest, including COVID-19-related as well as the exploratory outcomes that were 1423 assessed during sensitivity analyses.

#### 1425 **Primary Outcomes**

#### 1426 SARS-CoV-2 Testing

- Any medical services claim with a procedure code indicating polymerase chain reaction (PCR) testing for active SARS-CoV-2 infection 3/1/2020-6/30/2020
  - Identified using HCPCS codes: 87635, 87636, 87637

#### 1430 <u>COVID-19 Diagnosis</u>

- Any medical services claim with a diagnosis code indicating COVID-19 3/1/2020-6/30/2020
- Identified using ICD-10 code U07.1x

#### 1433 <u>COVID-19-Related Hospitalization</u>

- Any medical services claim occurring in an inpatient setting with a diagnosis code indicating COVID-19 3/1/2020-6/30/2020
- Identified using ICD-10 code U07.1x

#### 1439 **Exploratory Outcomes** (study observation period)

### 1440 Acute Cholecystitis-Related Service

- Any medical services claim occurring in an emergency room/inpatient setting with a diagnosis indicating acute cholecystitis 3/1/2020-6/30/2020
  - Identified using ICD-10 codes K81.0x

#### 1444 Acute Pancreatitis-Related Service

- Any medical services claim occurring in an emergency room/inpatient setting with a diagnosis indicating acute pancreatitis 3/1/2020-6/30/2020
- Identified using ICD-10 codes K85.x

### 14491450 *Exploratory Outcomes* (2019)

#### 1451 Acute Cholecystitis-Related Service

- Any medical services claim occurring in an emergency room/inpatient setting with a diagnosis indicating acute cholecystitis 7/1/2019-12/31/2019
  - Identified using ICD-10 codes K81.0x

## 1455Acute Pancreatitis-Related Service1456- Any medical services claim or

- Any medical services claim occurring in an emergency room/inpatient setting with a diagnosis indicating acute pancreatitis 7/1/2019-12/31/2019
- Identified using ICD-10 codes K85.x
- 1459Acute Bronchitis-Related Service1460- Any medical services claim
  - Any medical services claim with a diagnosis indicating acute bronchitis 7/1/2019-12/31/2019
  - Identified using ICD-10 codes J20.x-J21.x

#### 1462 <u>Acute Pneumonia-Related Service</u>

Any medical services claim with a diagnosis indicating acute bronchitis 7/1/2019-12/31/2019

1464 1465 1466	- Identified using ICD-10 codes J13.x-J18.x
1467	Osteonecrosis
1468 1469 1470 1471 1472 1473 1474 1475	<ul> <li><u>Osteonecrosis</u></li> <li>Any medical services claim with a diagnosis indicating drug-induced osteonecrosis 1/1/2019-6/30/2020</li> <li>Identified using ICD-10 codes M87.1x</li> </ul>
1476	Drug-Exposure Assignment
1477 1478 1479 1480	The following details the identification algorithms and associated inputs used for drug-exposure classification of study subjects into users/non-users of bisphosphonates, non-bisphosphonates osteoporosis medications, statins, antihypertensives, non-insulin antidiabetics, and antidepressants.
1481 1482 1483 1484	<ul> <li><u>Bisphosphonates</u></li> <li>Any outpatient prescription or in-office dispensing 1/1/2019-2/29/2020</li> <li>Drugs included: alendronate, alendronic acid, etidronate, ibandronate, ibandronic acid, pamidronate, risedronate, and zoledronic acid</li> </ul>
1485 1486 1487 1488	<ul> <li><u>Non-BP Anti-Resorptive Bone Health Medications</u></li> <li>Any outpatient prescription or in-office dispensing 1/1/2019-2/29/2020</li> <li>Drugs included: denosumab, calcitonin, raloxifene, romosozumab-aqqg, teriparatide, abaloparatide, or bazedoxifene</li> </ul>
1489 1490 1491 1492	<ul> <li><u>Statins</u></li> <li>Any outpatient prescription 1/1/2019-2/29/2020</li> <li>Drugs included: pravastatin, rosuvastatin, fluvastatin, atorvastatin, pitavastatin, or simvastatin</li> </ul>
1493 1494 1495 1496 1497 1498 1499 1500 1501	<ul> <li><u>Antihypertensives</u></li> <li>Any non-ophthalmic, non-injection, outpatient prescription claim for a beta-blocker, calcium channel blocker, or renin angiotensin system antagonist 1/1/2019-2/29/2020</li> <li>Drugs included: acebutolol, atenolol, betaxolol, bisoprolol, carvedilol, labetalol, metoprolol, nadolol, nebivolol, penbutolol, pindolol, propranolol, timolol, amlodipine, diltiazem, felodipine, isradipine, nicardipine, nifedipine, nisoldipine, verapamil, aliskiren, azilsartan, benazepril, candesartan, captopril, enalapril, eprosartan, fosinopril, irbesartan, lisinopril, losartan, moexipril, olmesartan, perindopril, quinapril, ramipril, sacubitril, telmisartan, trandolapril, valsartan</li> </ul>
1502 1503 1504 1505 1506 1507 1508	<ul> <li><u>Antidiabetics</u> <ul> <li>Any outpatient prescription claim for a non-insulin antidiabetic medication 1/1/2019- 2/29/2020</li> <li>Drugs included: metformin, chlorpropamide, glimepiride, glipizide, glyburide, tolazamide, tolbutamide, pioglitazone, rosiglitazone, alogliptin, linagliptin, saxagliptin, sitagliptin, albiglutide, dulaglutide, exenatide, liraglutide, lixisenatide, semaglutide, nateglinide, repaglinide, canagliflozin, dapagliflozin, empagliflozin, ertugliflozin</li> </ul> </li> </ul>
1509 1510 1511 1512	<ul> <li><u>Antidepressants</u></li> <li>Any outpatient prescription claim for a selective serotonin reuptake inhibitor, norepinephrine- dopamine reuptake inhibitor, serotonin-norepinephrine reuptake inhibitor, tricyclic, tetracyclic, modified cyclic, or MAO inhibitor medication 1/1/2019-2/29/2020</li> </ul>

1513 1514 1515 1516 1517 1518 1519 1520	<ul> <li>Drugs included: amoxapine, bupropion, citalopram, clomipramine, desipramine, desvenlafaxine, doxepin, duloxetine, escitalopram, esketamine, fluoxetine, fluvoxamine, imipramine, isocarboxazid, levomilnacipran, maprotiline, mirtazapine, nefazodone, nortriptyline, paroxetine, phenelzine, protriptyline, selegiline, sertraline, tranylcypromine, trazodone, trimipramine, venlafaxine, vilazodone, vortioxetine</li> </ul>
1521 1522	Charlson Comorbidity Condition Assignment
1523 1524 1525 1526	The following ICD-10 codes were used to assign the CCI condition-specific indicators that are used to calculate the overall CCI score. The time period used for identification of condition-specific indicators was the entire pre-observation period (1/1/2019-2/29/2020).
1527	<u>Myocardial infarction</u>
1528	- ICD-10 codes: I21.x, I22.x, I25.2
1529	<u>Congestive heart failure</u>
1530	- ICD-10 codes: I09.9, I11.0, I13.0, I13.2, I25.5, I42.0, I42.5 - I42.9, I43.x, I50.x, P29.0
1531	<u>Peripheral vascular disease</u>
1532	- ICD-10 codes: I70.x, I71.x, I73.8, I73.9, I77.1, I79.0, I79.2, K55.1, K55.8, K55.9, Z95.8,
1533	Z95.9
1534	<u>Cerebrovascular disease</u>
1535	- ICD-10 codes: G45.x, G46.x, H34.0, I60.x-I69.x
1536	<u>Dementia</u>
1537	- ICD-10 codes: F00.x - F03.x, F05.1, G30.x, G31.1
1538	<u>Chronic pulmonary disease</u>
1539	- ICD-10 codes: I27.8, I27.9, J40.x - J47.x, J60.x - J67.x, J68.4, J70.1, J70.3
1540	<u>Rheumatologic disease</u>
1541	- ICD-10 codes: M05.x, M06.x, M31.5, M32.x - M34.x, M35.1, M35.3, M36.0
1542	<u>Peptic ulcer disease</u>
1543	- ICD-10 codes: K25.x-K28.x
1544	<u>Mild liver disease</u>
1545	- ICD-10 codes: B18.x, K70.0 - K70.3, K70.9, K71.3 - K71.5, K71.7, K73.x, K74.x, K76.0,
1546	K76.2 - K76.4, K76.8, K76.9, Z94.4
1547 1548 1549 1550	<ul> <li><u>Diabetes without chronic complications</u></li> <li>ICD-10 codes: E10.0, E10.1, E10.6, E10.8, E10.9, E11.0, E11.1, E11.6, E11.8, E11.9, E12.0, E12.1, E12.6, E12.8, E12.9, E13.0, E13.1, E13.6, E13.8, E13.9, E14.0, E14.1, E14.6, E14.8, E14.9</li> </ul>
1551	<u>Diabetes with chronic complications</u>
1552	- ICD-10 codes: E10.2 - E10.5, E10.7, E11.2 - E11.5, E11.7, E12.2 - E12.5, E12.7, E13.2 -
1553	E13.5, E13.7, E14.2 - E14.5, E14.7
1554	<u>Hemiplegia or paraplegia</u>
1555	- ICD-10 codes: G04.1, G11.4, G80.1, G80.2, G81.x, G82.x, G83.0 - G83.4, G83.9
1556	<u>Renal disease</u>
1557	- ICD-10 codes: I12.0, I13.1, N03.2 - N03.7, N05.2 - N05.7, N18.x, N19.x, N25.0, Z49.0 -
1558	Z49.2, Z94.0, Z99.2
1559	Any tumor, leukemia, or lymphoma

- 1560 \_ ICD-10 codes: C00.x - C26.x, C30.x - C34.x, C37.x - C41.x, C43.x, C45.x - C58.x, C60.x -1561 C76.x, C81.x - C85.x, C88.x, C90.x - C97.x 1562 Moderate or severe liver disease 1563 ICD-10 codes: I85.0, I85.9, I86.4, I98.2, K70.4, K71.1, K72.1, K72.9, K76.5, K76.6, K76.7 1564 Metastatic solid tumor ICD-10 codes: C77.x - C80.x 1565 -1566 AIDS/HIV 1567 ICD-10 codes: B20.x - B22.x, B24.x 1568 1569 1570 Additional Condition Covariate Assignment 1571 The following details the ICD-10 diagnosis codes that were used to identify comorbid conditions. 1572 For all condition indicators classification was based on all medical claims occurring during the pre-1573 observation period (1/1/2019-2/29/2020). 1574 1575 Osteoporosis: M80.x, M81.x, M82.x 1576 Cardiovascular Disease Overall: I3x.x-I4x.x, I20.x-I28.x, I50.x-I52.x 1577 Cancer: C0x.x - C9x.x 1578 Chronic Kidney Disease (CKD)/ End-Stage Renal Disease (ESRD): 112.0, 113.1, N03.2 - N03.7, N05.2 - N05.7, N18.x, N19.x, N25.0, Z49.0 - Z49.2, Z94.0, Z99.2 1579 1580 Chronic Obstructive Pulmonary Disease (COPD): J43.x, J44.x 1581 Dementia: F00.x - F03.x, F05.1, G30.x, G31.1 1582 Depression: F32.x, F33.x 1583 Dyslipidemia: E78.x 1584 Heart Failure: I50.x, I11.0xx, I13.0xx, I13.2xx 1585 HIV/AIDS: B20.x - B22.x, B24.x 1586 Hypertension: I10.x, I12.x, I11.9xx, I13.1xx 1587 Liver Disease: B18.x, K70.0 - K70.3, K70.9, K71.3 - K71.5, K71.7, K73.x, K74.x, K76.0, K76.2 -1588 K76.4, K76.8, K76.9, Z94.4, I85.0, I85.9, I86.4, I98.2, K70.4, K71.1, K72.1, K72.9, 1589 K76.5, K76.6, K76.7 1590 Obesity: E66.x 1591 Sickle Cell Disease: D57.x 1592 Stroke: I63.x 1593 Type 2 Diabetes: E11.x 1594 1595
- 1596
- 1597
- 1598

Sensitivit	y Analysis (1):	COVID-19-Related Outcomes in "Bone-Rx" Cohort
- Th by me	limiting all BP nor dications during t	nalysis was performed to validate the robustness of the primary findin n-users to those who had used non-BP anti-resorptive bone health the pre-observation period, thus yielding a more comparable compara receiving bone health medication therapy.
coi Ch Re me	nfounding that ma arlson Comorbidi striction of the pa dication prior to p	e-comparator cohort was done to reduce the impact of unmeasured by have occurred in the primary analysis due to the use of the derived ty Index composite score as the only comorbidity matching covariate. tient population to users of any non-BP anti-resorptive bone health propensity-score matching improves the probability of having drug nes with more similar clinical characteristics.
ma me	tched user/non-u	vsis, further, also acted to increase the robustness and reliability of the ser outcome comparisons since non-BP anti-resorptive bone health presented the smaller portion of the total bone health medication-user bx" cohort) and therefore were matched to their best BP-user pair.
- (		al and prescription insurance coverage 1/1/2019-6/30/2020
- F	atients with ≥1 o	claim for any anti-resorptive bone health medication 1/1/2019-2/29/20
- Pa on	e of the following:	ned into the BP user cohort if they had any claim 1/1/2019-2/29/2020 alendronate, alendronic acid, etidronate, ibandronate, ibandronic acio onate, and zoledronic acid.
col cal	nort if: (1) they ha citonin, raloxifene	ned into the non-BP any anti-resorptive bone health medication user d any claim 1/1/2019-2/29/2020 for one of the following: denosumab, e, romosozumab-aqqg, teriparatide, abaloparatide, or bazedoxifene; a ms 1/1/2019-2/29/2020.
Outcomes		
- SA	RS-CoV-2 testing	, COVID-19 diagnosis, and COVID-19-related hospitalizations
ge pe	n-BP anti-resorpt nder, insurance ty	ive bone health medication users were matched to BP users based or pe, any PCP visit in 2019, and comorbidity score. Matching was ch region separately (northeast, midwest, south, west) and then comb te alone.

# 1643 Sensitivity Analysis (2): COVID-19-Related Outcomes in "Osteo-Dx-Rx" Cohort

- 1645 Overview & Rationale
- 1646-The second sensitivity analysis was performed to further assess the robustness of the primary<br/>analysis findings by performing a highly restricted comparator cohort matching that included<br/>patients diagnosed and treated for osteoporosis ("Osteo-Dx-Rx" cohort).
- The relationship between COVID-19-related outcomes and BP-exposure was modelled after
   restricting anti-resorptive bone health medication users to those most likely to use BPs and
   matching BP non-users to BP users based on the presence of comorbid diagnoses within
   insurance type in four states with early COVID-19 spread representing each to further reduce
   confounding related to differences in demographic/clinical characteristics amongst BP
   users/non-users, confounding due to socioeconomic status (insurance type as proxy), and
   confounding due to differences in COVID-19-exposure risk based on geography.
- 1656

1663

1672

- 1657 Analysis Cohort Definition(s)
- 1658 Continuous medical and prescription insurance coverage 1/1/2019-6/30/2020
- Patients with ≥1 claim for any osteoporosis medication 1/1/2019-2/29/2020 who also met the following criteria: (i) female; (ii) age 51 or older; (iii) identified as residing in New York, Illinois, Florida, or California; and (iv) had ≥1 medical claim indicating a diagnosis of osteoporosis 1/1/2019-2/29/2020
- 1664 Exposures of Interest
- Patients were assigned into the BP user cohort if they had any claim 1/1/2019-2/29/2020 for
   one of the following: alendronate, alendronic acid, etidronate, ibandronate, ibandronic acid,
   pamidronate, risedronate, and zoledronic acid.
- Patients were assigned into the non-BP anti-resorptive bone health medication user cohort if:
  (1) they had any claim 1/1/2019-2/29/2020 for one of the following: denosumab, calcitonin,
  raloxifene, romosozumab-aqqg, teriparatide, abaloparatide, or bazedoxifene; and (2) they had
  no BP claims 1/1/2019-2/29/2020.

#### 1673 Outcomes

1674 - SARS-CoV-2 testing, COVID-19 diagnosis, and COVID-19-related hospitalizations 1675

#### 1676 Cohort Matching

- Non- anti-resorptive bone health medication users were matched to BP users based on age,
   PCP visit in 2019, and the presence of the following comorbid conditions (assigned using ICD-10 codes on claims occurring 1/1/2019-2/29/2020): cancer, chronic obstructive pulmonary
- 1680 disease, depression, dyslipidaemia, heart failure, hypertension, obesity, and type 2 diabetes.
- Matching was performed within each state when stratified by insurance type (commercial, dual, Medicaid, Medicare).

#### 1684 Statistical Analyses

- Multivariate logistic regression analyses, modelled separately for each COVID-19-related
   outcome of interest, were performed on the unmatched and matched samples after combining
   all patient observations. In addition to the key exposure variable (indicating BP user versus
   non-BP user), the regression model also included demographic/clinical covariate for age group,
   region, insurance type, PCP visit in 2019, and the following comorbid conditions: osteoporosis,
   cancer, chronic obstructive pulmonary disease, depression, dyslipidaemia, hypertension,
   obesity, type 2 diabetes, cardiovascular disease overall, sickle cell anemia, stroke, dementia,
- 1692 HIV/AIDS, chronic kidney disease/end-stage renal disease, and liver disease.
- 1693

#### 1694 Sensitivity Analysis (3): Association of BP-use with Exploratory Negative Control Outcomes

- 1696 Overview & Rationale
- 1697-The third sensitivity analysis was performed to assess the relationship between BP-use and<br/>outcomes not anticipated to be impacted by the pharmacological mechanism of BPs.
- This was performed by modelling the relationship between BP-exposure and other outcomes occurring (1) during the study observation, and (2) during the second half of 2019 among BP users with claims during the first half of 2019 and their previously-assigned BP non-user matched pair, in the primary, "*Bone-Rx*", and "*Osteo-Dx-Rx*" cohorts.
- Outcomes modelled included any acute cholecystitis-related or acute pancreatitis-related
   inpatient/emergency-room (ER) service, used as exploratory outcomes not predicted to be
   modulated by BP exposure to assess the validity of the core COVID-19-related outcomes.
- 1707 Analysis Cohort Definition(s)

1706

1720

1738

- Patients who were included in the primary analysis cohort for assessment of (1) outcomes occurring during the study observation period; for (2) outcomes assessed during the second half of 2019 the cohort was restricted to among BP users with claims during the first half of 2019 and their previously-assigned BP non-user matched pair.
- Patients who met all eligibility criteria to be included in the '*Bone-Rx*' cohort for assessment of (1) outcomes occurring during the study observation period; for (2) outcomes assessed during the second half of 2019 the cohort was restricted to among BP users with claims during the first half of 2019 and their previously-assigned BP non-user matched pair.
- Patients who met all eligibility criteria to be included in the '*Osteo-Dx-Rx*' cohort for
  assessment of (1) outcomes occurring during the study observation period; for (2) outcomes
  assessed during the second half of 2019 the cohort was restricted to among BP users with
  claims during the first half of 2019 and their previously-assigned BP non-user matched pair.

1721 Exposures of Interest

- For the primary analysis cohort, the BP user / BP non-user assignment was the same as used in the core analyses.
- For the "Bone-Rx" and "Osteo-Dx-Rx" cohorts, assignment was the same as used in those
   analyses stratifying medication users into BP users and non-BP medication users.

1727 Outcomes

- Any medical claim from an ER/inpatient setting with a diagnosis indicating acute cholecystitis
   (ICD-10 code K81.0x) occurring 3/1/2020-6/30/2020 (observation period)
- 1730- Any medical claim from an ER/inpatient setting with a diagnosis indicating acute pancreatitis1731(ICD-10 code K85.x) occurring 3/1/2020-6/30/2020 (observation period)
- Any medical claim from an ER/inpatient setting with a diagnosis indicating acute cholecystitis
   (ICD-10 code K81.0x) occurring 7/1/2019-12/31/2019 (2019)
- Any medical claim from an ER/inpatient setting with a diagnosis indicating acute pancreatitis
   (ICD-10 code K85.x) occurring 7/1/2019-12/31/2019 (2019)

1737 Cohort Matching

- NA; all cohorts previously matched.

# 17391740 Statistical Analyses

- Multivariate logistic regression analyses were performed using the same methodologies
   employed when assessing COVID-19 outcomes that were cohort-build-specific (i.e. followed
- employed when assessing COVID-19 outcomes that were cohort-build-specific (i.e. followed
   previous approach detailed for each respective cohort build) to assess the odds of acute
   cholecystitis or acute pancreatitis.

1745	Sensitivity Analysis (4):	Association of BP-use with Exploratory Positive Control Outcomes
1746		in 2019
1747		

- 1748 Overview & Rationale
- 1749 The fourth sensitivity analysis was performed to assess the relationship between BP-use and select outcomes occurring in 2019 to validate the theorized BP mechanism of action.
- This was performed by modelling the relationship between BP-exposure in the first half of
   2019 and other outcomes occurring during the second half of 2019 in the primary, "*Bone-Rx*",
   and "*Osteo-Dx-Rx*" cohorts, specifically medical services for other infectious respiratory
   conditions (acute bronchitis, pneumonia), used to assess the validity of the relationship
   between BP-use and decreased respiratory infections.
- 17561757 Analysis Cohort Definition(s)
- 17631764 Exposures of Interest
- 1765 In all cohort build variations, the previously-classified BP user cohorts were restricted to those 1766 with any BP-claim 1/1/2019-6/30/2019; all other previously-classified BP users were excluded.
- 1768 Outcomes
  - Any medical claim with a diagnosis indicating acute bronchitis (ICD-10 code J20.x-J21.x) occurring 7/1/2019-12/31/2019
    - Any medical claim with a diagnosis indicating pneumonia (ICD-10 code J13.x-J18.x) occurring 7/1/2019-12/31/2019

#### 1774 Cohort Matching

- NA; all cohorts previously matched.

#### 1777 Statistical Analyses

- Multivariate logistic regression analyses were performed using the same methodologies
   employed when assessing COVID-19-related outcomes that were cohort-build-specific (i.e.
   followed previous approach detailed for each respective cohort build) to assess the odds of
   acute bronchitis, or pneumonia.
- 1782 1783

1767

1769

1770 1771

1772

1773

1775

1776

# 1784Sensitivity Analysis (5):Association between use of Other Drug Classes and COVID-19-1785Related Outcomes

#### 1787 Overview & Rationale

1786

- 1788 The fifth sensitivity analysis was performed to assess whether the observed protective effect of 1789 BPs may be associated with general healthier behaviours in patients using any medication 1790 rather than specifically BP use. To assess this unmeasured confounding due to the healthy 1791 adherer effect, which is a type of potential bias where patients may have better outcomes due 1792 to their heathier behaviours and not better outcomes related to active drug treatment itself, the 1793 first sensitivity analysis evaluated the association between use of other preventive medications 1794 (statin, antihypertensive, antidiabetic, antidepressant) and COVID-19-related outcomes were 1795 evaluated.
- 1796 This was performed following the same techniques used in the primary cohort matching and 1797 analyses but when assigned drug exposure cohorts based on the use of statin, 1798 antihypertensive, antidiabetic, or antidepressant medications. The consistency of methods was 1799 done to permit direct comparison on the association between drug-use and COVID-19-related 1800 outcomes to assess whether the healthy adherer effect alone accounts for the decrease in the 1801 odds of COVID-19 outcomes when comparing BP users to non-users in the primary analysis. 1802 Evidence to support the contention that the HAE is a significant source of unmeasured 1803 confounding would necessitate that other drug classes display a similar statistically significant 1804 trend and/or magnitude when comparing drug users to non-users. Variability in directional 1805 impact, magnitude, and/or statistical significance would, conversely, suggest that the healthy 1806 adherer effect itself does not account for the differences seen when comparing BP users to BP 1807 non-users.
- 1808 This sensitivity analysis, additionally, also employed a unique nested-matching technique \_ 1809 wherein BP users were matched to BP non-users within the other-medication-class matched 1810 populations when stratified into the already matched but mutually exclusive user/non-user 1811 cohorts. This was performed to: (1) assess whether the decreased odds of COVID-19-realted 1812 outcomes in BP users compared to BP non-users was robust, even amongst cohorts 1813 displaying an increase in the odds of COVID-19-related outcomes; and (2) to assess whether 1814 the magnitude of decrease in odds of COVID-19-related outcomes amongst BP users 1815 compared to BP non-users seen in the primary analysis is impacted by use of other 1816 medication classes, including some that have also been identified as being associated with a 1817 reduced incidence and/or severity of COVID-19-related outcomes. 1818
- 1819 Analysis Cohort Definition(s)
- 1820 Continuous medical and prescription insurance coverage 1/1/2019-6/30/2020 (*all*)
- Patients with any claim for another drug class of interest (statin, antihypertensive, antidiabetic, antidepressant) medication 1/1/2019-2/29/2020 were classified users
- Among the propensity-score matched drug user/non-user cohorts, a further stratification and propensity-score matching based on BP use 1/1/2019-2/29/2020 to yield the following: (i) drug user/BP user matched to drug user/BP non-user, (ii) drug non-user/BP user matched to drug non-user/BP non-user.
- 1827

1828 Exposures of Interest

- Patients were assigned into the statin user cohort if they had any claim 1/1/2019-2/29/2020 for
   one of the following: pravastatin, rosuvastatin, fluvastatin, atorvastatin, pitavastatin, or
   simvastatin
- Patients were assigned into the antihypertensive user cohort if they had any non-ophthalmic,
   non-injection claim 1/1/2019-2/29/2020 for a beta blocker, calcium channel blocker, or renin angiotensin system antagonist medication.

- 1835 Patients were assigned into the antidiabetic user cohort if they had any claim 1/1/2019-1836 2/29/2020 for one of the following non-insulin medications: metformin, chlorpropamide, 1837 alimepiride, alipizide, alvburide, tolazamide, tolbutamide, pioalitazone, rosialitazone, alogliptin, 1838 linagliptin, saxagliptin, sitagliptin, albiglutide, dulaglutide, exenatide, liraglutide, lixisenatide, 1839 semaglutide, nateglinide, repaglinide, canagliflozin, dapagliflozin, empagliflozin, ertugliflozin 1840 Patients were assigned into the antidepressant user cohort if they had any claim 1/1/2019-\_ 2/29/2020 for one of the following: amoxapine, bupropion, citalopram, clomipramine, 1841 1842 designamine, desvenlafaxine, doxepin, duloxetine, escitalopram, esketamine, fluoxetine, 1843 fluvoxamine, imipramine, isocarboxazid, levomilnacipran, maprotiline, mirtazapine, 1844 nefazodone, nortriptyline, paroxetine, phenelzine, protriptyline, selegiline, sertraline, 1845 tranylcypromine, trazodone, trimipramine, venlafaxine, vilazodone, vortioxetine 1846 1847 Outcomes 1848 SARS-CoV-2 testing, COVID-19 diagnosis, and COVID-19-related hospitalizations 1849 1850 Cohort Matching 1851 For the larger drug-class analyses, matching was performed following the same methods used 1852 in the primary analysis; users were matched to non-users based on age, gender, insurance 1853 type, any PCP visit in 2019, and comorbidity score. Matching was performed within each 1854 region separately (northeast, midwest, south, west) and then combined, as well as in NY-state 1855 alone. 1856 Following this matching procedure, a nested BP user to BP non-user propensity score match 1857 was then performed on the aforementioned matched populations (i.e. within the separate and 1858 already matched statin user and statin non-user populations). Matching was performed using 1859 the same list of demographic/clinical characteristics, and was also performed within each 1860 region separately (northeast, midwest, south, west) and then combined as well as in NY-state 1861 alone. 1862 1863 Statistical Analyses 1864 Same as was performed for the primary analysis cohort. 1865
- 1866 1867

# 1868 APPENDIX 2: Additional Study Results; Cohort Characteristics Pre/Post Match

1869

#### 1870 Primary Analysis Study Population

1871

#### 1872 Northeast Region

1873 A total of 2,152,560 patients identified as residing in the northeast were included in the unmatched 1874 primary analysis cohort comparisons, of which 119,728 (5.6%) and 2,032,832 (94.4%) were classified 1875 as BP users and BP non-users, respectively (Table S2a). Prior to propensity-score matching, there 1876 were significant differences across all demographic and clinical characteristics. Compared to BP nonusers, BP users were older (97.5% age ≥51 versus 49.8%; p<0.001), predominantly female (90.5% 1877 1878 versus 57.4%; p<0.001), with higher comorbidity burden (mean CCI=0.93 versus 0.65; p<0.001), 1879 insured by Medicare (46.5% versus 18.0%; p<0.001), and have had a primary-care physician (PCP) 1880 visit in 2019 (58.3% versus 42.8%; p<0.001). Propensity-score matching yielded 119,494 BP users 1881 and 119,494 BP non-users with no significant differences across examined characteristics. A total of 1882 234 BP users from the northeast region in the unmatched primary analysis cohort were not assigned 1883 an applicable BP non-user pair during the matching procedure and were excluded from the matched 1884 BP user population.

1885

### 1886 Midwest Region

1887 A total of 1,467,802 patients identified as residing in the midwest were included in the unmatched 1888 primary analysis cohort comparisons, of which 75,967 (5.2%) and 1,391,835 (94.8%) were classified 1889 as BP users and BP non-users, respectively (Table S2b). Prior to propensity-score matching, there 1890 were significant differences across all demographic and clinical characteristics. Compared to BP non-1891 users, BP users were older (96.6% age ≥51 versus 44.0%; p<0.001), predominantly female (90.3% 1892 versus 57.1%; p<0.001), with higher comorbidity burden (mean CCI=0.99 versus 0.56; p<0.001), 1893 insured by Medicare (43.6% versus 14.5%; p<0.001), and have had a primary-care physician (PCP) 1894 visit in 2019 (62.2% versus 51.0%; p<0.001). Propensity-score matching yielded 75,901 BP users and 1895 75.901 BP non-users with no significant differences across examined characteristics. A total of 66 BP 1896 users from the midwest region in the unmatched primary analysis cohort were not assigned an 1897 applicable BP non-user pair during the matching procedure and were excluded from the matched BP 1898 user population.

1899

#### 1900 South Region

1901 A total of 3.042.604 patients identified as residing in the south were included in the unmatched 1902 primary analysis cohort comparisons, of which 160,886 (5.3%) and 2,881,718 (94.7%) were classified 1903 as BP users and BP non-users, respectively (Table S2c). Prior to propensity-score matching, there 1904 were significant differences across all demographic and clinical characteristics. Compared to BP non-1905 users, BP users were older (96.8% age ≥51 versus 39.2%; p<0.001), predominantly female (90.6% 1906 versus 57.4%; p<0.001), with higher comorbidity burden (mean CCI=0.86 versus 0.55; p<0.001), 1907 insured by Medicare (41.0% versus 11.3%; p<0.001), and have had a primary-care physician (PCP) 1908 visit in 2019 (66.1% versus 49.2%; p<0.001). Propensity-score matching yielded 159,704 BP users 1909 and 159,704 BP non-users with no significant differences across examined characteristics. A total of 1910 1,182 BP users from the south region in the unmatched primary analysis cohort were not assigned an 1911 applicable BP non-user pair during the matching procedure and were excluded from the matched BP 1912 user population.

1913

#### 1914 West Region

1915 A total of 1,243,637 patients identified as residing in the west were included in the unmatched primary

- analysis cohort comparisons, of which 95,470 (7.7%) and 1,148,167 (92.3%) were classified as BP
- users and BP non-users, respectively (**Table S2d**). Prior to propensity-score matching, there were
- 1918 significant differences across all demographic and clinical characteristics. Compared to BP non-users,

BP users were older (97.8% age ≥51 versus 43.5%; p<0.001), predominantly female (88.7% versus

1920 56.4%; p<0.001), with higher comorbidity burden (mean CCI=1.08 versus 0.66; p<0.001), insured by 1921 Medicare (43.5% versus 11.0%; p<0.001), and have had a primary-care physician (PCP) visit in 2019

Medicare (43.5% versus 11.0%; p<0.001), and have had a primary-care physician (PCP) visit in 2019 (67.7% versus 45.3%; p<0.001). Propensity-score matching yielded 95,267 BP users and 95,267 BP

- non-users with no significant differences across examined characteristics. A total of 203 BP users
- 1924 from the west region in the unmatched primary analysis cohort were not assigned an applicable BP
- 1925 non-user pair during the matching procedure and were excluded from the matched BP user 1926 population.
- 1927

## 1928 New York State

A total of 968,296 patients identified as residing in New York state were included in the unmatched primary analysis NY-state restricted cohort, of which 50,035 (5.2%) and 918,261 (94.8%) were

1931 classified as BP users and BP non-users, respectively (**Table S2e**). Prior to propensity-score

1932 matching, there were significant differences across all demographic and clinical characteristics.

1933 Compared to BP non-users, BP users were older (98.1% age  $\geq$ 51 versus 50.7%; p<0.001),

- 1934 predominantly female (90.9% versus 57.5%; p<0.001), with higher comorbidity burden (mean
- 1935 CCI=0.95 versus 0.63; p<0.001), insured by Medicare (57.7% versus 19.5%; p<0.001), and have had
- a primary-care physician (PCP) visit in 2019 (62.7% versus 45.3%; p<0.001). Propensity-score
- matching yielded 49,862 BP users and 49,862 BP non-users with no significant differences across
   examined characteristics. A total of 173 BP users from the unmatched New York state primary
- analysis cohort were not assigned an applicable BP non-user pair during the matching procedure and
   were excluded from the matched BP user population.
- 1941
- 1942

# 1943 Bone-Rx Analysis Study Population

# 1944 All Observations (all regions combined)

1945 A total of 502,895 patients were included in the unmatched "Bone-Rx" analysis cohort comparisons, of 1946 which 452,051 (89.9%) and 50,844 (10.1%) were classified as BP users and BP non-users, 1947 respectively (**Table S6a**). Prior to propensity-score matching, there were significant differences across 1948 all demographic and clinical characteristics. Compared to BP non-users, BP users were younger (47.9% 1949 age  $\geq$ 71 versus 55.2%; p<0.001), predominantly female (90.1% versus 87.2%; p<0.001), with a lower 1950 comorbidity burden (mean CCI=0.95 versus 1.99; p<0.001), with a larger proportion of patients 1951 residing in the west (21.1% versus 15.8%; p<0.001), a lower proportion covered by Medicare (43.4% 1952 versus 47.5%; p<0.001), and a lower proportion have had a primary-care physician (PCP) visit in 1953 2019 (63.8% versus 64.3%; p=0.009). Propensity-score matching yielded 50,498 BP users and 1954 50,498 BP non-users with no significant differences across examined characteristics. A total of 346 1955 BP non-users from the unmatched "Bone-Rx" analysis cohort were not assigned an applicable BP 1956 user pair during the matching procedure and were excluded from the matched BP non-user 1957 population.

1958

# 1959 Northeast Region

1960 A total of 135,867 patients identified as residing in the northeast were included in the unmatched 1961 "Bone-Rx" analysis cohort comparisons, of which 119,728 (88.1%) and 16,139 (11.9%) were 1962 classified as BP users and BP non-users, respectively (Table S6b). Prior to propensity-score 1963 matching based on BP-use, there were significant differences across all demographic and clinical 1964 characteristics except for any PCP visit in 2019 (p=0.95). Compared to BP non-users, BP users were 1965 younger (48.1% age  $\geq$ 71 versus 54.8%; p<0.001), predominantly female (90.5% versus 87.5%; 1966 p<0.001), with a lower comorbidity burden (mean CCI=0.93 versus 1.97; p<0.001), and a lower 1967 proportion insured by Medicare (46.5% versus 54.0%; p<0.001). Propensity-score matching yielded

- 1968 15,993 BP users and 15,993 BP non-users with no significant differences across examined
- 1969 characteristics. A total of 146 BP non-users from the northeast region in the unmatched "*Bone-Rx*"

1970 analysis cohort were not assigned an applicable BP user pair during the matching procedure and

- 1971 were excluded from the matched BP non-user population.
- 1972

## 1973 Midwest Region

1974 A total of 85,391 patients identified as residing in the midwest were included in the unmatched "Bone-1975 Rx" analysis cohort comparisons, of which 75,967 (89.0%) and 9,424 (11.0%) were classified as BP 1976 users and BP non-users, respectively (Table S6c). Prior to propensity-score matching, there were significant differences across all demographic and clinical characteristics. Compared to BP non-users, 1977 1978 BP users were younger (43.0% age  $\geq$ 71 versus 54.1%; p<0.001), predominantly female (90.3%) 1979 versus 86.1%; p<0.001), with a lower comorbidity burden (mean CCI=0.99 versus 2.12; p<0.001), had 1980 a lower proportion insured by Medicare (43.6% versus 51.9%; p<0.001), with a lower proportion 1981 having a primary-care physician (PCP) visit in 2019 (62.2% versus 64.7%; p<0.001). Propensity-score 1982 matching vielded 9.360 BP users and 9.360 BP non-users with no significant differences across 1983 examined characteristics. A total of 64 BP non-users from the midwest region in the unmatched 1984 "Bone-Rx" analysis cohort were not assigned an applicable BP user pair during the matching 1985 procedure and were excluded from the matched BP non-user population.

1986

1999

## 1987 South Region

1988 A total of 178,118 patients identified as residing in the south were included in the unmatched "Bone-1989 Rx" analysis cohort comparisons, of which 160,886 (90.3%) and 17,232 (9.7%) were classified as BP 1990 users and BP non-users, respectively (Table S6d). Prior to propensity-score matching, there were 1991 significant differences across all demographic and clinical characteristics except for any PCP visit in 1992 2019 (p=0.45). Compared to BP non-users, BP users were younger (46.6% age  $\geq$ 71 versus 53.3%; 1993 p<0.001), predominantly female (90.6% versus 88.1%; p<0.001), with a lower comorbidity burden 1994 (mean CCI=0.86 versus 1.86; p<0.001), and a lower proportion insured by Medicare (41.0% versus 1995 44.0%; p<0.001). Propensity-score matching yielded 17,140 BP users and 17,140 BP non-users with 1996 no significant differences across examined characteristics. A total of 92 BP non-users from the south 1997 region in the unmatched "Bone-Rx" analysis cohort were not assigned an applicable BP user pair 1998 during the matching procedure and were excluded from the matched BP non-user population.

# 2000 West Region

2001 A total of 103,519 patients identified as residing in the west were included in the unmatched "Bone-Rx" 2002 analysis cohort comparisons, of which 95,470 (92.2%) and 8,049 (7.8%) were classified as BP users 2003 and BP non-users, respectively (Table S6e). Prior to propensity-score matching, there were 2004 significant differences across all demographic and clinical characteristics. Compared to BP non-users, 2005 BP users were younger (54.1% age  $\geq$ 71 versus 61.6%; p<0.001), predominantly female (88.7%) 2006 versus 86.2%; p<0.001), with a lower comorbidity burden (mean CCI=1.08 versus 2.17; p<0.001), insured by Medicare (43.5% versus 36.9%; p<0.001), with a lower proportion having a primary-care 2007 2008 physician (PCP) visit in 2019 (67.7% versus 71.6%; p<0.001). Propensity-score matching yielded 2009 8,005 BP users and 8,005 BP non-users with no significant differences across examined 2010 characteristics. A total of 44 BP non-users from the west region in the unmatched "Bone-Rx" analysis cohort were not assigned an applicable BP user pair during the matching procedure and were

- 2011 cohort were not assigned an applicable BP user pair during 2012 excluded from the matched BP non-user population.
- 2012
- 2014 New York State

A total of 57,397 patients identified as residing in New York state were included in the unmatched

2016 "Bone-Rx" analysis NY-state restricted cohort, of which 50,035 (87.2%) and 7,362 (12.8%) were

2017 classified as BP users and BP non-users, respectively (**Table S6f**). Prior to propensity-score matching,

- 2018 there were significant differences across all demographic and clinical characteristics except for any
- 2019 PCP visit in 2019 (p=0.35). Compared to BP non-users, BP users were younger (53.2% age  $\geq$ 11

comorbidity burden (mean CCI=0.95 versus 1.81; p<0.001), and a higher proportion insured by</li>
Medicaid (18.3% versus 13.8%; p<0.001). Propensity-score matching yielded 7,254 BP users and</li>
7,254 BP non-users with no significant differences across examined characteristics. A total of 108 BP
non-users from the unmatched New York state "*Bone-Rx*" analysis cohort were not assigned an
applicable BP user pair during the matching procedure and were excluded from the matched BP nonuser population.

2027

### 2028 Osteo-Dx-Rx Analysis Study Population

2029 A total of 60.043 female patients age  $\geq$ 51 with a diagnosis of osteoporosis who resided in New York 2030 (NY), Illinois (IL), Florida (FL), or California (CA) were included in the unmatched "Osteo-Dx-Rx" 2031 analysis cohort comparison, of which 51,651 (86.0%) and 8,392 (14.0%) were classified as BP users 2032 and BP non-users, respectively (Table S7). Prior to propensity-score matching, which was performed 2033 within each state by insurance type, there were significant differences across all demographic and 2034 clinical characteristics except the proportion of patients with a diagnosis of dyslipidemia (p=0.08). 2035 Compared to BP non-users, BP users were younger (18.8% age ≥81 versus 26.0%; p<0.001), with a larger proportion of patients residing in CA (42.5% versus 30.5%; p<0.001), insured by Medicaid (23.1% 2036 2037 versus 21.3%; p<0.001), have had a primary-care physician (PCP) visit in 2019 (77.4% versus 71.1%; 2038 p<0.001), had a higher proportion with a diagnosis of obesity (11.2% versus 9.6%; p<0.001, and had 2039 a lower proportion diagnosed with the following: cancer (11.8% versus 19.4%; p<0.001), COPD (10.1% 2040 versus 16.2%; p<0.001), heart failure (6.1% versus 10.7%; p<0.001), hypertension (58.0% versus 2041 60.9%; p<0.001), type 2 diabetes (25.6% versus 26.9%; p<0.01), and depression (13.9% versus 2042 15.2%; p<0.001). Propensity-score matching yielded 7,949 BP users and 7,949 BP non-users with no 2043 significant differences across examined characteristics. A total of 443 BP non-users from the 2044 unmatched "Osteo-Dx-Rx" analysis cohort were not assigned an applicable BP user pair during the 2045 matching procedure and were excluded from the matched BP non-user population.

2046

2047

2048 2049

## 2050 Statin User/Non-User Analysis

#### 2051 Statin-Use Comparison: All Observations (all regions combined)

2052 A total of 7,906,603 patients were included in the unmatched analysis cohort comparison of statin-use, 2053 of which 1,503,395 (19.0%) and 6,403,208 (81.0%) were classified as statin users and statin non-2054 users, respectively (Table S8a). Prior to propensity-score matching, there were significant differences 2055 across all demographic and clinical characteristics. Compared to statin non-users, statin users were 2056 older (87.9% age  $\geq$ 51 versus 37.1%; p<0.001), with a higher proportion of males (41.1% versus 40.9%; p<0.001), from the northeast (29.7% versus 26.6%; p<0.001), with higher comorbidity burden 2057 2058 (mean CCI=1.15 versus 0.49; p<0.001), insured by Medicare (32.7% versus 11.3%; p<0.001), and have had a primary-care physician (PCP) visit in 2019 (66.1% versus 44.1%; p<0.001). Propensity-2059 2060 score matching yielded 1,436,300 statin users and 1,436,300 statin non-users with no significant 2061 differences across age group, region, insurance type, and having had any PCP visit in 2019. The final 2062 matched population did, however, display statistically significant differences between statin users and 2063 statin non-users for gender (58.7% versus 58.4% male; p<0.001) and mean CCI (1.11 versus 1.12; 2064 p<0.001). These differences, however, are small in magnitude, and were statistically significant due to 2065 the underlying statistical power associated with the large sample size. A total of 67,095 statin users 2066 from the unmatched analysis cohort were not assigned an applicable statin non-user pair during the 2067 matching procedure and were excluded from the matched statin user population.

- 2068
- 2069 Statin-Use Comparison: New York State

A total of 968,296 patients identified as residing in New York state were included in the unmatched

analysis cohort comparison of statin-use, of which 206,301 (21.3%) and 761,995 (78.7%) were

2072 classified as statin users and statin non-users, respectively (**Table S8b**). Prior to propensity-score

2073 matching, there were significant differences across all demographic and clinical characteristics. 2074 Compared to statin non-users, statin users were older (90.3% age  $\geq$ 51 versus 43.1%; p<0.001), with a 2075 higher proportion of males (42.0% versus 40.4%; p<0.001), with higher comorbidity burden (mean 2076 CCI=1.17 versus 0.51; p<0.001), insured by Medicare (47.4% versus 14.5%; p<0.001), and have had 2077 a primary-care physician (PCP) visit in 2019 (64.0% versus 41.3%; p<0.001). Propensity-score 2078 matching yielded 185,536 statin users and 185,536 statin non-users with no significant differences 2079 across age group, gender, insurance type, and having had any PCP visit in 2019. The final matched 2080 population did, however, display statistically significant differences between statin users and statin 2081 non-users for mean CCI (1.06 versus 1.08; p<0.001). This difference, however, is small in magnitude, 2082 and was statistically significant due to the underlying statistical power associated with the large 2083 sample size. A total of 20,765 statin users from the unmatched analysis cohort were not assigned an 2084 applicable statin non-user pair during the matching procedure and were excluded from the matched 2085 statin user population.

2086

## 2087 BP-Use Comparison within Statin Users: All Regions Combined

2088 Of the 1,436,300 statin users from the statin user/non-user propensity-score matching analysis, a total 2089 of 217,981 (15.2%) and 1,218,319 (84.8%) were classified as BP users and BP non-users, 2090 respectively (**Table S8c**). Prior to propensity-score matching based on BP-use, there were significant 2091 differences across all demographic and clinical characteristics except for any PCP visit in 2019 2092 (p=0.27). Compared to BP non-users, BP users were older (98.9% age  $\geq$ 51 versus 85.3%; p<0.001), 2093 with a higher proportion of females (90.1% versus 53.1%; p<0.001), from the west (21.7% versus 2094 14.0%; p<0.001), with lower comorbidity burden (mean CCI=0.95 versus 1.13; p<0.001), and insured 2095 by Medicare (50.8% versus 29.7%; p<0.001). Propensity-score matching yielded 213,480 BP users 2096 and 213,480 BP non-users with no significant differences across examined characteristics. A total of 2097 4,501 BP users were not assigned an applicable BP non-user pair during the matching procedure and 2098 were excluded from the matched BP user population.

2099

## 2100 BP-Use Comparison within Statin Users: New York State

2101 Of the 185,536 statin users from the statin user/non-user propensity-score matching analysis on 2102 patients residing in New York state, a total of 23,863 (12.9%) and 161,673 (87.1%) were classified as 2103 BP users and BP non-users, respectively (Table S8d). Prior to propensity-score matching based on 2104 BP-use, there were significant differences across all demographic and clinical characteristics except 2105 for any PCP visit in 2019 (p=0.33). Compared to BP non-users, BP users were older (99.3% age ≥51 2106 versus 87.7%; p<0.001), with a higher proportion of females (91.2% versus 53.3%; p<0.001), with 2107 lower comorbidity burden (mean CCI=0.92 versus 1.08; p<0.001), and insured by Medicare (66.4% 2108 versus 41.9%; p<0.001). Propensity-score matching yielded 23,736 BP users and 23,736 BP non-2109 users with no significant differences across examined characteristics. A total of 127 BP users were 2110 not assigned an applicable BP non-user pair during the matching procedure and were excluded from 2111 the matched BP user population.

2112

#### 2113 BP-Use Comparison within Statin Non-users: All Regions Combined

Of the 1,436,300 statin non-users from the statin user/non-user propensity-score matching analysis, a total of 124,843 (8.7%) and 1,311,457 (91.3%) were classified as BP users and BP non-users,

- respectively (**Table S8e**). Prior to propensity-score matching based on BP-use, there were significant differences across all demographic and clinical characteristics. Compared to BP non-users, BP users
- were older (98.7% age  $\geq$ 51 versus 86.3%; p<0.001), with a higher proportion of females (89.6%
- 2119 versus 55.5%; p<0.001), from the west (21.4% versus 14.6%; p<0.001), with lower comorbidity
- 2120 burden (mean CCI=1.02 versus 1.13; p<0.001), insured by Medicare (45.8% versus 31.7%; p<0.001),
- and have had a primary-care physician (PCP) visit in 2019 (71.7% versus 63.9%; p<0.001).
- 2122 Propensity-score matching yielded 124,716 BP users and 124,716 BP non-users with no significant
- differences across examined characteristics. A total of 127 BP users were not assigned an applicable
- BP non-user pair during the matching procedure and were excluded from the matched BP user
- 2125 population.

#### 2126

#### 2127 BP-Use Comparison within Statin Non-users: New York State

2128 Of the 185,536 statin non-users from the statin user/non-user propensity-score matching analysis on 2129 patients residing in New York state, a total of 14,546 (7.8%) and 170,990 (92.2%) were classified as 2130 BP users and BP non-users, respectively (**Table S8f**). Prior to propensity-score matching based on 2131 BP-use, there were significant differences across all demographic and clinical characteristics. 2132 Compared to BP non-users, BP users were older (99.2% age  $\geq$ 51 versus 88.4%; p<0.001), with a 2133 higher proportion of females (90.6% versus 55.1%; p<0.001), with lower comorbidity burden (mean 2134 CCI=0.95 versus 1.09; p<0.001), insured by Medicare (59.7% versus 43.7%; p<0.001), and have had 2135 a primary-care physician (PCP) visit in 2019 (70.5% versus 59.4%; p<0.001). Propensity-score 2136 matching yielded 14,521 BP users and 14,521 BP non-users with no significant differences across 2137 examined characteristics. A total of 25 BP users were not assigned an applicable BP non-user pair during the matching procedure and were excluded from the matched BP user population.

2138 2139

2140

#### 2141 Antihypertensive User/Non-User Analysis

#### 2142 Antihypertensive-Use Comparison: All Observations (all regions combined)

2143 A total of 7,906,603 patients were included in the unmatched analysis cohort comparison of 2144 antihypertensive-use, of which 2,101,120 (26.6%) and 5,805,483 (73.4%) were classified as 2145 antihypertensive users and antihypertensive non-users, respectively (**Table S9a**). Prior to propensity-2146 score matching, there were significant differences across all demographic and clinical characteristics. 2147 Compared to antihypertensive non-users, antihypertensive users were older (80.8% age  $\geq 51$  versus 2148 34.4%; p<0.001), with a higher proportion of females (60.4% versus 58.6%; p<0.001), from the 2149 northeast (27.8% versus 27.0%; p<0.001), with higher comorbidity burden (mean CCI=1.13 versus 2150 0.43; p<0.001), insured by Medicare (29.5% versus 10.3%; p<0.001), and have had a primary-care 2151 physician (PCP) visit in 2019 (64.2% versus 39.2%; p<0.001). Propensity-score matching yielded 2152 1,786,001 antihypertensive users and 1,786,001 antihypertensive non-users with no significant 2153 differences across age group, gender, region, insurance type, and having had any PCP visit in 2019. 2154 The final matched population did, however, display statistically significant difference between 2155 antihypertensive users and antihypertensive non-users for mean CCI (1.64 versus 1.66; p<0.05). This 2156 difference, however, is small in magnitude, and was statistically significant due to the underlying 2157 statistical power associated with the large sample size. A total of 315,119 antihypertensive users from 2158 the unmatched analysis cohort were not assigned an applicable antihypertensive non-user pair during 2159 the matching procedure and were excluded from the matched antihypertensive user population.

2160

#### 2161 Antihypertensive-Use Comparison: New York State

2162 A total of 968.296 patients identified as residing in New York state were included in the unmatched 2163 analysis cohort comparison of antihypertensive-use, of which 258,652 (26.7%) and 709,644 (73.3%) 2164 were classified as antihypertensive users and antihypertensive non-users, respectively (Table S9b). 2165 Prior to propensity-score matching, there were significant differences across all demographic and 2166 clinical characteristics. Compared to antihypertensive non-users, antihypertensive users were older (86.6% age  $\geq$ 51 versus 40.9%; p<0.001), with a higher proportion of females (59.4% versus 59.2%; 2167 2168 p=0.02), with higher comorbidity burden (mean CCI=1.17 versus 0.46; p<0.001), insured by Medicare 2169 (45.9% versus 12.6%; p<0.001), and have had a primary-care physician (PCP) visit in 2019 (62.4% 2170 versus 40.3%; p<0.001). Propensity-score matching yielded 203,624 antihypertensive users and 2171 203,624 antihypertensive non-users with no significant differences across examined characteristics. A 2172 total of 55,028 antihypertensive users from the unmatched analysis cohort were not assigned an 2173 applicable antihypertensive non-user pair during the matching procedure and were excluded from the 2174 matched antihypertensive user population.

2175

#### 2176 BP-Use Comparison within Antihypertensive Users: All Regions Combined

2177 Of the 1,786,001 antihypertensive users from the antihypertensive user/non-user propensity-score 2178 matching analysis, a total of 206,613 (11.6%) and 1,579,388 (88.4%) were classified as BP users and 2179 BP non-users, respectively (**Table S9c**), Prior to propensity-score matching based on BP-use, there 2180 were significant differences across all demographic and clinical characteristics. Compared to BP non-2181 users, BP users were older (98.2% age  $\geq$ 51 versus 75.2%; p<0.001), with a higher proportion of 2182 females (89.7% versus 56.6%; p<0.001), from the west (22.0% versus 14.3%; p<0.001), with lower comorbidity burden (mean CCI=0.94 versus 0.95; p=0.02), insured by Medicare (48.6% versus 24.4%; 2183 2184 p<0.001), and have not had a primary-care physician (PCP) visit in 2019 (41.2% versus 40.1%; 2185 p<0.001). Propensity-score matching yielded 204,396 BP users and 204,396 BP non-users with no 2186 significant differences across examined characteristics. A total of 2,217 BP users were not assigned 2187 an applicable BP non-user pair during the matching procedure and were excluded from the matched 2188 BP user population.

2189

## 2190 BP-Use Comparison within Antihypertensive Users: New York State

2191 Of the 203,624 antihypertensive users from the antihypertensive user/non-user propensity-score 2192 matching analysis on patients residing in New York state, a total of 21,213 (10.4%) and 182,411 2193 (89.6%) were classified as BP users and BP non-users, respectively (Table S9d). Prior to propensity-2194 score matching based on BP-use, there were significant differences across all demographic and 2195 clinical characteristics. Compared to BP non-users, BP users were older (98.8% age ≥51 versus 2196 81.4%; p<0.001), with a higher proportion of females (90.9% versus 55.5%; p<0.001), with lower 2197 comorbidity burden (mean CCI=0.88 versus 0.95; p<0.001), insured by Medicare (64.1% versus 2198 35.9%; p<0.001), and have not had a primary-care physician (PCP) visit in 2019 (53.4% versus 55.7%; 2199 p<0.001). Propensity-score matching yielded 21,126 BP users and 21,126 BP non-users with no 2200 significant differences across examined characteristics. A total of 87 BP users were not assigned an 2201 applicable BP non-user pair during the matching procedure and were excluded from the matched BP 2202 user population.

2203

# 2204 BP-Use Comparison within Antihypertensive Non-users: All Regions Combined

2205 Of the 1,786,001 antihypertensive non-users from the antihypertensive user/non-user propensity-2206 score matching analysis, a total of 136,016 (7.6%) and 1,649,985 (92.4%) were classified as BP users 2207 and BP non-users, respectively (**Table S9e**). Prior to propensity-score matching based on BP-use, 2208 there were significant differences across all demographic and clinical characteristics. Compared to BP 2209 non-users, BP users were older (97.7% age  $\geq$ 51 versus 76.3%; p<0.001), with a higher proportion of 2210 females (90.5% versus 58.0%; p<0.001), from the west (20.3% versus 14.8%; p<0.001), with lower 2211 comorbidity burden (mean CCI=0.88 versus 0.96; p<0.001), insured by Medicare (40.7% versus 2212 26.0%; p<0.001), and have had a primary-care physician (PCP) visit in 2019 (68.0% versus 59.0%; 2213 p<0.001). Propensity-score matching yielded 135,724 BP users and 135,724 BP non-users with no 2214 significant differences across examined characteristics. A total of 292 BP users were not assigned an 2215 applicable BP non-user pair during the matching procedure and were excluded from the matched BP 2216 user population.

2217

## 2218 BP-Use Comparison within Antihypertensive Non-users: New York State

2219 Of the 203,624 antihypertensive non-users from the antihypertensive user/non-user propensity-score 2220 matching analysis on patients residing in New York state, a total of 14,051 (6.9%) and 189,573 2221 (93.1%) were classified as BP users and BP non-users, respectively (**Table S9f**). Prior to propensityscore matching based on BP-use, there were significant differences across all demographic and 2222 2223 clinical characteristics. Compared to BP non-users, BP users were older (98.7% age ≥51 versus 2224 82.1%; p<0.001), with a higher proportion of females (91.3% versus 56.8%; p<0.001), with lower 2225 comorbidity burden (mean CCI=0.81 versus 0.96; p<0.001), insured by Medicare (54.9% versus 2226 37.7%; p<0.001), and have had a primary-care physician (PCP) visit in 2019 (66.3% versus 54.7%; 2227 p<0.001). Propensity-score matching yielded 13,983 BP users and 13,983 BP non-users with no significant differences across examined characteristics. A total of 68 BP users were not assigned an 2228

2229 applicable BP non-user pair during the matching procedure and were excluded from the matched BP 2230 user population.

2231

#### 2232

### 2233 Antidiabetic User/Non-User Analysis

2234 Antidiabetic-Use Comparison: All Observations (all regions combined)

2235 A total of 7,906,603 patients were included in the unmatched analysis cohort comparison of 2236 antidiabetic-use, of which 755,252 (9.6%) and 7,151,351 (90.4%) were classified as antidiabetic users 2237 and antidiabetic non-users, respectively (**Table S10a**). Prior to propensity-score matching, there were 2238 significant differences across all demographic and clinical characteristics. Compared to antidiabetic 2239 non-users, antidiabetic users were older (79.4% age  $\geq$ 51 versus 43.3%; p<0.001), with a higher 2240 proportion of females (60.8% versus 58.9%; p<0.001), from the northeast (28.8% versus 27.1%; 2241 p<0.001), with higher comorbidity burden (mean CCI=1.25 versus 0.55; p<0.001), insured by 2242 Medicare (26.2% versus 14.2%; p<0.001), and have had a primary-care physician (PCP) visit in 2019 2243 (66.5% versus 43.6%; p<0.001). Propensity-score matching yielded 754,553 antidiabetic users and 2244 754,553 antidiabetic non-users with no significant differences across examined characteristics. A total 2245 of 699 antidiabetic users from the unmatched analysis cohort were not assigned an applicable 2246 antidiabetic non-user pair during the matching procedure and were excluded from the matched 2247 antidiabetic user population.

2248

2263

#### 2249 Antidiabetic-Use Comparison: New York State

2250 A total of 968,296 patients identified as residing in New York state were included in the unmatched 2251 analysis cohort comparison of antidiabetic-use, of which 105,117 (10.9%) and 863,179 (89.1%) were classified as antidiabetic users and antidiabetic non-users, respectively (Table S10b). Prior to 2252 2253 propensity-score matching, there were significant differences across all demographic and clinical 2254 characteristics. Compared to antidiabetic non-users, antidiabetic users were older (83.8% age ≥51 2255 versus 49.4%; p<0.001), with a higher proportion of males (42.2% versus 40.6%; p<0.001), with 2256 higher comorbidity burden (mean CCI=1.34 versus 0.56; p<0.001), insured by Medicare (40.5% 2257 versus 19.2%; p<0.001), and have had a primary-care physician (PCP) visit in 2019 (64.6% versus 2258 43.9%; p<0.001). Propensity-score matching yielded 104,691 antidiabetic users and 104.691 2259 antidiabetic non-users with no significant differences across examined characteristics. A total of 426 2260 antidiabetic users from the unmatched analysis cohort were not assigned an applicable antidiabetic 2261 non-user pair during the matching procedure and were excluded from the matched antidiabetic user 2262 population.

2264 BP-Use Comparison within Antidiabetic Users: All Regions Combined

2265 Of the 754,553 antidiabetic users from the antidiabetic user/non-user propensity-score matching 2266 analysis, a total of 80,529 (10.7%) and 674,024 (89.3%) were classified as BP users and BP non-2267 users, respectively (**Table S10c**). Prior to propensity-score matching based on BP-use, there were 2268 significant differences across all demographic and clinical characteristics. Compared to BP non-users, 2269 BP users were older (98.2% age  $\geq$ 51 versus 75.2%; p<0.001), with a higher proportion of females 2270 (98.5% versus 77.1%; p<0.001), from the west (22.2% versus 14.2%; p<0.001), with a higher 2271 comorbidity burden (mean CCI=1.32 versus 1.23; p<0.001), insured by Medicare (45.2% versus 2272 24.0%; p<0.001), and have had a primary-care physician (PCP) visit in 2019 (69.5% versus 66.1%; 2273 p<0.001). Propensity-score matching yielded 79,500 BP users and 79,500 BP non-users with no 2274 significant differences across examined characteristics. A total of 1,029 BP users were not assigned 2275 an applicable BP non-user pair during the matching procedure and were excluded from the matched 2276 BP user population.

2277 2278 BP-Use Comparison within Antidiabetic Users: New York State

2279 Of the 104,691 antidiabetic users from the antidiabetic user/non-user propensity-score matching 2280 analysis on patients residing in New York state, a total of 9,529 (9.1%) and 95,162 (90.9%) were

2281 classified as BP users and BP non-users, respectively (Table S10d). Prior to propensity-score 2282 matching based on BP-use, there were significant differences across all demographic and clinical 2283 characteristics. Compared to BP non-users, BP users were older (99.1% age  $\geq$ 51 versus 82.2%: 2284 p<0.001), with a higher proportion of females (90.1% versus 54.5%; p<0.001), with a higher 2285 comorbidity burden (mean CCI=1.46 versus 1.31; p<0.001), insured by Medicare (64.6% versus 2286 38.2%; p<0.001), and have had a primary-care physician (PCP) visit in 2019 (66.3% versus 64.4%; 2287 p<0.001). Propensity-score matching yielded 9,456 BP users and 9,456 BP non-users with no 2288 significant differences across examined characteristics. A total of 73 BP users were not assigned an 2289 applicable BP non-user pair during the matching procedure and were excluded from the matched BP 2290 user population.

#### 2291

#### 2292 BP-Use Comparison within Antidiabetic Non-users: All Regions Combined

2293 Of the 754,553 antidiabetic non-users from the antidiabetic user/non-user propensity-score matching 2294 analysis, a total of 73,173 (9.7%) and 681,380 (90.3%) were classified as BP users and BP non-users, 2295 respectively (Table S10e). Prior to propensity-score matching based on BP-use, there were 2296 significant differences across all demographic characteristics, but no difference was seen in mean 2297 CCI (1.24 versus 1.24; p=0.92). Compared to BP non-users, BP users were older (98.0% age ≥51 2298 versus 77.3%; p<0.001), with a higher proportion of females (88.9% versus 57.7%; p<0.001), from the 2299 west (20.1% versus 14.5%; p<0.001), insured by Medicare (40.0% versus 24.8%; p<0.001), and have 2300 had a primary-care physician (PCP) visit in 2019 (74.1% versus 65.7%; p<0.001). Propensity-score 2301 matching yielded 72,514 BP users and 72,514 BP non-users with no significant differences across 2302 examined characteristics. A total of 659 BP users were not assigned an applicable BP non-user pair 2303 during the matching procedure and were excluded from the matched BP user population. 2304

#### 2305 BP-Use Comparison within Antidiabetic Non-users: New York State

2306 Of the 104.691 antidiabetic non-users from the antidiabetic user/non-user propensity-score matching 2307 analysis on patients residing in New York state, a total of 9,275 (8.9%) and 95,416 (91.1%) were 2308 classified as BP users and BP non-users, respectively (Table S10f). Prior to propensity-score 2309 matching based on BP-use, there were significant differences across all demographic and clinical 2310 characteristics. Compared to BP non-users, BP users were older (99.0% age  $\geq$ 51 versus 82.2%; 2311 p<0.001), with a higher proportion of females (89.2% versus 54.7%; p<0.001), with a higher 2312 comorbidity burden (mean CCI=1.37 versus 1.32; p<0.01), insured by Medicare (57.7% versus 38.9%; 2313 p<0.001), and have had a primary-care physician (PCP) visit in 2019 (72.5% versus 63.8%; p<0.001). 2314 Propensity-score matching yielded 13,983 BP users and 13,983 BP non-users with no significant 2315 differences across examined characteristics. A total of 131 BP users were not assigned an applicable 2316 BP non-user pair during the matching procedure and were excluded from the matched BP user 2317 population.

2318 2319

## 2320 Antidepressant User/Non-User Analysis

#### 2321 Antidepressant-Use Comparison: All Observations (all regions combined)

2322 A total of 7,906,603 patients were included in the unmatched analysis cohort comparison of 2323 antidepressant-use, of which 1,571,005 (19.9%) and 6,335,598 (80.1%) were classified as 2324 antidepressant users and antidepressant non-users, respectively (Table S11a). Prior to propensity-2325 score matching, there were significant differences across all demographic and clinical characteristics. 2326 Compared to antidepressant non-users, antidepressant users were older (58.6% age ≥51 versus 2327 43.8%; p<0.001), with a higher proportion of females (72.8% versus 55.7%; p<0.001), from the 2328 midwest (22.1% versus 17.7%; p<0.001), with higher comorbidity burden (mean CCI=0.90 versus 2329 0.55; p<0.001), insured by Medicare (18.5% versus 14.6%; p<0.001), and have had a primary-care 2330 physician (PCP) visit in 2019 (61.1% versus 42.0%; p<0.001). Propensity-score matching yielded 2331 1,536,048 antidepressant users and 1,536,048 antidepressant non-users with no significant 2332 differences across examined characteristics. A total of 34,957 antidepressant users from the

unmatched analysis cohort were not assigned an applicable antidepressant non-user pair during the
 matching procedure and were excluded from the matched antidepressant user population.

## 2336 Antidepressant-Use Comparison: New York State

2337 A total of 968,296 patients identified as residing in New York state were included in the unmatched 2338 analysis cohort comparison of antidepressant-use, of which 136,081 (14.1%) and 832,215 (85.9%) 2339 were classified as antidepressant users and antidepressant non-users, respectively (Table S11b). 2340 Prior to propensity-score matching, there were significant differences across all demographic and 2341 clinical characteristics. Compared to antidepressant non-users, antidepressant users were older (66.3% 2342 age  $\geq$ 51 versus 51.0%; p<0.001), with a higher proportion of females (71.2% versus 57.3%; p<0.001), 2343 with higher comorbidity burden (mean CCI=0.98 versus 0.59; p<0.001), insured by Medicare (32.2% 2344 versus 19.8%; p<0.001), and have had a primary-care physician (PCP) visit in 2019 (60.7% versus 2345 43.8%; p<0.001). Propensity-score matching yielded 135,516 antidepressant users and 135,516 2346 antidepressant non-users with no significant differences across examined characteristics. A total of 2347 565 antidepressant users from the unmatched analysis cohort were not assigned an applicable 2348 antidepressant non-user pair during the matching procedure and were excluded from the matched 2349 antidepressant user population.

#### 2350

#### 2351 BP-Use Comparison within Antidepressant Users: All Regions Combined

2352 Of the 1.536.048 antidepressant users from the antidepressant user/non-user propensity-score 2353 matching analysis, a total of 145,109 (9.4%) and 1,390,939 (90.6%) were classified as BP users and 2354 BP non-users, respectively (Table S11c). Prior to propensity-score matching based on BP-use, there 2355 were significant differences across all demographic and clinical characteristics. Compared to BP non-2356 users, BP users were older (96.7% age  $\geq$ 51 versus 54.4%; p<0.001), with a higher proportion of 2357 females (91.9% versus 70.2%; p<0.001), from the west (19.6% versus 13.9%; p<0.001), with a higher 2358 comorbidity burden (mean CCI=1.09 versus 0.84; p<0.001), insured by Medicare (42.4% versus 2359 16.2%; p<0.001), and have had a primary-care physician (PCP) visit in 2019 (64.6% versus 60.2%; 2360 p<0.001). Propensity-score matching yielded 144,282 BP users and 144,282 BP non-users with no 2361 significant differences across examined characteristics. A total of 827 BP users were not assigned an 2362 applicable BP non-user pair during the matching procedure and were excluded from the matched BP 2363 user population.

#### 2364

#### 2365 BP-Use Comparison within Antidepressant Users: New York State

2366 Of the 135,516 antidepressant users from the antidepressant user/non-user propensity-score 2367 matching analysis on patients residing in New York state, a total of 12,950 (9.6%) and 122,566 2368 (90.4%) were classified as BP users and BP non-users, respectively (Table S11d). Prior to 2369 propensity-score matching based on BP-use, there were significant differences across all 2370 demographic and clinical characteristics. Compared to BP non-users, BP users were older (97.8% 2371 age  $\geq$ 51 versus 63.0%; p<0.001), with a higher proportion of females (92.6% versus 68.9%; p<0.001), 2372 with a higher comorbidity burden (mean CCI=1.13 versus 0.95; p<0.001), insured by Medicare (60.8% 2373 versus 29.1%; p<0.001), and have had a primary-care physician (PCP) visit in 2019 (65.3% versus 2374 60.1%; p<0.001). Propensity-score matching yielded 12,859 BP users and 12,859 BP non-users with 2375 no significant differences across examined characteristics. A total of 91 BP users were not assigned 2376 an applicable BP non-user pair during the matching procedure and were excluded from the matched 2377 BP user population.

2378

#### 2379 BP-Use Comparison within Antidepressant Non-users: All Regions Combined

Of the 1,536,048 antidepressant non-users from the antidepressant user/non-user propensity-score matching analysis, a total of 113,110 (7.4%) and 1,422,938 (92.6%) were classified as BP users and BP non-users, respectively (**Table S11e**). Prior to propensity-score matching based on BP-use, there were significant differences across all demographic characteristics. Compared to BP non-users, BP

users were older (97.1% age ≥51 versus 55.4%; p<0.001), with a higher proportion of females (93.2%

versus 70.6%; p<0.001), from the west (20.0% versus 14.0%; p<0.001), with a higher comorbidity</li>
burden (mean CCI=1.06 versus 0.85; p<0.001), insured by Medicare (40.4% versus 17.0%; p<0.001),</li>
and have had a primary-care physician (PCP) visit in 2019 (71.2% versus 59.8%; p<0.001).</li>
Propensity-score matching yielded 112,402 BP users and 112,402 BP non-users with no significant
differences across examined characteristics. A total of 708 BP users were not assigned an applicable
BP non-user pair during the matching procedure and were excluded from the matched BP user
population.

2392

#### 2393 BP-Use Comparison within Antidepressant Non-users: New York State

2394 Of the 135,516 antidepressant non-users from the antidepressant user/non-user propensity-score 2395 matching analysis on patients residing in New York state, a total of 10,174 (7.5%) and 125,342 (92.5%) were classified as BP users and BP non-users, respectively (Table S11f). Prior to propensity-2396 2397 score matching based on BP-use, there were significant differences across all demographic and 2398 clinical characteristics. Compared to BP non-users, BP users were older (98.4% age ≥51 versus 2399 63.7%; p<0.001), with a higher proportion of females (93.6% versus 69.4%; p<0.001), with a higher 2400 comorbidity burden (mean CCI=1.13 versus 0.95; p<0.01), insured by Medicare (60.0% versus 29.9%; p<0.001), and have had a primary-care physician (PCP) visit in 2019 (71.7% versus 59.7%; p<0.001). 2401 2402 Propensity-score matching vielded 10.091 BP users and 10.091 BP non-users with no significant 2403 differences across examined characteristics. A total of 83 BP users were not assigned an applicable 2404 BP non-user pair during the matching procedure and were excluded from the matched BP user 2405 population.

2406

# 2407 **APPENDIX 3: Post-hoc Analysis on the Impact of Censoring due to Death**

#### 2408

#### 2409 Background

2410 Following completion of all core study analyses, an additional post-hoc investigation was performed to 2411 assess whether censoring bias due to patient death could impact our current findings of a decrease in 2412 the odds of COVID-19 outcomes seen amongst BP users. Typically, it is very difficult to perform 2413 assessments on this type of bias due to the fact that insurance claims databases in the United States 2414 do not include this information. Some claims database providers, including Komodo Health, do have 2415 the capability to 'link' their de-identified claims data with external sources on decedent enrollees, but 2416 at the time of study initiation and data extraction there were enhanced HIPAA constraints associated 2417 with claims datasets that included COVID-identifying diagnosis/treatment codes due to the heightened 2418 risk of patient re-identification due to the then lower prevalence and high visibility associated for 2419 patients with COVID-19. Eventually the increased prevalence of COVID-19 reduced the HIPAA 2420 concerns on working with claims data that include COVID-19-identifiers, and in support of this 2421 analysis and the potentially significant public health implications of our findings, Komodo Health linked 2422 their COVID-identifiable dataset with mortality data sources that account for roughly 80-85% of 2423 available death records. In conjunction with Komodo Health, queries on this mortality-linked COVID-2424 19-identifiable dataset were performed to determine whether bias caused by patient censoring due to 2425 death could have impacted the validity and/or reliability of our current findings

2426 2427

### 2428 Methodological Concerns of Patient Censoring due to Death

2429 The single motivating factor for initiation of this post-hoc analysis was the fact that the decrease in 2430 odds of COVID-19 outcomes among BP users in this study was found to be statistically significant, 2431 large in magnitude, and robust across almost all analysis variations performed. The exhaustive use of 2432 methodological techniques to control for unmeasured confounding and/or outside sources of bias 2433 employed in this current study were undertaken not in search of statistical significance, but in search 2434 of non-significance. This was undertaken because the consistency seen in statistical significance, in 2435 addition to the magnitude of the decrease in the odds of our outcomes of interest, are typically not 2436 seen to this degree. As such, the next logical step after exhausting all methodological techniques is to 2437 search for other sources that could induce a large-enough bias on the underlying patient population 2438 itself, such as censoring of the target study cohort, that could drastically alter the typical composition 2439 of the overall sample and thus impact the reliability and validity of outcomes measured.

2440 The high rate of death associated with COVID-19 infection, which was even worse during the early 2441 months of the pandemic, represents such an instance where outside influences could impact the 2442 underlying data, and as such, the validity of research performed on that data. The primary concern is 2443 whether patients who have died are censored from the analytical sample due to the application of one 2444 of the most fundamental inclusion/exclusion criteria used in claims-based research, the requirement 2445 for continuous insurance eligibility over the entire study period that is needed so that healthcare 2446 resource utilization events from all subjects are captured and available in the data for analysis. If in 2447 our current sample, a larger number of BP users died after contracting COVID-19 and were censored 2448 due to insurance eligibility, and a lower number of BP non-users survived and thus met the insurance 2449 eligibility criteria, then the remaining study sample would be comprised of healthier-looking BP users 2450 and a higher number of BP non-users with COVID-19 related healthcare services.

The potential for such a censoring bias in this current study sample, and the impact of that bias on the magnitude and statistical significance of our core study findings, was assessed in this post-hoc analysis by: (1) adjusting eligibility criteria to prevent the censoring of patients that may have died during the first half of 2020; (2) replicating key exposure (BP-use, use of other non-BP bone health medications) and outcomes (COVID-19 diagnosis) in this expanded sample that aligns with the core study methods; (3) analysing the impact on study findings that would result from the retention and inclusion of deceased-patient observations in the core study sample on the odds of COVID-19

diagnosis; and (4) calculating the number of missing patient observations censored due to death that
 would be required to reach a statistically non-significant difference in the odds of COVID-19.

2462 **Post-Hoc Analysis** 

2463 2464 Methods

2461

2473

2486

2487

2490

2496

2497

2498

2499

2500

2501

2502

2503

- 2465 2466 Cohort Definition
- Continuous insurance eligibility 1/1/2019-12/31/2019; used to ensure that any censoring due to death occurs during the observation period of 1/1/2020-6/30/2020
- BP users compared to BP non-users to produce a cohort comparison similar to the primary
   analysis cohort
- BP users compared to users of non-BP anti-resorptive bone health medications to produce a cohort comparison similar to the "*Bone-Rx*" active comparator analysis

#### 2474 Exposures of Interest

- Patients were assigned into the BP user cohort if they had any claim 1/1/2019-2/29/2020 for one of the following: alendronate, alendronic acid, etidronate, ibandronate, ibandronic acid, pamidronate, risedronate, and zoledronic acid; for the cohort comparison of all osteoporosis medication users BP users were further restricted to those that had no claims for a non-BP anti-resorptive bone health medication 1/1/2019-2/29/2020.
- Patients were assigned into the non-BP anti-resorptive bone health medication user cohort if:
   (1) they had any claim 1/1/2019-2/29/2020 for one of the following: denosumab, calcitonin,
   raloxifene, romosozumab-aqqg, teriparatide, abaloparatide, or bazedoxifene; and (2) they had
   DBP claims
- 24842485 Outcomes / Endpoints
  - Patients were assigned into the COVID-19 diagnosis cohort based on any medical service claim with an ICD-10 diagnosis code of U07.1 occurring 1/1/2200-6/30/2020
- Patients with a date-of-death between 1/1/2020-6/30/2020 were classified into the deceased cohort


#### 2491 Statistical Analysis

- Chi-square testing was used to assess whether statistically significant differences exist
   between BP users and BP non-users in the unadjusted odds of having any COVID-19
   diagnosis during the first half of 2020 among cohorts that approximate the primary analysis
   and "Bone-Rx" study cohorts for the following:
  - 1. Among all patient-observations with a COVID-19 diagnosis to assess the potential 'true' comparison that would occur
  - With deceased patient-observations that had a known COVID-19 diagnosis removed prior to testing to replicate findings that would occur if these observations were censored
    - 3. When making the assumption that all patients who died during this period died due to COVID-19, and thus should be classified as having a COVID-19 diagnosis
- An additional analysis was performed on the last variation modelled (assuming all patients died due to COVID-19) to determine the additional BP user patient observations that would be needed to be classified as having had a COVID-19 diagnosis to yield a similar distribution of COVID-19 diagnosis (yes/no) as was seen in the BP non-user cohort to yield an odds ratio ~1.0

2509 2510 2511 2512	<ul> <li>Finally, the impact on odds ratio testing results comparing BP users to BP non-users was modelled based on the additional number of BP users needed to be classified as having been diagnosed with COVID-19 to reach statistical non-significance</li> </ul>
2513 2514	<u>Results</u>
2515 2516 2517 2518 2519 2520 2521 2522	<ul> <li>Patient Count Distribution</li> <li>Among the full sample a decreased rate of COVID-19 among BP users compared to BP non- users was seen in both the full sample population (1.2% versus 4.7%) as well as when restricted to users of non-BP anti-resorptive bone health medications (1.2% versus 4.3%) (Table S12a)</li> </ul>
2523 2524 2525 2526 2527 2528 2529	<ul> <li>Unadjusted Chi-Square Comparison Inclusive of Deceased Patients</li> <li>The decrease in the odds of any COVID-19 diagnosis amongst BP users compared to BP non- users was found to be robust in both the full (OR=0.24) and "Bone-Rx" (OR=0.35) comparisons when including deceased patients with a known COVID-19 diagnosis (Table S12b)</li> </ul>
2530 2531 2532 2533 2534 2535 2536	<ul> <li>Unadjusted Chi-Square Comparison with Deceased Patients Removed</li> <li>The decrease in the odds of any COVID-19 diagnosis amongst BP users compared to BP non- users was found to be robust in both the full (OR=0.23) and "Bone-Rx" (OR=0.26) comparisons when removing deceased patients with a known COVID-19 diagnosis (Table S12c)</li> </ul>
2530 2537 2538 2539 2540 2541	<ul> <li>Unadjusted Chi-Square Comparison Assuming all Deceased Patients had COVID-19</li> <li>The decrease in the odds of any COVID-19 diagnosis amongst BP users compared to BP non- users was found to be robust in both the full (OR=0.39) and "Bone-Rx" (OR=0.29) comparisons when assuming that all deceased patients had a COVID-19 diagnosis (Table S12d)</li> </ul>
2542 2543 2544	<ul> <li>Among this final analysis that assumes all deceased patients had a diagnosis of COVID-19, the percentage of BP non-users with an assumed COVID-19 diagnosis was 5.5% and 7.2% for the full and OPRX comparisons, respectively.</li> </ul>
2545 2546 2547	<ul> <li>These proportions were then used to estimate the number of additional BP users with a COVID-19 diagnosis that would be needed to have the same distribution and thus an odds ratio ~1.0 (Table S12e)</li> </ul>
2548 2549 2550	- It would require an additional 22,235 (37,095-14,860) BP-user patient observations from the full cohort comparison to be classified as having a COVID-19 diagnosis to have an equivalent odds of being diagnosed with COVID-19 as was seen among the BP non-user cohort
2551 2552 2553 2554 2555 2556 2557	<ul> <li>It would require an additional 32,598 (46,637-14,039) BP-user patient observations from the "Bone-Rx" cohort comparison to be classified as having a COVID-19 diagnosis to have an equivalent odds of being diagnosed with COVID-19 as was seen among the BP non-user cohort</li> </ul>

- In the full (all observations) comparison, the minimum number of additional BP users classified
   as having a COVID-19 diagnosis needed to reach statistical non-significance for the calculated
   unadjusted odds ratio was 21,860 (Figure S1)
- 2561
- 2562

# Figure S1: Full Cohort: Odds Ratio by Additional Number of BP Users Classified as having COVID-19 Diagnosis



2572


BP: bisphosphonate

<u>Legend</u>: Shown in Figure S1 is the forest plot of the change in the crude odds ratio (OR) of BP users having a COVID-19 diagnosis as a factor of the additional number of BP users needed to be classified as having a COVID-19 diagnosis to reach statistical non-significance for all observations.

- 2573 In the "Bone-Rx" comparison, the minimum number of additional BP users classified as having \_ 2574 a COVID-19 diagnosis needed to reach statistical non-significance for the calculated 2575 unadjusted odds ratio was 31.360 (Figure S2)
- 2576
- 2577

#### 2578 Figure S2: Bone-Rx Cohort: Odds Ratio by Additional Number of BP Users Classified as 2579 having COVID-19 Diagnosis

2580



**BP:** bisphosphonate

Legend: Shown in Figure S2 is the forest plot of the change in the crude odds ratio (OR) of BP users having a COVID-19 diagnosis as a factor of the additional number of BP users needed to be classified as having a COVID-19 diagnosis to reach statistical non-significance when comparing BP users to users of non-BP anti-resorptive bone medications.

#### 2589 **APPENDIX TABLES**

#### 2590

# 2591

#### Table S1: Most Recent Bisphosphonate Claim Among all Users

2592

Drug (route)	Ν	%
alendronate / alendronic acid (oral)	340,810	75.4%
etidronate (oral)	14	0.0%
ibandronate / ibandronic acid (oral)	37,988	8.4%
ibandronic acid (injection/infusion)	1,169	0.3%
pamidronate (injection/infusion)	1,121	0.2%
risedronate (oral)	18,991	4.2%
zoledronic acid (injection/infusion)	51,958	11.5%

2593

#### 2594 Table S2a: Primary Analysis Cohort (Region=Northeast), Patient Characteristics Pre/Post Match

2595

		R	egion=North	neast Un	matched					Region=N	lortheast	Matched		
	All		BP Non-u	users	BP Us	sers	n velue	A	.11	BP Non-	-users	BP Us	ers	n velue
	N	%	N	%	N	%	p-value	N	%	N	%	N	%	p-value
All Patients	2,152,560	100.0%	2,032,832	94.4%	119,728	5.6%		238,988	100.0%	119,494	50.0%	119,494	50.0%	
Age														
≤20	363,637	16.9%	363,401	17.9%	236	0.2%	<0.001	474	0.2%	238	0.2%	236	0.2%	1.00
21-40	397,377	18.5%	396,613	19.5%	764	0.6%		1,528	0.6%	764	0.6%	764	0.6%	
41-50	261,570	12.2%	259,528	12.8%	2,042	1.7%		4,084	1.7%	2,042	1.7%	2,042	1.7%	
51-60	372,238	17.3%	354,228	17.4%	18,010	15.0%		36,020	15.1%	18,010	15.1%	18,010	15.1%	
61-70	354,331	16.5%	313,237	15.4%	41,094	34.3%		82,233	34.4%	41,139	34.4%	41,094	34.4%	
71-80	252,712	11.7%	215,151	10.6%	37,561	31.4%		74,831	31.3%	37,393	31.3%	37,438	31.3%	
≥81	150,695	7.0%	130,674	6.4%	20,021	16.7%		39,818	16.7%	19,908	16.7%	19,910	16.7%	
Gender														
Female	1,275,611	59.3%	1,167,241	57.4%	108,370	90.5%	<0.001	216,273	90.5%	108,137	90.5%	108,136	90.5%	0.99
Male	876,949	40.7%	865,591	42.6%	11,358	9.5%		22,715	9.5%	11,357	9.5%	11,358	9.5%	
Insurance														
Commercial	1,050,795	48.8%	1,017,502	50.1%	33,293	27.8%	<0.001	66,552	27.8%	33,259	27.8%	33,293	27.9%	0.99
Dual	47,773	2.2%	40,168	2.0%	7,605	6.4%		15,114	6.3%	7,576	6.3%	7,538	6.3%	
Medicaid	631,863	29.4%	608,649	29.9%	23,214	19.4%		46,094	19.3%	23,047	19.3%	23,047	19.3%	
Medicare	422,129	19.6%	366,513	18.0%	55,616	46.5%		111,228	46.5%	55,612	46.5%	55,616	46.5%	
PCP Visit 2019														
No	1,212,394	56.3%	1,162,527	57.2%	49,867	41.7%	<0.001	99,741	41.7%	49,874	41.7%	49,867	41.7%	0.98
Yes	940,166	43.7%	870,305	42.8%	69,861	58.3%		139,247	58.3%	69,620	58.3%	69,627	58.3%	
						Continuo	us Outcom	es						
	mean	SD	mean	SD	mean	SD	p-value	mean	SD	mean	SD	mean	SD	p-value
CCI	0.67	1.42	0.65	1.40	0.93	1.71	<0.001	0.93	1.71	0.93	1.71	0.93	1.71	0.96

2596

#### 2597 Table S2b: Primary Analysis Cohort (Region=Midwest), Patient Characteristics Pre/Post Match

2598

		R	egion=Midw	est Unm	atched					Region=	Midwest	Matched		
	All		BP Non-u	isers	BP U	sers		A	II	BP Nor	n-users	BP U	sers	
	Ν	%	N	%	Ν	%	p-value	N	%	Ν	%	N	%	p-value
All Patients	1,467,802	100.0%	1,391,835	94.8%	75,967	5.2%		151,802	100.0%	75,901	50.0%	75,901	50.0%	
Age														
≤20	310,027	21.1%	309,759	22.3%	268	0.4%	<0.001	537	0.4%	269	0.4%	268	0.4%	1.00
21-40	287,236	19.6%	286,643	20.6%	593	0.8%		1,188	0.8%	595	0.8%	593	0.8%	
41-50	185,240	12.6%	183,556	13.2%	1,684	2.2%		3,367	2.2%	1,683	2.2%	1,684	2.2%	
51-60	246,230	16.8%	233,992	16.8%	12,238	16.1%		24,478	16.1%	12,240	16.1%	12,238	16.1%	
61-70	224,668	15.3%	196,172	14.1%	28,496	37.5%		56,991	37.5%	28,495	37.5%	28,496	37.5%	
71-80	130,563	8.9%	109,442	7.9%	21,121	27.8%		42,153	27.8%	21,075	27.8%	21,078	27.8%	
≥81	83,838	5.7%	72,271	5.2%	11,567	15.2%		23,088	15.2%	11,544	15.2%	11,544	15.2%	
Gender														
Female	863,156	58.8%	794,578	57.1%	68,578	90.3%	<0.001	137,028	90.3%	68,516	90.3%	68,512	90.3%	0.97
Male	604,646	41.2%	597,257	42.9%	7,389	9.7%		14,774	9.7%	7,385	9.7%	7,389	9.7%	
Insurance														
Commercial	885,651	60.3%	854,518	61.4%	31,133	41.0%	<0.001	62,243	41.0%	31,110	41.0%	31,133	41.0%	1.00
Dual	28,190	1.9%	24,584	1.8%	3,606	4.7%		7,211	4.8%	3,605	4.7%	3,606	4.8%	
Medicaid	318,596	21.7%	310,473	22.3%	8,123	10.7%		16,136	10.6%	8,079	10.6%	8,057	10.6%	
Medicare	235,365	16.0%	202,260	14.5%	33,105	43.6%		66,212	43.6%	33,107	43.6%	33,105	43.6%	
PCP Visit 2019														
No	711,308	48.5%	682,601	49.0%	28,707	37.8%	<0.001	57,398	37.8%	28,691	37.8%	28,707	37.8%	0.93
Yes	756,494	51.5%	709,234	51.0%	47,260	62.2%		94,404	62.2%	47,210	62.2%	47,194	62.2%	
						Continuo	ous Outcom	es						
	mean	SD	mean	SD	mean	SD	p-value	mean	SD	mean	SD	mean	SD	p-value
CCI	0.59	1.37	0.56	1.34	0.99	1.86	<0.001	0.99	1.86	0.99	1.85	1.00	1.86	0.77

2599

#### 2600 Table S2c: Primary Analysis Cohort (Region=South), Patient Characteristics Pre/Post Match

2601

			Region=Sou	uth Unm	atched					Region=	South M	latched		
	All		BP Non-ι	isers	BP Us	sers	n velue	A	.11	BP Non-	users	BP Us	sers	n volue
	N	%	N	%	N	%	p-value	N	%	N	%	N	%	p-value
All Patients	3,042,604	100.0%	2,881,718	94.7%	160,886	5.3%		319,408	100.0%	159,704	50.0%	159,704	50.0%	
Age														
≤20	890,677	29.3%	890,203	30.9%	474	0.3%	<0.001	943	0.3%	469	0.3%	474	0.3%	1.00
21-40	527,971	17.4%	526,794	18.3%	1,177	0.7%		2,364	0.7%	1,187	0.7%	1,177	0.7%	
41-50	338,262	11.1%	334,841	11.6%	3,421	2.1%		6,839	2.1%	3,418	2.1%	3,421	2.1%	
51-60	442,757	14.6%	417,664	14.5%	25,093	15.6%		50,186	15.7%	25,093	15.7%	25,093	15.7%	
61-70	409,854	13.5%	353,958	12.3%	55,896	34.7%		111,800	35.0%	55,904	35.0%	55,896	35.0%	
71-80	272,761	9.0%	222,156	7.7%	50,605	31.5%		99,223	31.1%	49,605	31.1%	49,618	31.1%	
≥81	160,322	5.3%	136,102	4.7%	24,220	15.1%		48,053	15.0%	24,028	15.0%	24,025	15.0%	
Gender														
Female	1,800,166	59.2%	1,654,351	57.4%	145,815	90.6%	<0.001	289,263	90.6%	144,630	90.6%	144,633	90.6%	0.99
Male	1,242,438	40.8%	1,227,367	42.6%	15,071	9.4%		30,145	9.4%	15,074	9.4%	15,071	9.4%	
Insurance														
Commercial	1,475,456	48.5%	1,416,166	49.1%	59,290	36.9%	<0.001	118,587	37.1%	59,297	37.1%	59,290	37.1%	1.00
Dual	53,474	1.8%	39,414	1.4%	14,060	8.7%		25,752	8.1%	12,874	8.1%	12,878	8.1%	
Medicaid	1,121,606	36.9%	1,099,957	38.2%	21,649	13.5%		43,299	13.6%	21,650	13.6%	21,649	13.6%	
Medicare	392,068	12.9%	326,181	11.3%	65,887	41.0%		131,770	41.3%	65,883	41.3%	65,887	41.3%	
PCP Visit 2019														
No	1,701,040	55.9%	1,646,572	57.1%	54,468	33.9%	<0.001	108,601	34.0%	54,275	34.0%	54,326	34.0%	0.85
Yes	1,341,564	44.1%	1,235,146	42.9%	106,418	66.1%		210,807	66.0%	105,429	66.0%	105,378	66.0%	
						Continuo	us Outcom	es						
	mean	SD	mean	SD	mean	SD	p-value	mean	SD	mean	SD	mean	SD	p-value
CCI	0.57	1.31	0.55	1.28	0.86	1.70	<0.001	0.86	1.70	0.86	1.70	0.86	1.71	0.84

2602

#### 2603 Table S2d: Primary Analysis Cohort (Region=West), Patient Characteristics Pre/Post Match

2604

			Region=We	st Unma	tched					Region	=West Ma	atched		
	All		BP Non-u	isers	BP U	lsers	n velue	A	JI	BP Nor	I-users	BP U	sers	n volue
	Ν	%	N	%	Ν	%	p-value	N	%	N	%	Ν	%	p-value
All Patients	1,243,637	100.0%	1,148,167	92.3%	95,470	7.7%		190,534	100.0%	95,267	50.0%	95,267	50.0%	
Age														
≤20	275,709	22.2%	275,559	24.0%	150	0.2%	<0.001	299	0.2%	149	0.2%	150	0.2%	1.00
21-40	234,415	18.8%	233,858	20.4%	557	0.6%		1,115	0.6%	558	0.6%	557	0.6%	
41-50	140,237	11.3%	138,833	12.1%	1,404	1.5%	1	2,806	1.5%	1,402	1.5%	1,404	1.5%	
51-60	188,965	15.2%	178,585	15.6%	10,380	10.9%	1	20,761	10.9%	10,381	10.9%	10,380	10.9%	
61-70	192,408	15.5%	161,016	14.0%	31,392	32.9%		62,798	33.0%	31,406	33.0%	31,392	33.0%	
71-80	127,739	10.3%	95,301	8.3%	32,438	34.0%	1	64,596	33.9%	32,293	33.9%	32,303	33.9%	
≥81	84,164	6.8%	65,015	5.7%	19,149	20.1%	1	38,159	20.0%	19,078	20.0%	19,081	20.0%	
Gender														
Female	732,027	58.9%	647,354	56.4%	84,673	88.7%	< 0.001	168,933	88.7%	84,463	88.7%	84,470	88.7%	0.96
Male	511,610	41.1%	500,813	43.6%	10,797	11.3%		21,601	11.3%	10,804	11.3%	10,797	11.3%	
Insurance														
Commercial	526,701	42.4%	503,359	43.8%	23,342	24.4%	< 0.001	46,688	24.5%	23,346	24.5%	23,342	24.5%	1.00
Dual	27,060	2.2%	20,924	1.8%	6,136	6.4%	1	11,859	6.2%	5,925	6.2%	5,934	6.2%	
Medicaid	522,435	42.0%	497,941	43.4%	24,494	25.7%	1	48,990	25.7%	24,496	25.7%	24,494	25.7%	
Medicare	167,441	13.5%	125,943	11.0%	41,498	43.5%	1	82,997	43.6%	41,500	43.6%	41,497	43.6%	
PCP Visit 2019														
No	658,955	53.0%	628,131	54.7%	30,824	32.3%	< 0.001	61,643	32.4%	30,819	32.4%	30,824	32.4%	0.98
Yes	584,682	47.0%	520,036	45.3%	64,646	67.7%		128,891	67.6%	64,448	67.6%	64,443	67.6%	
	•	•				Continuo	ous Outcom	es	•	•				
	mean	SD	mean	SD	p-value	mean	SD	mean	SD	mean	SD	p-value		
CCI	0.69	1.46	0.66	1.42	1.08	1.84	< 0.001	1.09	1.83	1.08	1.83	1.09	1.84	0.73

2605

2606 Table S2e: Primary Analysis Cohort (Region=New York State), Patient Characteristics Pre/Post Match

2607

		Reg	ion=New Y	ork State	Unmatcl	hed			R	egion=Nev	w York St	ate Match	ed	
	Α	II	BP Non-	users	BP U	sers			All	BP Nor	n-users	BP U	sers	
	N	%	N	%	Ν	%	p-value	N	%	N	%	Ν	%	p-value
All Patients	968,296	100.0%	918,261	94.8%	50,035	5.2%		99,724	100.0%	49,862	50.0%	49,862	50.0%	
Age														
≤20	133,178	13.8%	133,128	14.5%	50	0.1%	< 0.001	102	0.1%	52	0.1%	50	0.1%	1.00
21-40	192,959	19.9%	192,731	21.0%	228	0.5%	1	453	0.5%	225	0.5%	228	0.5%	
41-50	127,794	13.2%	127,139	13.8%	655	1.3%	1	1,311	1.3%	656	1.3%	655	1.3%	
51-60	172,444	17.8%	166,080	18.1%	6,364	12.7%	ĺ	12,732	12.8%	6,368	12.8%	6,364	12.8%	
61-70	159,912	16.5%	143,776	15.7%	16,136	32.2%	1	32,265	32.4%	16,129	32.3%	16,136	32.4%	
71-80	120,117	12.4%	102,655	11.2%	17,462	34.9%	1	34,693	34.8%	17,352	34.8%	17,341	34.8%	
≥81	61,892	6.4%	52,752	5.7%	9,140	18.3%	1	18,168	18.2%	9,080	18.2%	9,088	18.2%	
Gender														
Female	573,610	59.2%	528,152	57.5%	45,458	90.9%	< 0.001	90,567	90.8%	45,282	90.8%	45,285	90.8%	0.97
Male	394,686	40.8%	390,109	42.5%	4,577	9.1%	1	9,157	9.2%	4,580	9.2%	4,577	9.2%	
Insurance														
Commercial	500,918	51.7%	490,503	53.4%	10,415	20.8%	< 0.001	20,830	20.9%	10,415	20.9%	10,415	20.9%	1.00
Dual	6,814	0.7%	5,218	0.6%	1,596	3.2%	1	3,154	3.2%	1,581	3.2%	1,573	3.2%	
Medicaid	252,366	26.1%	243,191	26.5%	9,175	18.3%	1	18,044	18.1%	9,019	18.1%	9,025	18.1%	
Medicare	208,198	21.5%	179,349	19.5%	28,849	57.7%	1	57,696	57.9%	28,847	57.9%	28,849	57.9%	
PCP Visit 2019														
No	521,282	53.8%	502,609	54.7%	18,673	37.3%	< 0.001	37,253	37.4%	18,616	37.3%	18,637	37.4%	0.89
Yes	447,014	46.2%	415,652	45.3%	31,362	62.7%		62,471	62.6%	31,246	62.7%	31,225	62.6%	
	•		•	•	·	Continu	ous Outcom	es						
	mean	SD	mean	SD	mean	SD	p-value	mean	SD	mean	SD	mean	SD	p-value
CCI	0.65	1.39	0.63	1.37	0.95	1.68	< 0.001	0.95	1.68	0.95	1.67	0.95	1.68	0.93

2608

# 2609Table S3a: Unadjusted COVID-19-Related Outcomes Stratified by Age, Sex, & Age by Sex; Matched Primary Analysis Cohort, All-<br/>Regions Combined2610Regions Combined

2611

						Prim	ary Analy	sis Coho	rt, All R	egions	s Matc	hed					
	A	II		SAR	S-CoV-2	2 Test			COVIE	)-19 Dia	agnosis	;		COVID-	19 Hos	pitalizat	ion
	N	%	N	%	0	R	p-value	N	%	C	R	p-value	N	%	c	R	p-value
					LL	UL	•			LL	UL	•			LL	UL	
All Patients	900,732	100.0%	28,137	3.1%				16,289	1.8%				3,710	0.4%			
BP User	450,366	50.0%	5,189	1.2%	-	22	<0.001	3,024	0.7%	-	22	<0.001	715	0.2%	-	24	<0.001
BP Non-user	450,366	50.0%	22,948	5.1%	0.21	0.22		13,265	2.9%	0.21	0.23		2,995	0.7%	0.22	0.26	
By Age	0.050	100.00/	07	0.00/					0.00/					0.40/			
Age ≤20	2,253	100.0%	67	3.0%			0.00	14	0.6%		10	0.007	2	0.1%	<u> </u>		
BP User	1,128	50.1%	29	2.6%	0.		0.26	2	0.2%		16	0.007	2	0.2%		IA	NA
BP Non-user	1,125	49.9%	38	3.4%	0.46	1.23		12	1.1%	0.04	0.74		0	0.0%	NA	NA	
Age 21-40	6,195	100.0%	335	5.4%	-			115	1.9%	-			13	0.2%			
BP User	3,091	49.9%	58	1.9%		20	<0.001	15	0.5%		15	<0.001	4	0.1%	-	45	0.27
BP Non-user	3,104	50.1%	277	8.9%	0.15	0.26		100	3.2%	0.08	0.25		9	0.3%	0.14	1.45	
Age 41-50	17,096	100.0%	894	5.2%				270	1.6%				54	0.3%			
BP User	8,551	50.0%	188	2.2%	0.		<0.001	48	0.6%		21	<0.001	14	0.2%		35	<0.001
BP Non-user	8,545	50.0%	706	8.3%	0.21	0.29		222	2.6%	0.15	0.29		40	0.5%	0.19	0.64	
Age 51-60	131,445	100.0%	5,765	4.4%				2,371	1.8%				397	0.3%			
BP User	65,721	50.0%	1,104	1.7%	0.		<0.001	456	0.7%		23	<0.001	83	0.1%		26	<0.001
BP Non-user	65,724	50.0%	4,661	7.1%	0.21	0.24		1,915	2.9%	0.21	0.26		314	0.5%	0.21	0.34	
Age 61-70	313,822	100.0%	10,438	3.3%				5,029	1.6%				1,035	0.3%			
BP User	156,878	50.0%	1,843	1.2%	0.		<0.001	939	0.6%		23	<0.001	173	0.1%	_	20	<0.001
BP Non-user	156,944	50.0%	8,595	5.5%	0.20	0.22		4,090	2.6%	0.21	0.24		862	0.5%	0.17	0.24	
Age 71-80	280,803	100.0%	7,179	2.6%				4,827	1.7%				1,212	0.4%			
BP User	140,437	50.0%	1,309	0.9%	0.		<0.001	877	0.6%		22	<0.001	234	0.2%		24	<0.001
BP Non-user	140,366	50.0%	5,870	4.2%	0.20	0.23		3,950	2.8%	0.20	0.23		978	0.7%	0.21	0.27	
Age ≥81	149,118	100.0%	3,459	2.3%				3,663	2.5%				997	0.7%			
BP User	74,560	50.0%	658	0.9%	0.		< 0.001	687	0.9%		22	< 0.001	205	0.3%		26	<0.001
BP Non-user	74,558	50.0%	2,801	3.8%	0.21	0.25		2,976	4.0%	0.21	0.24		792	1.1%	0.22	0.30	
Female Patients	811,497	100.0%	24,936	3.1%				14,367	1.8%				3,127	0.4%			
BP User	405,751	50.0%	4,519	1.1%	0.	21	< 0.001	2,667	0.7%	0.	22	< 0.001	593	0.1%	0.	23	<0.001
BP Non-user	405,746	50.0%	20,417	5.0%	0.21	0.22		11,700	2.9%	0.21	0.23		2,534	0.6%	0.21	0.25	
By Age																	
Age ≤20	885	100.0%	26	2.9%				7	0.8%				1	0.1%			
BP User	442	49.9%	11	2.5%	0.	73	0.43	1	0.2%	0.	17	0.12	1	0.2%	N	A	NA
BP Non-user	443	50.1%	15	3.4%	0.33	1.60	1	6	1.4%	0.02	1.38	1	0	0.0%	NA	NA	
Age 21-40	3,765	100.0%	218	5.8%				64	1.7%				9	0.2%			
BP User	1,879	49.9%	40	2.1%	0.	21	< 0.001	12	0.6%	0.	23	< 0.001	3	0.2%	0.	50	0.51
BP Non-user	1,886	50.1%	178	9.4%	0.15	0.30		52	2.8%	0.12	0.43		6	0.3%	0.13	2.01	
Age 41-50	13,542	100.0%	730	5.4%				206	1.5%				37	0.3%			
BP User	6,774	50.0%	157	2.3%	0.	26	< 0.001	43	0.6%	0.	26	< 0.001	11	0.2%	0.	42	0.01
BP Non-user	6,768	50.0%	573	8.5%	0.21	0.31	ĺ	163	2.4%	0.18	0.36	ĺ	26	0.4%	0.21	0.85	
Age 51-60	119,205	100.0%	5,200	4.4%				2,093	1.8%				327	0.3%			
BP User	59,602	50.0%	973	1.6%	0.	22	< 0.001	399	0.7%	0.	23	< 0.001	64	0.1%	0.	24	<0.001
BP Non-user	59,603	50.0%	4,227	7.1%	0.20	0.23	1	1,694	2.8%	0.21	0.26	1	263	0.4%	0.18	0.32	
Age 61-70	290,276	100.0%	9,474	3.3%				4.506	1.6%				885	0.3%			

BP User	145,131	50.0%	1,639	1.1%	0.20	)	<0.001	851	0.6%	0.	23	<0.001	144	0.1%	0.	19	<0.001
BP Non-user	145,145	50.0%	7,835	5.4%	0.19 (	0.21		3,655	2.5%	0.21	0.25		741	0.5%	0.16	0.23	
Age 71-80	253,094	100.0%	6,304	2.5%				4,254	1.7%				1,026	0.4%			
BP User	126,559	50.0%	1,140	0.9%	0.21		<0.001	769	0.6%	0.	22	< 0.001	193	0.2%	0.1	23	<0.001
BP Non-user	126,535	50.0%	5,164	4.1%	0.20 (	0.23		3,485	2.8%	0.20	0.23		833	0.7%	0.20	0.27	
Age ≥81	130,730	100.0%	2,984	2.3%				3,237	2.5%				842	0.6%			
BP User	65,364	50.0%	559	0.9%	0.22	2	<0.001	592	0.9%	0.	22	<0.001	177	0.3%	0.3	26	<0.001
BP Non-user	65,366	50.0%	2,425	3.7%	0.20 0	0.25		2,645	4.0%	0.20	0.24		665	1.0%	0.22	0.31	
Male Patients	89,235	100.0%	3,201	3.6%				1,922	2.2%				583	0.7%			
BP User	44,615	50.0%	670	1.5%	0.25	5	<0.001	357	0.8%	0.	22	<0.001	122	0.3%	0.1	26	<0.001
BP Non-user	44,620	50.0%	2,531	5.7%	0.23 (	0.28		1,565	3.5%	0.20	0.25		461	1.0%	0.22	0.32	
By Age																	
Age ≤20	1,368	100.0%	41	3.0%				7	0.5%				1	0.1%			
BP User	686	50.1%	18	2.6%	0.77	7	0.42	1	0.1%	0.	16	0.07	1	0.1%	N	A	NA
BP Non-user	682	49.9%	23	3.4%	0.41 1	1.44		6	0.9%	0.02	1.37		0	0.0%	NA	NA	
Age 21-40	2,430	100.0%	117	4.8%				51	2.1%				4	0.2%			
BP User	1,212	49.9%	18	1.5%	0.17	7	<0.001	3	0.2%	0.	06	< 0.001	1	0.1%	0.	33	0.63
BP Non-user	1,218	50.1%	99	8.1%	0.10 (	0.28		48	3.9%	0.02	0.19		3	0.2%	0.03	3.22	
Age 41-50	3,554	100.0%	164	4.6%				64	1.8%				17	0.5%			
BP User	1,777	50.0%	31	1.7%	0.22	2	<0.001	5	0.3%	0.	08	< 0.001	3	0.2%	0.1	21	0.01
BP Non-user	1,777	50.0%	133	7.5%	0.15 (	0.33		59	3.3%	0.03	0.21		14	0.8%	0.06	0.74	
Age 51-60	12,240	100.0%	565	4.6%				278	2.3%				70	0.6%			
BP User	6,119	50.0%	131	2.1%	0.29	)	<0.001	57	0.9%	0.	25	< 0.001	19	0.3%	0.3	37	<0.001
BP Non-user	6,121	50.0%	434	7.1%	0.24 (	0.35		221	3.6%	0.19	0.34		51	0.8%	0.22	0.63	
Age 61-70	23,546	100.0%	964	4.1%				523	2.2%				150	0.6%			
BP User	11,747	49.9%	204	1.7%	0.26	6	<0.001	88	0.7%	0.	20	< 0.001	29	0.2%	0.1	24	< 0.001
BP Non-user	11,799	50.1%	760	6.4%	0.22 (	0.30		435	3.7%	0.16	0.25		121	1.0%	0.16	0.36	
Age 71-80	27,709	100.0%	875	3.2%				573	2.1%				186	0.7%			
BP User	13,878	50.1%	169	1.2%	0.23	}	<0.001	108	0.8%	0.	23	< 0.001	41	0.3%	0.1	28	<0.001
BP Non-user	13,831	49.9%	706	5.1%	0.19 (	0.27		465	3.4%	0.18	0.28		145	1.0%	0.20	0.40	
Age ≥81	18,388	100.0%	475	2.6%				426	2.3%				155	0.8%			
BP User	9,196	50.0%	99	1.1%	0.26	3	<0.001	95	1.0%	0.	28	< 0.001	28	0.3%	0.1	22	<0.001
BP Non-user	9,192	50.0%	376	4.1%	0.20 0	0.32		331	3.6%	0.22	0.35		127	1.4%	0.14	0.33	
		0 = 0 /	<i>e</i>		· · · · · ·												

BP: bisphosphonate; LL: lower 95% confidence interval level; NA: not applicable; OR: odds ratio; UL: upper 95% confidence interval level

#### 2615 Table S3b: Unadjusted COVID-19-Related Outcomes Stratified by Age, Sex, & Age by Sex; Matched Primary Analysis Cohort, 2616 2617 Region=Northeast

							Regio	n=North	east M	atche	d							
	A	11		SAR	S-CoV-2	2 Test			COVI	D-19 Di	iagnosi	s	COVID-19 Hospitalization					
	N	%	N	%		RUL	p-value	N	%			p-value	N	%		RUL	p-value	
All Patients	238,988	100.0%	8,831	3.7%		_		7,820	3.3%		_		1,505	0.6%				
BP User	119,494	50.0%	1,684	1.4%	0.2	22	<0.001	1,578	1.3%	0.	.24	< 0.001	314	0.3%	0.	26	<0.001	
BP Non-user	119,494	50.0%	7,147	6.0%	0.21	0.24		6,242	5.2%	0.23	0.26		1,191	1.0%	0.23	0.30		
By Age																		
Age ≤20	474	100.0%	14	3.0%				7	1.5%				2	0.4%				
BP User	236	49.8%	7	3.0%	1.0	01	0.99	2	0.8%	0.	.40	0.45	2	0.8%	N	A	NA	
BP Non-user	238	50.2%	7	2.9%	0.35	2.92		5	2.1%	0.08	2.07		0	0.0%	NA	NA		
Age 21-40	1,528	100.0%	93	6.1%				55	3.6%				5	0.3%				
BP User	764	50.0%	14	1.8%	0.1	16	<0.001	7	0.9%	0.	.14	<0.001	1	0.1%	0.	25	0.37	
BP Non-user	764	50.0%	79	10.3%	0.09	0.29		48	6.3%	0.06	0.31		4	0.5%	0.03	2.23		
Age 41-50	4,084	100.0%	234	5.7%				118	2.9%				18	0.4%				
BP User	2,042	50.0%	53	2.6%	0.3		<0.001	17	0.8%	0.	.16	<0.001	6	0.3%	0.	50	0.16	
BP Non-user	2,042	50.0%	181	8.9%	0.20	0.37		101	4.9%	0.10	0.27		12	0.6%	0.19	1.33		
Age 51-60	36,020	100.0%	1,863	5.2%				1,190	3.3%				160	0.4%				
BP User	18,010	50.0%	353	2.0%	0.3	22	<0.001	237	1.3%	0.	.24	<0.001	38	0.2%	0.	31	<0.001	
BP Non-user	18,010	50.0%	1,510	8.4%	0.19	0.25		953	5.3%	0.21	0.28		122	0.7%	0.22	0.45		
Age 61-70	82,233	100.0%	3,200	3.9%				2,424	2.9%				403	0.5%				
BP User	41,094	50.0%	597	1.5%	0.3	22	<0.001	507	1.2%	0.	.26	<0.001	79	0.2%	0.	24	<0.001	
BP Non-user	41,139	50.0%	2,603	6.3%	0.20	0.24		1,917	4.7%	0.23	0.28		324	0.8%	0.19	0.31		
Age 71-80	74,831	100.0%	2,266	3.0%				2,306	3.1%				493	0.7%				
BP User	37,438	50.0%	442	1.2%	0.3	23	<0.001	475	1.3%	0.	.25	<0.001	99	0.3%	0.	25	<0.001	
BP Non-user	37,393	50.0%	1,824	4.9%	0.21	0.26		1,831	4.9%	0.23	0.28		394	1.1%	0.20	0.31		
Age ≥81	39,818	100.0%	1,161	2.9%				1,720	4.3%				424	1.1%				
BP User	19,910	50.0%	218	1.1%	0.3	22	<0.001	333	1.7%	0.	.23	<0.001	89	0.4%	0.	26	<0.001	
BP Non-user	19,908	50.0%	943	4.7%	0.19	0.26		1,387	7.0%	0.20	0.26		335	1.7%	0.21	0.33		
Female Patients	216,273	100.0%	7,897	3.7%				6,941	3.2%				1,263	0.6%				
BP User	108,136	50.0%	1,483	1.4%	0.3	22	<0.001	1,392	1.3%	0.	.24	<0.001	255	0.2%	0.	25	<0.001	
BP Non-user	108,137	50.0%	6,414	5.9%	0.21	0.23		5,549	5.1%	0.23	0.26		1,008	0.9%	0.22	0.29		
By Age																		
Age ≤20	180	100.0%	4	2.2%				3	1.7%				1	0.6%				
BP User	90	50.0%	2	2.2%	1.0	00	1.00	1	1.1%	0.	49	1.00	1	1.1%	N	A	NA	
BP Non-user	90	50.0%	2	2.2%	0.14	7.26		2	2.2%	0.04	5.55		0	0.0%	NA	NA		
Age 21-40	864	100.0%	59	6.8%				32	3.7%				4	0.5%				
BP User	431	49.9%	10	2.3%	0.	19	<0.001	6	1.4%		.22	<0.001	1	0.2%		33	0.62	
BP Non-user	433	50.1%	49	11.3%	0.09	0.37		26	6.0%	0.09	0.54		3	0.7%	0.03	3.22		
Age 41-50	3,176	100.0%	176	5.5%				87	2.7%				13	0.4%				
BP User	1,588	50.0%	40	2.5%	0.3		<0.001	15	0.9%	0.	.20	<0.001	5	0.3%		62	0.40	
BP Non-user	1,588	50.0%	136	8.6%	0.19	0.40		72	4.5%	0.11	0.35		8	0.5%	0.20	1.91		
Age 51-60	32,612	100.0%	1,690	5.2%				1,048	3.2%				125	0.4%				
BP User	16,306	50.0%	310	1.9%	0.3	21	<0.001	206	1.3%	0.	.24	<0.001	31	0.2%	0.	33	<0.001	
BP Non-user	16,306	50.0%	1,380	8.5%	0.18	0.24		842	5.2%	0.20	0.27		94	0.6%	0.22	0.49		
Age 61-70	76,403	100.0%	2,933	3.8%				2,181	2.9%				343	0.4%				

BP User	38,200	50.0%	536	1.4%	0.21	< 0.001	456	1.2%	0.2	6	<0.001	63	0.2%	0.2	22	< 0.001
BP Non-user	38,203	50.0%	2,397	6.3%	0.19 0.23		1,725	4.5%	0.23	0.28		280	0.7%	0.17	0.29	
Age 71-80	67,857	100.0%	2,021	3.0%			2,063	3.0%				416	0.6%			
BP User	33,930	50.0%	393	1.2%	0.23	<0.001	413	1.2%	0.2	4	<0.001	77	0.2%	0.2	23	<0.001
BP Non-user	33,927	50.0%	1,628	4.8%	0.21 0.26		1,650	4.9%	0.22	0.27		339	1.0%	0.18	0.29	
Age ≥81	35,181	100.0%	1,014	2.9%			1,527	4.3%				361	1.0%			
BP User	17,591	50.0%	192	1.1%	0.23	<0.001	295	1.7%	0.2	3	<0.001	77	0.4%	0.:	27	<0.001
BP Non-user	17,590	50.0%	822	4.7%	0.19 0.26		1,232	7.0%	0.20	0.26		284	1.6%	0.21	0.34	
Male Patients	22,715	100.0%	934	4.1%			879	3.9%				242	1.1%			
BP User	11,358	50.0%	201	1.8%	0.26	<0.001	186	1.6%	0.2	6	<0.001	59	0.5%	0.3	32	< 0.001
BP Non-user	11,357	50.0%	733	6.5%	0.22 0.31		693	6.1%	0.22	0.30		183	1.6%	0.24	0.43	
By Age																
Age ≤20	294	100.0%	10	3.4%			4	1.4%				1	0.3%			
BP User	146	49.7%	5	3.4%	1.01	0.98	1	0.7%	0.3	3	0.62	1	0.7%	N	A	NA
BP Non-user	148	50.3%	5	3.4%	0.29 3.58		3	2.0%	0.03	3.24		0	0.0%	NA	NA	
Age 21-40	664	100.0%	34	5.1%			23	3.5%				1	0.2%			
BP User	333	50.2%	4	1.2%	0.12	<0.001	1	0.3%	0.0	4	<0.001	0	0.0%	N	A	NA
BP Non-user	331	49.8%	30	9.1%	0.04 0.35		22	6.6%	0.01	0.32		1	0.3%	NA	NA	
Age 41-50	908	100.0%	58	6.4%			31	3.4%				5	0.6%			
BP User	454	50.0%	13	2.9%	0.27	<0.001	2	0.4%	0.0	6	<0.001	1	0.2%	0.:	25	0.37
BP Non-user	454	50.0%	45	9.9%	0.14 0.50		29	6.4%	0.02	0.27		4	0.9%	0.03	2.23	
Age 51-60	3,408	100.0%	173	5.1%			142	4.2%				35	1.0%			
BP User	1,704	50.0%	43	2.5%	0.31	<0.001	31	1.8%	0.2	7	<0.001	7	0.4%	0.:	25	<0.001
BP Non-user	1,704	50.0%	130	7.6%	0.22 0.45		111	6.5%	0.18	0.40		28	1.6%	0.11	0.57	
Age 61-70	5,830	100.0%	267	4.6%			243	4.2%				60	1.0%			
BP User	2,894	49.6%	61	2.1%	0.29	<0.001	51	1.8%	0.2	6	<0.001	16	0.6%	0.3	37	<0.001
BP Non-user	2,936	50.4%	206	7.0%	0.21 0.38		192	6.5%	0.19	0.35		44	1.5%	0.21	0.65	
Age 71-80	6,974	100.0%	245	3.5%			243	3.5%				77	1.1%			
BP User	3,508	50.3%	49	1.4%	0.24	<0.001	62	1.8%	0.3	3	<0.001	22	0.6%	0.3	39	<0.001
BP Non-user	3,466	49.7%	196	5.7%	0.17 0.32		181	5.2%	0.24	0.44		55	1.6%	0.24	0.64	
Age ≥81	4,637	100.0%	147	3.2%			193	4.2%				63	1.4%			
BP User	2,319	50.0%	26	1.1%	0.21	<0.001	38	1.6%	0.2	3	<0.001	12	0.5%	0.2	23	<0.001
BP Non-user	2,318	50.0%	121	5.2%	0.13 0.32		155	6.7%	0.16	0.33		51	2.2%	0.12	0.43	

BP: bisphosphonate; LL: lower 95% confidence interval level; NA: not applicable; OR: odds ratio; UL: upper 95% confidence interval level

#### 2620 Table S3c: Unadjusted COVID-19-Related Outcomes Stratified by Age, Sex, & Age by Sex; Matched Primary Analysis Cohort, 2621 2622 Region=Midwest

							Regio	n=Midw	est Mat	ched									
	A	JI		SAR	S-CoV-	2 Test			COVI	D-19 Di	agnosi	s	COVID-19 Hospitalization						
	N			0/	C	R		N	0/	0	R			0/	C	DR			
	N	%	N	%	LL	UL	p-value	N	%	LL	UL	p-value	N	%	LL	UL	p-value		
All Patients	151,802	100.0%	4,451	2.9%				2,099	1.4%				636	0.4%					
BP User	75,901	50.0%	868	1.1%	0.	23	< 0.001	383	0.5%	0.	22	< 0.001	121	0.2%	0.	.23	<0.001		
BP Non-user	75,901	50.0%	3,583	4.7%	0.22	0.25		1,716	2.3%	0.20	0.25		515	0.7%	0.19	0.29			
By Age																			
Age ≤20	537	100.0%	15	2.8%				2	0.4%				0	0.0%					
BP User	268	49.9%	6	2.2%	0.	66	0.44	0	0.0%	N	A	NA	0	0.0%	N	A	NA		
BP Non-user	269	50.1%	9	3.3%	0.23	1.89		2	0.7%	NA	NA		0	0.0%	NA	NA			
Age 21-40	1,188	100.0%	62	5.2%				17	1.4%				1	0.1%					
BP User	593	49.9%	7	1.2%	0.	12	< 0.001	2	0.3%	0.	13	0.002	0	0.0%	N	A	NA		
BP Non-user	595	50.1%	55	9.2%	0.05	0.26		15	2.5%	0.03	0.57		1	0.2%	NA	NA			
Age 41-50	3.367	100.0%	184	5.5%				46	1.4%				16	0.5%					
BP User	1.684	50.0%	36	2.1%	0.	23	< 0.001	10	0.6%	0.	27	< 0.001	2	0.1%	0.	14	0.002		
BP Non-user	1,683	50.0%	148	8.8%	0.16	0.33		36	2.1%	0.14	0.55		14	0.8%	0.03	0.62			
Age 51-60	24,478	100.0%	951	3.9%				293	1.2%				80	0.3%					
BP User	12,238	50.0%	180	1.5%	0.	22	< 0.001	52	0.4%	0.	21	< 0.001	15	0.1%	0.	.23	< 0.001		
BP Non-user	12.240	50.0%	771	6.3%	0.19	0.26		241	2.0%	0.16	0.29		65	0.5%	0.13	0.40			
Age 61-70	56.991	100.0%	1.764	3.1%	0.10	0.20		671	1.2%	0.10	0.20		189	0.3%	0.10	00			
BP User	28.496	50.0%	322	1.1%	0	21	< 0.001	123	0.4%	0	22	< 0.001	35	0.1%	0	.23	< 0.001		
BP Non-user	28,495	50.0%	1.442	5.1%	0.19	0.24	0.001	548	1.9%	0.18	0.27	0.001	154	0.5%	0.16	0.33	0.001		
Age 71-80	42.153	100.0%	1.009	2.4%	0.10	0.21		577	1.4%	0.10	0.21		200	0.5%	0.10	0.00			
BP User	21.078	50.0%	209	1.0%	0	25	< 0.001	95	0.5%	0	19	< 0.001	37	0.2%	0	.23	< 0.001		
BP Non-user	21,075	50.0%	800	3.8%	0.22	0.30	0.001	482	2.3%	0.16	0.24	0.001	163	0.8%	0.16	0.32	0.001		
Age ≥81	23,088	100.0%	466	2.0%	0.22	0.00		493	2.1%	00	0.2.		150	0.6%	0.10	0.02			
BP User	11.544	50.0%	108	0.9%	0	30	< 0.001	101	0.9%	0	25	< 0.001	32	0.3%	0	.27	< 0.001		
BP Non-user	11.544	50.0%	358	3.1%	0.24	0.37	0.001	392	3.4%	0.20	0.31	0.001	118	1.0%	0.18	0.40	0.001		
Female Patients	137,028	100.0%	3.945	2.9%	0.24	0.07		1,828	1.3%	0.20	0.01		543	0.4%	0.10	0.40			
BP User	68,512	50.0%	762	1.1%	0	23	< 0.001	333	0.5%	0	22	< 0.001	103	0.2%	0	.23	< 0.001		
BP Non-user	68.516	50.0%	3,183	4.6%	0.21	0.25	-0.001	1,495	2.2%	0.19	0.25	\$0.001	440	0.6%	0.19	0.29	-0.001		
By Age	00,010	30.070	0,100	4.070	0.21	0.20		1,400	2.270	0.15	0.20		440	0.070	0.15	0.25			
Age ≤20	226	100.0%	7	3.1%				1	0.4%				0	0.0%					
BP User	113	50.0%	3	2.7%	0	74	1.00	0	0.4%	N	Δ	NA	0	0.0%	N	A	NA		
BP Non-user	113	50.0%	4	3.5%	0.16	3.40	1.00	1	0.0%	NA	NA		0	0.0%	NA	NA			
Age 21-40	700	100.0%	34	4.9%	0.10	5.40		7	1.0%	11/4	IN/A		0	0.0%	11/4				
BP User	349	49.9%	6	4.9%	0	20	<0.001	1	0.3%	0	17	0.12	0	0.0%	N	A	NA		
BP User BP Non-user	349	49.9% 50.1%	28	8.0%	0.08	0.49	<b>\0.001</b>	6	1.7%	0.02	1.38	0.12	0	0.0%	NA	NA	IN/A		
Age 41-50	2.639	100.0%	157	5.9%	0.00	0.49		32	1.7%	0.02	1.50		10	0.0%	IN/A	IN/A			
BP User	1,319	50.0%	31	2.4%	0	23	<0.001	32 8	0.6%	0	33	0.005	10	0.4%	0	.11	0.02		
BP User BP Non-user	1,319	50.0%	126	9.5%	0.15	23	<0.00T	0 24	1.8%	0.15	0.74	0.005	9	0.1%	0.01	0.87	0.02		
	22.101	100.0%	856	9.5%	0.15	0.34		24	1.8%	0.15	0.74		9 70	0.7%	0.01	0.07			
Age 51-60	, -				0	22	<0.004			0	22	<0.004			0	22	-0.004		
BP User	11,050	50.0%	159	1.4%	÷.	22	<0.001	47	0.4%	0.	22	<0.001	13	0.1%	-	.23	<0.001		
BP Non-user	11,051	50.0%	697	6.3%	0.18	0.26		213	1.9%	0.16	0.30		57	0.5%	0.12	0.42			
Age 61-70	52,520	100.0%	1,594	3.0%				591	1.1%				165	0.3%					

BP User	26,260	50.0%	286	1.1%	0.	21	< 0.001	107	0.4%	0.2	22	< 0.001	29	0.1%	0.1	21	< 0.001
BP Non-user	26,260	50.0%	1,308	5.0%	0.18	0.24		484	1.8%	0.18	0.27		136	0.5%	0.14	0.32	
Age 71-80	38,367	100.0%	877	2.3%				501	1.3%				172	0.4%			
BP User	19,184	50.0%	180	0.9%	0.	25	<0.001	85	0.4%	0.3	20	<0.001	33	0.2%	0.1	24	< 0.001
BP Non-user	19,183	50.0%	697	3.6%	0.21	0.30		416	2.2%	0.16	0.25		139	0.7%	0.16	0.35	
Age ≥81	20,475	100.0%	420	2.1%				436	2.1%				126	0.6%			
BP User	10,237	50.0%	97	0.9%	0.	29	<0.001	85	0.8%	0.3	24	<0.001	27	0.3%	0.1	27	<0.001
BP Non-user	10,238	50.0%	323	3.2%	0.23	0.37		351	3.4%	0.19	0.30		99	1.0%	0.18	0.41	
Male Patients	14,774	100.0%	506	3.4%				271	1.8%				93	0.6%			
BP User	7,389	50.0%	106	1.4%	0.	25	<0.001	50	0.7%	0.2	22	<0.001	18	0.2%	0.1	24	<0.001
BP Non-user	7,385	50.0%	400	5.4%	0.20	0.32		221	3.0%	0.16	0.30		75	1.0%	0.14	0.40	
By Age																	
Age ≤20	311	100.0%	8	2.6%				1	0.3%				0	0.0%			
BP User	155	49.8%	3	1.9%	0.	60	0.72	0	0.0%	N	A	NA	0	0.0%	N	A	NA
BP Non-user	156	50.2%	5	3.2%	0.14	2.54		1	0.6%	NA	NA		0	0.0%	NA	NA	
Age 21-40	488	100.0%	28	5.7%				10	2.0%				1	0.2%			
BP User	244	50.0%	1	0.4%	0.	03	<0.001	1	0.4%	0.	11	0.02	0	0.0%	N	A	NA
BP Non-user	244	50.0%	27	11.1%	0.00	0.25		9	3.7%	0.01	0.85		1	0.4%	NA	NA	
Age 41-50	728	100.0%	27	3.7%				14	1.9%				6	0.8%			
BP User	365	50.1%	5	1.4%	0.	22	<0.001	2	0.5%	0.	16	0.007	1	0.3%	0.1	20	0.12
BP Non-user	363	49.9%	22	6.1%	0.08	0.57		12	3.3%	0.04	0.73		5	1.4%	0.02	1.69	
Age 51-60	2,377	100.0%	95	4.0%				33	1.4%				10	0.4%			
BP User	1,188	50.0%	21	1.8%	0.	27	< 0.001	5	0.4%	0.1	18	< 0.001	2	0.2%	0.1	25	0.11
BP Non-user	1,189	50.0%	74	6.2%	0.17	0.44		28	2.4%	0.07	0.46		8	0.7%	0.05	1.17	
Age 61-70	4,471	100.0%	170	3.8%				80	1.8%				24	0.5%			
BP User	2,236	50.0%	36	1.6%	0.	26	<0.001	16	0.7%	0.3	24	<0.001	6	0.3%	0.3	33	0.01
BP Non-user	2,235	50.0%	134	6.0%	0.18	0.37		64	2.9%	0.14	0.42		18	0.8%	0.13	0.84	
Age 71-80	3,786	100.0%	132	3.5%				76	2.0%				28	0.7%			
BP User	1,894	50.0%	29	1.5%	0.	27	<0.001	10	0.5%	0.	15	<0.001	4	0.2%	0.	16	< 0.001
BP Non-user	1,892	50.0%	103	5.4%	0.18	0.41		66	3.5%	0.08	0.29		24	1.3%	0.06	0.48	
Age ≥81	2,613	100.0%	46	1.8%				57	2.2%				24	0.9%			
BP User	1,307	50.0%	11	0.8%	0.	31	<0.001	16	1.2%	0.3	38	<0.001	5	0.4%	0.3	26	0.004
BP Non-user	1,306	50.0%	35	2.7%	0.16	0.61		41	3.1%	0.21	0.69		19	1.5%	0.10	0.70	

BP: bisphosphonate; LL: lower 95% confidence interval level; NA: not applicable; OR: odds ratio; UL: upper 95% confidence interval level

### 2626 Table S3d: Unadjusted COVID-19-Related Outcomes Stratified by Age, Sex, & Age by Sex; Matched Primary Analysis Cohort, 2627 2628 Region=South

							Reg	gion=So	uth Mat	tched							
	Α	11		SAR	S-CoV-	2 Test			COVI	D-19 Di	agnosi	s		COVID	D-19 Ho	spitalizat	ion
	N	%	N	%	O LL		p-value	N	%			p-value	N	%		DR UL	p-value
All Patients	319,408	100.0%	8,418	2.6%				3,535	1.1%			-	849	0.3%			
BP User	159,704	50.0%	1,553	1.0%	0.2	22	<0.001	624	0.4%	0.	21	< 0.001	167	0.1%	0	.24	< 0.001
BP Non-user	159,704	50.0%	6,865	4.3%	0.21	0.23		2,911	1.8%	0.19	0.23		682	0.4%	0.21	0.29	
By Age																	
Age ≤20	943	100.0%	29	3.1%				4	0.4%				0	0.0%			
BP User	474	50.3%	15	3.2%	1.0	06	0.87	0	0.0%	N	IA	NA	0	0.0%	1	NA	NA
BP Non-user	469	49.7%	14	3.0%	0.51	2.23		4	0.9%	NA	NA		0	0.0%	NA	NA	
Age 21-40	2,364	100.0%	113	4.8%				25	1.1%				4	0.2%			
BP User	1,177	49.8%	20	1.7%	0.2		<0.001	4	0.3%	0.	19	< 0.001	2	0.2%	1	.01	1.00
BP Non-user	1,187	50.2%	93	7.8%	0.12	0.33		21	1.8%	0.06	0.55		2	0.2%	0.14	7.17	
Age 41-50	6,839	100.0%	329	4.8%				73	1.1%				10	0.1%			
BP User	3,421	50.0%	72	2.1%	0.2		<0.001	18	0.5%	0.	32	< 0.001	5	0.1%	1	.00	0.99
BP Non-user	3,418	50.0%	257	7.5%	0.20	0.34		55	1.6%	0.19	0.55		5	0.1%	0.29	3.45	
Age 51-60	50,186	100.0%	1,999	4.0%				584	1.2%				103	0.2%			
BP User	25,093	50.0%	393	1.6%	0.2	23	< 0.001	114	0.5%	0.	24	< 0.001	23	0.1%	0	.29	< 0.001
BP Non-user	25,093	50.0%	1,606	6.4%	0.21	0.26		470	1.9%	0.19	0.29		80	0.3%	0.18	0.46	
Age 61-70	111,800	100.0%	3,246	2.9%				1,106	1.0%				247	0.2%			
BP User	55,896	50.0%	583	1.0%	0.2	21	<0.001	191	0.3%	0.	21	< 0.001	38	0.1%	0	.18	< 0.001
BP Non-user	55,904	50.0%	2,663	4.8%	0.19	0.23		915	1.6%	0.18	0.24		209	0.4%	0.13	0.26	
Age 71-80	99,223	100.0%	1,942	2.0%				1,029	1.0%				260	0.3%			
BP User	49,618	50.0%	322	0.6%	0.1	19	<0.001	170	0.3%	0.	20	< 0.001	55	0.1%	0	.27	< 0.001
BP Non-user	49,605	50.0%	1,620	3.3%	0.17	0.22		859	1.7%	0.17	0.23		205	0.4%	0.20	0.36	
Age ≥81	48,053	100.0%	760	1.6%				714	1.5%				225	0.5%			
BP User	24,025	50.0%	148	0.6%	0.2	24	<0.001	127	0.5%	0.	21	< 0.001	44	0.2%	0	.24	< 0.001
BP Non-user	24,028	50.0%	612	2.5%	0.20	0.28		587	2.4%	0.18	0.26		181	0.8%	0.17	0.34	
Female Patients	289,263	100.0%	7,519	2.6%				3,159	1.1%				745	0.3%			
BP User	144,633	50.0%	1,365	0.9%	0.2	21	<0.001	562	0.4%	0.	21	< 0.001	143	0.1%	0	.24	< 0.001
BP Non-user	144,630	50.0%	6,154	4.3%	0.20	0.23		2,597	1.8%	0.19	0.23		602	0.4%	0.20	0.28	
By Age	Í Í		,					Ĺ									
Age ≤20	372	100.0%	11	3.0%				3	0.8%				0	0.0%			
BP User	185	49.7%	6	3.2%	1.2	22	0.75	0	0.0%	N	A	NA	0	0.0%	1	NA	NA
BP Non-user	187	50.3%	5	2.7%	0.37	4.07		3	1.6%	NA	NA		0	0.0%	NA	NA	
Age 21-40	1,543	100.0%	81	5.2%				16	1.0%				3	0.2%			
BP User	770	49.9%	14	1.8%	0.2	20	<0.001	4	0.5%	0.	33	0.08	2	0.3%	2	.01	0.62
BP Non-user	773	50.1%	67	8.7%	0.11	0.35		12	1.6%	0.11	1.03		1	0.1%	0.18	22.22	
Age 41-50	5,569	100.0%	273	4.9%				66	1.2%				9	0.2%			
BP User	2,787	50.0%	65	2.3%	0.3	30	<0.001	18	0.6%	0.	37	< 0.001	5	0.2%	1	.25	1.00
BP Non-user	2,782	50.0%	208	7.5%	0.22	0.39		48	1.7%	0.21	0.64		4	0.1%	0.33	4.65	
Age 51-60	46,012	100.0%	1,819	4.0%				521	1.1%	1			89	0.2%			
BP User	23,007	50.0%	358	1.6%	0.2	23	<0.001	100	0.4%	0.	23	<0.001	16	0.1%	0	.22	< 0.001
BP Non-user	23,005	50.0%	1.461	6.4%	0.21	0.26		421	1.8%	0.19	0.29		73	0.3%	0.13	0.38	
Age 61-70	103,825	100.0%	2.948	2.8%				1.007	1.0%		5.25		218	0.2%			

BP User	51,910	50.0%	517	1.0%	0.2	-	<0.001	177	0.3%	0.		<0.001	33	0.1%	-	.18	<0.001
BP Non-user	51,915	50.0%	2,431	4.7%	0.19	0.23		830	1.6%	0.18	0.25		185	0.4%	0.12	0.26	
Age 71-80	89,474	100.0%	1,729	1.9%				915	1.0%				230	0.3%			
BP User	44,742	50.0%	283	0.6%	0.1	9	<0.001	153	0.3%	0.	20	<0.001	47	0.1%	0	.26	<0.001
BP Non-user	44,732	50.0%	1,446	3.2%	0.17	0.22		762	1.7%	0.17	0.24		183	0.4%	0.19	0.35	
Age ≥81	42,468	100.0%	658	1.5%				631	1.5%				196	0.5%			
BP User	21,232	50.0%	122	0.6%	0.2	2	<0.001	110	0.5%	0.	21	<0.001	40	0.2%	0	.26	<0.001
BP Non-user	21,236	50.0%	536	2.5%	0.18	0.27		521	2.5%	0.17	0.25		156	0.7%	0.18	0.36	
Male Patients	30,145	100.0%	899	3.0%				376	1.2%				104	0.3%			
BP User	15,071	50.0%	188	1.2%	0.2	6	<0.001	62	0.4%	0.	19	<0.001	24	0.2%	0	.30	< 0.001
BP Non-user	15,074	50.0%	711	4.7%	0.22	0.30		314	2.1%	0.15	0.26		80	0.5%	0.19	0.47	
By Age																	
Age ≤20	571	100.0%	18	3.2%				1	0.2%				0	0.0%			
BP User	289	50.6%	9	3.1%	0.9	8	0.96	0	0.0%	N	A	NA	0	0.0%		NA	NA
BP Non-user	282	49.4%	9	3.2%	0.38	2.49		1	0.4%	NA	NA		0	0.0%	NA	NA	
Age 21-40	821	100.0%	32	3.9%				9	1.1%				1	0.1%			
BP User	407	49.6%	6	1.5%	0.2	2	<0.001	0	0.0%	N	A	NA	0	0.0%		NA	NA
BP Non-user	414	50.4%	26	6.3%	0.09	0.55		9	2.2%	NA	NA		1	0.2%	NA	NA	
Age 41-50	1,270	100.0%	56	4.4%				7	0.6%				1	0.1%			
BP User	634	49.9%	7	1.1%	0.1	3	<0.001	0	0.0%	N	A	NA	0	0.0%		NA	NA
BP Non-user	636	50.1%	49	7.7%	0.06	0.30		7	1.1%	NA	NA		1	0.2%	NA	NA	
Age 51-60	4,174	100.0%	180	4.3%				63	1.5%				14	0.3%			
BP User	2,086	50.0%	35	1.7%	0.2	3	<0.001	14	0.7%	0.	28	<0.001	7	0.3%	1	.00	0.99
BP Non-user	2,088	50.0%	145	6.9%		0.33		49	2.3%	0.15	0.51		7	0.3%	0.35	2.86	
Age 61-70	7,975	100.0%	298	3.7%				99	1.2%				29	0.4%			
BP User	3,986	50.0%	66	1.7%	0.2	7	<0.001	14	0.4%	0.	16	<0.001	5	0.1%	0	.21	< 0.00
BP Non-user	3,989	50.0%	232	5.8%	0.21	0.36		85	2.1%	0.09	0.29		24	0.6%	0.08	0.54	
Age 71-80	9,749	100.0%	213	2.2%				114	1.2%				30	0.3%			
BP User	4,876	50.0%	39	0.8%	0.2	2	<0.001	17	0.3%	0.	17	<0.001	8	0.2%	0	.36	0.01
BP Non-user	4,873	50.0%	174	3.6%	0.15	0.31		97	2.0%	0.10	0.29		22	0.5%	0.16	0.81	
Age ≥81	5,585	100.0%	102	1.8%				83	1.5%				29	0.5%			
BP User	2,793	50.0%	26	0.9%	0.3	4	<0.001	17	0.6%	0.	25	<0.001	4	0.1%	0	.16	< 0.00
BP Non-user	2.792	50.0%	76	2.7%		0.53		66	2.4%	0.15			25	0.9%	0.06	0.46	
: bisphosphona	te II · Iou	er 95% c	onfidenc	e inter	val leve	∍I· N∆	· not appli	cable: (	DR· od	de rati	0. I II .	unner 050	% con	fidence	inton	امريما ادر	

### 2632 Table S3e: Unadjusted COVID-19-Related Outcomes Stratified by Age, Sex, & Age by Sex; Matched Primary Analysis Cohort, 2633 2634 Region=West

							Regi	on=Wes	st Match	ned							
	Α	11		SAR	S-CoV-2	2 Test			COVI	D-19 Dia	agnosi	S		COVID	-19 Hos	spitaliza	tion
	Ν	%	N	%		RUL	p-value	N	%	O LL		p-value	N	%		RUL	p-value
All Patients	190,534	100.0%	6,437	3.4%		_		2,835	1.5%				720	0.4%			
BP User	95,267	50.0%	1,084	1.1%	0.	19	<0.001	439	0.5%	0.1		<0.001	113	0.1%	0.	19	<0.001
BP Non-user	95,267	50.0%	5,353	5.6%	0.18	0.21		2,396	2.5%	0.16	0.20		607	0.6%	0.15	0.23	
By Age																	
Age ≤20	299	100.0%	9	3.0%				1	0.3%				0	0.0%			
BP User	150	50.2%	1	0.7%	-	12	0.02	0	0.0%	N		NA	0	0.0%		IA	NA
BP Non-user	149	49.8%	8	5.4%	0.01	0.96		1	0.7%	NA	NA		0	0.0%	NA	NA	
Age 21-40	1,115	100.0%	67	6.0%				18	1.6%				3	0.3%			
BP User	557	50.0%	17	3.1%	0.	32	<0.001	2	0.4%	0.1		0.001	1	0.2%		50	1.00
BP Non-user	558	50.0%	50	9.0%	0.18	0.56		16	2.9%	0.03	0.53		2	0.4%	0.05	5.53	
Age 41-50	2,806	100.0%	147	5.2%				33	1.2%				10	0.4%			
BP User	1,404	50.0%	27	1.9%	0.		<0.001	3	0.2%	0.1		<0.001	1	0.1%		11	0.01
BP Non-user	1,402	50.0%	120	8.6%	0.14	0.32		30	2.1%	0.03	0.32		9	0.6%	0.01	0.87	
Age 51-60	20,761	100.0%	952	4.6%				304	1.5%				54	0.3%			
BP User	10,380	50.0%	178	1.7%		22	<0.001	53	0.5%	0.2		<0.001	7	0.1%		15	<0.001
BP Non-user	10,381	50.0%	774	7.5%	0.18	0.26		251	2.4%	0.15	0.28		47	0.5%	0.07	0.33	
Age 61-70	62,798	100.0%	2,228	3.5%				828	1.3%				196	0.3%			
BP User	31,392	50.0%	341	1.1%	÷.	17	<0.001	118	0.4%		16	<0.001	21	0.1%	-	12	<0.001
BP Non-user	31,406	50.0%	1,887	6.0%	0.15	0.19		710	2.3%	0.13	0.20		175	0.6%	0.08	0.19	
Age 71-80	64,596	100.0%	1,962	3.0%				915	1.4%				259	0.4%			
BP User	32,303	50.0%	336	1.0%		20	<0.001	137	0.4%	0.1		<0.001	43	0.1%	-	20	<0.001
BP Non-user	32,293	50.0%	1,626	5.0%	0.18	0.22		778	2.4%	0.14	0.21		216	0.7%	0.14	0.27	
Age ≥81	38,159	100.0%	1,072	2.8%				736	1.9%				198	0.5%			
BP User	19,081	50.0%	184	1.0%		20	<0.001	126	0.7%	0.2		<0.001	40	0.2%		25	<0.001
BP Non-user	19,078	50.0%	888	4.7%	0.17	0.23		610	3.2%	0.17	0.24		158	0.8%	0.18	0.36	
Female Patients	168,933	100.0%	5,575	3.3%				2,439	1.4%				576	0.3%			
BP User	84,470	50.0%	909	1.1%	0.	19	<0.001	380	0.4%	0.1	-	<0.001	92	0.1%	-	19	<0.001
BP Non-user	84,463	50.0%	4,666	5.5%	0.17	0.20		2,059	2.4%	0.16	0.20		484	0.6%	0.15	0.24	
By Age																	
Age ≤20	107	100.0%	4	3.7%				0	0.0%				0	0.0%			
BP User	54	50.5%	0	0.0%	N		NA	0	0.0%	N		NA	0	0.0%		IA	NA
BP Non-user	53	49.5%	4	7.5%	NA	NA		0	0.0%	NA	NA		0	0.0%	NA	NA	
Age 21-40	658	100.0%	44	6.7%				9	1.4%				2	0.3%			
BP User	329	50.0%	10	3.0%		27	<0.001	1	0.3%	0.		0.04	0	0.0%		IA	NA
BP Non-user	329	50.0%	34	10.3%	0.13	0.56		8	2.4%	0.02	0.98		2	0.6%	NA	NA	
Age 41-50	2,158	100.0%	124	5.7%				21	1.0%				5	0.2%			
BP User	1,080	50.0%	21	1.9%	<b>.</b>	19	<0.001	2	0.2%	0.		<0.001	0	0.0%		IA	NA
BP Non-user	1,078	50.0%	103	9.6%	0.12	0.30		19	1.8%	0.02	0.45		5	0.5%	NA	NA	
Age 51-60	18,480	100.0%	835	4.5%				264	1.4%				43	0.2%			
BP User	9,239	50.0%	146	1.6%	-	20	<0.001	46	0.5%	0.2		<0.001	4	0.0%	-	10	<0.001
BP Non-user	9,241	50.0%	689	7.5%	0.17	0.24		218	2.4%	0.15	0.29		39	0.4%	0.04	0.29	
Age 61-70	57,528	100.0%	1,999	3.5%				727	1.3%				159	0.3%			

BP User	28,761	50.0%	300	1.0%	0.1	17	< 0.001	111	0.4%	0.1	18	< 0.001	19	0.1%	0.	14	< 0.001
BP Non-user	28,767	50.0%	1,699	5.9%	0.15	0.19		616	2.1%	0.14	0.22		140	0.5%	0.08	0.22	
Age 71-80	57,396	100.0%	1,677	2.9%				775	1.4%				208	0.4%			
BP User	28,703	50.0%	284	1.0%	0.3	20	<0.001	118	0.4%	0.1	18	< 0.001	36	0.1%	0.1	21	<0.001
BP Non-user	28,693	50.0%	1,393	4.9%	0.17	0.22		657	2.3%	0.14	0.21		172	0.6%	0.15	0.30	
Age ≥81	32,606	100.0%	892	2.7%				643	2.0%				159	0.5%			
BP User	16,304	50.0%	148	0.9%	0.	19	<0.001	102	0.6%	0.1	18	<0.001	33	0.2%	0.3	26	<0.001
BP Non-user	16,302	50.0%	744	4.6%	0.16	0.23		541	3.3%	0.15	0.23		126	0.8%	0.18	0.38	
Male Patients	21,601	100.0%	862	4.0%				396	1.8%				144	0.7%			
BP User	10,797	50.0%	175	1.6%	0.	24	<0.001	59	0.5%	0.1	17	<0.001	21	0.2%	0.	17	<0.001
BP Non-user	10,804	50.0%	687	6.4%	0.21	0.29		337	3.1%	0.13	0.23		123	1.1%	0.11	0.27	
By Age																	
Age ≤20	192	100.0%	5	2.6%				1	0.5%				0	0.0%			
BP User	96	50.0%	1	1.0%	0.3	24	0.37	0	0.0%	N	A	NA	0	0.0%	N	A	NA
BP Non-user	96	50.0%	4	4.2%	0.03	2.21		1	1.0%	NA	NA		0	0.0%	NA	NA	
Age 21-40	457	100.0%	23	5.0%				9	2.0%				1	0.2%			
BP User	228	49.9%	7	3.1%	0.4	42	0.06	1	0.4%	0.1	12	0.04	1	0.4%	N	A	NA
BP Non-user	229	50.1%	16	7.0%	0.17	1.05		8	3.5%	0.02	0.98		0	0.0%	NA	NA	
Age 41-50	648	100.0%	23	3.5%				12	1.9%				5	0.8%			
BP User	324	50.0%	6	1.9%	0.	34	0.02	1	0.3%	0.0	)9	0.006	1	0.3%	0.1	25	0.37
BP Non-user	324	50.0%	17	5.2%	0.13	0.88		11	3.4%	0.01	0.69		4	1.2%	0.03	2.23	
Age 51-60	2,281	100.0%	117	5.1%				40	1.8%				11	0.5%			
BP User	1,141	50.0%	32	2.8%	0.3	36	<0.001	7	0.6%	0.2	21	<0.001	3	0.3%	0.	37	0.15
BP Non-user	1,140	50.0%	85	7.5%	0.24	0.54		33	2.9%	0.09	0.47		8	0.7%	0.10	1.41	
Age 61-70	5,270	100.0%	229	4.3%				101	1.9%				37	0.7%			
BP User	2,631	49.9%	41	1.6%	0.	21	<0.001	7	0.3%	0.0	)7	<0.001	2	0.1%	0.	06	<0.001
BP Non-user	2,639	50.1%	188	7.1%	0.15	0.29		94	3.6%	0.03	0.16		35	1.3%	0.01	0.24	
Age 71-80	7,200	100.0%	285	4.0%				140	1.9%				51	0.7%			
BP User	3,600	50.0%	52	1.4%	0.2	21	<0.001	19	0.5%	0.1	15	<0.001	7	0.2%	0.	16	<0.001
BP Non-user	3,600	50.0%	233	6.5%	0.16	0.29		121	3.4%	0.09	0.25		44	1.2%	0.07	0.35	
Age ≥81	5,553	100.0%	180	3.2%				93	1.7%				39	0.7%			
BP User	2,777	50.0%	36	1.3%	0.2	24	<0.001	24	0.9%	0.3	34	<0.001	7	0.3%	0.3	22	<0.001
BP Non-user	2,776	50.0%	144	5.2%	0.17	0.35		69	2.5%	0.21	0.55		32	1.2%	0.10	0.49	

BP: bisphosphonate; LL: lower 95% confidence interval level; NA: not applicable; OR: odds ratio; UL: upper 95% confidence interval level

### 2637 Table S3f: Unadjusted COVID-19-Related Outcomes Stratified by Age, Sex, & Age by Sex; Matched Primary Analysis Cohort, 2638 2639 Region=New York State

							Region=	New Yo	rk Stat	e Matc	hed						
	ļ	All		SAR	S-CoV-2	2 Test			COV	/ID-19 D	Diagnosis			COVID	-19 Hos	spitaliza	tion
	N	%	N	%		R	p-value	N	%		OR	p-value	N	%		DR	p-value
					LL	UL	p-value			LL	UL	p-value			LL	UL	p-value
All Patients	99,724	100.0%	3,598	3.6%				3,607	3.6%				622	0.6%			
BP User	49,862	50.0%	772	1.5%	-	26	<0.001	811	1.6%		).28	<0.001	136	0.3%	-	.28	<0.001
BP Non-user	49,862	50.0%	2,826	5.7%	0.24	0.28		2,796	5.6%	0.26	0.30		486	1.0%	0.23	0.34	
By Age																	
Age ≤20	102	100.0%	4	3.9%				2	2.0%				1	1.0%			
BP User	50	49.0%	2	4.0%		04	1.00	1	2.0%		1.04	1.00	1	2.0%		IA	NA
BP Non-user	52	51.0%	2	3.8%	0.14	7.69		1	1.9%	0.06	17.11		0	0.0%	NA	NA	
Age 21-40	453	100.0%	21	4.6%				15	3.3%				1	0.2%			
BP User	228	50.3%	3	1.3%	-	15	<0.001	2	0.9%		).14	0.004	1	0.4%	N	IA	NA
BP Non-user	225	49.7%	18	8.0%	0.04	0.53		13	5.8%	0.03	0.65		0	0.0%	NA	NA	
Age 41-50	1,311	100.0%	77	5.9%				36	2.7%				4	0.3%			
BP User	655	50.0%	22	3.4%		38	<0.001	8	1.2%		).28	< 0.001	1	0.2%		.33	0.62
BP Non-user	656	50.0%	55	8.4%	0.23	0.63		28	4.3%	0.13	0.61		3	0.5%	0.03	3.21	
Age 51-60	12,732	100.0%	688	5.4%				527	4.1%				58	0.5%			
BP User	6,364	50.0%	155	2.4%	0.	27	< 0.001	118	1.9%	(	).28	< 0.001	17	0.3%	0.	41	0.002
BP Non-user	6,368	50.0%	533	8.4%	0.23	0.33		409	6.4%	0.22	0.34		41	0.6%	0.23	0.73	
Age 61-70	32,265	100.0%	1,294	4.0%				1,150	3.6%				141	0.4%			
BP User	16,136	50.0%	277	1.7%	0.	26	<0.001	267	1.7%	(	).29	< 0.001	27	0.2%	0.	24	< 0.001
BP Non-user	16,129	50.0%	1,017	6.3%	0.23	0.30		883	5.5%	0.25	0.33		114	0.7%	0.15	0.36	
Age 71-80	34,693	100.0%	957	2.8%				1,196	3.4%				240	0.7%			
BP User	17,341	50.0%	204	1.2%	0.	26	<0.001	257	1.5%	(	).26	< 0.001	45	0.3%	0.	.23	< 0.001
BP Non-user	17,352	50.0%	753	4.3%	0.22	0.31		939	5.4%	0.23	0.30		195	1.1%	0.17	0.32	
Age ≥81	18,168	100.0%	557	3.1%	-			681	3.7%				177	1.0%	-		
BP User	9,088	50.0%	109	1.2%	0.	23	< 0.001	158	1.7%	(	).29	< 0.001	44	0.5%	0.	.33	< 0.001
BP Non-user	9,080	50.0%	448	4.9%	0.19	0.29		523	5.8%	0.24	0.35		133	1.5%	0.23	0.46	
Female Patients	90.567	100.0%	3,255	3.6%	0.10	0.20		3,235	3.6%	0.21	0.00		537	0.6%	0.20	0.10	
BP User	45,285	50.0%	687	1.5%	0	26	<0.001	726	1.6%	(	).28	< 0.001	108	0.2%	0	.25	< 0.001
BP Non-user	45,282	50.0%	2,568	5.7%	0.24	0.28	0.001	2,509	5.5%	0.26	0.30	10.001	429	0.9%	0.20	0.31	0.001
By Age	10,202	00.070	2,000	0.170	0.21	0.20		2,000	0.070	0.20	0.00		120	0.070	0.20	0.01	
Age ≤20	33	100.0%	0	0.0%				1	3.0%				1	3.0%			
BP User	16	48.5%	0	0.0%	N	A	NA	1	6.3%		NA	NA	1	6.3%	N	A	NA
BP Non-user	17	51.5%	0	0.0%	NA	NA		0	0.0%	NA	NA		0	0.0%	NA	NA	
Age 21-40	261	100.0%	16	6.1%	101			8	3.1%		100		1	0.4%	10.	10.	
BP User	132	50.6%	2	1.5%	0	13	0.002	2	1.5%	(	).32	0.17	1	0.8%	N	A	NA
BP Non-user	129	49.4%	14	10.9%	0.03	0.57	0.002	6	4.7%	0.06	1.59	0.17	0	0.0%	NA	NA	IN/A
Age 41-50	1,032	100.0%	58	5.6%	0.00	0.07		28	2.7%	0.00	1.00		3	0.3%	11/1	11/1	
BP User	516	50.0%	18	3.5%	0	43	0.003	7	1.4%	(	).32	0.007	0	0.0%	N	A	NA
BP Oser BP Non-user	516	50.0%	40	7.8%	0.24	0.76	0.000	21	4.1%	0.14	0.77	0.007	3	0.6%	NA	NA	
Age 51-60	11.699	100.0%	637	5.4%	0.24	0.70		482	4.1%	0.14	0.77		47	0.0%	INA	IN/A	
BP User	5,849	50.0%	138	2.4%	0	26	<0.001	110	4.1%	-	).28	<0.001	47	0.4%	0	.42	0.006
BP User BP Non-user	5,849	50.0%	499	<u>2.4%</u> 8.5%	0.21	26 0.31	<b>\0.001</b>	372	6.4%	0.23	0.35	<b>\0.001</b>	33	0.2%	0.23	0.79	0.000
					0.21	0.51		-	-	0.23	0.35		126		0.23	0.79	
Age 61-70	30,115	100.0%	1,204	4.0%				1,070	3.6%				120	0.4%			

BP User	15.060	50.0%	257	1.7%	0.26	< 0.001	248	1.6%	0.29	< 0.001	23	0.2%	0.22	< 0.001
BP Non-user	15,000	50.0%	947	6.3%	0.20	<0.001	822	5.5%	0.29	<0.001	103	0.2%	0.22	<0.001
Age 71-80	31,385	100.0%	858	2.7%	0.22 0.30		1,052	3.4%	0.23 0.33		208	0.7%	0.14 0.33	
BP User	15.688	50.0%	176	1.1%	0.25	< 0.001	221	1.4%	0.26	< 0.001	33	0.7%	0.19	< 0.001
BP Non-user	15,688	50.0%	682	4.3%	0.23	<0.001	831	5.3%	0.20	<0.001	175	1.1%	0.13 0.27	<0.001
Age ≥81	16.042	100.0%	482	3.0%	0.21 0.30		594	3.7%	0.22 0.30		175	0.9%	0.13 0.27	
BP User	8.024	50.0%	402 96	1.2%	0.24	<0.001	137	1.7%	0.29	<0.001	36	0.9%	0.31	<0.001
BP Non-user	8.024	50.0%	386	4.8%	0.24	<0.001	457	5.7%	0.29	<0.001	115	1.4%	0.31	<0.001
Male Patients	9,157	100.0%	343	3.7%	0.19 0.30		372	4.1%	0.24 0.35		85	0.9%	0.21 0.45	
BP User	4.577	50.0%	343 85	1.9%	0.32	< 0.001	85	1.9%	0.28	< 0.001	<b>05</b> 28	0.9%	0.49	0.002
BP Non-user	4,577	50.0%	258	5.6%	0.32	<0.001	287	6.3%	0.20	<0.001	57	1.2%	0.49	0.002
	4,560	50.0%	230	5.0%	0.25 0.41		207	0.3%	0.22 0.30		57	1.270	0.31 0.77	
By Age	69	100.0%	4	5.8%			1	1.4%			0	0.0%		
Age ≤20 BP User	34		4		1.03	1.00	0	0.0%	NA	NA	0		NA	NA
	34	49.3%		5.9%		1.00	0			NA	-	0.0%		NA
BP Non-user	192	50.7%	2	5.7%	0.14 7.77		7	2.9%	NA NA		0	0.0%	NA NA	
Age 21-40 BP User	96	100.0% 50.0%	5	2.6%	0.24	0.37	0	3.6%	NA	NA	0	0.0%	NA	NA
			1	1.0%	·	0.37	7	7.3%		NA	-			NA
BP Non-user	96	50.0%	4	4.2%	0.03 2.21		'	-	NA NA		0	0.0%	NA NA	
Age 41-50	279	100.0%	19	6.8%		0.00	8	2.9%		0.07	1	0.4%		
BP User	139	49.8%	4	2.9%	0.25	0.02	1	0.7%	0.14	0.07	1	0.7%	NA	NA
BP Non-user	140	50.2%	15	10.7%	0.08 0.76		7	5.0%	0.02 1.13		0	0.0%	NA NA	
Age 51-60	1,033	100.0%	51	4.9%			45	4.4%			11	1.1%		
BP User	515	49.9%	17	3.3%	0.49	0.02	8	1.6%	0.21	<0.001	3	0.6%	0.37	0.22
BP Non-user	518	50.1%	34	6.6%	0.27 0.88		37	7.1%	0.09 0.44		8	1.5%	0.10 1.42	
Age 61-70	2,150	100.0%	90	4.2%			80	3.7%			15	0.7%		
BP User	1,076	50.0%	20	1.9%	0.27	<0.001	19	1.8%	0.30	<0.001	4	0.4%	0.36	0.08
BP Non-user	1,074	50.0%	70	6.5%	0.16 0.45		61	5.7%	0.18 0.50		11	1.0%	0.11 1.14	
Age 71-80	3,308	100.0%	99	3.0%			144	4.4%			32	1.0%		
BP User	1,653	50.0%	28	1.7%	0.38	<0.001	36	2.2%	0.32	<0.001	12	0.7%	0.60	0.16
BP Non-user	1,655	50.0%	71	4.3%	0.25 0.60		108	6.5%	0.22 0.47		20	1.2%	0.29 1.23	
Age ≥81	2,126	100.0%	75	3.5%			87	4.1%			26	1.2%		
BP User	1,064	50.0%	13	1.2%	0.20	<0.001	21	2.0%	0.30	<0.001	8	0.8%	0.44	0.05
BP Non-user	1,062	50.0%	62	5.8%	0.11 0.37		66	6.2%	0.18 0.50		18	1.7%	0.19 1.02	

BP: bisphosphonate; LL: lower 95% confidence interval level; NA: not applicable; OR: odds ratio; UL: upper 95% confidence interval level

#### 2642 Table S4: 'Bone-Rx' Cohort Unadjusted/Adjusted Odds Ratio for COVID-19-Related Outcomes, Stratified by Region and New York 2643 State

2644

			SARS-	-CoV-2 T	est		COVID-	19 Diagr	iosis	C	OVID-19	Hospita	lization
		OR	LL	UL	p value	OR	LL	UL	p value	OR	LL	UL	p value
All	Unadjusted	0.22	0.21	0.22	<0.001	0.22	0.21	0.23	<0.001	0.24	0.22	0.26	<0.001
All	Adjusted	0.22	0.21	0.23	<0.001	0.23	0.22	0.24	<0.001	0.26	0.24	0.29	<0.001
Northeast	Unadjusted	0.22	0.21	0.24	<0.001	0.24	0.23	0.26	<0.001	0.26	0.23	0.30	<0.001
Northeast	Adjusted	0.23	0.21	0.24	<0.001	0.25	0.23	0.26	<0.001	0.29	0.26	0.33	<0.001
Midwest	Unadjusted	0.23	0.22	0.25	<0.001	0.22	0.20	0.25	<0.001	0.23	0.19	0.29	<0.001
Midwest	Adjusted	0.24	0.22	0.26	<0.001	0.24	0.22	0.27	<0.001	0.26	0.21	0.32	<0.001
South	Unadjusted	0.22	0.21	0.23	<0.001	0.21	0.19	0.23	<0.001	0.24	0.21	0.29	<0.001
South	Adjusted	0.22	0.21	0.23	<0.001	0.22	0.20	0.24	<0.001	0.26	0.23	0.30	<0.001
West	Unadjusted	0.19	0.18	0.21	<0.001	0.18	0.16	0.20	<0.001	0.19	0.15	0.23	<0.001
west	Adjusted	0.20	0.18	0.21	<0.001	0.19	0.17	0.21	<0.001	0.20	0.16	0.25	<0.001
New York	Unadjusted	0.26	0.24	0.28	<0.001	0.28	0.26	0.30	<0.001	0.28	0.23	0.34	<0.001
New TOPK	Adjusted	0.26	0.24	0.28	<0.001	0.28	0.26	0.31	<0.001	0.33	0.27	0.40	<0.001

2645

## 2646 Table S5a: Statin Use Sensitivity Analysis, Unadjusted/Adjusted Odds Ratio for COVID-19-Related Outcomes, Stratified by

# 2647 **Region and New York State**

2648

			SARS	-CoV-2 1	Test		COVID-	19 Diag	nosis	С	OVID-19	Hospita	lization
						Stat			Non-users				
		OR	LL	UL	p value	OR	LL	UL	p value	OR	LL	UL	p value
All	Unadjusted	0.90	0.89	0.91	< 0.001	0.91	0.90	0.92	< 0.001	1.12	1.09	1.15	< 0.001
All	Adjusted	0.87	0.86	0.87	< 0.001	0.79	0.78	0.81	<0.001	0.99	0.96	1.02	0.48
Northeast	Unadjusted	0.87	0.85	0.88	<0.001	0.88	0.86	0.90	<0.001	1.16	1.11	1.21	<0.001
Northeast	Adjusted	0.85	0.84	0.87	<0.001	0.77	0.75	0.78	<0.001	1.03	0.98	1.07	0.22
Midwest	Unadjusted	0.97	0.95	0.99	0.02	1.10	1.07	1.14	<0.001	1.27	1.19	1.36	<0.001
mawest	Adjusted	0.92	0.90	0.94	<0.001	0.99	0.96	1.03	0.75	1.15	1.08	1.23	<0.001
South	Unadjusted	0.90	0.88	0.91	<0.001	0.90	0.88	0.93	<0.001	1.00	0.95	1.06	0.90
South	Adjusted	0.85	0.84	0.87	<0.001	0.80	0.78	0.83	<0.001	0.88	0.83	0.94	< 0.001
West	Unadjusted	0.88	0.86	0.90	<0.001	0.83	0.80	0.86	<0.001	1.02	0.95	1.10	0.58
west	Adjusted	0.86	0.83	0.88	<0.001	0.71	0.68	0.74	<0.001	0.87	0.80	0.94	<0.001
New York	Unadjusted	0.91	0.89	0.93	<0.001	0.93	0.91	0.96	<0.001	1.21	1.14	1.29	<0.001
NewTOR	Adjusted	0.92	0.90	0.95	<0.001	0.79	0.77	0.82	<0.001	1.05	0.98	1.13	0.15
					BP Us		us BP No	on-users	among Statin	Users			
		OR	LL	UL	p value	OR	LL	UL	p value	OR	LL	UL	p value
All	Unadjusted	0.23	0.22	0.24	<0.001	0.26	0.25	0.28	<0.001	0.26	0.23	0.29	<0.001
All	Adjusted	0.23	0.22	0.24	<0.001	0.27	0.25	0.29	<0.001	0.28	0.25	0.32	<0.001
Northeast	Unadjusted	0.25	0.23	0.27	<0.001	0.29	0.27	0.31	<0.001	0.28	0.24	0.34	<0.001
Northeast	Adjusted	0.25	0.23	0.27	<0.001	0.29	0.27	0.32	<0.001	0.32	0.26	0.38	<0.001
Midwest	Unadjusted	0.24	0.22	0.27	<0.001	0.22	0.19	0.25	<0.001	0.21	0.16	0.27	<0.001
Midwest	Adjusted	0.25	0.23	0.29	<0.001	0.23	0.22	0.25	<0.001	0.22	0.17	0.30	<0.001
South	Unadjusted	0.22	0.21	0.24	<0.001	0.26	0.23	0.29	<0.001	0.26	0.21	0.33	<0.001
oouin	Adjusted	0.22	0.20	0.24	<0.001	0.27	0.24	0.31	<0.001	0.28	0.22	0.36	<0.001
West	Unadjusted	0.20	0.18	0.22	<0.001	0.22	0.19	0.25	<0.001	0.25	0.20	0.33	<0.001
West	Adjusted	0.20	0.18	0.22	<0.001	0.23	0.20	0.27	<0.001	0.28	0.21	0.36	<0.001
New York	Unadjusted	0.27	0.24	0.30	<0.001	0.31	0.28	0.35	<0.001	0.30	0.23	0.39	<0.001
New York	Adjusted	0.28	0.25	0.32	<0.001	0.31	0.28	0.35	<0.001	0.33	0.25	0.44	<0.001
									mong Statin N				
		OR	LL	UL	p value	OR	LL	UL	p value	OR	LL	UL	p value
All	Unadjusted	0.23	0.21	0.24	<0.001	0.21	0.19	0.23	<0.001	0.21	0.17	0.25	<0.001
7.0	Adjusted	0.24	0.22	0.25	<0.001	0.23	0.21	0.25	<0.001	0.25	0.21	0.30	<0.001
Northeast	Unadjusted	0.25	0.22	0.27	< 0.001	0.22	0.20	0.25	< 0.001	0.24	0.19	0.31	< 0.001
	Adjusted	0.26	0.23	0.29	< 0.001	0.25	0.22	0.28	< 0.001	0.29	0.22	0.37	< 0.001
Midwest	Unadjusted	0.24	0.21	0.28	< 0.001	0.22	0.18	0.27	< 0.001	0.21	0.14	0.31	< 0.001
	Adjusted	0.24	0.20	0.28	< 0.001	0.25	0.20	0.32	< 0.001	0.26	0.17	0.39	< 0.001
South	Unadjusted	0.23	0.21	0.25	<0.001	0.19	0.15	0.22	< 0.001	0.18	0.12	0.27	< 0.001
	Adjusted	0.24	0.21	0.27	<0.001	0.21	0.17	0.25	< 0.001	0.22	0.15	0.33	< 0.001
West	Unadjusted	0.19	0.17	0.22	< 0.001	0.18	0.15	0.22	< 0.001	0.16	0.11	0.25	< 0.001
	Adjusted	0.20	0.17	0.23	< 0.001	0.19	0.18	0.21	< 0.001	0.18	0.11	0.29	< 0.001
New York	Unadjusted	0.26	0.23	0.30	< 0.001	0.26	0.22	0.30	< 0.001	0.27	0.19	0.39	< 0.001
	Adjusted	0.26	0.22	0.31	<0.001	0.25	0.21	0.30	< 0.001	0.35	0.23	0.52	<0.001

2649

### 2650 Table S5b: Antihypertensive Use Sensitivity Analysis, Unadjusted/Adjusted Odds Ratio for COVID-19-Related Outcomes,

# 2651 Stratified by Region and New York State

2652

		0	dds of S	ARS-Co	V-2 Test	Od	ds of CO	VID-19 [	Diagnosis	Odds	of COVI	D-19 Hos	pitalization
					Α	ntihyper	tensive	Users ve	ersus Non-use	rs			
		OR	LL	UL	p value	OR	LL	UL	p value	OR	LL	UL	p value
A 11	Unadjusted	0.91	0.90	0.92	< 0.001	0.86	0.85	0.87	< 0.001	1.13	1.10	1.17	< 0.001
All	Adjusted	0.87	0.86	0.88	< 0.001	0.75	0.74	0.76	< 0.001	0.98	0.95	1.00	0.10
Marthaast	Unadjusted	0.86	0.84	0.87	<0.001	0.83	0.82	0.85	< 0.001	1.20	1.15	1.25	< 0.001
Northeast	Adjusted	0.82	0.81	0.83	< 0.001	0.72	0.71	0.73	< 0.001	1.04	0.99	1.08	0.10
Midwest	Unadjusted	1.00	0.98	1.02	0.98	1.06	1.03	1.10	< 0.001	1.28	1.20	1.36	< 0.001
mawest	Adjusted	0.94	0.91	0.96	<0.001	0.94	0.90	0.97	<0.001	1.11	1.04	1.19	0.002
South	Unadjusted	0.93	0.92	0.94	<0.001	0.88	0.86	0.90	<0.001	1.02	0.96	1.07	0.58
South	Adjusted	0.88	0.87	0.89	<0.001	0.78	0.76	0.80	<0.001	0.89	0.84	0.94	<0.001
West	Unadjusted	0.90	0.88	0.92	<0.001	0.75	0.73	0.78	<0.001	0.99	0.92	1.06	0.83
west	Adjusted	0.87	0.85	0.89	<0.001	0.65	0.62	0.67	<0.001	0.84	0.78	0.90	<0.001
New York	Unadjusted	0.92	0.90	0.94	<0.001	0.90	0.87	0.92	<0.001	1.23	1.15	1.31	<0.001
New York	Adjusted	0.90	0.87	0.92	<0.001	0.75	0.73	0.77	<0.001	1.01	0.95	1.09	0.70
					BP Users ve	rsus BP	Non-use	ers amo	ng Antihypert	ensive U	sers		
		OR	LL	UL	p value	OR	LL	UL	p value	OR	LL	UL	p value
All	Unadjusted	0.23	0.22	0.24	< 0.001	0.26	0.25	0.28	< 0.001	0.26	0.23	0.29	< 0.001
All	Adjusted	0.23	0.22	0.24	<0.001	0.26	0.25	0.28	<0.001	0.27	0.24	0.30	<0.001
Northeast	Unadjusted	0.24	0.22	0.26	<0.001	0.28	0.26	0.31	<0.001	0.27	0.22	0.32	<0.001
Northeast	Adjusted	0.23	0.21	0.26	< 0.001	0.28	0.26	0.31	< 0.001	0.29	0.24	0.34	< 0.001
Midwoot	Unadjusted	0.26	0.23	0.29	<0.001	0.27	0.23	0.31	<0.001	0.27	0.21	0.35	<0.001
Midwest	Adjusted	0.27	0.24	0.30	< 0.001	0.28	0.26	0.30	< 0.001	0.27	0.20	0.35	< 0.001
0 a uth	Unadjusted	0.23	0.21	0.25	< 0.001	0.24	0.22	0.28	< 0.001	0.26	0.20	0.32	<0.001
South	Adjusted	0.23	0.21	0.25	< 0.001	0.24	0.21	0.28	< 0.001	0.25	0.20	0.32	<0.001
Weet	Unadjusted	0.20	0.18	0.22	<0.001	0.21	0.18	0.25	< 0.001	0.24	0.18	0.31	<0.001
West	Adjusted	0.20	0.18	0.22	<0.001	0.22	0.18	0.25	< 0.001	0.24	0.18	0.33	<0.001
New York	Unadjusted	0.26	0.23	0.29	<0.001	0.30	0.26	0.33	< 0.001	0.29	0.22	0.38	< 0.001
New YORK	Adjusted	0.25	0.22	0.29	<0.001	0.30	0.26	0.34	< 0.001	0.33	0.24	0.44	< 0.001
				E	<b>BP Users vers</b>	us BP N	on-users	s among	Antihyperten	sive Nor	-users		
		OR	LL	UL	p value	OR	LL	UL	p value	OR	LL	UL	p value
All	Unadjusted	0.21	0.20	0.22	<0.001	0.20	0.18	0.22	<0.001	0.21	0.17	0.25	<0.001
All	Adjusted	0.21	0.20	0.22	<0.001	0.22	0.20	0.24	<0.001	0.27	0.22	0.32	<0.001
Northeast	Unadjusted	0.21	0.19	0.23	<0.001	0.22	0.19	0.24	<0.001	0.23	0.18	0.31	<0.001
Northeast	Adjusted	0.22	0.20	0.25	<0.001	0.25	0.22	0.28	<0.001	0.30	0.22	0.40	<0.001
Midwest	Unadjusted	0.22	0.19	0.25	<0.001	0.16	0.12	0.20	<0.001	0.20	0.13	0.31	<0.001
Muwest	Adjusted	0.21	0.18	0.25	<0.001	0.18	0.14	0.23	<0.001	0.26	0.16	0.42	<0.001
South	Unadjusted	0.20	0.18	0.22	<0.001	0.19	0.16	0.22	<0.001	0.22	0.15	0.32	<0.001
South	Adjusted	0.20	0.18	0.22	<0.001	0.21	0.17	0.25	<0.001	0.28	0.19	0.41	<0.001
West	Unadjusted	0.19	0.17	0.22	<0.001	0.18	0.15	0.22	<0.001	0.15	0.09	0.24	<0.001
west	Adjusted	0.20	0.17	0.22	<0.001	0.20	0.16	0.25	<0.001	0.19	0.11	0.32	<0.001
New York	Unadjusted	0.26	0.23	0.31	<0.001	0.25	0.21	0.29	<0.001	0.23	0.15	0.36	<0.001
	Adjusted	0.27	0.23	0.32	< 0.001	0.26	0.22	0.31	< 0.001	0.26	0.16	0.43	< 0.001

2653 2654

## 2655 Table S5c: Antidiabetic Use Sensitivity Analysis, Unadjusted/Adjusted Odds Ratio for COVID-19-Related Outcomes, Stratified by

# 2656 **Region and New York State**

2657

		0	dds of S	ARS-Co	V-2 Test	Ode	ds of CO	VID-19	Diagnosis	Odds	of COVI	D-19 Hos	pitalization
									us Non-users				
		OR	LL	UL	p value	OR	LL	UL	p value	OR	LL	UL	p value
A 11	Unadjusted	0.98	0.97	0.99	0.01	1.15	1.13	1.18	< 0.001	1.50	1.45	1.56	<0.001
All	Adjusted	0.92	0.90	0.93	< 0.001	0.88	0.86	0.90	<0.001	1.13	1.08	1.18	<0.001
Northcost	Unadjusted	1.00	0.98	1.02	0.92	1.11	1.09	1.14	<0.001	1.55	1.47	1.64	<0.001
Northeast	Adjusted	0.94	0.92	0.97	< 0.001	0.84	0.81	0.86	<0.001	1.18	1.11	1.27	<0.001
Midwoot	Unadjusted	1.04	1.01	1.08	0.01	1.39	1.33	1.46	<0.001	1.61	1.47	1.76	<0.001
Midwest	Adjusted	0.95	0.91	0.99	0.01	1.11	1.04	1.17	<0.001	1.30	1.17	1.44	<0.001
South	Unadjusted	0.97	0.95	0.99	0.01	1.16	1.12	1.21	<0.001	1.39	1.29	1.50	<0.001
South	Adjusted	0.90	0.88	0.93	<0.001	0.91	0.87	0.95	<0.001	1.04	0.95	1.14	0.40
West	Unadjusted	0.91	0.88	0.94	<0.001	1.07	1.01	1.12	0.01	1.43	1.30	1.58	<0.001
West	Adjusted	0.86	0.82	0.89	<0.001	0.80	0.75	0.85	<0.001	0.97	0.86	1.09	0.60
New York	Unadjusted	1.06	1.03	1.10	<0.001	1.15	1.11	1.19	<0.001	1.59	1.46	1.72	<0.001
New TOTK	Adjusted	1.06	1.02	1.10	0.007	0.87	0.83	0.90	<0.001	1.18	1.07	1.30	0.001
					BP Users				nong Antidiab		rs		
		OR	LL	UL	p value	OR	LL	UL	p value	OR	LL	UL	p value
All	Unadjusted	0.26	0.24	0.28	<0.001	0.29	0.27	0.32	<0.001	0.28	0.24	0.33	<0.001
All	Adjusted	0.26	0.24	0.28	<0.001	0.29	0.27	0.32	<0.001	0.29	0.25	0.34	<0.001
Northeast	Unadjusted	0.28	0.24	0.32	<0.001	0.32	0.28	0.35	<0.001	0.29	0.23	0.36	<0.001
Northeast	Adjusted	0.28	0.24	0.32	<0.001	0.31	0.27	0.35	<0.001	0.30	0.24	0.39	<0.001
Midwest	Unadjusted	0.27	0.22	0.33	<0.001	0.30	0.24	0.38	<0.001	0.28	0.19	0.41	<0.001
Midwest	Adjusted	0.27	0.22	0.34	<0.001	0.32	0.26	0.41	<0.001	0.29	0.19	0.42	<0.001
South	Unadjusted	0.29	0.26	0.33	<0.001	0.31	0.26	0.36	<0.001	0.35	0.26	0.47	<0.001
3000	Adjusted	0.30	0.26	0.34	<0.001	0.30	0.25	0.36	<0.001	0.36	0.26	0.48	<0.001
West	Unadjusted	0.19	0.16	0.22	<0.001	0.20	0.17	0.25	<0.001	0.21	0.15	0.30	<0.001
	Adjusted	0.19	0.16	0.23	<0.001	0.21	0.17	0.26	<0.001	0.22	0.15	0.31	<0.001
New York	Unadjusted	0.33	0.27	0.40	<0.001	0.34	0.29	0.39	<0.001	0.35	0.26	0.49	<0.001
New TOTK	Adjusted	0.32	0.26	0.40	<0.001	0.32	0.28	0.36	<0.001	0.40	0.28	0.56	<0.001
						ersus BP	Non-us		ng Antidiabeti		sers		
		OR	LL	UL	p value	OR	LL	UL	p value	OR	LL	UL	p value
All	Unadjusted	0.24	0.23	0.26	<0.001	0.24	0.22	0.26	<0.001	0.24	0.20	0.29	<0.001
	Adjusted	0.25	0.23	0.27	<0.001	0.25	0.23	0.28	<0.001	0.27	0.22	0.33	<0.001
Northeast	Unadjusted	0.24	0.22	0.28	< 0.001	0.26	0.22	0.29	< 0.001	0.25	0.19	0.34	< 0.001
	Adjusted	0.25	0.22	0.29	< 0.001	0.27	0.24	0.32	< 0.001	0.28	0.20	0.39	< 0.001
Midwest	Unadjusted	0.27	0.22	0.32	< 0.001	0.22	0.17	0.30	< 0.001	0.26	0.16	0.42	< 0.001
	Adjusted	0.28	0.24	0.31	< 0.001	0.23	0.17	0.31	< 0.001	0.26	0.16	0.45	< 0.001
South	Unadjusted	0.24	0.21	0.27	< 0.001	0.25	0.20	0.30	<0.001	0.29	0.20	0.43	< 0.001
	Adjusted	0.24	0.21	0.27	< 0.001	0.24	0.21	0.28	<0.001	0.33	0.22	0.49	< 0.001
West	Unadjusted	0.23	0.20	0.27	< 0.001	0.18	0.14	0.24	< 0.001	0.13	0.07	0.23	< 0.001
	Adjusted	0.23	0.20	0.28	< 0.001	0.20	0.15	0.26	< 0.001	0.15	0.08	0.28	< 0.001
New York	Unadjusted	0.30	0.25	0.37	< 0.001	0.30	0.25	0.36	< 0.001	0.22	0.14	0.36	< 0.001
	Adjusted	0.30	0.25	0.37	<0.001	0.31	0.25	0.37	<0.001	0.24	0.14	0.41	<0.001

2658

LL: lower 95% confidence interval level; OR: odds ratio; UL: upper 95% confidence interval level

# 2660 Table S5d: Antidepressant Use Sensitivity Analysis, Unadjusted/Adjusted Odds Ratio for COVID-19-Related Outcomes, Stratified

# 2661 by Region and New York State

2662

		0	dds of S.	ARS-Co	V-2 Test	Ode	ds of CO	VID-19 [	Diagnosis	Odds	of COVI	D-19 Hos	pitalization
					-	Antidepre	essant U	lsers ver	sus Non-user	s			
		OR	LL	UL	p value	OR	LL	UL	p value	OR	LL	UL	p value
All	Unadjusted	1.04	1.03	1.05	< 0.001	0.71	0.70	0.72	< 0.001	0.81	0.78	0.83	<0.001
All	Adjusted	1.00	0.99	1.01	0.61	0.65	0.64	0.66	<0.001	0.75	0.73	0.78	<0.001
Northeast	Unadjusted	1.01	0.99	1.02	0.54	0.71	0.69	0.72	<0.001	0.84	0.80	0.88	<0.001
Northeast	Adjusted	0.97	0.95	0.99	0.001	0.65	0.63	0.66	<0.001	0.77	0.73	0.82	<0.001
Midwest	Unadjusted	1.10	1.08	1.12	<0.001	0.75	0.72	0.78	<0.001	0.84	0.78	0.90	<0.001
mawest	Adjusted	1.05	1.03	1.07	<0.001	0.69	0.66	0.71	<0.001	0.78	0.73	0.84	<0.001
South	Unadjusted	1.04	1.02	1.05	<0.001	0.68	0.66	0.70	<0.001	0.74	0.70	0.79	<0.001
South	Adjusted	0.99	0.98	1.01	0.49	0.64	0.62	0.66	<0.001	0.72	0.68	0.77	<0.001
West	Unadjusted	1.04	1.02	1.06	0.00	0.70	0.67	0.73	<0.001	0.77	0.70	0.84	<0.001
west	Adjusted	0.99	0.97	1.02	0.46	0.64	0.61	0.66	<0.001	0.70	0.64	0.77	<0.001
New York	Unadjusted	1.00	0.97	1.03	0.86	0.77	0.74	0.80	<0.001	0.83	0.76	0.91	<0.001
New fork	Adjusted	0.98	0.95	1.01	0.27	0.72	0.70	0.75	<0.001	0.77	0.70	0.85	<0.001
					BP Users v	ersus Bl	P Non-us	sers amo	ong Antidepre	ssant Us	ers		
		OR	LL	UL	p value	OR	LL	UL	p value	OR	LL	UL	p value
All	Unadjusted	0.27	0.26	0.28	<0.001	0.30	0.28	0.32	<0.001	0.31	0.27	0.36	<0.001
All	Adjusted	0.27	0.25	0.28	<0.001	0.30	0.28	0.32	<0.001	0.33	0.28	0.38	<0.001
Northeast	Unadjusted	0.28	0.26	0.31	<0.001	0.33	0.30	0.37	<0.001	0.36	0.29	0.45	<0.001
Northeast	Adjusted	0.28	0.25	0.30	<0.001	0.32	0.29	0.36	<0.001	0.37	0.29	0.47	<0.001
Midwest	Unadjusted	0.30	0.27	0.34	<0.001	0.26	0.22	0.31	<0.001	0.25	0.18	0.34	<0.001
mawest	Adjusted	0.30	0.26	0.34	<0.001	0.27	0.22	0.33	<0.001	0.26	0.18	0.36	<0.001
South	Unadjusted	0.26	0.24	0.29	<0.001	0.27	0.23	0.31	<0.001	0.32	0.24	0.41	<0.001
South	Adjusted	0.26	0.24	0.28	<0.001	0.27	0.23	0.32	<0.001	0.32	0.24	0.43	<0.001
West	Unadjusted	0.25	0.22	0.28	<0.001	0.27	0.22	0.32	<0.001	0.29	0.20	0.41	<0.001
west	Adjusted	0.24	0.21	0.27	<0.001	0.29	0.28	0.30	<0.001	0.33	0.23	0.48	<0.001
New York	Unadjusted	0.30	0.26	0.34	<0.001	0.33	0.28	0.38	<0.001	0.24	0.16	0.36	<0.001
New TOIK	Adjusted	0.30	0.25	0.34	<0.001	0.31	0.27	0.37	<0.001	0.25	0.16	0.39	<0.001
					<b>BP Users vers</b>	sus BP N	lon-user	's amon	g Antidepress	ant Non-	users		
		OR	LL	UL	p value	OR	LL	UL	p value	OR	LL	UL	p value
All	Unadjusted	0.20	0.19	0.22	<0.001	0.22	0.20	0.24	<0.001	0.24	0.20	0.28	<0.001
All	Adjusted	0.21	0.19	0.22	<0.001	0.23	0.21	0.25	<0.001	0.27	0.22	0.32	<0.001
Northeast	Unadjusted	0.21	0.19	0.24	<0.001	0.23	0.20	0.26	<0.001	0.25	0.19	0.32	<0.001
Northeast	Adjusted	0.22	0.19	0.25	<0.001	0.24	0.22	0.25	<0.001	0.29	0.22	0.39	<0.001
Midwest	Unadjusted	0.22	0.19	0.26	<0.001	0.23	0.18	0.28	<0.001	0.28	0.19	0.39	<0.001
Miuwest	Adjusted	0.21	0.18	0.25	<0.001	0.26	0.24	0.27	<0.001	0.32	0.22	0.47	<0.001
South	Unadjusted	0.20	0.18	0.22	<0.001	0.21	0.18	0.25	<0.001	0.21	0.15	0.30	<0.001
3000	Adjusted	0.20	0.18	0.23	<0.001	0.23	0.19	0.27	<0.001	0.22	0.16	0.32	<0.001
West	Unadjusted	0.18	0.16	0.21	<0.001	0.20	0.16	0.25	<0.001	0.20	0.13	0.30	<0.001
West	Adjusted	0.19	0.16	0.22	<0.001	0.20	0.20	0.21	<0.001	0.22	0.14	0.35	<0.001
New York	Unadjusted	0.26	0.22	0.32	<0.001	0.27	0.23	0.32	<0.001	0.29	0.19	0.43	<0.001
New TORK	Adjusted	0.26	0.23	0.30	< 0.001	0.26	0.22	0.32	< 0.001	0.35	0.22	0.54	< 0.001

# 2665 **Table S6a:** "*Bone-Rx*" Cohort (All Regions), Patient Characteristics Pre/Post Match

2666

	•	"Bone-Rx"	Cohort /	All Obser	vations Ur	matched			"Bone-Rx	" Cohort /	All Obse	rvations I	Matched	
	A	11	BP No	n-user	BP U	ser		A		BP No	n-user	BP L	Jser	
	N	%	N	%	N	%	p-value	Ν	%	N	%	N	%	p-value
All Patients	502,895	100.0%	50,844	10.1%	452,051	89.9%		100,996	100.0%	50,498	50.0%	50,498	50.0%	
Age														
≤20	1,164	0.2%	36	0.1%	1,128	0.2%	<0.001	67	0.1%	36	0.1%	31	0.1%	0.97
21-40	3,501	0.7%	410	0.8%	3,091	0.7%		790	0.8%	403	0.8%	387	0.8%	
41-50	9,631	1.9%	1,080	2.1%	8,551	1.9%		2,107	2.1%	1,069	2.1%	1,038	2.1%	
51-60	72,139	14.3%	6,418	12.6%	65,721	14.5%		12,777	12.7%	6,395	12.7%	6,382	12.6%	
61-70	171,687	34.1%	14,809	29.1%	156,878	34.7%	1	29,509	29.2%	14,751	29.2%	14,758	29.2%	
71-80	157,877	31.4%	16,152	31.8%	141,725	31.4%		32,129	31.8%	16,055	31.8%	16,074	31.8%	
≥81	86,896	17.3%	11,939	23.5%	74,957	16.6%		23,617	23.4%	11,789	23.3%	11,828	23.4%	
Gender														
Female	451,790	89.8%	44,354	87.2%	407,436	90.1%	<0.001	88,552	87.7%	44,235	87.6%	44,317	87.8%	0.43
Male	51,105	10.2%	6,490	12.8%	44,615	9.9%	1	12,444	12.3%	6,263	12.4%	6,181	12.2%	
Region														
Midwest	85,391	17.0%	9,424	18.5%	75,967	16.8%	< 0.001	18,720	18.5%	9,360	18.5%	9,360	18.5%	1.00
Northeast	135,867	27.0%	16,139	31.7%	119,728	26.5%	1	31,986	31.7%	15,993	31.7%	15,993	31.7%	
South	178,118	35.4%	17,232	33.9%	160,886	35.6%		34,280	33.9%	17,140	33.9%	17,140	33.9%	
West	103,519	20.6%	8,049	15.8%	95,470	21.1%		16,010	15.9%	8,005	15.9%	8,005	15.9%	
Insurance														
Commercial	164,150	32.6%	17,092	33.6%	147,058	32.5%	<0.001	33,977	33.6%	16,963	33.6%	17,014	33.7%	0.91
Dual	33,969	6.8%	2,562	5.0%	31,407	6.9%		5,056	5.0%	2,547	5.0%	2,509	5.0%	
Medicaid	84,514	16.8%	7,034	13.8%	77,480	17.1%	1	13,925	13.8%	6,986	13.8%	6,939	13.7%	
Medicare	220,262	43.8%	24,156	47.5%	196,106	43.4%	1	48,038	47.6%	24,002	47.5%	24,036	47.6%	
PCP Visit 2019														
No	181,996	36.2%	18,130	35.7%	163,866	36.2%	0.009	35,943	35.6%	17,979	35.6%	17,964	35.6%	0.92
Yes	320,899	63.8%	32,714	64.3%	288,185	63.8%		65,053	64.4%	32,519	64.4%	32,534	64.4%	
						Continu	ous Outcom	es						
	mean	SD	mean	SD	mean	SD	p-value	mean	SD	mean	SD	mean	SD	p-value
CCI	1.05	1.91	1.99	2.71	0.95	1.76	<0.001	1.93	2.59	1.93	2.60	1.92	2.59	0.76

2667 BP: bisphosphonate; CCI: Charlson Comorbidity Index; PCP: primary care physician; SD: standard deviation

2669 **Table S6b:** "*Bone-Rx*" Cohort (Region=Northeast), Patient Characteristics Pre/Post Match

	"	Bone-Rx"	Cohort / F	Region=N	ortheast U	nmatche	d		"Bone-Rx	" Cohort /	Region=	Northeast	Matched	
	A		BP No		BP U			ļ	All	BP No		BP L		
	N	%	N	%	N	%	p-value	N	%	N	%	N	%	p-value
All Patients	135,867	100.0%	16,139	11.9%	119,728	88.1%		31,986	100.0%	15,993	50.0%	15,993	50.0%	
Age														
≤20	245	0.2%	≤10	0.1%	236	0.2%	<0.001	15	0.0%	≤10	0.1%	≤10	0.0%	0.99
21-40	891	0.7%	127	0.8%	764	0.6%		250	0.8%	124	0.8%	126	0.8%	
41-50	2,340	1.7%	298	1.8%	2,042	1.7%	]	570	1.8%	290	1.8%	280	1.8%	
51-60	20,069	14.8%	2,059	12.8%	18,010	15.0%	]	4,088	12.8%	2,049	12.8%	2,039	12.7%	
61-70	45,896	33.8%	4,802	29.8%	41,094	34.3%		9,526	29.8%	4,767	29.8%	4,759	29.8%	
71-80	42,828	31.5%	5,267	32.6%	37,561	31.4%		10,465	32.7%	5,226	32.7%	5,239	32.8%	
≥81	23,598	17.4%	3,577	22.2%	20,021	16.7%		7,072	22.1%	3,528	22.1%	3,544	22.2%	
Gender														
Female	122,485	90.2%	14,115	87.5%	108,370	90.5%	<0.001	28,157	88.0%	14,062	87.9%	14,095	88.1%	0.57
Male	13,382	9.8%	2,024	12.5%	11,358	9.5%		3,829	12.0%	1,931	12.1%	1,898	11.9%	
Insurance														
Commercial	37,810	27.8%	4,517	28.0%	33,293	27.8%	<0.001	8,927	27.9%	4,459	27.9%	4,468	27.9%	0.99
Dual	8,434	6.2%	829	5.1%	7,605	6.4%		1,637	5.1%	824	5.2%	813	5.1%	
Medicaid	25,296	18.6%	2,082	12.9%	23,214	19.4%		4,122	12.9%	2,067	12.9%	2,055	12.8%	
Medicare	64,327	47.3%	8,711	54.0%	55,616	46.5%		17,300	54.1%	8,643	54.0%	8,657	54.1%	
PCP Visit 2019														
No	56,593	41.7%	6,726	41.7%	49,867	41.7%	0.95	13,307	41.6%	6,654	41.6%	6,653	41.6%	0.99
Yes	79,274	58.3%	9,413	58.3%	69,861	58.3%		18,679	58.4%	9,339	58.4%	9,340	58.4%	
						Continu	ous Outcom	es						
	mean	SD	mean	SD	mean	SD	p-value	mean	SD	mean	SD	mean	SD	p-value
CCI	1.06	1.89	1.97	2.70	0.93	1.71	<0.001	1.89	2.57	1.89	2.58	1.89	2.57	0.91

2671

BP: bisphosphonate; CCI: Charlson Comorbidity Index; PCP: primary care physician; SD: standard deviation

2672 Table S6c: "Bone-Rx" Cohort (Region=Midwest), Patient Characteristics Pre/Post Match	ch
---	----

		"Bone-Rx"	Cohort	Region=	Midwest L	Inmatche	d		"Bone-Ry	(" Cohort	/ Region=	-Midwest	Matched	
	ŀ			on-user	BP L			ŀ			on-user		User	
	N	%	N	%	N	%	p-value	N	%	N	%	N	%	p-value
All Patients	85,391	100.0%	9,424	11.0%	75,967	89.0%		18,720	100.0%	9,360	50.0%	9,360	50.0%	
Age														
≤20	274	0.3%	≤10	0.1%	268	0.4%	<0.001	13	0.1%	≤10	0.1%	≤10	0.1%	1.00
21-40	672	0.8%	79	0.8%	593	0.8%		154	0.8%	78	0.8%	76	0.8%	
41-50	1,886	2.2%	202	2.1%	1,684	2.2%		389	2.1%	200	2.1%	189	2.0%	
51-60	13,522	15.8%	1,284	13.6%	12,238	16.1%		2,559	13.7%	1,280	13.7%	1,279	13.7%	
61-70	31,256	36.6%	2,760	29.3%	28,496	37.5%		5,512	29.4%	2,754	29.4%	2,758	29.5%	
71-80	23,887	28.0%	2,766	29.4%	21,121	27.8%		5,492	29.3%	2,748	29.4%	2,744	29.3%	
≥81	13,894	16.3%	2,327	24.7%	11,567	15.2%		4,601	24.6%	2,294	24.5%	2,307	24.6%	
Gender														
Female	76,696	89.8%	8,118	86.1%	68,578	90.3%	< 0.001	16,223	86.7%	8,102	86.6%	8,121	86.8%	0.68
Male	8,695	10.2%	1,306	13.9%	7,389	9.7%		2,497	13.3%	1,258	13.4%	1,239	13.2%	
Insurance														
Commercial	34,494	40.4%	3,361	35.7%	31,133	41.0%	< 0.001	6,699	35.8%	3,345	35.7%	3,354	35.8%	0.96
Dual	4,042	4.7%	436	4.6%	3,606	4.7%		852	4.6%	429	4.6%	423	4.5%	
Medicaid	8,856	10.4%	733	7.8%	8,123	10.7%		1,441	7.7%	729	7.8%	712	7.6%	
Medicare	37,999	44.5%	4,894	51.9%	33,105	43.6%		9,728	52.0%	4,857	51.9%	4,871	52.0%	
PCP Visit 2019														
No	32,037	37.5%	3,330	35.3%	28,707	37.8%	< 0.001	6,628	35.4%	3,312	35.4%	3,316	35.4%	0.95
Yes	53,354	62.5%	6,094	64.7%	47,260	62.2%		12,092	64.6%	6,048	64.6%	6,044	64.6%	
						Continu	uous Outcom	es						
	mean	SD	mean	SD	mean	SD	p-value	mean	SD	mean	SD	mean	SD	p-value
CCI	1.12	2.02	2.12	2.83	0.99	1.86	< 0.001	2.05	2.72	2.06	2.72	2.05	2.72	0.91

2674 2675 BP: bisphosphonate; CCI: Charlson Comorbidity Index; PCP: primary care physician; SD: standard deviation

2676	Table S6d: "Bone-Rx" Cohort (Region=South), Patient Characteristics Pre/Post Match
------	--

		"Bone-Rx	Cohort	/ Region=	South Unr	natched			"Bone-l	Rx" Cohoi	rt / Regio	n=South N	latched	
	Α		BP No		BP U			A	All	BP No		BP L		
	Ν	%	N	%	N	%	p-value	N	%	N	%	N	%	p-value
All Patients	178,118	100.0%	17,232	9.7%	160,886	90.3%		34,280	100.0%	17,140	50.0%	17,140	50.0%	
Age														
≤20	490	0.3%	16	0.1%	474	0.3%	<0.001	31	0.1%	16	0.1%	15	0.1%	1.00
21-40	1,313	0.7%	136	0.8%	1,177	0.7%		262	0.8%	134	0.8%	128	0.7%	
41-50	3,866	2.2%	445	2.6%	3,421	2.1%		884	2.6%	444	2.6%	440	2.6%	
51-60	27,389	15.4%	2,296	13.3%	25,093	15.6%		4,574	13.3%	2,290	13.4%	2,284	13.3%	
61-70	61,038	34.3%	5,142	29.8%	55,896	34.7%		10,271	30.0%	5,129	29.9%	5,142	30.0%	
71-80	56,126	31.5%	5,521	32.0%	50,605	31.5%		10,990	32.1%	5,493	32.0%	5,497	32.1%	
≥81	27,896	15.7%	3,676	21.3%	24,220	15.1%		7,268	21.2%	3,634	21.2%	3,634	21.2%	
Gender														
Female	160,994	90.4%	15,179	88.1%	145,815	90.6%	<0.001	30,322	88.5%	15,149	88.4%	15,173	88.5%	0.69
Male	17,124	9.6%	2,053	11.9%	15,071	9.4%		3,958	11.5%	1,991	11.6%	1,967	11.5%	
Insurance														
Commercial	66,332	37.2%	7,042	40.9%	59,290	36.9%	<0.001	14,052	41.0%	7,007	40.9%	7,045	41.1%	0.95
Dual	14,829	8.3%	769	4.5%	14,060	8.7%		1,523	4.4%	769	4.5%	754	4.4%	
Medicaid	23,492	13.2%	1,843	10.7%	21,649	13.5%		3,639	10.6%	1,829	10.7%	1,810	10.6%	
Medicare	73,465	41.2%	7,578	44.0%	65,887	41.0%		15,066	43.9%	7,535	44.0%	7,531	43.9%	
PCP Visit 2019														
No	60,253	33.8%	5,785	33.6%	54,468	33.9%	0.454	11,462	33.4%	5,736	33.5%	5,726	33.4%	0.91
Yes	117,865	66.2%	11,447	66.4%	106,418	66.1%		22,818	66.6%	11,404	66.5%	11,414	66.6%	
						Continu	ous Outcom	es		-				
	mean	SD	mean	SD	mean	SD	p-value	mean	SD	mean	SD	mean	SD	p-value
CCI	0.95	1.84	1.86	2.65	0.86	1.70	<0.001	1.80	2.54	1.80	2.54	1.79	2.53	0.78

# 2681 Table S6e: "*Bone-Rx*" Cohort (Region=West), Patient Characteristics Pre/Post Match

		"Bone-Rx	" Cohort	/ Region=	West Uni	matched			"Bone-l	Rx" Coho	rt / Regio	n=West M	Matched	
	Α			on-user	BP L		n velve	4	All		on-user		User	n velve
	Ν	%	N	%	N	%	p-value	N	%	N	%	N	%	p-value
All Patients	103,519	100.0%	8,049	7.8%	95,470	92.2%		16,010	100.0%	8,005	50.0%	8,005	50.0%	
Age														
≤20	155	0.1%	≤10	0.1%	150	0.2%	< 0.001	≤10	0.0%	≤10	0.1%	≤10	0.0%	0.96
21-40	625	0.6%	68	0.8%	557	0.6%		124	0.8%	67	0.8%	57	0.7%	
41-50	1,539	1.5%	135	1.7%	1,404	1.5%	1	264	1.6%	135	1.7%	129	1.6%	
51-60	11,159	10.8%	779	9.7%	10,380	10.9%		1,556	9.7%	776	9.7%	780	9.7%	
61-70	33,497	32.4%	2,105	26.2%	31,392	32.9%	1	4,200	26.2%	2,101	26.2%	2,099	26.2%	
71-80	35,036	33.8%	2,598	32.3%	32,438	34.0%		5,182	32.4%	2,588	32.3%	2,594	32.4%	
≥81	21,508	20.8%	2,359	29.3%	19,149	20.1%		4,676	29.2%	2,333	29.1%	2,343	29.3%	
Gender														
Female	91,615	88.5%	6,942	86.2%	84,673	88.7%	<0.001	13,850	86.5%	6,922	86.5%	6,928	86.5%	0.89
Male	11,904	11.5%	1,107	13.8%	10,797	11.3%	1	2,160	13.5%	1,083	13.5%	1,077	13.5%	
Insurance														
Commercial	25,514	24.6%	2,172	27.0%	23,342	24.4%	<0.001	4,299	26.9%	2,152	26.9%	2,147	26.8%	1.00
Dual	6,664	6.4%	528	6.6%	6,136	6.4%	1	1,044	6.5%	525	6.6%	519	6.5%	
Medicaid	26,870	26.0%	2,376	29.5%	24,494	25.7%		4,723	29.5%	2,361	29.5%	2,362	29.5%	
Medicare	44,471	43.0%	2,973	36.9%	41,498	43.5%		5,944	37.1%	2,967	37.1%	2,977	37.2%	
PCP Visit 2019														
No	33,113	32.0%	2,289	28.4%	30,824	32.3%	<0.001	4,546	28.4%	2,277	28.4%	2,269	28.3%	0.89
Yes	70,406	68.0%	5,760	71.6%	64,646	67.7%	1	11,464	71.6%	5,728	71.6%	5,736	71.7%	
					-	Continu	ious Outcom	es						
	mean	SD	mean	SD	mean	SD	p-value	mean	SD	mean	SD	mean	SD	p-value
CCI	1.17	1.94	2.17	2.67	1.08	1.84	<0.001	2.12	2.59	2.12	2.59	2.12	2.59	0.93

Table S6f: "Bone-Rx" Cohort (Region=New York State), Patient Characteristics Pre/Post Match

	"Bo	one-Rx" Co	hort / Re	gion=New	Vork Sta	te Unmate	ched	"E	Bone-Rx" C	ohort / R	egion=Ne	w York S	tate Matcl	ned
		AII		n-user	BP L				All		on-user		User	
	Ν	%	N	%	N	%	p-value	N	%	Ν	%	N	%	p-value
All Patients	57,397	100.0%	7,362	12.8%	50,035	87.2%		14,508	100.0%	7,254	50.0%	7,254	50.0%	
Age														
≤20	56	0.1%	≤10	0.1%	50	0.1%	<0.001	11	0.1%	≤10	0.1%	≤10	0.1%	0.96
21-40	272	0.5%	44	0.6%	228	0.5%		76	0.5%	42	0.6%	34	0.5%	
41-50	775	1.4%	120	1.6%	655	1.3%		207	1.4%	107	1.5%	100	1.4%	
51-60	7,249	12.6%	885	12.0%	6,364	12.7%		1,744	12.0%	871	12.0%	873	12.0%	
61-70	18,433	32.1%	2,297	31.2%	16,136	32.2%		4,540	31.3%	2,264	31.2%	2,276	31.4%	
71-80	19,944	34.7%	2,482	33.7%	17,462	34.9%		4,934	34.0%	2,455	33.8%	2,479	34.2%	
≥81	10,668	18.6%	1,528	20.8%	9,140	18.3%		2,996	20.7%	1,509	20.8%	1,487	20.5%	
Gender														
Female	52,047	90.7%	6,589	89.5%	45,458	90.9%	<.001	13,106	90.3%	6,526	90.0%	6,580	90.7%	0.13
Male	5,350	9.3%	773	10.5%	4,577	9.1%		1,402	9.7%	728	10.0%	674	9.3%	
Insurance														
Commercial	12,309	21.4%	1,894	25.7%	10,415	20.8%	<0.001	3,706	25.5%	1,850	25.5%	1,856	25.6%	1.00
Dual	1,750	3.0%	154	2.1%	1,596	3.2%		307	2.1%	153	2.1%	154	2.1%	
Medicaid	10,191	17.8%	1,016	13.8%	9,175	18.3%		1,968	13.6%	987	13.6%	981	13.5%	
Medicare	33,147	57.8%	4,298	58.4%	28,849	57.7%		8,527	58.8%	4,264	58.8%	4,263	58.8%	
PCP Visit 2019														
No	21,462	37.4%	2,789	37.9%	18,673	37.3%	0.35	5,468	37.7%	2,744	37.8%	2,724	37.6%	0.73
Yes	35,935	62.6%	4,573	62.1%	31,362	62.7%		9,040	62.3%	4,510	62.2%	4,530	62.4%	
						Continu	ous Outcom	es						
	mean	SD	mean	SD	mean	SD	p-value	mean	SD	mean	SD	mean	SD	p-value
CCI	1.06	1.84	1.81	2.56	0.95	1.68	< 0.001	1.69	2.35	1.69	2.36	1.69	2.35	0.98

	"C	steo-Dx-R					hed	•	Osteo-Dx-I					ed
	l l	All	BP No	on-user	BP l	Jser	p-value		<b>A</b> II	BP No	on-user	BP	User	p-value
	N	%	N	%	N	%	p-value	N	%	N	%	N	%	p-value
All Patients	60,043	100.0%	8,392	14.0%	51,651	86.0%		15,898	100.0%	7,949	50.0%	7,949	50.0%	
Age														
51-60	6,443	10.7%	753	9.0%	5,690	11.0%	<0.001	1,430	9.0%	723	9.1%	707	8.9%	0.95
61-70	20,187	33.6%	2,492	29.7%	17,695	34.3%		4,821	30.3%	2,397	30.2%	2,424	30.5%	
71-80	21,545	35.9%	2,964	35.3%	18,581	36.0%		5,677	35.7%	2,841	35.7%	2,836	35.7%	
≥81	11,868	19.8%	2,183	26.0%	9,685	18.8%		3,970	25.0%	1,988	25.0%	1,982	24.9%	
State														
CA	24,489	40.8%	2,558	30.5%	21,931	42.5%	<0.001	4,886	30.7%	2,443	30.7%	2,443	30.7%	1.00
FL	11,904	19.8%	1,767	21.1%	10,137	19.6%		3,256	20.5%	1,628	20.5%	1,628	20.5%	
IL	4,447	7.4%	678	8.1%	3,769	7.3%		1,168	7.3%	584	7.3%	584	7.3%	
NY	19,203	32.0%	3,389	40.4%	15,814	30.6%		6,588	41.4%	3,294	41.4%	3,294	41.4%	
Insurance	· · ·							, i i i i i i i i i i i i i i i i i i i		, í				
Commercial	12,990	21.6%	2,048	24.4%	10,942	21.2%	< 0.001	3,736	23.5%	1,868	23.5%	1,868	23.5%	1.00
Dual	3,652	6.1%	313	3.7%	3,339	6.5%		554	3.5%	277	3.5%	277	3.5%	
Medicaid	13,698	22.8%	1,785	21.3%	11,913	23.1%		3,392	21.3%	1,696	21.3%	1,696	21.3%	
Medicare	29,703	49.5%	4,246	50.6%	25,457	49.3%		8,216	51.7%	4,108	51.7%	4,108	51.7%	
PCP Visit 2019	í í							Í Í		· ·				
No	14,089	23.5%	2,427	28.9%	11,662	22.6%	<0.001	4,487	28.2%	2,243	28.2%	2,244	28.2%	0.99
Yes	45,954	76.5%	5,965	71.1%	39,989	77.4%		11,411	71.8%	5,706	71.8%	5,705	71.8%	
Cancer Dx			-,					,		-,		,		
No	52,301	87.1%	6,765	80.6%	45,536	88.2%	< 0.001	13,116	82.5%	6,548	82.4%	6,568	82.6%	0.68
Yes	7,742	12.9%	1,627	19.4%	6,115	11.8%		2,782	17.5%	1,401	17.6%	1,381	17.4%	
COPD Dx	-,		.,		-,			_,		.,		.,		
No	53,446	89.0%	7,035	83.8%	46,411	89.9%	< 0.001	13,705	86.2%	6,834	86.0%	6,871	86.4%	0.39
Yes	6,597	11.0%	1,357	16.2%	5,240	10.1%	0.001	2,193	13.8%	1,115	14.0%	1,078	13.6%	0.00
Heart Failure Dx	0,001	11.070	1,001	10.270	0,210	10.170		2,100	10.070	1,110	11.070	1,010	10.070	
No	56,005	93.3%	7,492	89.3%	48,513	93.9%	< 0.001	14,475	91.0%	7,218	90.8%	7,257	91.3%	0.28
Yes	4,038	6.7%	900	10.7%	3,138	6.1%	0.001	1,423	9.0%	731	9.2%	692	8.7%	0.20
Hypertension Dx	1,000	0.170	000	10.170	0,100	0.170		1,120	0.070		0.270	002	0.170	
No	24,966	41.6%	3,281	39.1%	21,685	42.0%	< 0.001	6,268	39.4%	3,137	39.5%	3,131	39.4%	0.92
Yes	35,077	58.4%	5,111	60.9%	29,966	58.0%	-0.001	9,630	60.6%	4,812	60.5%	4,818	60.6%	0.02
Dyslipidemia Dx	00,011	00.470	0,111	00.070	20,000	00.070		0,000	00.070	4,012	00.070	4,010	00.070	
No	24,095	40.1%	3,295	39.3%	20,800	40.3%	0.08	6,187	38.9%	3,101	39.0%	3,086	38.8%	0.81
Yes	35,948	59.9%	5,097	60.7%	30,851	59.7%	0.00	9,711	61.1%	4,848	61.0%	4,863	61.2%	0.01
Obesity Dx	33,340	59.970	5,057	00.7 /0	30,031	33.170		3,711	01.170	4,040	01.070	4,000	01.270	
No	53,453	89.0%	7,583	90.4%	45,870	88.8%	<0.001	14,468	91.0%	7,217	90.8%	7,251	91.2%	0.35
Yes	6,590	11.0%	809	9.6%	5,781	11.2%	<0.001	1,430	9.0%	732	9.2%	698	8.8%	0.00
Type 2 Diabetes Dx	0,000	11.070	003	3.070	5,701	11.2/0		1,400	3.070	152	3.270	030	0.070	
No	44,565	74.2%	6,132	73.1%	38,433	74.4%	0.009	11,759	74.0%	5,859	73.7%	5,900	74.2%	0.46
Yes	15,478	25.8%	2,260	26.9%	13,218	25.6%	0.009	4,139	26.0%	2,090	26.3%	2,049	25.8%	0.40
Depression Dx	15,470	20.070	2,200	20.970	10,210	20.070		4,139	20.070	2,090	20.370	2,049	20.070	
No	51,609	86.0%	7,114	84.8%	44,495	86.1%	0.001	13,697	86.2%	6,844	86.1%	6,853	86.2%	0.84
	8,434	14.0%	1,278	15.2%	7,156	13.9%	0.001	2,201	13.8%	1,105	13.9%	1,096	13.8%	0.04
Yes							diagnosis							

### 2691 Table S7: "Osteo-Dx-Rx" Cohort, Patient Characteristics Pre/Post Match

2692

BP: bisphosphonate; CCI: Charlson Comorbidity Index; CA: California; Dx: diagnosis; FL: Florida; IL: Illinois; NY: New York; PCP: primary care physician

# 2693 Table S8a: Statin Cohort (All Regions), Patient Characteristics Pre/Post Match

		All Obs	ervations by	y Statin	Use: Unmat	ched			All Ob	servations	by Statir	n Use: Matc	hed	
	All		Statin Non	-users	Statin U	sers	a contra	All		Statin Non	-users	Statin U	sers	
	Ν	%	N	%	Ν	%	p-value	N	%	N	%	N	%	p-value
All Patients	7,906,603	100.0%	6,403,208	81.0%	1,503,395	19.0%		2,872,600	100.0%	1,436,300	50.0%	1,436,300	50.0%	
Age														
≤20	1,840,050	23.3%	1,838,665	28.7%	1,385	0.1%	<0.001	2,772	0.1%	1,387	0.1%	1,385	0.1%	0.11
21-40	1,446,999	18.3%	1,402,606	21.9%	44,393	3.0%		88,760	3.1%	44,371	3.1%	44,389	3.1%	
41-50	925,309	11.7%	789,385	12.3%	135,924	9.0%		271,615	9.5%	135,748	9.5%	135,867	9.5%	
51-60	1,250,190	15.8%	888,510	13.9%	361,680	24.1%		710,481	24.7%	354,449	24.7%	356,032	24.8%	
61-70	1,181,261	14.9%	728,702	11.4%	452,559	30.1%		857,269	29.8%	428,326	29.8%	428,943	29.9%	
71-80	783,775	9.9%	452,267	7.1%	331,508	22.1%		605,360	21.1%	303,279	21.1%	302,081	21.0%	
≥81	479,019	6.1%	303,073	4.7%	175,946	11.7%		336,343	11.7%	168,740	11.7%	167,603	11.7%	
Gender														
Female	4,670,960	59.1%	3,785,061	59.1%	885,899	58.9%	<0.001	1,682,354	58.6%	839,207	58.4%	843,147	58.7%	< 0.001
Male	3,235,643	40.9%	2,618,147	40.9%	617,496	41.1%		1,190,246	41.4%	597,093	41.6%	593,153	41.3%	
Region														
Midwest	1,467,802	18.6%	1,188,569	18.6%	279,233	18.6%	< 0.001	542,638	18.9%	271,319	18.9%	271,319	18.9%	1.00
Northeast	2,152,560	27.2%	1,706,021	26.6%	446,539	29.7%		847,868	29.5%	423,934	29.5%	423,934	29.5%	
South	3,042,604	38.5%	2,490,630	38.9%	551,974	36.7%		1,046,224	36.4%	523,112	36.4%	523,112	36.4%	
West	1,243,637	15.7%	1,017,988	15.9%	225,649	15.0%		435,870	15.2%	217,935	15.2%	217,935	15.2%	
Insurance														
Commercial	3,938,603	49.8%	3,350,332	52.3%	588,271	39.1%	<0.001	1,175,472	40.9%	587,847	40.9%	587,625	40.9%	0.34
Dual	156,497	2.0%	73,532	1.1%	82,965	5.5%		110,207	3.8%	54,851	3.8%	55,356	3.9%	
Medicaid	2,594,500	32.8%	2,254,531	35.2%	339,969	22.6%		641,345	22.3%	320,434	22.3%	320,911	22.3%	
Medicare	1,217,003	15.4%	724,813	11.3%	492,190	32.7%		945,576	32.9%	473,168	32.9%	472,408	32.9%	
PCP Visit 2019														
No	4,283,697	54.2%	3,773,784	58.9%	509,913	33.9%	<0.001	1,016,313	35.4%	508,587	35.4%	507,726	35.3%	0.29
Yes	3,622,906	45.8%	2,629,424	41.1%	993,482	66.1%		1,856,287	64.6%	927,713	64.6%	928,574	64.7%	
				•		Continuo	ous Outcom	es						
	mean	SD	mean	SD	mean	SD	p-value	mean	SD	mean	SD	mean	SD	p-value
CCI	0.62	1.38	0.49	1.23	1.15	1.79	<0.001	1.11	1.77	1.12	1.79	1.11	1.75	-0.001

# 2698 Table S8b: Statin Cohort (Region=New York State), Patient Characteristics Pre/Post Match

2699

		Regi	on=NY by S	Statin Us	e: Unmatcl	hed			Rec	ion=NY by	Statin U	se: Matche	ed	
	Α		Statin No		Statin L			A		Statin No		Statin L		m such se
	N	%	N	%	N	%	p-value	N	%	N	%	Ν	%	p-value
All Patients	968,296	100.0%	761,995	78.7%	206,301	21.3%		371,072	100.0%	185,536	50.0%	185,536	50.0%	
Age														
≤20	133,178	13.8%	133,111	17.5%	67	0.0%	<0.001	134	0.0%	67	0.0%	67	0.0%	1.00
21-40	192,959	19.9%	188,446	24.7%	4,513	2.2%	1	9,019	2.4%	4,508	2.4%	4,511	2.4%	
41-50	127,794	13.2%	112,342	14.7%	15,452	7.5%	1	30,860	8.3%	15,420	8.3%	15,440	8.3%	
51-60	172,444	17.8%	128,472	16.9%	43,972	21.3%	1	86,136	23.2%	43,068	23.2%	43,068	23.2%	
61-70	159,912	16.5%	100,884	13.2%	59,028	28.6%	1	106,460	28.7%	53,233	28.7%	53,227	28.7%	
71-80	120,117	12.4%	64,549	8.5%	55,568	26.9%	1	91,337	24.6%	45,675	24.6%	45,662	24.6%	
≥81	61,892	6.4%	34,191	4.5%	27,701	13.4%	1	47,126	12.7%	23,565	12.7%	23,561	12.7%	
Gender														
Female	573,610	59.2%	454,050	59.6%	119,560	58.0%	<0.001	215,375	58.0%	107,420	57.9%	107,955	58.2%	0.08
Male	394,686	40.8%	307,945	40.4%	86,741	42.0%	1	155,697	42.0%	78,116	42.1%	77,581	41.8%	
Insurance														
Commercial	500,918	51.7%	442,990	58.1%	57,928	28.1%	< 0.001	116,123	31.3%	58,206	31.4%	57,917	31.2%	0.57
Dual	6,814	0.7%	2,410	0.3%	4,404	2.1%	1	4,447	1.2%	2,190	1.2%	2,257	1.2%	
Medicaid	252,366	26.1%	206,109	27.0%	46,257	22.4%	]	83,550	22.5%	41,703	22.5%	41,847	22.6%	
Medicare	208,198	21.5%	110,486	14.5%	97,712	47.4%	]	166,952	45.0%	83,437	45.0%	83,515	45.0%	
PCP Visit 2019														
No	521,282	53.8%	446,929	58.7%	74,353	36.0%	<0.001	146,967	39.6%	73,675	39.7%	73,292	39.5%	0.20
Yes	447,014	46.2%	315,066	41.3%	131,948	64.0%	1	224,105	60.4%	111,861	60.3%	112,244	60.5%	
						Continue	ous Outcom	ies						
	mean	SD	mean	SD	mean	SD	p-value	mean	SD	mean	SD	mean	SD	p-value
CCI	0.65	1.39	0.51	1.24	1.17	1.77	<0.001	1.07	1.73	1.08	1.76	1.06	1.70	<0.001

2700 CCI: Charlson Comorbidity Index; PCP: primary care physician; SD: standard deviation

2701

2703 Table S8c: Statin User Cohort (All Regions) by BP Use, Patient Characteristics Pre/Post Match of BP Users/Non-users

		All S	Statin Users	by BP: L	Inmatched	1			Α	II Statin Us	ers by Bl	P: Matched	l	
	All		BP Non-		BP U			А		BP Non		BP U		
	N	%	N	%	N	%	p-value	N	%	N	%	N	%	p-value
All Patients	1,436,300	100.0%	1,218,319	84.8%	217,981	15.2%		426,960	100.0%	213,480	50.0%	213,480	50.0%	
Age														
≤20	1,385	0.1%	1,365	0.1%	20	0.0%	<0.001	42	0.0%	22	0.0%	20	0.0%	1.00
21-40	44,389	3.1%	44,042	3.6%	347	0.2%		704	0.2%	357	0.2%	347	0.2%	
41-50	135,867	9.5%	133,850	11.0%	2,017	0.9%		4,033	0.9%	2,016	0.9%	2,017	0.9%	
51-60	356,032	24.8%	333,325	27.4%	22,707	10.4%		45,439	10.6%	22,732	10.6%	22,707	10.6%	
61-70	428,943	29.9%	356,208	29.2%	72,735	33.4%		144,861	33.9%	72,341	33.9%	72,520	34.0%	
71-80	302,081	21.0%	223,651	18.4%	78,430	36.0%		150,527	35.3%	75,316	35.3%	75,211	35.2%	
≥81	167,603	11.7%	125,878	10.3%	41,725	19.1%		81,354	19.1%	40,696	19.1%	40,658	19.0%	
Gender														
Female	843,147	58.7%	646,846	53.1%	196,301	90.1%	<0.001	383,586	89.8%	191,786	89.8%	191,800	89.8%	0.94
Male	593,153	41.3%	571,473	46.9%	21,680	9.9%		43,374	10.2%	21,694	10.2%	21,680	10.2%	
Region														
Midwest	271,319	18.9%	237,718	19.5%	33,601	15.4%	<0.001	67,050	15.7%	33,525	15.7%	33,525	15.7%	1.00
Northeast	423,934	29.5%	366,936	30.1%	56,998	26.1%		113,308	26.5%	56,654	26.5%	56,654	26.5%	
South	523,112	36.4%	442,996	36.4%	80,116	36.8%		157,838	37.0%	78,919	37.0%	78,919	37.0%	
West	217,935	15.2%	170,669	14.0%	47,266	21.7%		88,764	20.8%	44,382	20.8%	44,382	20.8%	
Insurance														
Commercial	587,625	40.9%	533,843	43.8%	53,782	24.7%	<0.001	107,552	25.2%	53,774	25.2%	53,778	25.2%	1.00
Dual	55,356	3.9%	42,041	3.5%	13,315	6.1%		24,380	5.7%	12,183	5.7%	12,197	5.7%	
Medicaid	320,911	22.3%	280,799	23.0%	40,112	18.4%		76,121	17.8%	38,050	17.8%	38,071	17.8%	
Medicare	472,408	32.9%	361,636	29.7%	110,772	50.8%		218,907	51.3%	109,473	51.3%	109,434	51.3%	
PCP Visit 2019														
No	507,726	35.3%	430,446	35.3%	77,280	35.5%	0.27	151,395	35.5%	75,614	35.4%	75,781	35.5%	0.59
Yes	928,574	64.7%	787,873	64.7%	140,701	64.5%		275,565	64.5%	137,866	64.6%	137,699	64.5%	
						Continuo	us Outcom	es						
	mean	SD	mean	SD	mean	SD	p-value	mean	SD	mean	SD	mean	SD	p-value
CCI	1.11	1.75	1.13	1.77	0.95	1.66	<0.001	0.97	1.66	0.97	1.66	0.97	1.67	0.79

BP: bisphosphonate; CCI: Charlson Comorbidity Index; PCP: primary care physician; SD: standard deviation

#### Table S8d: Statin User Cohort (Region=New York State) by BP Use, Patient Characteristics Pre/Post Match of BP Users/Nonusers

		Region=	NY Statin l	Jsers by	BP: Unm	atched			Regio	n=NY Stat	in Users	by BP: Ma	itched	
	Α	I	BP Non	-user	BP U	Jser	n volue	4	All	BP No	n-user	BP L	Jser	n volue
	Ν	%	N	%	N	%	p-value	Ν	%	N	%	N	%	p-value
All Patients	185,536	100.0%	161,673	87.1%	23,863	12.9%		47,472	100.0%	23,736	50.0%	23,736	50.0%	
Age														
≤20	67	0.0%	67	0.0%	0	0.0%	<0.001	52	0.1%	26	0.1%	26	0.1%	1.00
21-40	4,511	2.4%	4,485	2.8%	26	0.1%		304	0.6%	152	0.6%	152	0.6%	
41-50	15,440	8.3%	15,288	9.5%	152	0.6%		4,381	9.2%	2,192	9.2%	2,189	9.2%	
51-60	43,068	23.2%	40,879	25.3%	2,189	9.2%		14,717	31.0%	7,358	31.0%	7,359	31.0%	
61-70	53,227	28.7%	45,861	28.4%	7,366	30.9%		18,189	38.3%	9,092	38.3%	9,097	38.3%	
71-80	45,662	24.6%	36,474	22.6%	9,188	38.5%		9,829	20.7%	4,916	20.7%	4,913	20.7%	
≥81	23,561	12.7%	18,619	11.5%	4,942	20.7%		0	0.0%		0.0%		0.0%	
Gender														
Female	107,955	58.2%	86,194	53.3%	21,761	91.2%	<0.001	43,265	91.1%	21,631	91.1%	21,634	91.1%	0.96
Male	77,581	41.8%	75,479	46.7%	2,102	8.8%		4,207	8.9%	2,105	8.9%	2,102	8.9%	
Insurance														
Commercial	57,917	31.2%	54,411	33.7%	3,506	14.7%	< 0.001	7,008	14.8%	3,502	14.8%	3,506	14.8%	1.00
Dual	2,257	1.2%	1,664	1.0%	593	2.5%		1,128	2.4%	564	2.4%	564	2.4%	
Medicaid	41,847	22.6%	37,926	23.5%	3,921	16.4%		7,644	16.1%	3,821	16.1%	3,823	16.1%	
Medicare	83,515	45.0%	67,672	41.9%	15,843	66.4%		31,692	66.8%	15,849	66.8%	15,843	66.7%	
PCP Visit 2019														
No	73,292	39.5%	63,797	39.5%	9,495	39.8%	0.33	18,870	39.7%	9,434	39.7%	9,436	39.8%	0.99
Yes	112,244	60.5%	97,876	60.5%	14,368	60.2%		28,602	60.3%	14,302	60.3%	14,300	60.2%	
						Continu	ous Outcom	es						
	mean	SD	mean	SD	mean	SD	p-value	mean	SD	mean	SD	mean	SD	p-value
CCI	1.06	1.70	1.08	1.71	0.92	1.59	< 0.001	0.92	1.58	0.92	1.57	0.93	1.59	0.64

Table S8e: Statin Non-user Cohort (All Regions) by BP Use, Patient Characteristics Pre/Post Match of BP Users/Non-users

		All Statin	Non-users	by BP U	se: Unmat	tched			All S	Statin Non-	users by	<b>BP: Match</b>	ed	
	All		BP Non-u		BP Us			A	11	BP Non-	users	BP Us	sers	n velve
	Ν	%	Ν	%	N	%	p-value	N	%	N	%	Ν	%	p-valu
All Patients	1,436,300	100.0%	1,311,457	91.3%	124,843	8.7%		249,432	100.0%	124,716	50.0%	124,716	50.0%	
Age														
≤20	1,387	0.1%	1,383	0.1%	4	0.0%	<0.001	6	0.0%	2	0.0%	4	0.0%	0.99
21-40	44,371	3.1%	44,170	3.4%	201	0.2%		413	0.2%	212	0.2%	201	0.2%	ĺ
41-50	135,748	9.5%	134,305	10.2%	1,443	1.2%		2,880	1.2%	1,437	1.2%	1,443	1.2%	1
51-60	354,449	24.7%	336,779	25.7%	17,670	14.2%		35,335	14.2%	17,665	14.2%	17,670	14.2%	1
61-70	428,326	29.8%	381,936	29.1%	46,390	37.2%		92,791	37.2%	46,401	37.2%	46,390	37.2%	1
71-80	303,279	21.1%	264,157	20.1%	39,122	31.3%		78,077	31.3%	39,037	31.3%	39,040	31.3%	1
≥81	168,740	11.7%	148,727	11.3%	20,013	16.0%		39,930	16.0%	19,962	16.0%	19,968	16.0%	ĺ
Gender														
Female	839,207	58.4%	727,324	55.5%	111,883	89.6%	<0.001	223,501	89.6%	111,745	89.6%	111,756	89.6%	0.94
Male	597,093	41.6%	584,133	44.5%	12,960	10.4%		25,931	10.4%	12,971	10.4%	12,960	10.4%	
Region														
Midwest	271,319	18.9%	249,383	19.0%	21,936	17.6%	<0.001	43,870	17.6%	21,935	17.6%	21,935	17.6%	1.00
Northeast	423,934	29.5%	390,134	29.7%	33,800	27.1%		67,594	27.1%	33,797	27.1%	33,797	27.1%	
South	523,112	36.4%	480,680	36.7%	42,432	34.0%		84,618	33.9%	42,309	33.9%	42,309	33.9%	ĺ
West	217,935	15.2%	191,260	14.6%	26,675	21.4%		53,350	21.4%	26,675	21.4%	26,675	21.4%	ĺ
Insurance														
Commercial	587,847	40.9%	552,487	42.1%	35,360	28.3%	<0.001	70,725	28.4%	35,365	28.4%	35,360	28.4%	1.00
Dual	54,851	3.8%	46,371	3.5%	8,480	6.8%		16,696	6.7%	8,342	6.7%	8,354	6.7%	
Medicaid	320,434	22.3%	296,591	22.6%	23,843	19.1%		47,674	19.1%	23,832	19.1%	23,842	19.1%	
Medicare	473,168	32.9%	416,008	31.7%	57,160	45.8%		114,337	45.8%	57,177	45.8%	57,160	45.8%	
PCP Visit 2019														
No	508,587	35.4%	473,241	36.1%	35,346	28.3%	< 0.001	70,689	28.3%	35,343	28.3%	35,346	28.3%	0.99
Yes	927,713	64.6%	838,216	63.9%	89,497	71.7%		178,743	71.7%	89,373	71.7%	89,370	71.7%	
	•					Continuo	us Outcom							
	mean	SD	mean	SD	mean	SD	p-value	mean	SD	mean	SD	mean	SD	p-valu
CCI	1.12	1.79	1.13	1.79	1.02	1.86	< 0.001	1.02	1.85	1.02	1.84	1.02	1.86	0.49

#### Table S8f: Statin Non-user Cohort (Region=New York State) by BP Use, Patient Characteristics Pre/Post Match of BP Users/Nonusers

		Region=N	Y Statin No	n-users k	by BP: Un	matched			Region=	NY Statin	Non-user	s by BP: I	Matched	
	Α		BP Non		BP U			4	All	BP Nor	-users	BP U	sers	n volue
	Ν	%	N	%	N	%	p-value	N	%	N	%	N	%	p-value
All Patients	185,536	100.0%	170,990	92.2%	14,546	7.8%		29,042	100.0%	14,521	50.0%	14,521	50.0%	
Age														
≤20	67	0.0%	67	0.0%	0	0.0%	<0.001	0	0.0%	0	0.0%	0	0.0%	1.00
21-40	4,508	2.4%	4,498	2.6%	10	0.1%		23	0.1%	13	0.1%	10	0.1%	
41-50	15,420	8.3%	15,314	9.0%	106	0.7%		211	0.7%	105	0.7%	106	0.7%	
51-60	43,068	23.2%	41,317	24.2%	1,751	12.0%		3,502	12.1%	1,751	12.1%	1,751	12.1%	
61-70	53,233	28.7%	48,148	28.2%	5,085	35.0%		10,174	35.0%	5,089	35.0%	5,085	35.0%	
71-80	45,675	24.6%	40,731	23.8%	4,944	34.0%		9,877	34.0%	4,937	34.0%	4,940	34.0%	
≥81	23,565	12.7%	20,915	12.2%	2,650	18.2%		5,255	18.1%	2,626	18.1%	2,629	18.1%	
Gender														
Female	107,420	57.9%	94,242	55.1%	13,178	90.6%	<0.001	26,304	90.6%	13,151	90.6%	13,153	90.6%	0.97
Male	78,116	42.1%	76,748	44.9%	1,368	9.4%		2,738	9.4%	1,370	9.4%	1,368	9.4%	
Insurance														
Commercial	58,206	31.4%	56,313	32.9%	1,893	13.0%	<0.001	3,785	13.0%	1,892	13.0%	1,893	13.0%	0.96
Dual	2,190	1.2%	1,754	1.0%	436	3.0%		883	3.0%	449	3.1%	434	3.0%	
Medicaid	41,703	22.5%	38,177	22.3%	3,526	24.2%		6,994	24.1%	3,491	24.0%	3,503	24.1%	
Medicare	83,437	45.0%	74,746	43.7%	8,691	59.7%		17,380	59.8%	8,689	59.8%	8,691	59.9%	
PCP Visit 2019														
No	73,675	39.7%	69,382	40.6%	4,293	29.5%	<0.001	8,564	29.5%	4,280	29.5%	4,284	29.5%	0.96
Yes	111,861	60.3%	101,608	59.4%	10,253	70.5%		20,478	70.5%	10,241	70.5%	10,237	70.5%	
						Continu	ous Outcom	es						
	mean	SD	mean	SD	mean	SD	p-value	mean	SD	mean	SD	mean	SD	p-value
CCI	1.08	1.76	1.09	1.76	0.95	1.75	< 0.001	0.95	1.74	0.95	1.73	0.95	1.75	0.82

# 2724 Table S9a: Antihypertensive Cohort (All Regions), Patient Characteristics Pre/Post Match

	All C	Observati	ons by Anti	hyperter	nsive Use: L	<b>Jnmatch</b>	ed	AI	Observa	tions by An	tihypert	ensive Use:	Matche	d
	All		HTN Non-		HTN Us			All		HTN Non-		HTN Us		
	N	%	N	%	N	%	p-value	N	%	N	%	N	%	p-value
All Patients	7,906,603	100.0%	5,805,483	73.4%	2,101,120	26.6%		3,572,002	100.0%	1,786,001	50.0%	1,786,001	50.0%	
Age														
≤20	1,840,050	23.3%	1,823,229	31.4%	16,821	0.8%	<0.001	33,574	0.9%	16,785	0.9%	16,789	0.9%	0.44
21-40	1,446,999	18.3%	1,299,520	22.4%	147,479	7.0%		293,445	8.2%	146,712	8.2%	146,733	8.2%	
41-50	925,309	11.7%	685,931	11.8%	239,378	11.4%		463,130	13.0%	231,312	13.0%	231,818	13.0%	
51-60	1,250,190	15.8%	759,987	13.1%	490,203	23.3%		870,549	24.4%	434,995	24.4%	435,554	24.4%	
61-70	1,181,261	14.9%	626,235	10.8%	555,026	26.4%		918,823	25.7%	459,192	25.7%	459,631	25.7%	
71-80	783,775	9.9%	381,957	6.6%	401,818	19.1%		619,578	17.3%	309,898	17.4%	309,680	17.3%	
≥81	479,019	6.1%	228,624	3.9%	250,395	11.9%		372,903	10.4%	187,107	10.5%	185,796	10.4%	
Gender														
Female	4,670,960	59.1%	3,402,357	58.6%	1,268,603	60.4%	<0.001	2,159,365	60.5%	1,079,468	60.4%	1,079,897	60.5%	0.64
Male	3,235,643	40.9%	2,403,126	41.4%	832,517	39.6%		1,412,637	39.5%	706,533	39.6%	706,104	39.5%	
Region														
Midwest	1,467,802	18.6%	1,065,772	18.4%	402,030	19.1%	<0.001	694,206	19.4%	347,103	19.4%	347,103	19.4%	1.00
Northeast	2,152,560	27.2%	1,568,239	27.0%	584,321	27.8%		997,132	27.9%	498,566	27.9%	498,566	27.9%	
South	3,042,604	38.5%	2,240,163	38.6%	802,441	38.2%		1,338,570	37.5%	669,285	37.5%	669,285	37.5%	
West	1,243,637	15.7%	931,309	16.0%	312,328	14.9%		542,094	15.2%	271,047	15.2%	271,047	15.2%	
Insurance														
Commercial	3,938,603	49.8%	3,060,354	52.7%	878,249	41.8%	<0.001	1,695,516	47.5%	848,106	47.5%	847,410	47.4%	0.80
Dual	156,497	2.0%	55,827	1.0%	100,670	4.8%		93,467	2.6%	46,774	2.6%	46,693	2.6%	
Medicaid	2,594,500	32.8%	2,091,349	36.0%	503,151	23.9%		812,737	22.8%	406,012	22.7%	406,725	22.8%	
Medicare	1,217,003	15.4%	597,953	10.3%	619,050	29.5%		970,282	27.2%	485,109	27.2%	485,173	27.2%	
PCP Visit 2019														
No	4,283,697	54.2%	3,531,914	60.8%	751,783	35.8%	<0.001	1,438,005	40.3%	719,756	40.3%	718,249	40.2%	0.10
Yes	3,622,906	45.8%	2,273,569	39.2%	1,349,337	64.2%		2,133,997	59.7%	1,066,245	59.7%	1,067,752	59.8%	
				•		Continuo	us Outcome	es					•	
	mean	SD	mean	SD	mean	SD	p-value	mean	SD	mean	SD	mean	SD	p-valu
CCI	0.62	1.38	0.43	1.14	1.13	1.80	<0.001	0.95	1.65	0.96	1.66	0.95	1.64	<0.05

#### Table S9b: Antihypertensive Cohort (Region=New York State), Patient Characteristics Pre/Post Match

	F	Region=N	/ by Antihy	pertensi	ve Use: Un	matched			Region=I	NY by Antil	nyperten	sive Use: N	latched	
	Α		HTN Non	-users	HTN U	sers	n velve	A	II	HTN Nor	n-users	HTN U	Isers	
	Ν	%	N	%	N	%	p-value	N	%	N	%	N	%	p-value
All Patients	968,296	100.0%	709,644	73.3%	258,652	26.7%		407,248	100.0%	203,624	50.0%	203,624	50.0%	
Age														
≤20	133,178	13.8%	132,352	18.7%	826	0.3%	< 0.001	1,622	0.4%	811	0.4%	811	0.4%	1.00
21-40	192,959	19.9%	181,447	25.6%	11,512	4.5%		22,930	5.6%	11,465	5.6%	11,465	5.6%	
41-50	127,794	13.2%	105,490	14.9%	22,304	8.6%		43,846	10.8%	21,923	10.8%	21,923	10.8%	
51-60	172,444	17.8%	119,643	16.9%	52,801	20.4%		96,318	23.7%	48,159	23.7%	48,159	23.7%	
61-70	159,912	16.5%	92,103	13.0%	67,809	26.2%		109,858	27.0%	54,929	27.0%	54,929	27.0%	
71-80	120,117	12.4%	54,076	7.6%	66,041	25.5%		88,734	21.8%	44,367	21.8%	44,367	21.8%	
≥81	61,892	6.4%	24,533	3.5%	37,359	14.4%		43,940	10.8%	21,970	10.8%	21,970	10.8%	
Gender														
Female	573,610	59.2%	419,901	59.2%	153,709	59.4%	0.02	240,930	59.2%	120,465	59.2%	120,465	59.2%	1.00
Male	394,686	40.8%	289,743	40.8%	104,943	40.6%		166,318	40.8%	83,159	40.8%	83,159	40.8%	
Insurance														
Commercial	500,918	51.7%	425,181	59.9%	75,737	29.3%	<0.001	150,918	37.1%	75,459	37.1%	75,459	37.1%	1.00
Dual	6,814	0.7%	1,659	0.2%	5,155	2.0%		2,986	0.7%	1,493	0.7%	1,493	0.7%	
Medicaid	252,366	26.1%	193,207	27.2%	59,159	22.9%		95,032	23.3%	47,516	23.3%	47,516	23.3%	
Medicare	208,198	21.5%	89,597	12.6%	118,601	45.9%		158,312	38.9%	79,156	38.9%	79,156	38.9%	
PCP Visit 2019														
No	521,282	53.8%	423,952	59.7%	97,330	37.6%	<0.001	181,234	44.5%	90,617	44.5%	90,617	44.5%	1.00
Yes	447,014	46.2%	285,692	40.3%	161,322	62.4%		226,014	55.5%	113,007	55.5%	113,007	55.5%	
						Continue	ous Outcom	es						
	mean	SD	mean	SD	mean	SD	p-value	mean	SD	mean	SD	mean	SD	p-valu
CCI	0.65	1.39	0.46	1.16	1.17	1.80	<0.001	0.95	1.60	0.95	1.60	0.95	1.60	1.00

Table S9c: Antihypertensive User Cohort (All Regions) by BP Use, Patient Characteristics Pre/Post Match of BP Users/Non-users

		All Antiby	pertensive L	leare hy	<b>BD</b> · Unma	atchod			All Anti	hypertensi	va Heare	by BP: Ma	tchod	
	All		BP Non-		BP U			A		BP Nor		BP U		
	N	%	N	%	N	%	p-value	N	%	N	%	N	%	p-value
All Patients	1,786,001	100.0%	1,579,388	88.4%	206,613	11.6%		408,792	100.0%	204,396	50.0%	204,396	50.0%	
Age	-,,		-,,							,				
≤20	16,789	0.9%	16,586	1.1%	203	0.1%	< 0.001	411	0.1%	208	0.1%	203	0.1%	1.00
21-40	146,733	8.2%	145,872	9.2%	861	0.4%		1,728	0.4%	868	0.4%	860	0.4%	
41-50	231,818	13.0%	229,150	14.5%	2,668	1.3%		5,333	1.3%	2,667	1.3%	2,666	1.3%	
51-60	435,554	24.4%	413,155	26.2%	22,399	10.8%		44,796	11.0%	22,399	11.0%	22,397	11.0%	
61-70	459,631	25.7%	390,664	24.7%	68,967	33.4%		137,730	33.7%	68,862	33.7%	68,868	33.7%	
71-80	309,680	17.3%	237,749	15.1%	71,931	34.8%		140,882	34.5%	70,439	34.5%	70,443	34.5%	
≥81	185,796	10.4%	146,212	9.3%	39,584	19.2%		77,912	19.1%	38,953	19.1%	38,959	19.1%	
Gender														
Female	1,079,897	60.5%	894,472	56.6%	185,425	89.7%	<0.001	366,424	89.6%	183,212	89.6%	183,212	89.6%	1.00
Male	706,104	39.5%	684,916	43.4%	21,188	10.3%		42,368	10.4%	21,184	10.4%	21,184	10.4%	
Region														
Midwest	347,103	19.4%	313,523	19.9%	33,580	16.3%	<0.001	67,058	16.4%	33,529	16.4%	33,529	16.4%	1.00
Northeast	498,566	27.9%	444,828	28.2%	53,738	26.0%		107,150	26.2%	53,575	26.2%	53,575	26.2%	
South	669,285	37.5%	595,410	37.7%	73,875	35.8%		146,890	35.9%	73,445	35.9%	73,445	35.9%	
West	271,047	15.2%	225,627	14.3%	45,420	22.0%		87,694	21.5%	43,847	21.5%	43,847	21.5%	
Insurance														
Commercial	847,410	47.4%	787,519	49.9%	59,891	29.0%	<0.001	119,737	29.3%	59,863	29.3%	59,874	29.3%	1.00
Dual	46,693	2.6%	37,153	2.4%	9,540	4.6%		17,884	4.4%	8,945	4.4%	8,939	4.4%	
Medicaid	406,725	22.8%	369,893	23.4%	36,832	17.8%		70,769	17.3%	35,387	17.3%	35,382	17.3%	
Medicare	485,173	27.2%	384,823	24.4%	100,350	48.6%		200,402	49.0%	100,201	49.0%	100,201	49.0%	
PCP Visit 2019														
No	718,249	40.2%	633,042	40.1%	85,207	41.2%	<0.001	168,255	41.2%	84,128	41.2%	84,127	41.2%	1.00
Yes	1,067,752	59.8%	946,346	59.9%	121,406	58.8%		240,537	58.8%	120,268	58.8%	120,269	58.8%	
							us Outcom	es						
	mean	SD	mean	SD	mean	SD	p-value	mean	SD	mean	SD	mean	SD	p-value
CCI	0.95	1.64	0.95	1.64	0.94	1.68	0.02	0.95	1.67	0.95	1.67	0.95	1.68	0.68

BP: bisphosphonate; CCI: Charlson Comorbidity Index; PCP: primary care physician; SD: standard deviation

# 2739 Table S9d: Antihypertensive User Cohort (Region=New York State) by BP Use, Patient Characteristics Pre/Post Match of BP

2740 Users/Non-users

2741

	Reg	ion=NY A	ntihyperten	sive Use	rs by BP:	Unmatc	hed	F	Region=NY	Antihype	tensive L	Jsers by B	P: Match	ed
	Α		BP Non		BP U					BP No	n-user	BP L	Jser	n volue
	N	%	N	%	N	%	p-value	N	%	N	%	N	%	p-value
All Patients	203,624	100.0%	182,411	89.6%	21,213	10.4%		42,252	100.0%	21,126	50.0%	21,126	50.0%	
Age														
≤20	811	0.4%	798	0.4%	13	0.1%	<0.001	27	0.1%	14	0.1%	13	0.1%	1.00
21-40	11,465	5.6%	11,396	6.2%	69	0.3%	]	137	0.3%	68	0.3%	69	0.3%	
41-50	21,923	10.8%	21,747	11.9%	176	0.8%	]	354	0.8%	178	0.8%	176	0.8%	
51-60	48,159	23.7%	46,047	25.2%	2,112	10.0%		4,218	10.0%	2,108	10.0%	2,110	10.0%	
61-70	54,929	27.0%	48,022	26.3%	6,907	32.6%		13,804	32.7%	6,902	32.7%	6,902	32.7%	
71-80	44,367	21.8%	36,409	20.0%	7,958	37.5%	]	15,777	37.3%	7,886	37.3%	7,891	37.4%	
≥81	21,970	10.8%	17,992	9.9%	3,978	18.8%	1	7,935	18.8%	3,970	18.8%	3,965	18.8%	
Gender														
Female	120,465	59.2%	101,190	55.5%	19,275	90.9%	<0.001	38,380	90.8%	19,190	90.8%	19,190	90.8%	1.00
Male	83,159	40.8%	81,221	44.5%	1,938	9.1%	1	3,872	9.2%	1,936	9.2%	1,936	9.2%	
Insurance														
Commercial	75,459	37.1%	71,460	39.2%	3,999	18.9%	< 0.001	7,993	18.9%	3,997	18.9%	3,996	18.9%	1.00
Dual	1,493	0.7%	1,151	0.6%	342	1.6%	1	643	1.5%	322	1.5%	321	1.5%	
Medicaid	47,516	23.3%	44,248	24.3%	3,268	15.4%	ĺ	6,414	15.2%	3,207	15.2%	3,207	15.2%	
Medicare	79,156	38.9%	65,552	35.9%	13,604	64.1%	1	27,202	64.4%	13,600	64.4%	13,602	64.4%	
PCP Visit 2019														
No	90,617	44.5%	80,739	44.3%	9,878	46.6%	< 0.001	19,672	46.6%	9,837	46.6%	9,835	46.6%	0.98
Yes	113,007	55.5%	101,672	55.7%	11,335	53.4%	1	22,580	53.4%	11,289	53.4%	11,291	53.4%	
						Continu	ous Outcom	es						
	mean	SD	mean	SD	mean	SD	p-value	mean	SD	mean	SD	mean	SD	p-value
CCI	0.95	1.60	0.95	1.61	0.88	1.54	<0.001	0.87	1.53	0.87	1.52	0.87	1.53	0.87

BP: bisphosphonate; CCI: Charlson Comorbidity Index; PCP: primary care physician; SD: standard deviation

2742 2743

#### Table S9e: Antihypertensive Non-user Cohort (All Regions) by BP Use, Patient Characteristics Pre/Post Match of BP Users/Non-2745 users

2746

2747

	All	Antihype	rtensive Nor	n-users	by BP: Un	matched			All Antihy	pertensive	Non-use	ers by BP:	Matched	
	All		BP Non-		BP U			A	II	BP Nor	-user	BP U	ser	
	N	%	N	%	N	%	p-value	N	%	N	%	N	%	p-value
All Patients	1,786,001	100.0%	1,649,985	92.4%	136,016	7.6%		271,448	100.0%	135,724	50.0%	135,724	50.0%	
Age														
≤20	16,785	0.9%	16,767	1.0%	18	0.0%	<0.001	34	0.0%	16	0.0%	18	0.0%	1.00
21-40	146,712	8.2%	146,210	8.9%	502	0.4%		1,009	0.4%	507	0.4%	502	0.4%	
41-50	231,312	13.0%	228,725	13.9%	2,587	1.9%		5,163	1.9%	2,577	1.9%	2,586	1.9%	
51-60	434,995	24.4%	410,636	24.9%	24,359	17.9%		48,700	17.9%	24,349	17.9%	24,351	17.9%	
61-70	459,192	25.7%	404,445	24.5%	54,747	40.3%		109,415	40.3%	54,711	40.3%	54,704	40.3%	
71-80	309,898	17.4%	271,617	16.5%	38,281	28.1%		76,139	28.0%	38,070	28.0%	38,069	28.0%	
≥81	187,107	10.5%	171,585	10.4%	15,522	11.4%		30,988	11.4%	15,494	11.4%	15,494	11.4%	
Gender														
Female	1,079,468	60.4%	956,403	58.0%	123,065	90.5%	<0.001	245,537	90.5%	122,762	90.4%	122,775	90.5%	0.93
Male	706,533	39.6%	693,582	42.0%	12,951	9.5%		25,911	9.5%	12,962	9.6%	12,949	9.5%	
Region														
Midwest	347,103	19.4%	321,267	19.5%	25,836	19.0%	<0.001	51,638	19.0%	25,819	19.0%	25,819	19.0%	1.00
Northeast	498,566	27.9%	463,273	28.1%	35,293	25.9%		70,544	26.0%	35,272	26.0%	35,272	26.0%	
South	669,285	37.5%	622,064	37.7%	47,221	34.7%		93,980	34.6%	46,990	34.6%	46,990	34.6%	
West	271,047	15.2%	243,381	14.8%	27,666	20.3%		55,286	20.4%	27,643	20.4%	27,643	20.4%	
Insurance														
Commercial	848,106	47.5%	798,579	48.4%	49,527	36.4%	<0.001	99,039	36.5%	49,523	36.5%	49,516	36.5%	1.00
Dual	46,774	2.6%	40,212	2.4%	6,562	4.8%		12,645	4.7%	6,319	4.7%	6,326	4.7%	
Medicaid	406,012	22.7%	381,472	23.1%	24,540	18.0%		49,025	18.1%	24,516	18.1%	24,509	18.1%	
Medicare	485,109	27.2%	429,722	26.0%	55,387	40.7%		110,739	40.8%	55,366	40.8%	55,373	40.8%	
PCP Visit 2019														
No	719,756	40.3%	676,255	41.0%	43,501	32.0%	<0.001	86,956	32.0%	43,478	32.0%	43,478	32.0%	1.00
Yes	1,066,245	59.7%	973,730	59.0%	92,515	68.0%		184,492	68.0%	92,246	68.0%	92,246	68.0%	
						Continuo	us Outcom	es						
	mean	SD	mean	SD	mean	SD	p-value	mean	SD	mean	SD	mean	SD	p-value
CCI	0.96	1.66	0.96	1.65	0.88	1.76	<0.001	0.88	1.75	0.88	1.74	0.88	1.75	0.76

BP: bisphosphonate; CCI: Charlson Comorbidity Index; PCP: primary care physician; SD: standard deviation

#### 2751 Table S9f: Antihypertensive Non-user Cohort (Region=New York State) by BP Use, Patient Characteristics Pre/Post Match of BP

2752 Users/Non-users

2753

	Regio	n=NY Anti	hypertensiv	ve Non-U	sers by B	P: Unma	tched	Reg	gion=NY Ar	ntihyperte	nsive Nor	1-users by	BP: Mate	ched
	A		BP Non		BP L			, All and a second s	All	BP No	n-user	BP L	Jser	n volue
	N	%	N	%	Ν	%	p-value	N	%	N	%	N	%	p-value
All Patients	203,624	100.0%	189,573	93.1%	14,051	6.9%		27,966	100.0%	13,983	50.0%	13,983	50.0%	
Age														
≤20	811	0.4%	810	0.4%	1	0.0%	<0.001	2	0.0%	1	0.0%	1	0.0%	1.00
21-40	11,465	5.6%	11,451	6.0%	14	0.1%	]	28	0.1%	14	0.1%	14	0.1%	
41-50	21,923	10.8%	21,762	11.5%	161	1.1%	1	324	1.2%	163	1.2%	161	1.2%	
51-60	48,159	23.7%	46,035	24.3%	2,124	15.1%		4,245	15.2%	2,121	15.2%	2,124	15.2%	
61-70	54,929	27.0%	49,409	26.1%	5,520	39.3%		11,027	39.4%	5,512	39.4%	5,515	39.4%	
71-80	44,367	21.8%	39,789	21.0%	4,578	32.6%		9,054	32.4%	4,528	32.4%	4,526	32.4%	
≥81	21,970	10.8%	20,317	10.7%	1,653	11.8%		3,286	11.7%	1,644	11.8%	1,642	11.7%	
Gender														
Female	120,465	59.2%	107,632	56.8%	12,833	91.3%	<0.001	25,530	91.3%	12,764	91.3%	12,766	91.3%	0.97
Male	83,159	40.8%	81,941	43.2%	1,218	8.7%	1	2,436	8.7%	1,219	8.7%	1,217	8.7%	
Insurance														
Commercial	75,459	37.1%	73,115	38.6%	2,344	16.7%	<0.001	4,683	16.7%	2,342	16.7%	2,341	16.7%	1.00
Dual	1,493	0.7%	1,211	0.6%	282	2.0%		554	2.0%	277	2.0%	277	2.0%	
Medicaid	47,516	23.3%	43,809	23.1%	3,707	26.4%		7,295	26.1%	3,648	26.1%	3,647	26.1%	
Medicare	79,156	38.9%	71,438	37.7%	7,718	54.9%	]	15,434	55.2%	7,716	55.2%	7,718	55.2%	
PCP Visit 2019														
No	90,617	44.5%	85,875	45.3%	4,742	33.7%	<0.001	9,461	33.8%	4,728	33.8%	4,733	33.8%	0.95
Yes	113,007	55.5%	103,698	54.7%	9,309	66.3%	]	18,505	66.2%	9,255	66.2%	9,250	66.2%	
						Continu	ous Outcom	es						
	mean	SD	mean	SD	mean	SD	p-value	mean	SD	mean	SD	mean	SD	p-value
CCI	0.95	1.60	0.96	1.60	0.81	1.60	<0.001	0.81	1.59	0.81	1.58	0.81	1.59	0.92

2754 BP: bisphosphonate; CCI: Charlson Comorbidity Index; PCP: primary care physician; SD: standard deviation

# 2757 Table S10a: Antidiabetic Cohort (All Regions), Patient Characteristics Pre/Post Match

2758

		Obsorva	tions by Ant	idiabati	lleo: llnr	natchod		^		ations by A	htidiaba	tic Llea: M	atchod	
	All	Observa	DIAB Non		DIAB L			ہر All		DIAB Nor		DIAB U		
	N	%	N	-users %	N	%	p-value	N All	%	N	%	N	%	p-value
All Patients	7,906,603	100.0%	7,151,351	90.4%	755,252	9.6%		1,509,106	100.0%	754,553	<i>5</i> 0.0%	754,553	<i>5</i> 0.0%	
Age	7,900,003	100.0 /6	7,151,351	50.4 /0	155,252	9.0 /0		1,509,100	100.0 /6	754,555	50.0 /0	754,555	50.0 /0	
≤20	1,840,050	23.3%	1,833,838	25.6%	6,212	0.8%	<0.001	12,422	0.8%	6,211	0.8%	6,211	0.8%	1.00
21-40	1,446,999	18.3%	1,389,243	19.4%	57,756	7.6%	<0.001	115,448	7.7%	57,723	7.6%	57,725	7.7%	1.00
41-50	925,309	11.7%	833,333	11.7%	91.976	12.2%		183,810	12.2%	91,905	12.2%	91,905	12.2%	
51-60	1,250,190	15.8%	1,058,878	14.8%	191,312	25.3%		382,390	25.3%	191,196	25.3%	191,194	25.3%	
61-70	1,181,261	14.9%	973,670	13.6%	207,591	27.5%		414,869	27.5%	207,435	27.5%	207,434	27.5%	
71-80	783,775	9.9%	645,256	9.0%	138,519	18.3%		276,619	18.3%	138,310	18.3%	138,309	18.3%	
≥81	479,019	6.1%	417,133	5.8%	61,886	8.2%		123,548	8.2%	61,773	8.2%	61,775	8.2%	
Gender	475,015	0.170	417,100	0.070	01,000	0.270		120,040	0.270	01,770	0.270	01,770	0.270	
Female	4,670,960	59.1%	4,212,086	58.9%	458.874	60.8%	< 0.001	916,914	60.8%	458,455	60.8%	458.459	60.8%	0.99
Male	3,235,643	40.9%	2,939,265	41.1%	296,378	39.2%	0.001	592,192	39.2%	296,098	39.2%	296,094	39.2%	0.00
Region	0,200,010	10.070	2,000,200	11.170	200,010	00.270		002,102	00.270	200,000	00.270	200,001	00.270	
Midwest	1.467.802	18.6%	1.333.631	18.6%	134,171	17.8%	< 0.001	268,044	17.8%	134,022	17.8%	134,022	17.8%	1.00
Northeast	2,152,560	27.2%	1,935,311	27.1%	217,249	28.8%		434,080	28.8%	217,040	28.8%	217,040	28.8%	
South	3,042,604	38.5%	2,752,618	38.5%	289,986	38.4%		579,562	38.4%	289,781	38.4%	289,781	38.4%	
West	1,243,637	15.7%	1,129,791	15.8%	113,846	15.1%		227,420	15.1%	113,710	15.1%	113,710	15.1%	
Insurance	, , , , , , , , , , , , , , , , , , , ,		, , , ,		- ,	-		, -	-	- , -	-	- , -		
Commercial	3,938,603	49.8%	3,631,514	50.8%	307,089	40.7%	< 0.001	614,045	40.7%	307,022	40.7%	307,023	40.7%	1.00
Dual	156,497	2.0%	113,496	1.6%	43,001	5.7%		85,209	5.6%	42,603	5.6%	42,606	5.6%	
Medicaid	2,594,500	32.8%	2,387,519	33.4%	206,981	27.4%		413,743	27.4%	206,875	27.4%	206,868	27.4%	
Medicare	1,217,003	15.4%	1,018,822	14.2%	198,181	26.2%		396,109	26.2%	198,053	26.2%	198,056	26.2%	
PCP Visit 2019														
No	4,283,697	54.2%	4,030,804	56.4%	252,893	33.5%	<0.001	505,500	33.5%	252,752	33.5%	252,748	33.5%	0.99
Yes	3,622,906	45.8%	3,120,547	43.6%	502,359	66.5%		1,003,606	66.5%	501,801	66.5%	501,805	66.5%	
						Continuo	us Outcom	es						
	mean	SD	mean	SD	mean	SD	p-value	mean	SD	mean	SD	mean	SD	p-value
CCI	0.62	1.38	0.55	1.30	1.25	1.84	<0.001	1.24	1.82	1.24	1.82	1.24	1.82	0.99

2759

CCI: Charlson Comorbidity Index; DIAB: antidiabetic; PCP: primary care physician; SD: standard deviation

#### Table S10b: Antidiabetic Cohort (Region=New York State), Patient Characteristics Pre/Post Match

		Region=	NY by Ant	idiabetic	Use: Unm	atched			Regior	n=NY by Ai	ntidiabeti	c Use: Mat	tched	
	Α		DIAB No		DIAB L			A		DIAB No		DIAB U		and the last
	Ν	%	N	%	Ν	%	p-value	N	%	N	%	N	%	p-value
All Patients	968,296	100.0%	863,179	89.1%	105,117	10.9%		209,382	100.0%	104,691	50.0%	104,691	50.0%	
Age								-						
≤20	133,178	13.8%	132,723	15.4%	455	0.4%	< 0.001	910	0.4%	455	0.4%	455	0.4%	1.00
21-40	192,959	19.9%	186,785	21.6%	6,174	5.9%		12,328	5.9%	6,164	5.9%	6,164	5.9%	ĺ
41-50	127,794	13.2%	117,342	13.6%	10,452	9.9%		20,880	10.0%	10,440	10.0%	10,440	10.0%	
51-60	172,444	17.8%	148,040	17.2%	24,404	23.2%		48,735	23.3%	24,369	23.3%	24,366	23.3%	
61-70	159,912	16.5%	130,968	15.2%	28,944	27.5%		57,638	27.5%	28,819	27.5%	28,819	27.5%	
71-80	120,117	12.4%	95,621	11.1%	24,496	23.3%		48,625	23.2%	24,311	23.2%	24,314	23.2%	
≥81	61,892	6.4%	51,700	6.0%	10,192	9.7%		20,266	9.7%	10,133	9.7%	10,133	9.7%	
Gender														
Female	573,610	59.2%	512,889	59.4%	60,721	57.8%	<0.001	120,937	57.8%	60,467	57.8%	60,470	57.8%	0.99
Male	394,686	40.8%	350,290	40.6%	44,396	42.2%		88,445	42.2%	44,224	42.2%	44,221	42.2%	
Insurance														
Commercial	500,918	51.7%	468,804	54.3%	32,114	30.6%	< 0.001	64,200	30.7%	32,100	30.7%	32,100	30.7%	1.00
Dual	6,814	0.7%	4,408	0.5%	2,406	2.3%		4,389	2.1%	2,196	2.1%	2,193	2.1%	
Medicaid	252,366	26.1%	224,334	26.0%	28,032	26.7%		55,853	26.7%	27,925	26.7%	27,928	26.7%	
Medicare	208,198	21.5%	165,633	19.2%	42,565	40.5%		84,940	40.6%	42,470	40.6%	42,470	40.6%	ĺ
PCP Visit 2019														
No	521,282	53.8%	484,071	56.1%	37,211	35.4%	<0.001	74,215	35.4%	37,106	35.4%	37,109	35.4%	0.99
Yes	447,014	46.2%	379,108	43.9%	67,906	64.6%		135,167	64.6%	67,585	64.6%	67,582	64.6%	
						Continue	ous Outcom	es						
	mean	SD	mean	SD	mean	SD	p-value	mean	SD	mean	SD	mean	SD	p-value
CCI	0.65	1.39	0.56	1.30	1.34	1.84	<0.001	1.32	1.79	1.32	1.79	1.32	1.79	0.98

Table S10c: Antidiabetic User Cohort (All Regions) by BP Use, Patient Characteristics Pre/Post Match of BP Users/Non-users

		All Ant	idiabetic Us	sers by E	BP: Unma	tched			All An	tidiabetic	Users by	BP: Mato	ched	
	Α		BP Non		BP U		n volue	A	11	BP No	n-user	BP L	Jser	n volue
	Ν	%	N	%	N	%	p-value	N	%	N	%	N	%	p-valu
All Patients	754,553	100.0%	674,024	89.3%	80,529	10.7%		159,000	100.0%	79,500	50.0%	79,500	50.0%	
Age														
≤20	6,211	0.8%	6,169	0.9%	42	0.1%	<0.001	83	0.1%	41	0.1%	42	0.1%	1.00
21-40	57,725	7.7%	57,535	8.5%	190	0.2%		380	0.2%	190	0.2%	190	0.2%	
41-50	91,905	12.2%	90,952	13.5%	953	1.2%		1,905	1.2%	952	1.2%	953	1.2%	
51-60	191,194	25.3%	182,922	27.1%	8,272	10.3%		16,536	10.4%	8,268	10.4%	8,268	10.4%	
61-70	207,434	27.5%	180,895	26.8%	26,539	33.0%		53,028	33.4%	26,512	33.3%	26,516	33.4%	
71-80	138,309	18.3%	107,467	15.9%	30,842	38.3%		60,240	37.9%	30,121	37.9%	30,119	37.9%	
≥81	61,775	8.2%	48,084	7.1%	13,691	17.0%		26,828	16.9%	13,416	16.9%	13,412	16.9%	
Gender														
Female	458,459	60.8%	386,400	57.3%	72,059	89.5%	<0.001	142,068	89.4%	71,027	89.3%	71,041	89.4%	0.91
Male	296,094	39.2%	287,624	42.7%	8,470	10.5%		16,932	10.6%	8,473	10.7%	8,459	10.6%	
Region														
Midwest	134,022	17.8%	123,909	18.4%	10,113	12.6%	<0.001	20,168	12.7%	10,084	12.7%	10,084	12.7%	1.00
Northeast	217,040	28.8%	196,723	29.2%	20,317	25.2%		40,446	25.4%	20,223	25.4%	20,223	25.4%	
South	289,781	38.4%	257,599	38.2%	32,182	40.0%		63,740	40.1%	31,870	40.1%	31,870	40.1%	
West	113,710	15.1%	95,793	14.2%	17,917	22.2%		34,646	21.8%	17,323	21.8%	17,323	21.8%	
nsurance	,		Í Í									· · ·		
Commercial	307,023	40.7%	290,957	43.2%	16,066	20.0%	<0.001	32,086	20.2%	16,043	20.2%	16,043	20.2%	1.00
Dual	42,606	5.6%	32,797	4.9%	9,809	12.2%		18,653	11.7%	9,321	11.7%	9,332	11.7%	
Medicaid	206,868	27.4%	188,638	28.0%	18,230	22.6%		35,513	22.3%	17,759	22.3%	17,754	22.3%	
Medicare	198,056	26.2%	161,632	24.0%	36,424	45.2%		72,748	45.8%	36,377	45.8%	36,371	45.7%	
PCP Visit 2019	,		, , , , , , , , , , , , , , , , , , ,									· · ·		
No	252,748	33.5%	228,203	33.9%	24,545	30.5%	<0.001	48,374	30.4%	24,184	30.4%	24,190	30.4%	0.97
Yes	501,805	66.5%	445,821	66.1%	55,984	69.5%		110,626	69.6%	55,316	69.6%	55,310	69.6%	
	,					Continu	ous Outcom	es	•				<u>.</u>	
	mean	SD	mean	SD	mean	SD	p-value	mean	SD	mean	SD	mean	SD	p-valu
CCI	1.24	1.82	1.23	1.81	1.32	1.90	< 0.001	1.31	1.88	1.31	1.87	1.32	1.88	0.75

# 2770 Table S10d: Antidiabetic User Cohort (Region=New York State) by BP Use, Patient Characteristics Pre/Post Match of BP

- 2771 Users/Non-users
- 2772

	R	egion=NY	Antidiabet	ic Users	by BP: U	Inmatche	d		Region=N	Y Antidia	betic Use	rs by BP	: Matched	
	A	II	BP No	n-user	BP	User	n volue		All	BP No	on-user	BP	User	n volue
	N	%	N	%	N	%	p-value	N	%	N	%	Ν	%	p-value
All Patients	104,691	100.0%	95,162	90.9%	9,529	9.1%		18,912	100.0%	9,456	50.0%	9,456	50.0%	
Age														
≤20	455	0.4%	454	0.5%	1	0.0%	<0.001	2	0.0%	1	0.0%	1	0.0%	1.00
21-40	6,164	5.9%	6,152	6.5%	12	0.1%		25	0.1%	13	0.1%	12	0.1%	
41-50	10,440	10.0%	10,363	10.9%	77	0.8%		151	0.8%	75	0.8%	76	0.8%	
51-60	24,366	23.3%	23,532	24.7%	834	8.8%		1,665	8.8%	831	8.8%	834	8.8%	
61-70	28,819	27.5%	25,939	27.3%	2,880	30.2%		5,741	30.4%	2,870	30.4%	2,871	30.4%	
71-80	24,314	23.2%	20,338	21.4%	3,976	41.7%		7,880	41.7%	3,941	41.7%	3,939	41.7%	
≥81	10,133	9.7%	8,384	8.8%	1,749	18.4%		3,448	18.2%	1,725	18.2%	1,723	18.2%	
Gender														
Female	60,470	57.8%	51,884	54.5%	8,586	90.1%	<0.001	17,022	90.0%	8,509	90.0%	8,513	90.0%	0.92
Male	44,221	42.2%	43,278	45.5%	943	9.9%		1,890	10.0%	947	10.0%	943	10.0%	
Insurance														
Commercial	32,100	30.7%	31,172	32.8%	928	9.7%	<0.001	1,849	9.8%	924	9.8%	925	9.8%	1.00
Dual	2,193	2.1%	1,693	1.8%	500	5.2%		978	5.2%	490	5.2%	488	5.2%	
Medicaid	27,928	26.7%	25,978	27.3%	1,950	20.5%		3,793	20.1%	1,897	20.1%	1,896	20.1%	
Medicare	42,470	40.6%	36,319	38.2%	6,151	64.6%		12,292	65.0%	6,145	65.0%	6,147	65.0%	
PCP Visit 2019														
No	37,109	35.4%	33,894	35.6%	3,215	33.7%	<.001	6,363	33.6%	3,182	33.7%	3,181	33.6%	0.99
Yes	67,582	64.6%	61,268	64.4%	6,314	66.3%		12,549	66.4%	6,274	66.3%	6,275	66.4%	
						Continu	ous Outcom	ies						
	mean	SD	mean	SD	mean	SD	p-value	mean	SD	mean	SD	mean	SD	p-value
CCI	1.32	1.79	1.31	1.79	1.46	1.87	<0.001	1.44	1.83	1.44	1.82	1.45	1.84	0.75

BP: bisphosphonate; CCI: Charlson Comorbidity Index; PCP: primary care physician; SD: standard deviation

2773 2774

Table S10e: Antidiabetic Non-user Cohort (All Regions) by BP Use, Patient Characteristics Pre/Post Match of BP Users/Non-users

		All Antidi	abetic Non	-users by	/ BP: Unn	natched			All Antic	liabetic No	on-users	by BP: Ma	atched	
	A	11	BP Non	-user	BP U	Jser	n velve	A	11	BP No	n-user	BP L	Jser	n velve
	N	%	N	%	N	%	p-value	Ν	%	Ν	%	N	%	p-value
All Patients	754,553	100.0%	681,380	90.3%	73,173	9.7%		145,028	100.0%	72,514	50.0%	72,514	50.0%	
Age														
≤20	6,211	0.8%	6,199	0.9%	12	0.0%	< 0.001	24	0.0%	12	0.0%	12	0.0%	1.00
21-40	57,723	7.6%	57,497	8.4%	226	0.3%		455	0.3%	229	0.3%	226	0.3%	
41-50	91,905	12.2%	90,693	13.3%	1,212	1.7%		2,421	1.7%	1,209	1.7%	1,212	1.7%	
51-60	191,196	25.3%	180,332	26.5%	10,864	14.8%		21,721	15.0%	10,860	15.0%	10,861	15.0%	
61-70	207,435	27.5%	180,825	26.5%	26,610	36.4%		53,115	36.6%	26,558	36.6%	26,557	36.6%	
71-80	138,310	18.3%	114,018	16.7%	24,292	33.2%		47,723	32.9%	23,861	32.9%	23,862	32.9%	
≥81	61,773	8.2%	51,816	7.6%	9,957	13.6%		19,569	13.5%	9,785	13.5%	9,784	13.5%	
Gender														
Female	458,455	60.8%	393,376	57.7%	65,079	88.9%	< 0.001	128,836	88.8%	64,411	88.8%	64,425	88.8%	0.91
Male	296,098	39.2%	288,004	42.3%	8,094	11.1%		16,192	11.2%	8,103	11.2%	8,089	11.2%	
Region														
Midwest	134,022	17.8%	123,283	18.1%	10,739	14.7%	< 0.001	21,390	14.7%	10,695	14.7%	10,695	14.7%	1.00
Northeast	217,040	28.8%	197,710	29.0%	19,330	26.4%		38,510	26.6%	19,255	26.6%	19,255	26.6%	
South	289,781	38.4%	261,382	38.4%	28,399	38.8%		55,812	38.5%	27,906	38.5%	27,906	38.5%	
West	113,710	15.1%	99,005	14.5%	14,705	20.1%		29,316	20.2%	14,658	20.2%	14,658	20.2%	
Insurance														
Commercial	307,022	40.7%	289,018	42.4%	18,004	24.6%	< 0.001	35,983	24.8%	17,988	24.8%	17,995	24.8%	1.00
Dual	42,603	5.6%	33,444	4.9%	9,159	12.5%		17,221	11.9%	8,611	11.9%	8,610	11.9%	
Medicaid	206,875	27.4%	190,166	27.9%	16,709	22.8%		33,264	22.9%	16,636	22.9%	16,628	22.9%	
Medicare	198,053	26.2%	168,752	24.8%	29,301	40.0%		58,560	40.4%	29,279	40.4%	29,281	40.4%	
PCP Visit 2019														
No	252,752	33.5%	233,775	34.3%	18,977	25.9%	< 0.001	37,812	26.1%	18,903	26.1%	18,909	26.1%	0.97
Yes	501,801	66.5%	447,605	65.7%	54,196	74.1%		107,216	73.9%	53,611	73.9%	53,605	73.9%	
						Continu	ous Outcom	es						
	mean	SD	mean	SD	mean	SD	p-value	mean	SD	mean	SD	mean	SD	p-value
CCI	1.24	1.82	1.24	1.81	1.24	1.89	0.92	1.24	1.87	1.24	1.87	1.25	1.88	0.63

BP: bisphosphonate; CCI: Charlson Comorbidity Index; PCP: primary care physician; SD: standard deviation

# 2781 Table S10f: Antidiabetic Non-user Cohort (Region=New York State) by BP Use, Patient Characteristics Pre/Post Match of BP

2782 Users/Non-users

2783

	Reg	ion=NY Ar	tidiabetic	Non-use	rs by BP	: Unmatc	hed	F	Region=NY	Antidiabe	etic Non-u	sers by E	3P: Match	ed
	Α	11	BP No	n-user	BP	User	n volue	/	AII	BP No	on-user	BP	User	m velue
	N	%	N	%	Ν	%	p-value	N	%	Ν	%	Ν	%	p-value
All Patients	104,691	100.0%	95,416	91.1%	9,275	8.9%		18,288	100.0%	9,144	50.0%	9,144	50.0%	
Age														
≤20	455	0.4%	455	0.5%	0	0.0%	<0.001	0	0.0%	0	0.0%	0	0.0%	1.00
21-40	6,164	5.9%	6,146	6.4%	18	0.2%	]	36	0.2%	18	0.2%	18	0.2%	
41-50	10,440	10.0%	10,367	10.9%	73	0.8%	]	147	0.8%	74	0.8%	73	0.8%	
51-60	24,369	23.3%	23,304	24.4%	1,065	11.5%		2,128	11.6%	1,064	11.6%	1,064	11.6%	
61-70	28,819	27.5%	25,720	27.0%	3,099	33.4%		6,190	33.8%	3,097	33.9%	3,093	33.8%	
71-80	24,311	23.2%	20,826	21.8%	3,485	37.6%		6,839	37.4%	3,419	37.4%	3,420	37.4%	
≥81	10,133	9.7%	8,598	9.0%	1,535	16.5%		2,948	16.1%	1,472	16.1%	1,476	16.1%	
Gender														
Female	60,467	57.8%	52,194	54.7%	8,273	89.2%	<0.001	16,291	89.1%	8,146	89.1%	8,145	89.1%	0.98
Male	44,224	42.2%	43,222	45.3%	1,002	10.8%	1	1,997	10.9%	998	10.9%	999	10.9%	
Insurance														
Commercial	32,100	30.7%	31,095	32.6%	1,005	10.8%	<0.001	2,002	10.9%	1,000	10.9%	1,002	11.0%	1.00
Dual	2,196	2.1%	1,675	1.8%	521	5.6%		1,006	5.5%	502	5.5%	504	5.5%	
Medicaid	27,925	26.7%	25,530	26.8%	2,395	25.8%		4,575	25.0%	2,289	25.0%	2,286	25.0%	
Medicare	42,470	40.6%	37,116	38.9%	5,354	57.7%	]	10,705	58.5%	5,353	58.5%	5,352	58.5%	
PCP Visit 2019														
No	37,106	35.4%	34,553	36.2%	2,553	27.5%	<0.001	5,039	27.6%	2,518	27.5%	2,521	27.6%	0.96
Yes	67,585	64.6%	60,863	63.8%	6,722	72.5%		13,249	72.4%	6,626	72.5%	6,623	72.4%	
						Continu	ious Outcom	es						
	mean	SD	mean	SD	mean	SD	p-value	mean	SD	mean	SD	mean	SD	p-value
CCI	1.32	1.79	1.32	1.79	1.37	1.81	0.007	1.37	1.78	1.36	1.78	1.37	1.79	0.92

2784 BP: bisphosphonate; CCI: Charlson Comorbidity Index; PCP: primary care physician; SD: standard deviation

2785

# 2787 Table S11a: Antidepressant Cohort (All Regions), Patient Characteristics Pre/Post Match

	All	Observat	ions by Anti	depress	ant Use: Ur	matche	d	A	I Observa	ations by Ar	ntidepres	ssant Use: N	latched	
ĺ	All		DEPR Non	-users	DEPR U	sers	n volue	All		DEPR Non	-users	DEPR U	sers	n volue
	Ν	%	N	%	N	%	p-value	N	%	N	%	N	%	p-value
All Patients	7,906,603	100.0%	6,335,598	80.1%	1,571,005	19.9%		3,072,096	100.0%	1,536,048	50.0%	1,536,048	50.0%	
Age														
≤20	1,840,050	23.3%	1,750,435	27.6%	89,615	5.7%	<0.001	179,136	5.8%	89,565	5.8%	89,571	5.8%	1.00
21-40	1,446,999	18.3%	1,128,316	17.8%	318,683	20.3%		631,186	20.5%	315,593	20.5%	315,593	20.5%	
41-50	925,309	11.7%	683,455	10.8%	241,854	15.4%		466,681	15.2%	233,336	15.2%	233,345	15.2%	
51-60	1,250,190	15.8%	899,512	14.2%	350,678	22.3%		667,305	21.7%	333,650	21.7%	333,655	21.7%	
61-70	1,181,261	14.9%	879,560	13.9%	301,701	19.2%		592,345	19.3%	296,182	19.3%	296,163	19.3%	
71-80	783,775	9.9%	613,922	9.7%	169,853	10.8%		338,594	11.0%	169,295	11.0%	169,299	11.0%	
≥81	479,019	6.1%	380,398	6.0%	98,621	6.3%		196,849	6.4%	98,427	6.4%	98,422	6.4%	
Gender														
Female	4,670,960	59.1%	3,527,859	55.7%	1,143,101	72.8%	<0.001	2,219,179	72.2%	1,109,580	72.2%	1,109,599	72.2%	0.98
Male	3,235,643	40.9%	2,807,739	44.3%	427,904	27.2%		852,917	27.8%	426,468	27.8%	426,449	27.8%	
Region														
Midwest	1,467,802	18.6%	1,120,969	17.7%	346,833	22.1%	<0.001	671,016	21.8%	335,508	21.8%	335,508	21.8%	1.00
Northeast	2,152,560	27.2%	1,765,134	27.9%	387,426	24.7%		766,046	24.9%	383,023	24.9%	383,023	24.9%	
South	3,042,604	38.5%	2,428,383	38.3%	614,221	39.1%		1,192,058	38.8%	596,029	38.8%	596,029	38.8%	
West	1,243,637	15.7%	1,021,112	16.1%	222,525	14.2%		442,976	14.4%	221,488	14.4%	221,488	14.4%	
Insurance														
Commercial	3,938,603	49.8%	3,230,475	51.0%	708,128	45.1%	<0.001	1,415,351	46.1%	707,675	46.1%	707,676	46.1%	1.00
Dual	156,497	2.0%	94,682	1.5%	61,815	3.9%		109,676	3.6%	54,836	3.6%	54,840	3.6%	
Medicaid	2,594,500	32.8%	2,083,688	32.9%	510,812	32.5%		972,897	31.7%	486,446	31.7%	486,451	31.7%	
Medicare	1,217,003	15.4%	926,753	14.6%	290,250	18.5%		574,172	18.7%	287,091	18.7%	287,081	18.7%	
PCP Visit 2019														
No	4,283,697	54.2%	3,672,879	58.0%	610,818	38.9%	<0.001	1,210,520	39.4%	605,256	39.4%	605,264	39.4%	0.99
Yes	3,622,906	45.8%	2,662,719	42.0%	960,187	61.1%		1,861,576	60.6%	930,792	60.6%	930,784	60.6%	
						Continuo	us Outcom	es						
	mean	SD	mean	SD	mean	SD	p-value	mean	SD	mean	SD	mean	SD	p-value
CCI	0.62	1.38	0.55	1.29	0.90	1.65	< 0.001	0.87	1.60	0.87	1.60	0.87	1.60	0.98

#### Table S11b: Antidepressant Cohort (Region=New York State), Patient Characteristics Pre/Post Match

		Region=N	Y by Antid	epressar	nt Use: Uni	natched			Region=	NY by Anti	idepressa	ant Use: M	atched	
	Α		DEPR No		DEPR I			A		DEPR No		DEPR		
	N	%	N	%	N	%	p-value	N	%	N	%	N	%	p-value
All Patients	968,296	100.0%	832,215	85.9%	136,081	14.1%		271,032	100.0%	135,516	50.0%	135,516	50.0%	
Age								, i						
≤20	133,178	13.8%	128,810	15.5%	4,368	3.2%	<0.001	8,728	3.2%	4,365	3.2%	4,363	3.2%	1.00
21-40	192,959	19.9%	170,076	20.4%	22,883	16.8%		45,666	16.8%	22,832	16.8%	22,834	16.8%	ĺ
41-50	127,794	13.2%	109,184	13.1%	18,610	13.7%		36,965	13.6%	18,483	13.6%	18,482	13.6%	
51-60	172,444	17.8%	142,702	17.1%	29,742	21.9%		58,966	21.8%	29,481	21.8%	29,485	21.8%	1
61-70	159,912	16.5%	132,317	15.9%	27,595	20.3%		55,083	20.3%	27,543	20.3%	27,540	20.3%	
71-80	120,117	12.4%	99,040	11.9%	21,077	15.5%		42,076	15.5%	21,038	15.5%	21,038	15.5%	ĺ
≥81	61,892	6.4%	50,086	6.0%	11,806	8.7%		23,548	8.7%	11,774	8.7%	11,774	8.7%	ĺ
Gender														
Female	573,610	59.2%	476,684	57.3%	96,926	71.2%	<0.001	192,930	71.2%	96,468	71.2%	96,462	71.2%	0.98
Male	394,686	40.8%	355,531	42.7%	39,155	28.8%		78,102	28.8%	39,048	28.8%	39,054	28.8%	
Insurance														
Commercial	500,918	51.7%	449,071	54.0%	51,847	38.1%	<0.001	103,658	38.2%	51,829	38.2%	51,829	38.2%	1.00
Dual	6,814	0.7%	5,072	0.6%	1,742	1.3%		3,191	1.2%	1,591	1.2%	1,600	1.2%	
Medicaid	252,366	26.1%	213,705	25.7%	38,661	28.4%		77,136	28.5%	38,569	28.5%	38,567	28.5%	ĺ
Medicare	208,198	21.5%	164,367	19.8%	43,831	32.2%		87,047	32.1%	43,527	32.1%	43,520	32.1%	ĺ
PCP Visit 2019														
No	521,282	53.8%	467,739	56.2%	53,543	39.3%	<0.001	106,797	39.4%	53,397	39.4%	53,400	39.4%	0.99
Yes	447,014	46.2%	364,476	43.8%	82,538	60.7%		164,235	60.6%	82,119	60.6%	82,116	60.6%	
			•			Continue	ous Outcom	ies			•			
	mean	SD	mean	SD	mean	SD	p-value	mean	SD	mean	SD	mean	SD	p-value
CCI	0.65	1.39	0.59	1.32	0.98	1.71	< 0.001	0.96	1.68	0.96	1.68	0.96	1.68	0.99

2797 Table S11c: Antidepressant User Cohort (All Regions) by BP Use, Patient Characteristics Pre/Post Match of BP Users/Non-users

		All Antide	epressant U	sers by I	BP: Unma	tched			All Ant	idepressa	nt Users	by BP: Mat	ched	
	All		BP Non-		BP U		n value	A		BP Nor		BP U		
	N	%	N	%	N	%	p-value	N	%	N	%	N	%	p-value
All Patients	1,536,048	100.0%	1,390,939	90.6%	145,109	9.4%		288,564	100.0%	144,282	50.0%	144,282	50.0%	
Age														
≤20	89,571	5.8%	89,415	6.4%	156	0.1%	<0.001	313	0.1%	157	0.1%	156	0.1%	1.00
21-40	315,593	20.5%	314,429	22.6%	1,164	0.8%		2,326	0.8%	1,162	0.8%	1,164	0.8%	
41-50	233,345	15.2%	229,878	16.5%	3,467	2.4%		6,933	2.4%	3,467	2.4%	3,466	2.4%	
51-60	333,655	21.7%	310,316	22.3%	23,339	16.1%		46,674	16.2%	23,339	16.2%	23,335	16.2%	
61-70	296,163	19.3%	244,247	17.6%	51,916	35.8%		103,798	36.0%	51,905	36.0%	51,893	36.0%	
71-80	169,299	11.0%	126,089	9.1%	43,210	29.8%		85,292	29.6%	42,643	29.6%	42,649	29.6%	
≥81	98,422	6.4%	76,565	5.5%	21,857	15.1%		43,228	15.0%	21,609	15.0%	21,619	15.0%	
Gender														
Female	1,109,599	72.2%	976,214	70.2%	133,385	91.9%	<0.001	265,123	91.9%	132,553	91.9%	132,570	91.9%	0.91
Male	426,449	27.8%	414,725	29.8%	11,724	8.1%		23,441	8.1%	11,729	8.1%	11,712	8.1%	
Region														
Midwest	335,508	21.8%	309,597	22.3%	25,911	17.9%	<0.001	51,754	17.9%	25,877	17.9%	25,877	17.9%	1.00
Northeast	383,023	24.9%	347,944	25.0%	35,079	24.2%		70,010	24.3%	35,005	24.3%	35,005	24.3%	
South	596,029	38.8%	540,382	38.9%	55,647	38.3%		110,518	38.3%	55,259	38.3%	55,259	38.3%	
West	221,488	14.4%	193,016	13.9%	28,472	19.6%		56,282	19.5%	28,141	19.5%	28,141	19.5%	
Insurance														
Commercial	707,676	46.1%	664,625	47.8%	43,051	29.7%	<0.001	86,053	29.8%	43,023	29.8%	43,030	29.8%	1.00
Dual	54,840	3.6%	43,171	3.1%	11,669	8.0%		22,384	7.8%	11,193	7.8%	11,191	7.8%	
Medicaid	486,451	31.7%	457,656	32.9%	28,795	19.8%		56,959	19.7%	28,479	19.7%	28,480	19.7%	
Medicare	287,081	18.7%	225,487	16.2%	61,594	42.4%		123,168	42.7%	61,587	42.7%	61,581	42.7%	
PCP Visit 2019														
No	605,264	39.4%	553,886	39.8%	51,378	35.4%	<0.001	102,148	35.4%	51,064	35.4%	51,084	35.4%	0.94
Yes	930,784	60.6%	837,053	60.2%	93,731	64.6%		186,416	64.6%	93,218	64.6%	93,198	64.6%	
	•	•	•	•	•	Continuo	us Outcom	es	•	•	•			
	mean	SD	mean	SD	mean	SD	p-value	mean	SD	mean	SD	mean	SD	p-value
CCI	0.87	1.60	0.84	1.58	1.09	1.81	< 0.001	1.09	1.79	1.08	1.78	1.09	1.79	0.56

2799 BP: bisphosphonate; CCI: Charlson Comorbidity Index; PCP: primary care physician; SD: standard deviation

2800

# 2802 Table S11d: Antidepressant User Cohort (Region=New York State) by BP Use, Patient Characteristics Pre/Post Match of BP

2803 Users/Non-users

2804

	Re	gion=NY A	Intidepress	ant User	s by BP:	Unmatch	ed		Region=N	Antidepr	essant Us	sers by Bl	P: Matche	d
	A	Î	BP Non	-user	BP U	Jser	n velue	4		BP No	n-user	BP L	Jser	n volue
	Ν	%	N	%	N	%	p-value	N	%	N	%	N	%	p-value
All Patients	135,516	100.0%	122,566	90.4%	12,950	9.6%		25,718	100.0%	12,859	50.0%	12,859	50.0%	
Age														
≤20	4,363	3.2%	4,357	3.6%	6	0.0%	<0.001	12	0.0%	6	0.0%	6	0.0%	1.00
21-40	22,834	16.8%	22,770	18.6%	64	0.5%	]	126	0.5%	62	0.5%	64	0.5%	
41-50	18,482	13.6%	18,263	14.9%	219	1.7%	1	440	1.7%	221	1.7%	219	1.7%	
51-60	29,485	21.8%	27,702	22.6%	1,783	13.8%		3,570	13.9%	1,788	13.9%	1,782	13.9%	
61-70	27,540	20.3%	23,385	19.1%	4,155	32.1%		8,292	32.2%	4,146	32.2%	4,146	32.2%	
71-80	21,038	15.5%	16,548	13.5%	4,490	34.7%		8,863	34.5%	4,430	34.5%	4,433	34.5%	
≥81	11,774	8.7%	9,541	7.8%	2,233	17.2%	1	4,415	17.2%	2,206	17.2%	2,209	17.2%	
Gender														
Female	96,462	71.2%	84,469	68.9%	11,993	92.6%	<0.001	23,810	92.6%	11,906	92.6%	11,904	92.6%	0.96
Male	39,054	28.8%	38,097	31.1%	957	7.4%	1	1,908	7.4%	953	7.4%	955	7.4%	
Insurance														
Commercial	51,829	38.2%	49,332	40.2%	2,497	19.3%	< 0.001	4,991	19.4%	2,495	19.4%	2,496	19.4%	1.00
Dual	1,600	1.2%	1,221	1.0%	379	2.9%	1	710	2.8%	356	2.8%	354	2.8%	
Medicaid	38,567	28.5%	36,366	29.7%	2,201	17.0%	1	4,269	16.6%	2,131	16.6%	2,138	16.6%	
Medicare	43,520	32.1%	35,647	29.1%	7,873	60.8%	1	15,748	61.2%	7,877	61.3%	7,871	61.2%	
PCP Visit 2019														
No	53,400	39.4%	48,911	39.9%	4,489	34.7%	<0.001	8,901	34.6%	4,449	34.6%	4,452	34.6%	0.97
Yes	82,116	60.6%	73,655	60.1%	8,461	65.3%		16,817	65.4%	8,410	65.4%	8,407	65.4%	
						Continu	ous Outcom	es						
	mean	SD	mean	SD	mean	SD	p-value	mean	SD	mean	SD	mean	SD	p-value
CCI	0.96	1.68	0.95	1.66	1.13	1.78	< 0.001	1.12	1.76	1.12	1.75	1.12	1.77	0.86

2805 2806 BP: bisphosphonate; CCI: Charlson Comorbidity Index; PCP: primary care physician; SD: standard deviation

#### 2807 Table S11e: Antidepressant Non-user Cohort (All Regions) by BP Use, Patient Characteristics Pre/Post Match of BP Users/Nonusers

2808

2809

	AI	All Antidepressant Non-users by BP: Unmatched							All Antide	epressant	Non-user	s by BP: N	latched	
	All		BP Non-	user	BP U	ser	n walve	Α	II	BP Non	i-user	BP U	ser	
	N	%	N	%	N	%	p-value	N	%	N	%	N	%	p-value
All Patients	1,536,048	100.0%	1,422,938	92.6%	113,110	7.4%		224,804	100.0%	112,402	50.0%	112,402	50.0%	
Age														
≤20	89,565	5.8%	89,486	6.3%	79	0.1%	<0.001	155	0.1%	76	0.1%	79	0.1%	1.00
21-40	315,593	20.5%	314,815	22.1%	778	0.7%		1,562	0.7%	784	0.7%	778	0.7%	
41-50	233,336	15.2%	230,961	16.2%	2,375	2.1%		4,746	2.1%	2,371	2.1%	2,375	2.1%	
51-60	333,650	21.7%	314,109	22.1%	19,541	17.3%		39,072	17.4%	19,536	17.4%	19,536	17.4%	
61-70	296,182	19.3%	254,286	17.9%	41,896	37.0%		83,664	37.2%	41,834	37.2%	41,830	37.2%	
71-80	169,295	11.0%	136,746	9.6%	32,549	28.8%		64,163	28.5%	32,073	28.5%	32,090	28.5%	
≥81	98,427	6.4%	82,535	5.8%	15,892	14.1%		31,442	14.0%	15,728	14.0%	15,714	14.0%	
Gender														
Female	1,109,580	72.2%	1,004,112	70.6%	105,468	93.2%	<0.001	209,510	93.2%	104,743	93.2%	104,767	93.2%	0.84
Male	426,468	27.8%	418,826	29.4%	7,642	6.8%		15,294	6.8%	7,659	6.8%	7,635	6.8%	
Region														
Midwest	335,508	21.8%	315,179	22.1%	20,329	18.0%	<0.001	40,548	18.0%	20,274	18.0%	20,274	18.0%	1.00
Northeast	383,023	24.9%	356,184	25.0%	26,839	23.7%		53,590	23.8%	26,795	23.8%	26,795	23.8%	
South	596,029	38.8%	552,754	38.8%	43,275	38.3%		85,440	38.0%	42,720	38.0%	42,720	38.0%	
West	221,488	14.4%	198,821	14.0%	22,667	20.0%		45,226	20.1%	22,613	20.1%	22,613	20.1%	
Insurance														
Commercial	707,675	46.1%	672,990	47.3%	34,685	30.7%	<0.001	69,354	30.9%	34,675	30.8%	34,679	30.9%	1.00
Dual	54,836	3.6%	44,281	3.1%	10,555	9.3%		19,871	8.8%	9,927	8.8%	9,944	8.8%	
Medicaid	486,446	31.7%	463,857	32.6%	22,589	20.0%		45,057	20.0%	22,537	20.1%	22,520	20.0%	
Medicare	287,091	18.7%	241,810	17.0%	45,281	40.0%		90,522	40.3%	45,263	40.3%	45,259	40.3%	
PCP Visit 2019														
No	605,256	39.4%	572,701	40.2%	32,555	28.8%	<0.001	64,959	28.9%	32,483	28.9%	32,476	28.9%	0.97
Yes	930,792	60.6%	850,237	59.8%	80,555	71.2%		159,845	71.1%	79,919	71.1%	79,926	71.1%	
						Continuo	us Outcom	es						
	mean	SD	mean	SD	mean	SD	p-value	mean	SD	mean	SD	mean	SD	p-value
CCI	0.87	1.60	0.85	1.58	1.06	1.84	<0.001	1.06	1.82	1.05	1.81	1.06	1.83	0.57

2810 BP: bisphosphonate; CCI: Charlson Comorbidity Index; PCP: primary care physician; SD: standard deviation

# 2812 Table S11f: Antidepressant Non-user Cohort (Region=New York State) by BP Use, Patient Characteristics Pre/Post Match of BP

2813 Users/Non-users

2814

	Regio	Region=NY Antidepressant Non-users by BP: Unadjusted							gion=NY A	ntidepres	sant Non	-users by	BP: Matc	hed
	Α		BP Non	-user	BP L	lser		4	All	BP No	n-user	BP L	Jser	in tradition
	Ν	%	N	%	Ν	%	p-value	N	%	N	%	N	%	p-value
All Patients	135,516	100.0%	125,342	92.5%	10,174	7.5%		20,182	100.0%	10,091	50.0%	10,091	50.0%	
Age														
≤20	4,365	3.2%	4,364	3.5%	1	0.0%	<0.001	2	0.0%	1	0.0%	1	0.0%	1.00
21-40	22,832	16.8%	22,799	18.2%	33	0.3%		66	0.3%	33	0.3%	33	0.3%	
41-50	18,483	13.6%	18,350	14.6%	133	1.3%		267	1.3%	134	1.3%	133	1.3%	
51-60	29,481	21.8%	28,038	22.4%	1,443	14.2%		2,879	14.3%	1,440	14.3%	1,439	14.3%	
61-70	27,543	20.3%	24,197	19.3%	3,346	32.9%		6,686	33.1%	3,345	33.1%	3,341	33.1%	
71-80	21,038	15.5%	17,695	14.1%	3,343	32.9%		6,589	32.6%	3,294	32.6%	3,295	32.7%	
≥81	11,774	8.7%	9,899	7.9%	1,875	18.4%		3,693	18.3%	1,844	18.3%	1,849	18.3%	
Gender														
Female	96,468	71.2%	86,945	69.4%	9,523	93.6%	<0.001	18,892	93.6%	9,446	93.6%	9,446	93.6%	1.00
Male	39,048	28.8%	38,397	30.6%	651	6.4%		1,290	6.4%	645	6.4%	645	6.4%	
Insurance														
Commercial	51,829	38.2%	50,405	40.2%	1,424	14.0%	<0.001	2,848	14.1%	1,425	14.1%	1,423	14.1%	1.00
Dual	1,591	1.2%	1,210	1.0%	381	3.7%		690	3.4%	345	3.4%	345	3.4%	
Medicaid	38,569	28.5%	36,303	29.0%	2,266	22.3%		4,449	22.0%	2,226	22.1%	2,223	22.0%	
Medicare	43,527	32.1%	37,424	29.9%	6,103	60.0%		12,195	60.4%	6,095	60.4%	6,100	60.4%	
PCP Visit 2019														
No	53,397	39.4%	50,515	40.3%	2,882	28.3%	<0.001	5,723	28.4%	2,863	28.4%	2,860	28.3%	0.96
Yes	82,119	60.6%	74,827	59.7%	7,292	71.7%		14,459	71.6%	7,228	71.6%	7,231	71.7%	
	Continuous Outc													
	mean	SD	mean	SD	mean	SD	p-value	mean	SD	mean	SD	mean	SD	p-value
CCI	0.96	1.68	0.95	1.66	1.13	1.81	<0.001	1.11	1.77	1.11	1.76	1.12	1.78	0.78

2815 BP: bisphosphonate; CCI: Charlson Comorbidity Index; PCP: primary care physician; SD: standard deviation

2816

medRxiv preprint doi: https://doi.org/10.1101/2022.06.14.22276397; this version posted June 21, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.

## 2818 Table S12a: Patient Count Distribution Inclusive of Deceased Enrollees

	All O	bservations		ealth Rx Users one-Rx")
	BP Users	BP Non-users	BP Users	BP Non-users
Total (N)	672,913	10,978,373	645,118	75,195
Deceased (N) [any reason]	7,364	101,282	6,922	2,450
COVID-19 Dx (N)	7,927	519,387	7,527	3,201
COVID-19 Dx (%)	1.2%	4.7%	1.2%	4.3%
COVID-19 Dx & Deceased (N)	431	15,470	410	215
COVID-19 Dx & Deceased (%)	5.4%	3.0%	5.4%	6.7%
Dx: diagnosis				

2819

# 2820

# Z821 Table S12b: Unadjusted Chi-Square Comparison Inclusive of Deceased Patients

			Observations eceased)
COVID-19 Dx	No COVID-19 Dx	COVID-19 Dx	No COVID-19 Dx
7,927	664,986	7,527	637,591
519,387	10,458,986	2,450	71,994
Odds Ratio	0.24	Odds Ratio	0.35
95 % CI:	0.2347 to 0.2455	95 % CI:	0.3312 to 0.3633
p-value	P < 0.0001	p-value	P < 0.0001
	(with a COVID-19 Dx 7,927 519,387 Odds Ratio 95 % CI: p-value	7,927         664,986           519,387         10,458,986           Odds Ratio         0.24           95 % CI:         0.2347 to 0.2455           p-value         P < 0.0001	(with deceased)         (with deceased)           COVID-19 Dx         No COVID-19 Dx         COVID-19 Dx           7,927         664,986         7,527           519,387         10,458,986         2,450           Odds Ratio         0.24         Odds Ratio           95 % CI:         0.2347 to 0.2455         95 % CI:

2822

BP: bisphosphonate; CI: confidence interval; Dx: diagnosis

### 2823 2824

### Table S12c: Unadjusted Chi-Square Comparison with Deceased Patients Removed

		servations		Observations									
	(withou	it deceased)	(without o	deceased)									
	COVID-19 Dx	No COVID-19 Dx	COVID-19 Dx	No COVID-19 Dx									
BP users	7,496	657,622	7,117	630,669									
BP Non-users	503,917	10,357,704	2,986	69,544									
	Odds Ratio	0.23	Odds Ratio	0.26									
	95 % CI:	0.2290 to 0.2397	95 % CI:	0.2516 to 0.2745									
	p-value	P < 0.0001	p-value	P < 0.0001									
			D										

### 2825 2826

BP: bisphosphonate; CI: confidence interval; Dx: diagnosis

# Table S12d: Unadjusted Chi-Square Comparison Assuming all Deceased Patients had COVID-

2828 **19** 

	All Observations (assume deceased = COVID-19)		"Bone-Rx" Observations (assume deceased = COVID-19)			
	COVID-19 Dx	No COVID-19 Dx	COVID-19 Dx	No COVID-19 Dx		
BP users	14,860	658,053	14,039	631,079		
BP Non-users	605,199	10,373,174	5,436	69,759		
	Odds Ratio	0.39	Odds Ratio	0.29		
	95 % CI:	0.3807 to 0.3935	95 % CI:	0.2764 to 0.2948		
	p-value	P < 0.0001	p-value	P < 0.0001		
BP: bisphosphonate; CI: confidence interval; Dx: diagnosis						

### 2829

2830 2831

### Table S12e: Unadjusted Chi-Square Comparison to Yield Odds Ratio = 1.00 (no difference)

	All Observations (assume deceased = COVID-19)		"Bone-Rx" Observations (assume deceased = COVID-19)	
	COVID-19 Dx	No COVID-19 Dx	COVID-19 Dx	No COVID-19 Dx
BP users	37,095	635,818	46,637	598,481
BP Non-users	605,199	10,373,174	5,436	69,759
	Odds Ratio	1.00	Odds Ratio	1.00
	95 % CI:	0.9893 to 1.0108	95 % CI:	0.9713 to 1.0296
	p-value	P = 0.9987	p-value	P = 0.9999

BP: bisphosphonate; CI: confidence interval; Dx: diagnosis